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Abstract 
This thesis is divided into five chapters where each corresponds to different 
research projects inspired and influenced by each other. Every chapter highlights one 
of the multiple aspects of modern organic synthesis, the application of the obtained 
targets either for the elucidation of biological phenomena or as a tool to shine a 
different light on the chemistry of life. The corresponding current state of the research 
is also enclosed in each chapter along with a brief introduction in this particular 
domain. Experimental data, spectroscopic analysis and appendices can be found at the 
end of this thesis.  
Chapter 1 starts with a general introduction on the use of natural products and its 
relationship to total synthesis in a historical progression. 
Chapter 2 includes a detailed description of the stereoselective synthesis of the 
neuritogenic steroid lactone withanolide A. Key for the successful total synthesis were 
mostly strategic considerations for the sequential order of the installment of the enone 
moiety. The total synthesis was achieved by singlet oxygen ene-reaction, Wharton 
transposition, a Corey-Seebach homologation and a vinylogous aldol reaction. 
Biological evaluation demonstrated neurite outgrowth, which further supports the 
potential neuritogenic role of this compound in traditional Indian medicine. 
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In Chapter 3 the development of a molecular surface modification platform based 
on biomimetic nitrocatechol derivatives is reported. This allowed for small molecule 
functionalization on TiO2 under mild aqueous conditions and efficient release 
triggered by light therefore uncaging a small molecule cargo on demand. Small 
molecules may be markers which become fluorescent upon decaging as shown in the 
proof-of-principle study or bioactive small molecules for drug release as shown in the 
following Chapter 4. 
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Here the use of caged retinoic acid derivatives as controllable probes for nerve cell 
differentiation is explained. These investigations should allow to navigate the axonal 
growth cones by an extrinsic guidance therefore directing neurite outgrowth by the 
developed release strategy. 
The first total syntheses of the piericidin natural products JBIR-02 and 
Mer-A2026B, and related piericidins are the topic of Chapter 5. Key features of the 
unified synthetic strategy involved an Ir-catalyzed one pot C-H activation/oxidation 
procedure for the preparation of multiple hydroxypyridines, a vinylogous Mukaiyama 
aldol reaction and a Negishi cross-coupling of an advanced pyridine intermediate with 
the fully elaborated allylic side chain. Following the successful total synthesis, the 
absolute configurations of Mer-A2026B and JBIR-02 were established as (9R,10R).  
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Chapter 6 describes briefly the synthesis of electron-rich 2,2’-bipyridine-systems 
as sensors for proton coupled electron transfer. The heteroaromatic core structure 
from the natural product JBIR-02 was successfully implemented to generate various 
bipyridines. 
Keywords: Natural Products, Total Synthesis, Neurite Outgrowth, Photocleavable 
Surface Hybrids, Steroids, Piericidins, Retinoids and Bipyridines 
 
 
 
vii 
 
Kurzbeschreibung 
Die vorliegende Doktorarbeit gliedert sich in fünf individuelle Teile, die sich 
gegenseitig mehr oder weniger inspirieren und beeinflussen. Jedes Kapitel beschreibt 
einen der zahllosen Aspekte moderner organischer Synthesechemie mit Schwerpunkt 
auf der Anwendung des jeweiligen Synthesetargets, entweder zur Untersuchung 
komplexer biologischer Systeme oder als “Hilfsmittel”, um die Chemie des Lebens in 
einem anderen Licht zu sehen. Jedes Kapitel enthält eine kurze Einführung zum 
aktuellen Stand der Forschung im jeweiligen Gebiet. Am Ende der Doktorarbeit sind 
die experimentellen Vorschriften als auch die entsprechenden spektroskopischen 
Daten aller Verbindungen in einem eigenen Kapitel angehängt.  
Kapitel 1 startet mit einer Einleitung zur Verwendung von Naturstoffen und deren 
Verbindung zum Gebiet der Totalsynthese im historischen Kontext.  
Die stereoselektive Synthese des Steroidlactons Withanolid A ist das Thema des 
2. Kapitel. Schlüssel für die erste Totalsynthese waren vor allem strategische 
Überlegungen zur Installierung des sensitive A Rings. Schlussendlich führten eine 
Corey-Seebach-Homologisierung, eine vinyloge Aldolreaktion, eine regioselektive 
Schenk-En-Reaktion unter Verwendung von Singulett-Sauerstoff sowie eine 
Wharton-Verschiebung zur erfolgreichen Herstellung. Biologische Untersuchungen 
demonstrieren Neuritenwachstum, was die potenziell neuroaktive Wirkung dieses 
Naturstoffs in der traditionellen indischen Medizin stützt. 
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Alken Umlagerung via  Schenck-
En-Reaktion und dirigierende
Epoxidierung
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 mit Lactonisierung
 
In Kapitel 3 wird die Entwicklung einer Oberflächenmodifizierung auf moleku-
larem Level beschrieben. Basierend auf biomimetischen Nitrocatecholen erlaubt diese 
Ankerstrategie TiO2-Partikel unter milden Bedingungen mit gewünschten Verbindun-
gen zu funktionalisieren, um diese bei Bedarf durch Licht wieder freizusetzen. Die 
verwendeten Verbindungen (small molecules) können Fluorophore sein wie in einer 
viii 
 
ersten konzeptionellen Untersuchung gezeigt oder aber auch bioaktive Moleküle, die 
bei Bedarf freigesetzt werden, siehe dazu Kapitel 4.  
Fluorophor, bioaktives Moleküle
Polymer, Protein, DNA, etc.
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In Kapitel 4 wird die Verwendung von photoaktivierbaren Retinoiden als Proben 
für die Zelldifferenzierung erklärt. Die Synthese dieser Verbindungen sollte es 
erlauben, die Ausbreitung von Axonen zu beeinflussen und damit letztendlich 
Neuritenwachstum auf Oberflächen zu dirigieren.  
Die ersten Totalsynthesen der piericidinen Naturstoffe JBIR-02 und Mer-A2026B 
sowie verwandter Piericidine sind in Kapitel 5 zusammengefasst. Zu den Schlüssel-
schritten dieser Strategie zählen neben einer Ir-katalysierten C-H Aktivierung-
Oxidations Sequenz, die zur Herstellung einer Vielzahl von 4-Hydroxypyridinen 
führt, eine vinyloge Mukaiyama Aldolreaktion sowie eine Negishi-Kreuzkupplung 
eines hochfunktionalisierten Pyridins mit dem sorgfältig konstruierten Seitenketten-
vorläufer. Zusätzlich wurden durch die erfolgreichen Totalsynthesen erstmals die 
absoluten Konfigurationen von JBIR-02 und Mer-A2026B als (9R,10R) etabliert.  
N
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Oxidation
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HWE Reaktion
Kobayashi's Mukaiyama 
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Kapitel 6 beschreibt die Synthese von elektronenreichen 2,2’-Bipyridin-Systemen 
als Sensoren für protonengekoppelten Elektronentransfer. Dabei wurde die Ver-
wendung des Heteroaromaten aus Kapitel 5 erfolgreich implementiert. 
Schlüsselwörter: Naturstoffe, Totalsynthese, Neuritenwachstum, Fotospaltbare 
Oberflächenhybride, Steroide, Piericidine, Retinoide und Bipyridine 
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1 INTRODUCTION 
1.1 Natural Products: Inherent Evolutionary Wisdom 
Natural products and their sources have been used by mankind ever since and have 
been tightly associated with the evolution of our culture. Owing to the diverse 
biological benefits and medicinal potentials of natural products, every civilization has 
collected experience of their use as aliment, drug or poison e.g. Indian Ayurveda or 
traditional Chinese medicine.1 The earliest records come from ancient Mesopotamia, 
circa 2600 BC, describing the use of approximately 1,000 plants and plant-derived 
substances for the treatment of various illnesses. Other natural compounds originate 
from microbial or marine sources, usually effecting their isolation and characteri-
zation challenging due to very small available quantities.1  
Nature has optimized biological active compounds in an evolutionary process - its 
own high-throughput screening - over millions of years to function in the required 
way as messenger, repellent or attractant.2,3 At present, natural product motifs still 
contribute to more than 40% of pharmaceutical lead-structures in drug-discovery, 
whereas only one new molecular entity from a combinatorial research program was 
approved as a drug in the last 25 years.1 Thus, synthesis of natural products as potent 
drug targets remains even in times of modern biotechnology essential to gain an 
understanding of their inherent pharmaceutical properties by structure-activity 
relationship (SAR) studies. 
1.2 Total Synthesis: Blending Organic Synthesis and the Game 
of Chess 
Synthetic chemistry (Greek: synthesis = the process of putting together) is the 
handcraft of constructing molecules from simple available precursors. Through which 
aspects these precursors are chosen, availability, costs or quality, and in which way 
                                                
1  D. J. Newman, G. M. Cragg, K. M. Snader, J. Nat. Prod. 2003, 66, 1022-1037. 
2  I. Paterson, E. A. Anderson, Science 2005, 310, 451-453. 
3  a) K. Gademann, Chimia 2006, 60, 841-845; b) H.-F. Ji, X.-J. Li, H.-Y. Zhang, EMBO 
Rep. 2009, 10, 194-200; c) A. Eschenmoser, Angew. Chem. 2011, 123, 12618-12681. 
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connectivity is established is the purpose of organic chemistry especially when the 
target molecule is a natural product of total synthesis. 
Total synthesis can be best compared to the game of chess sharing some of the 
same characteristics: frustrations, dead-ends and glorious moments.4,5 The object of 
chess is to outmaneuver the opponent’s king by a combination of moves with the 
ensemble of chessmen. Similarly in total synthesis, the goal is to reach the target 
compound by a foresighted strategy (using synthetic transformations) to overcome 
nature’s hurdles (complex architectures). In both cases, the effects of the opening 
moves are felt right to the end game and can be hardly anticipated before.6 The 
correspondence of both disciplines is also pictured in the following statement of the 
former chess world champion Emanuel Lasker (1868-1941): ‘When you see a good 
move, look for a better one,’ which inspires chemist to fine-tune synthetic routes 
towards the same target or molecular framework over and over.  
While the game of chess in its todays form is around 300 years old, the birth of 
total synthesis is marked with the synthesis of urea (1.1)7 by F. Wöhler in 1828 when 
it became apparent that molecules originating from living organisms could be created 
by men using inorganic ‘death’ starting materials (Figure 1.1). Headed by the 
German laboratories in Giessen (J. von Liebig, 1803-1873) and Berlin (A. W. von 
Hofman, 1818-1892) a prospering synthetic period started mainly to understand 
fundamental rules of connectivity. Later the first simple amino acids (Strecker, 
1850),8 aromatics (Reimer and Tiemann, 1876),9 sugars (E. Fischer, 1891)10 and 
steroids were obtained by means of synthesis to confirm the structures of isolated 
natural products. Sir R. Robinson’s (1886-1975) tropinone synthesis (1.2)11 highlights 
                                                
4  K. C. Nicolaou, E. J. Sorensen, Classics in Total Synthesis, Wiley-VCH, 1995, pp. 2-17. 
5  ‘A chess game is divided into three stages: the first, when you hope you have the 
advantage, the second when you believe you have an advantage, and the third ... when you 
know you are going to lose!’ Savielly Tartakower (1887-1956) 
 ‘Chess is not relaxing; it is stressful even if you win.’ Jennifer Shahade (born 1980) 
6  In chess around 1,300 different named openings are classified: D. Hooper, K. Whyld, The 
Oxford Companion to Chess, Oxford University Press, 1984. 
7  F. Wöhler, Ann. Phys. Chem. 1828, 12, 253-256. 
8  A. Strecker, Liebigs Ann. Chem. 1850, 75, 27-45. 
9  K. Reimer, F. Tiemann, Ber. Deutsch. Chem. Ges. 1876, 9, 824-828. 
10  E. Fischer, Ber. Deutsch. Chem. Ges. 1890, 23, 799-805. 
11  R. Robinson, J. Chem. Soc. 1917, 762-768. 
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another milestone in the history of total synthesis through its innovative simplicity 
and biomimetic character.  
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Figure 1.1. Milestones in the field of total synthesis: urea (1.1, F. Wöhler, 1828)7, 
tropinone (1.2, Robertson, 1917)11, equilenin (1.3, W. E. Bachmann, 1939)12, strych-
nine (1.4, R. B. Woodward, 1954)13, prostagladine E2 (1.5, E. J. Corey, 1969)14 and 
calicheamicin γ1I (1.6, K. C. Nicolaou, 1992; S. J. Danishefsky, 1994)15. 
After World War II, due to the more sophisticated analytical toolbox (NMR and 
X-ray structure analysis), first R. B. Woodward (1917-1979) with his foresight and 
later E. J. Corey (born 1928) with his systematical retrosynthetic disconnections of 
complex architectures, raised total synthesis to another level. At this stage nature’s 
challenges represented no longer a puzzle about the right structure but the drive for a 
new generation of chemists equipped with a variety of new methods, reagents and 
catalysts developed for special strategic maneuvers as for example enantioselective 
reactions. The following area in the early 1990s was towered by K. C. Nicolaou (born 
1946), D. A. Evans (born 1941), S. J. Danishefsky (born 1936) and their co-workers 
who demonstrated that nearly every natural product, being a ‘small molecule’ (e.g. 
                                                
12  W. E. Bachmann, W. Cole, A. L. Cole, J. Am. Chem. Soc. 1939, 61, 974-975. 
13  R. B. Woodward, M. P. Cava, W. D. Ollis, A. Hunger, H. U. Daeniker, K. Schenker, J. 
Am. Chem. Soc. 1954, 76, 4749-4751. 
14  E. J. Corey, N. M. Weinshenker, T. K. Schaaf, W. Huber, J. Am. Chem. Soc. 1969, 91, 
5675-5677. 
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calicheamicin γ1I , 1.6) 15  can be accessed by synthetic organic chemists in a 
reasonable timeframe.  
In this regard total synthesis has reached a dead-end street where the performance 
of synthetic chemistry itself is no longer the sole motivation to pursue a total 
synthesis of a molecule (except for a few famous examples). But instead it requires 
additional justification, supplementary to the proof of a structure, the assignment of 
stereogenic centers or the challenge of a complex assembly. 
 
Figure 1.2. Chessboard. Final position in Game 6: J. Kasparov vs. Deep Blue.  
Similarly, the development of more powerful computers has significantly changed 
the game of chess in the last two decades. Analogous to total synthesis a blockade was 
reached when grandmasters were no longer able to compete with machines and 
programs once developed by men started to become dominant (Figure 1.2).16 
1.3 Modern Synthetic Chemistry 
Nevertheless, the future for synthetic organic chemistry looks bright. It has the 
enormous advantage over most other scientific disciplines that it can create its own 
object, what is reflected in the famous words of French chemist M. Berthelot (1827-
1907):17 ‘This creative faculty, similar to arts itself, distinguishes it essentially from 
                                                
15  a) K. C. Nicolaou, C. W. Hummel, E. N. Pitsinos, M. Nakada, A. L. Smith, K. Shibayama, 
H. Saimoto, J. Am. Chem. Soc. 1992, 114, 10082-100084; b) S. A. Hitchcock, S. H. Boyer, 
M. Y. Chu-Moyer, S. H. Olson, S. J. Danishefsky, Angew. Chem. Int. Ed. 1994, 33, 857-
862. 
16  The reigning chess word champion Garry Kasparov lost against the chess-playing 
computer Deep Blue developed by IBM on March 11, 1997 with 3½:2½ (in 6 games).  
17  French original: « La chimie crée son objet. Cette faculté créatrice, semblable à celle de 
l’art lui-même, la distingue essentiellement des sciences naturelles et historiques. »   
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natural and historical sciences.’ Because of this innovative power, new disciplines 
such as chemical biology were established investigating fundamental interaction of 
bioactive small molecules, being a natural product or not, with its biological 
environment.18 Here, sophisticated tools for a better understanding of the most 
fundamental and complex processes at the cutting edge of biology and chemistry are 
established by synthetic chemists and applied in an interdisciplinary fashion by other 
researchers leading for example to ‘high-tech drugs’ as seen in Figure 1.3 for a 
hybrid of calicheamicin γ1I and a target-specific antibody (1.6).19  
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OSugar
NHCOOCH3
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OSugar
NHCOOCH3
O
HO
OSugar
NHCOOCH3
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S
1.6
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OSugar
NHCOOCH3
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Figure 1.3. Proposed mechanism for the action of calicheamicin γ1I (1.6): Formation of 
a reactive aromatic diradical through a cascade reaction (accompanied with a sp2-sp3 
hybridisation change) induces double-strand cleavage of dublex DNA, thereby causing 
apoptosis.20 Delivery of this highly cytotoxic agent by a selective antibody resulted in 
the development of a recently approved anti-cancer drug. 
Another prominent example improving the pharmacological properties of a natural 
product by synthetic chemistry is the recently developed anticancer drug eribulin or 
E7389 (1.8, Figure 1.4).21 This molecule is a simplified analog of the mitotic 
inhibitor halichondrin B (1.7), a secondary metabolite from the marine sponge 
Halichondria okadai. Eribulin was first synthesized in collaboration of the Kishi 
group and Eisai Co. Ltd (Tokyo) in 1992 and was approved by the US FDA in 2010 
for the treatment of late-stage breast cancer.22 The structurally complexity of the 
                                                
18  H. Waldmann, Angew. Chem. Int. Ed. 2012, 51, 6284-6285. 
19  F. E. Koehn, G. T. Carter, Nature Drug Disc. Rev. 2005, 4, 206-220. 
20  R. C. Hawley, L. L. Kiessling, S. L. Schreiber, Proc. Natl. Acad. Sci. USA 1989, 86, 1105-
1109. 
21  A. Kirschning, F. Hahn, Angew. Chem. Int. Ed. 2012, 51, 4012-4022. 
22  a) T. D. Aicher, K. R. Buszek, F. G. Fang, C. J. Forsyth, S. H. Jung, Y. Kishi, M. C. 
Matelich, P. M. Scola, S. K. Spero, S. K. Yoon, J. Am. Chem. Soc. 1992, 114, 3162-3164; 
b) D.-S. Kim, C.-G. Dong, J. T. Kim, H. Guo, J. Huang, P. S. Tiseni, Y. Kishi, J. Am. 
Chem. Soc. 2009, 131, 15636-15641; c) C.-G. Dong, J. A. Henderson, Y. Kaburagi, T. 
Sasaki, D.-S. Kim, J. T. Kim, D. Urabe, H. Guo, Y. Kishi, J. Am. Chem. Soc. 2009, 131, 
15642-15646. 
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western fragment was substituted by a simplfied amino alcohol subunit, retaining its 
biological activity and modifying the structure a bit more druglike. Here contempo-
rary synthesis shows its capacity to meet the requirement of supplying this fully 
synthetic molecule incorporating 18 stereogenic centers in gramm quantities. 
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Figure 1.4. Structure of halichondrin B (1.7) and eribulin (1.8, the structural 
simplification with respect to halichondrin B is highlighted in red). 
Similar the immunosuppressive polyketide discodermolide 1.9 was prepared by 
S. J. Mickel and coworkers at Novartis in 2002 on process-scale (>100 g of natural 
product).23 In their campaign to obtain quantities of the natural product (1.9) for 
clinical development the asymmetric total synthesis was performed as biotechnology 
approaches utilizing polyketide synthatases have not yet been demonstarted on such a 
significant scale. Examination of various published synthetic approaches 24  with 
particulary view on the scale-up lead in less then 20 months to a 36 steps route with 
an overall yield of 0.2% and only 15 chromatographic purification necessary. 
Unfortunately unexpected toxicity of the compound in clinical trials did not lead to 
the manufactoring of the drug, but set a new standard for what is possible though total 
synthesis especially in an industrial research program.  
O H3C CH3
HO
OH
CH3
CH3
OH
HO
H3C
CH3
OH
CH3
O NH2
O
CH3
1.9  
Figure 1.5. Structure of discodermolide (1.9). 
                                                
23  a) S. J. Mickel, Strategies and Tactics in Organic Synthesis, Vol. 6, Elsevier, 2005, pp. 
269-317; b) S. J. Mickel, Pure Appl. Chem. 2007, 79, 685-700. 
24  For reviews: a) A. B. Smith III, B. S. Freeze, Tetrahedron 2008, 64, 261-298; b) G. J. 
Florence, N. M. Gardner, I. Paterson, Nat. Prod. Rep. 2008, 25, 342-375. 
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A more recent scafold investigated in the Waldmann group is the natural product 
family of secoyohimbanes to which the epimeric rhynchophylline (1.10) and 
isorhynchophylline (1.11) belong.25 These spiro indol alkaloids exhibit potential 
neuromodulatory activities, which is reflected in a substaintial increase of single 
neurite length and a rise of the number of neurites per neuron. Through an asymmeric 
catalytic domino Michael-Mannich reaction a small collection of natural products 
analogues of type 1.12 was obtained an evaluated in rat hippocampal neurons as well 
as in mouse models to investigate on their strucural activity relationship.25d 
N
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O
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H Ar
1.12  
Figure 1.6. Structures of neuroactive rhynchophylline (1.10), isorhynchophylline 
(1.11) and the core structure of analogues (1.12) from the Waldmann group. 
To summarize, organic chemists of the 21st century especially the ones dealing 
with the total synthesis of natural products do not singularly face problems associated 
with the development of reliable, economical and well-designed syntheses, but also 
involve in applying their obtained targets to related disciplines such as biology, 
pharmacology, medicine or even physics. 
This thesis will present the possible use of natural products obtained by the means 
of total synthesis to elaborate questions from neuroscience in the context of cell 
differentiation as well as navigation of these differentiated neurites. Furthermore, it 
will be shown how modern organic chemistry can generate simple ‘tools’ adjustable 
to a particular demand e.g. a new innovative surface anchors inspired by natures 
structures and functionalities. Finally, new synthetic tactics for the total synthesis of 
structurally complex natural products will be disclosed and pragmatically applied in 
related research. 
                                                
25  For the total synthesis: a) R. Stahl, H. J. Borschberg, P. Acklin, Helv. Chim. Acta 1996, 
79, 1361-1378; b) A. Lerchner, E. M. Carreira, J. Am. Chem Soc. 2002, 124, 14826-
14827; c) A. Deiters, M. Pettersson, S. F. Martin, J. Org. Chem. 2006, 71, 6547-6561; d) 
A. P. Antonchick, S. López-Tosco, J. Parga, S. Sievers, M. Schürmann, H. Preut, S. 
Höing, H. R. Schöler, J. Sternckert, D. Rauh, H. Waldmann, Chemistry & Biology 2013, 
20, 500-509. 
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2 WITHANOLIDE A: SYNTHESIS AND EVALUATION ON 
ITS NEURITOGENIC PROPERTIES 
2.1 Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by 
amyloid plaques formation, dysfunctional neurons and loss of cognitive functions.26 
The numbers of people suffering from this disease is increasing at an alarming rate, 
with death occurring approximately 9 years after first diagnosis.27 The pathogenesis of 
AD is yet to be fully understood, with both genetic and environmental factors 
contributing to the progress of the disease.28 Currently, dementia is treated mainly 
with acetylcholine esterase inhibitors that delay the progression rather than actually 
restoring the brain function. Giving about the prevalence of AD and unmet long-term 
therapies, there is a demanding requirement for the evaluation of new drug leads for 
AD and associated diseases.26 Additional to the inherent challenge for CNS drugs to 
bypass the blood-brain-barrier, clinical studies to observe significant differences in 
patients vs. control requires an undefined length as the initiation and the manifestation 
of the disease are usually separated by decades.  
 
Figure 2.1. Withania somniferia (on an Indian stamp): Highlight the value of this tradi-
tional plant and the Ayurvedic medicine in general for the Indian society. 
Ashwagandha (from the roots of Withania somniferia, also known as Indian 
Ginseng) is one of the most prominent drugs in traditional Ayurvedic medicine. It is 
                                                
26  Alzheimer’s Disease International, World Alzheimer Report 2012, 1-13. 
27  Review: P. Williams, A. Sorribas, M.-J. R. Howes, Nat. Prod. Rep. 2011, 28, 48-77. 
28  D. K. Lahiri, B. Maloney, M. R. Basha, Y. W. Ge, N. H. Zawia, Curr. Alzheimer Res. 
2007, 4, 219-228. 
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used as nootropic to improve the intellectual performance of the elderly29 in the 
context of anti-aging, memory reconstruction and more recently as cognitive 
enhancers for healthy subjects.30 
One of the most active constituents of the methanolic extracts, withanolide A 2.1 
showed very promising neuroactive properties in human neuroblastoma cell model as 
well as in mice: axonal outgrowth, regeneration of neurites and recovery of damaged 
synapses.31,32 
H
HH
HO
O
OH O
O
O
H
2.1  
Figure 2.2. Structure of withanolide A (2.1). 
These remarkable biological properties are further extended by a recent study 
documenting that withanolide A (2.1) modulates several secretase targets with regard 
to neurodegenerative diseases. Chan and co-workers lately demonstrated that this 
steroid lactone 2.1 downregulates BACE1 and upregulates ADAM10 in primary rat 
cortical neurons.33 These combined reports provide a strong pharmacological ratio-
nale for synthetic investigation of withanolide A (2.1), for which no preparation from 
simple steroid precursors has yet been reported.34 
                                                
29  Selected articles: a) J. Harris, R. C. Kessler, M. Gazzaniga, P. Campbell, M. J. Farah, 
Nature 2008, 456, 702-705; b) M. J. Farah, J. Illes, R. Cook-Deegan, H. Gardner, E. 
Kandel, P. King, E. Parens, B. Sahakian, P. R. Wolpe, Nature Neurosci. Rev. 2004, 5, 421-
425. 
30  http://www.cerebralhealth.com/brainhealthsupplements.php 
31  For neuroactive properties of withanolide A: a) T. Kuboyama, C. Tohda, J. Zhao, N. 
Nakamura, M. Hattori, K. Komatsu, Neuroreport 2002, 13, 1715-1720; b) J. Zhao, N. 
Nakamura, M. Hattori, T. Kuboyama, C. Tohda, K. Komatsu, Chem. Phar. Bull. 2002, 50, 
760-765; c) T. Kuboyama, C. Tohda, K. Komatsu, Brit. J. Pharmacol. 2005, 144, 961-
971. 
32  For neuroactive properties of ashwagandha: S. Jain, S. D. Shukla, K. Sharma, M. 
Bathnagar, Phytother. Res. 2001, 15, 544-548. 
33  S. P. Patil, S. Maki, S. A. Khedkar, A. C. Rigby, C. Chan, J. Nat. Prod. 2010, 73, 1196–
1202. 
34  P. Neogi, M. Kawai, Y. Butsugan, Y. Mori, M. Suzuki, Bull. Chem. Soc. Jpn. 1988, 61, 
4479-4481. 
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Figure 2.3. General numbering for steroid backbones and structure of the 
commercially available retrosynthetic precursor pregneolone (2.2) 
Withanolide A is a highly oxygenated steroidal lactone offering several challenges 
in the context of a total synthesis. The natural product family consists of the A, B, C 
and D ring and the lactone side chain (SC, Figure 2.3).35,36 Withanolide A possess a 
reactive enone moiety in the A ring, an epoxy alcohol in the B ring, and a 
tetrasubstituted unsaturated lactone as the side chain. It is obvious that the main 
synthetic challenges arise in the stereoselective construction of the side chain and the 
oxidation pattern of the A and B ring, but the diastereoselective installment of a 
tertiary alcohol at C-20 was also found to be not-trivial. Approaching the synthesis of 
a steroid, it was proposed to start from the commercially available and inexpensive 
steroidal precursor pregnenolone 2.2.  
The following chapters will disclose the synthetic evolution observed through 
different approaches undertaken towards the first total synthesis of withanolide A, 
including those that were unsuccessful. 37  Furthermore, we envisioned that the 
synthesis of withanolide A derivatives should be accessible using semi-synthetic 
transformations starting from the natural product. Besides the acquired knowledge 
concerning the reactivity pattern of the natural product for its total synthesis, these 
compounds should help to better understand the pharmacological properties of 2.1. 
The derivatization should be mainly focused on the A ring of withanolide A as its 
                                                
35  Reviews on withanolide structures, bioactivities and synthetic approaches: a) L.-X. Chen, 
H. He, F. Qiu, Nat. Prod. Rep. 2011, 28, 705-740; b) I. Kirson, E. Glotter, J. Nat. Prod. 
1981, 44, 633-647; c) N. V. Kovganko, Z. N. Kahkan, Chem. Nat. Compd. 1997, 33, 133-
145.  
36  Synthetic investigations on withanolides: a) K. Gamoh, M. Hirayama, N. Ikekawa, J. 
Chem. Soc., Perkin Trans. I 1984, 449-454; b) A. Perez-Medrano, P. A. Grieco, J. Am. 
Chem. Soc. 1991, 113, 1057-1059; c) E. Glotter, S. Kumar, M. Sahai, A. Goldman, I. 
Kirson, M. Medelovici, J. Chem. Soc., Perkin Trans. I 1991, 739-745; d) M. Ishiguro, A. 
Kajikawa, T. Haruyama, Y. Ogura, M. Okubayashi, M. Morisaki, N. Ikekawa, J. Chem. 
Soc., Perkin Trans. I 1975, 2295-2302. 
37  T. Woods, Research report, EPF Lausanne, 2010. 
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reactivity showed to be critical for successful transformations, what will be explained 
in more detail in the following sections. Finally, the natural product as well as its 
analogues will be tested in cell assays to improve the understanding of the biological 
mode of action regarding their neurite outgrowth abilities.  
2.2 Results and Discussion 
2.2.1 1st Generation Approach: The B Ring Hurdle37  
The first generation approach commenced with the investigation towards the 
synthesis of the B ring. It was envisioned that an epoxidation of the 5,6-double bond 
followed by the opening of the corresponding epoxide with a nucleophile would 
furnish the desired tertiary alcohol at C-5, thereby allowing functionalization of the B 
ring first.  
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H
HH
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O
TMSO
Base
H H H
H
2.3 2.4 2.5
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a b,c
 
Scheme 2.1. Investigations on the B ring synthesis of withanolide A: a) m-CPBA, 
CH2Cl2, RT, 99%, (dr 3:1); b) BiCl3, dioxane, 80 °C, 76%; c) i) TMSOTf, 2,6-lutidine, 
CH2Cl2, -15 °C to RT; ii) HCl in THF, 90%. 
Thus, commercially available pregnenolone acetate 2.3 was treated with meta-
chloroperoxybenzoic acid (m-CPBA) in CH2Cl2 to afford epoxide 2.4 as a 3:1 mixture 
of the α- and β-epoxides in quantitative yield (Scheme 2.1). Recrystallization from 
EtOAc/hexane gave the desired α-isomer. Following the procedure of Pinto et al.,38 
the epoxide 2.4 was opened with the use of BiCl3 in dioxane at elevated temperatures 
giving the expected regioselectivity and provided chlorohydrin in a 76% yield. Tri-
                                                
38  R. M. A. Pinto, J. A. R. Salvador, C. Le Roux, Tetrahedron 2007, 63, 9221-9228. 
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methylsilylation was performed using TMSOTf to form the TMS ether 2.5 in 90% 
yield. During the cause of this reaction, the formation of the enol ether at the methyl 
ketone (C-20) was initially observed, followed by much slower alcohol protection. 
However, once all the starting material was converted to the bis-silyl intermediate, the 
crude material was exposed to HCl in THF, and resulting in mono-desilylation to give 
the TMS protected alcohol 2.5. With chlorohydrin 2.5 in hands, it was expected that 
the elimination process of 2.5 to give 2.6 would be a facile step by using a strong 
base. 
Unfortunately, all attempts for this transformation proved unsuccessful. X-ray 
analysis of chloride 2.5 confirmed its structure and more importantly, the diaxial 
arrangement of the chloride and hydrogen needed for E2 elimination. Attempts to 
form the analogous bromohydrin and iodohydrin were unsuccessful and consequently 
this approach was abandoned.37  
2.2.2 2nd Generation Approach: Elaboration of the A and B Ring37  
Before exploring the chemistry of the B ring, the homologation required for the 
side chain was carried out using a known Corey-Seebach umpolung strategy.39 Thus, 
the 3β-OH of pregnenolone 2.2 was protected as TBS ether under standard reaction 
conditions (Scheme 2.2). The methyl ketone was treated with the lithiated dithiane to 
afford the tertiary alcohol 2.7 in a 95% yield (dr 15:1). The removal of the dithiane 
moiety by treatment with HgCl2 afforded the globally deprotected α-hydroxy 
aldehyde, which was found to be unstable and partial decomposition (probably via a 
1,2-rearrangement) was observed. The reprotection of the aldehyde was necessary for 
the oxidative modifications in the A and B rings and was achieved by using 
propanediol, methylorthoformate and catalytic amount of Sc(OTf)3 and to afford the 
acetal 2.8 in reasonable yield. With 2.8 available, functionalization of the B ring could 
then be explored.  
Accordingly, diol 2.8 was epoxidized with m-CPBA in CH2Cl2 in a 95% yield with 
a 4.5:1 diastereomeric ratio in favour of the desired α-epoxide 2.9.37 Several attempts 
were made to affect the key epoxide-allylic-alcohol-rearrangement to allylic alcohol 
2.10 without success using strong bases such as LDA or KOt-Bu (Scheme 2.2). It was 
                                                
39  B. B. Shingate, B. G. Hazra, V. S. Pore, R. G. Gonnade, M. Bhadbhade, Tetrahedron 
2007, 63, 5622-5635. 
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thought that the presence of two unprotected hydroxy functions might be the reason 
for the failure.  
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Scheme 2.2. Second generation approach towards the total synthesis of diol 2.10: a) 
TBSCl, imidazole, THF; b) 1,3-dithiane, n-BuLi, THF, -78 °C to RT, 82% (2 steps, 
dr 15:1); c) HgCl2, HgO, CH3CN, H2O; d) Sc(OTf)3, (MeO)3CH, 1,3-propandiol, 47% 
(2 steps); e) m-CPBA, CH2Cl2, RT, 95% (dr 4.5:1). 
To address this problem the tertiary alcohol was protected as methoxymethyl 
(MOM) ether 2.11 after the removal of the dithiane protecting group (similar to 
Scheme 2.2). Following a method described by Sharpless et al. for the oxidative 
opening of epoxides,40 a reduction of (PhSe)2 with NaBH4 in EtOH was followed by 
treatment with MOM protected epoxide and H2O2, to afford the desired allylic alcohol 
2.13 in 42% yield (79% brsm, Scheme 2.3). The undesired β-epoxide was not 
reactive towards these conditions and separation was easily achieved. Allylic alcohol 
2.12 was sensitive to acidic conditions and was prone to rearrange to the presumably 
more stable trisubstituted olefin. The allylic alcohol 2.12 was then transformed to the 
epoxy alcohol 2.13 using m-CPBA in 88% yield. In this reaction, the allylic hydroxyl 
group adequately directed the epoxidation to achieve a high diastereoselectivity. Next, 
the secondary alcohol 2.13 was oxidized using tetrapropylammonium perruthenate 
(TPAP) and N-methyl morpholine N-oxide (NMO), and the resulting ketone was 
converted to its silyl enol ether using TIPSOTf. After allylic oxidation with DDQ and 
                                                
40   K. B. Sharpless, R. F. Lauer, J. Am. Chem. Soc. 1973, 95, 2697-2699. 
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t-BuOOH turned out to be unsuccessful,41 Saegusa oxidation of the enol ether was 
performed instead.42 The TIPS enol ether was treated with 1 eq. of Pd(OAc)2 in 
CH3CN and the desired α,β-unsaturated ketone was isolated in quantitative yield. 
Epoxidation of the unsaturated ketone under basic conditions gave the bis-epoxide 
2.14 in 79% yield with complete diastereoselectivity. K2CO3 was found to be the best 
choice of base, whereas stronger bases such as NaOH and KOt-Bu gave complex 
mixtures of products. 
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Scheme 2.3. MOM protected tertiary alcohol as precursor for the installment of the A 
and B ring: a) i) (PhSe)2, NaBH4, EtOH; ii) 2.11, THF; iii) H2O2, 42% (79% brsm); 
b) m-CPBA, CH2Cl2, 88%; c) TPAP, NMO, CH2Cl2; d) TIPSOTf, Et3N, CH2Cl2; 
e) Pd(OAc)2, CH3CN, 63% (3 steps); f) K2CO3, H2O2, THF, H2O, 79%; g) N2H4·HCl, 
Et3N, CH3CN, 52%; f) TPAP, NMO, CH2Cl2, 85%. 
Having synthesized the keto epoxide 2.14 the stage was set for the Wharton 
transposition. Nevertheless, Wharton’s original conditions (N2H4!H2O, AcOH) 
afforded the desired allylic alcohol in poor yield (28%).43 However in 1989, Dupuy 
and Luche reported revised conditions for the Wharton transposition using basic 
conditions.44 Satisfyingly, these conditions gave the allylic alcohol in an improved 
yield of 52%. Oxidation of allylic alcohol again with TPAP, NMO afforded the 
                                                
41  J.-Q. Yu, H.-C.Wu, E. J. Corey, Org. Lett. 2005, 7, 1415-1417; b) A. J. Catino, R. E. 
Forslund, M. P. Doyle, J. Am. Chem. Soc. 2004, 126, 13622-13623. 
42  Y. Ito, T. Hirao, T. Saegusa, J. Org. Chem. 1978, 43, 1011-1013. 
43  P. S. Wharton, D. H. Bohlen, J. Org. Chem. 1961, 26, 3615-3616. 
44  C. Dupuy, J. L. Luche, Tetrahedron 1989, 45, 3437-3444. 
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α,β-unsaturated ketone 2.15 in 85% yield and therefore completed the construction of 
the A and the B rings.  
The following plan was to unmask the aldehyde (2.16) and to introduce the eastern 
side chain in order to form the desired lactone. However, the removal of the acetal 
protecting group was proved to be extremely difficult. Almost all sets of conditions 
attempted initially removed the MOM protecting group, whereas others were too 
harsh and led to complex mixtures of products due to decomposition. This approach 
had to be abandoned at this stage and a search for suitable protecting group was 
necessary to complete the target, which is outlined below. 
2.2.3 3rd Generation Approach: New Protecting Group Strategy37 
Careful consideration of alternative protecting groups resulted in the use of the 
para-methoxybenzyl (PMB) group, which would require the reduction of the 
aldehyde prior to its attachment. The chemistry of this approach is analogous to the 
one of the second generation, which had proven reliable. It was further anticipated 
that we could use a procedure developed by Ikekawa to form the lactone from a 
simple steroidal aldehyde by a vinylogous Mukaiyama aldol reaction in the last step. 
Several methods were investigated to induce the cleavage of the dithiane moiety in 
2.7, with the main concern being the stability of the TBS protecting group. Conditions 
based on HgCl2, NBS and I2 both with and without addition of base were unsuccessful 
and resulted in either desilylation, formation of the thioacetal or more complex 
mixtures. Pleasingly, simple treatment of dithiane 2.7 with NCS in a CH2Cl2/H2O 
mixture in an open vessel at room temperature afforded the desired α-hydroxy-
aldehyde in 73%.  
The resulting alcohol was MOM-protected using N,N-diisopropylethylamine 
(DIPEA) and MOMI in 94%. The conversion of the reaction was found to be 
depended on the quality of the starting materials, in particular, the NaI was dried 
under high vacuum at 100 °C for several hours and the MOMCl was freshly distilled 
before use. A simple filtration of the crude reaction mixture through a short pad of 
silica was sufficient to provide material for the next step. Subsequent, reduction of 
aldehyde 2.17 with NaBH4 in MeOH furnished the desired alcohol as a white solid, 
which was used in the next step without further purification.The PMB protection was 
then performed utilizing PMBCl and a catalytic amount of tertabutylammonium 
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iodide (TBAI) to furnish benzyl ether 2.18. Epoxidation of the olefin proceeded 
smoothly affording a 4.1:1 diastereomeric ratio of the desired α-epoxide 2.18 in 71% 
yield over three steps. The inseparable diastereomers were used as a mixture in the 
next step, at which point the desired product was separated by column 
chomatography. Rearrangement of epoxide 2.18 to allylic alcohol 2.19 was carried 
out as described earlier,40 affording a 48% yield of compound 2.19, and the remaining 
unreacted starting material could be recycled. The second epoxidation of allylic 
alcohol 2.19 with m-CPBA afforded the allylic epoxide with complete selectivity and 
in high yield (96%). 
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Scheme 2.4. Third generation approach for the total synthesis of withanolide A: 
a) NCS, CH2Cl2, H2O; b) NaI, MOMCl, DIPEA, DME, 69% (2 steps); c) NaBH4, 
MeOH; d) NaH, PMBCl, TBAI, THF, DMF; e) m-CPBA, CH2Cl2, 71% (3 steps, 
dr 4.1:1); f) i) (PhSe)2, NaBH4, EtOH; ii) 2.18, THF, iii) H2O2, 48% (72% brsm); 
g) m-CPBA, CH2Cl2; h) TBAF, THF, 82% (2 steps); i) TPAP, NMO, CH2Cl2; 
j) TIPSOTf, Et3N, CH2Cl2; k) Pd(OAc)2, CH3CN, 43% (3 steps); l) K2CO3, H2O2, THF, 
H2O; m) N2H4·HCl, Et3N, CH3CN; n) DDQ, CH2Cl2, H2O, 27% (3 steps); o) TPAP, 
NMO, CH2Cl2, 75%. 
For the synthesis of western A ring, the TBS group was deprotected using tetra-
butylammonium fluoride (TBAF) to deliver alcohol 2.20. Following oxidation, silyl 
enol ether formation, and Saegusa oxidation, enone 2.21 was prepared in 43% over 
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3 steps. Epoxidation of the enone 2.21 with basic H2O2 afforded the bis-epoxide, 
which was converted under the Wharton transposition conditions using N2H4·HCl and 
Et3N. Subsequent PMB deprotection using DDQ afforded the primery alcohol 2.22 in 
27% yield over 3 steps. The primary and secondary dialcohols at C-1 respectively at 
C-22 were then oxidized simultaneously with TPAP, NMO to complete the synthesis 
of the A ring and to furnish the desired aldehyde 2.23.  
The final two steps in the synthesis, vinylogous aldol reaction and MOM 
deprotection, turned out to be problematic and no promising results were obtained.37 It 
was anticipated that this is most likely due to the reactivity of the enone moiety and 
therefore an alternative approach was proposed as follows.  
2.2.4 Final Approach – Total Synthesis of Withanolide A 
The problematic lactonisation step in presence of the α,β-unsaturated ketone was 
addressed by reversing the order of the synthetic steps. After semi-synthetic investi-
gations on the isolated natural product, the stablility of the eastern lactone became 
apparent as formation of the derived lactam could not be accomplished. So, prior to 
the functionalization of the B ring and especially the sensitive A ring, the lactone 
moiety was succesfully introduced via the previously mentioned Mukaiyama aldol 
reaction (Scheme 2.5). 
b H
HH
HO
HO
O OH
2.27
H
HH
TBSO
MOMO
O OHCOOEt
2.17
2.26
2.24a
 
         
Scheme 2.5. Diasterostereoselective lactonisation: a) i) 2.24, LiHMDS, DMPU, THF,  
-78 °C; ii) 2.17, THF, -78 °C to RT, 87% (dr 93:7); b) HCl, H2O, THF, 74%.  
The aldehyde 2.17 was reacted with the vinylogous enolate, derived from ethyl 
2,3-dimethylbut-2-enoate (2.24) and LiHMDS to undergo a stereoselective aldol 
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reaction and delivered the unsaturated lactone 2.26 in high yield and stereoselectivity 
(87%, dr 93:7).45 It should also be mentioned that the protection of the tertiary alcohol 
as MOM ether was a crucial manipulation, ensuring minimized side reaction and 
allowing the unhindered nucleophilic attack during the aldol process. The correct 
diastereselective installment of the side chain was unambigiously confirmed by X-ray 
crystal structure of the globaly deprotected steroid (2.27).  
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Scheme 2.6. Total synthesis of withanolide A: a) i) Na-lamp, O2, TPP, pyridine; ii) 
PPh3, 61%; b) m-CPBA, CH2Cl2; c) HCl, THF, 74% (2 steps); d) TPAP, NMO, 
CH2Cl2; e) IBX, Et3N, CH2Cl2, 77% (2 steps); f) H2O2, Triton B; g) N2H4!HCl, Et3N, 
CH3CN; h) PDC, CH2Cl2, 30% (3 steps) 
Our next plan was to address the correct oxidation pattern in the B ring of the 
steroid 2.1. As previously mentioned, the challenge consisted in the regioselective 
installment of the epoxy alcohol in the presence of the unsaturated lactone. Consi-
dering the limitations associated with phenylselenium-chemistry, we recognized that 
the singlet oxygen mediated photo-oxygenative olefin migration (Schenck-ene 
reaction) could be a straightforward method for the synthesis of the allylic alcohol 
2.28.46 Therefore, the olefin 2.26 was allowed to react with singlet oxygen generated 
in situ from O2 in the presence of meso-tetraphenylporphyrin (TPP) as sensitizer 
under irradiation with Na-light. The formed hydroperoxide was reduced using PPh3 to 
                                                
45  M. Ishiguro, M. Hirayama, H. Saito, A. Kajikawa, N. Ikekawa, Heterocyles 1981, 15, 823-
834. 
46  a) G. O. Schenck, DE-B 933925, 1943; b) G. O. Schenck, Naturwissenschaften 1948, 35, 
28-29. 
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the allylic alcohol 2.28 in satisfying 61% yield.47 Directed epoxidation of allylic 
alcohol 2.28 mediated by m-CPBA proceeded as anticipated to provide after removal 
of the protecting groups (exposure to HCl) the desired epoxy alcohol 2.29 in excellent 
yield.  
Having established the correct functionalization of both B ring and the side chain, 
we then focused on the synthesis of the A ring. The initial oxidation of the triol 2.29 
using TPAP and NMO to the ketone was followed by exposure to 2-iodoxybenzoic 
acid (IBX) to afford the corresponding enone 2.30 (81%).48 Saegusa oxidation in this 
case provided lower yields whereas DDQ did not result in the formation of enone 
2.30. The unsaturated ketone 2.30 was converted to the epoxy ketone by basic 
aqueous H2O2 (Triton B). 49  Finaly, the stage was now set for the Wharton 
transposition of the epoxy ketone. The resulting epoxy ketone was reacted with 
hydrazine (NH2NH2) in the presence of Et3N to give the rearranged allylic alcohol. 
This reaction proceeded smoothly to furnish, after subsequent oxidation by 
pyridinium dichromate (PDC), withanolide A 2.1 in moderate 30% yield over 3 steps. 
 
Figure 2.4. 1H NMR spectra of the synthetic and the isolated withanolide A. 
                                                
47  a) W. Adam, E. Staab, Liebigs Ann. Chem. 1988, 757-759; b) Review: M. Prein, W. 
Adam, Angew. Chem. Int. Ed. 1996, 35, 477-494. 
48  K. C. Nicolaou, T. Montagnon, P. S. Baran, Angew. Chem. Int. Ed. 2002, 41, 993-996. 
49  M. T. Barros, C. D. Maycock, M. R. Ventura, Tetrahedron 1999, 55, 3233-3244. 
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All analytical data (1H NMR (Figure 2.4) and 13C NMR, optical rotation, UV, 
M.p.) for synthetic and isolated natural product were found to be in full agreement. 
The final proof of identity of synthetic and isolated natural sample (2.1) was 
established by co-injection and analysis of both samples by HPLC. 
2.2.5 Natural Product Hybrids 
After the completion of the synthesis of withanolide A, gaining insight into the 
intrinsic structural features of the natural product, the project was extended to 
investigate on the mode of action. For this purpose we proposed to use the strategy of 
natural products hybrids referring sometimes to chemical or molecular editing.50  
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HO
HOOC
a
2.32  
Scheme 2.7. Protection of the diol as its acetate: a) Ac2O, DMAP, Et3N, CH2Cl2, 85%; 
b) NaH, BnBr, THF. 
In this regard, the alcohol intermediate 2.27 was acetylated to the protected 
secondary alcohol 2.31 to evaluate the feasibility of this intermediate for further SAR 
studies. Treatment with stronger bases such as NaH to introduce various other 
substituents for example an benzyl group at the same position resulted in decom-
position and in the opening of the lactone to the double unsaturated side chain 2.32. 
Further, diol 2.27 was linked to the catechol-anchoring unit (for details on nitro-
catechols see Chapter 3) or fluorescent dansyl markers to elaborate on the location of 
the biological target in cells (Scheme 2.8). Diol 2.27 was first treated with succinic 
anhydride to afford carboxylic acid 2.33 as a colorless solid (M.p. = 200-202 °C) in 
85% yield, which was then converted to desired hybrid by simple use of peptide 
                                                
50  a) J.-Y. Wach, K. Gademann, Synlett 2012, 163-170; b) A. Fürstner, E. Kattnig, G. Kelter, 
H. H. Fiebig, Chem. Eur. J. 2009, 15, 4030-4043; c) A. Fürstner, D. Kirk, M. D. B. 
Fenster, C. Aissa, D. de Souza, O. Müller, Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 8103-
8108; d) T. Oskarsson, P. Nagorny, I. J. Krauss, L. Perez, M. Mandal, G. Yang, O. 
Ouerfelli, D. Xiao, M. A. S. Moore, J. Massagué, S. J. Danishefsky, J. Am. Chem. 
Soc. 2010, 132, 3224-3228; e) A. M. Szpilman, E. M. Carreira, Angew. Chem. Int. 
Ed. 2010, 49, 9592-9628. 
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coupling chemistry: Catechol 2.33 obtained using nitrocatechol hydrosulfate was and 
N,N’-disuccinimidy carbonate (DSC) in 14% yield after reverse phase HPLC 
purification, whereas dansyl derivative 2.35 was formed by the use of 1-(3-dimetyl-
aminopropyl)-3-ethylcarbodiimid (EDC) and 1-hydroxybenzotriazol (HOBt) in 71%.  
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Scheme 2.8. Formation of natural product hybrids: a) succinic anhydride, Et3N, 
DMAP, CH2Cl2, RT, 85%; b) dansyl-NH2, HOBt, EDC, Et3N, CH3CN, RT, 71%; c) 
nitrodopamine, DSC, pyridine, CH3CN, RT, 14%. 
Both hybrids were evaluated in cell assays (for details see Chapter 2.3), but 
exhibit unfortunately cytotoxic activities and therefore could not provide further 
insight into the complex phenomenon of cell differentiation. Future candidates will be 
derived directly from the natural product with additional hydroxy and epoxy 
functionalities in the B ring, therefore more closely mimicking the natural steroid.  
2.2.6 Semisynthetic Studies 
In order to access such derivatives for biological studies, we initiated semi-
synthetic studies starting from withanolide A (2.1).51 The steroidal lactone was 
therefore isolated from the dried and powdered roots of Withania somnifera 
(Ashwagandha) by a modification of the literature procedure:52 First, dried roots were 
percolated with MeOH several times. The MeOH extracts were washed with pentane 
to remove grease and non-polar components. Rotary evaporation gave a residue which 
                                                
51  R. Liffert, Master Thesis, Basel, 2012. 
52  S. S. Subramanian, P. D. Sethi, E. Glotter, I. Kirson, D. Lavie, Phytochemistry 1971, 10, 
685-688. 
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was resuspended in EtOAc, washed with H2O to remove the more polar ingredients 
and concentrated to a brown oil, which was purified by multiple silica gel 
chromatography to afford steroid 2.1 as a colorless solid in 0.025% yield from the 
mass of the dried roots (Figure 2.5). 
 
Figure 2.5. TLC (SiO2, EtOAc:CHCl3:hexane 8:1:1) of the individual purifications for 
the extraction-process of withanolide A (2.1) from the dried roots of Ashwagandha. 
After an extensive survey of different approaches commonly employed in semi-
synthesis to functionalize complex natural products, we notized that only the A ring of 
withanolide A (2.1) was feasible for chemical modification. In addition, A ring 
analogues, bearing a 3β-hydroxy group comparable with sominone - an aglycon of 
withanoside IV, were found to display neuritogenic properties as shown from the 
work of Tohda and co-workers.53 
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Scheme 2.9. Regioselective reduction of withanolide A: a) CeCl3, NaBH4, CHCl3, 
MeOH, 75%; b) Crabtree's catatyst, H2, CH2Cl2, quant. 
                                                
53  a) T. Kuboyama, C. Tohda, K. Komatsu, Eur. J. Neurosci. 2006, 23, 1417-1426; b) C. 
Tohda, E. Joyashiki, Brit. J. Pharmacol. 2009, 157, 1427-1440.  
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We first targeted the regio- and stereoselective Luche reduction of withanolide A 
resulting in the allylic alcohol 2.36, which was envisioned to serve as building block 
to a variety of new functionalities at C-1 (Scheme 2.9). Surprisingly, the same 
diastereoselective outcome was observed when the reaction was performed in the 
absence of CeCl3. Regioselective hydrogenation of the 2,3-double bond was per-
formed by using 2 mol % Crabtree’s catalyst under a hydrogen atmosphere of 10 bar 
to obtain the saturated alcohol 2.37. Unfortunately, all attempts to further functio-
nalize the C-1 hydroxy group or acetylation reactions were unsuccessful, except the 
acylation with Boc protected amino acid (Scheme 2.10), which upon exposure to TFA 
afforded a primary amine function (2.38) suitable for further transformations.  
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Scheme 2.10. Acylation of the Luche reduction product to form a primary amine: a) 
BocNH(CH2)5COCl, DIPEA, AgNO3, CH2Cl2, RT; b) TFA, CH2Cl2, RT, 68% 
(2 steps). 
Due to the reluctance of allylic alcohol 2.36 to undergo further functionalization, a 
new strategy for the derivatization of the natural product needed to be developed.51 
Inspired by the SAR studies on sominone by Tohda et al.,53 we developed a synthetic 
route starting from natural withanolide A to introduce hydroxyl substituents at C-3. 
We thought to epoxidize the natural product followed by an epoxide opening under 
reductive conditions, developed earlier for the B ring functionalization, which would 
lead to the alcohol 2.40 (Scheme 2.11). Given the less sterical hinderance of alcohol 
2.40 compared to 2.36, we predicted it should be facilitated to introduce various 
substituents at this position. Hence, the same procedure for the epoxidation as in the 
successful total synthesis of withanolide A was applied. A small-scale approach for 
the epoxidation with aqueous H2O2 in the presence of triton B yielded 2.39 already in 
48%. Unfortunately, up-scaling these conditions resulted in a dramatic reduced yield 
(11% for 100 mg of starting material, 2.1). Additionally, the long reaction time of 24-
48 h and the formation of the epoxidized lactone as a side-product were disadvantages 
of the developed protocol. After extensive investigation of different conditions 
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(solvent, base and oxidizing agent),54 we found fluoride-promoted epoxidation of 
α,β-unsaturated carbonyl compounds described by Yoshikoshi and co-workers was 
compatible with our system.55 In their protocol the use of TBAF as a base and H2O2 
or tert-butyl hydroperoxide (t-BuOOH) as an oxidation reagent in DMSO proved to 
be superior. The adapted conditions enriched the yield reliable to 84% (on a 150 mg 
scale) when the solvent was finally changed to CH2Cl2 and t-BuOOH was used as an 
oxidant. 
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Scheme 2.11. Semisynthetic transformations of withanolide A to access A ring 
derivatives:51 a) t-BuOOH, TBAF, CH2Cl2, 84%; b) i) (PhSe)2, NaBH4, EtOH; ii) 2.39, 
AcOH, CH2Cl2, 80%; c) Ac2O, DMAP, Et3N, CH2Cl2, 77%; d) NaBH4, CHCl3, MeOH, 
70%; e) N2H4·H2O, AcOH, MeOH, CH2Cl2, 61%; f) Ac2O, DMAP, Et3N, CH2Cl2, 
87%; g) i) 4-NO2(C6H4)COOH, DEAD, PPh3, CH2Cl2; ii) NaOH, TBAH, THF, 
CH2Cl2, 50%. 
After completion of this building block, the organoselenium-mediated reduction of 
the α,β-epoxy ketones 2.39 to the corresponding β-hydroxy ketone was investigated. 
Alcohol 2.40 was obtained in good yields when adding the ethanolic solution of the 
active reagent (Na[PhSe(OEt)3]) and AcOH to a solution of epoxy ketone 2.39 in 
                                                
54  a) F. E. Ziegler, K.-J. Hwang, J. F. Kadow, S. I. Klein, U. K. Pati, T.-F. Wang, J. Org. 
Chem. 1986, 51, 4573-4579; b) F. J. Moreno-Dorado, F. M. Guerra, F. J. Aladro, J. M. 
Bustamante, Z. D. Jorge, G. M. Massanet, Tetrahedron 1999, 55, 6997-7010; c) R. Takagi, 
K. Tojo, M. Iwata, K. Ohkata, Org. Biomol. Chem. 2005, 3, 2031-2036. 
55  M. Miyashita, T. Suzuki, A. Yoshikoshi, Chem. Lett. 1987, 285-288. 
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CH2Cl2.56 The chemical shift of the equatorial H-3 in 2.40 was found at 4.11 ppm, 
whereas the axial one is reported for the C-3 diastereomeric natural product (2.46)57 
surprisingly at 4.91 ppm (Figure 2.5).  
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Figure 2.6. Natural 3-hydroxy withanolide (2.46) isolated from Withania somnifera.57 
Efficiently, acetylation of alcohol 2.40 under Steglich conditions (Ac2O, DMAP, 
Et3N in CH2Cl2) delivered acetate 2.41 in 77% yield without detectable amount of 
eliminated side-product (2.1). This example demonstrates the opportunity to introduce 
carboxylate residues of choice at this position. Reduction of 2.40 was performed using 
NaBH4 and a new polar product was observed by TLC analysis. Although the 
formation of tetraol 2.42 was confirmed by mass spectrometry, the isolation of this 
hydrophilic compound turned out to be difficult. Nevertheless, work-up with saturated 
Rochelle’s solution liberated tetraol 2.42 and its structure was elucidated by NMR 
spectroscopy. The stereochemical outcome of 2.42 was anticipated from the NaBH4 
mediated reduction of withanolide A 2.1 and could be confirmed by NOE analysis 
which showed interactions of H-1 with H-2, H-4 and H-19. 
Focusing on the introduction of substituents at C-3, another possibility was the 
transformation of epoxy ketone 2.39 to allylic alcohol 2.43 (Scheme 2.11). For this 
manipulation, the Wharton carbonyl transposition was reinvestigated using the 
conditions from the final key step of the successful total synthesis. Consequently, 
epoxy ketone 2.39 was treated with NH2NH2!HCl in the presence of Et3N in CH3CN, 
but no product formation was observed. To our surprise, Wharton transposition under 
acidic conditions improved the yield to 40%.58 Due to the low solubility of 2.39 in 
                                                
56  a) M. Miyashita, T. Suzuki, A. Yoshikoshi, Tetrahedron Lett. 1987, 28, 4293-4296; b) M. 
Miyashita, M. Hoshino, A. Yoshikoshi, Tetrahedron Lett. 1988, 29, 347-350. 
57  M. I. Choudhary, S. Yousuf, S. A. Nawaz, S. Ahmed, A. Rahman, Chem. Pharm. Bull. 
2004, 52, 1358-1361. 
58  H. Y. Wang, G. A. O'Doherty, Chem. Commun. 2011, 47, 10251-10253. 
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methanol, the reaction was further optimized and the best conditions were to conduct 
the reaction in a 1:1 mixture of methanol and CH2Cl2 to obtain the allylic alcohol 2.43 
in 61% yield. The structure of 2.43 was confirmed by X-ray crystal structure analysis 
and the stereochemistry of the 3α-hydroxyl group was herein retained from the 
epoxidation step of withanolide A. 
Next, we investigated the introduction of functional groups at the newly formed 
secondary alcohol in order to probe if 2.43 can be used as a chemical probe (see 
Chapter 2.2.5). Acetylation of allylic alcohol 2.43 was performed again under 
standard acetylation conditions and afforded acetate 2.44 in good yield. Inversion of 
the C-3 hydroxyl group in 2.43 was accomplished using the Mitsunobu procedure. 
Esterification with para-nitrobenzoic acid, followed by saponification with aqueous 
NaOH in the presence of tetrabutylammonium hydroxide (TBAH) as phase-transfer 
catalyst afforded 3β-allylic alcohol 2.45 in 50% yield over the two steps. 
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Scheme 2.12. Hydrogenation of allylic alcohol 2.43: a) 10 mol% Pd/C, H2 (30 bar), 
EtOAc, quant.; b) 2 mol% Crabtree's catalyst, H2 (10 bar), CH2Cl2, quant. 
To further access novel derivatives, the double bond of allylic alcohol 2.43 was 
reduced with 10 mol % Pd on activated charcoal. Quantitative conversion provided 
alcohol 2.47 as an inseparable 1:1 mixture with the isomerized saturated ketone 2.29b 
– an intermediate from the total synthesis (Scheme 2.12).59 Taking into account that 
we were interested in alcohol 2.47, Crabtree’s catalyst turned out to be efficient for 
hydrogenation of 2.43 to quantitatively yield alcohol 2.47.  
                                                
59  R. Uma, C. Crévisy, R. Grée, Chem. Rev. 2003, 103, 27-51. 
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Scheme 2.13. Formation of oxime analogues of withanolide A: a) RONH2·HCl, 
pyridine, 70 °C, from 2.1: R = H, 58%, R = CH3, 58%, R = allyl, 72%, R = Bn, 63%, 
from 2.39: R = allyl, 58%. 
Oxime derivatives of withanolide A as prodrugs may improve the solubility as well 
as the bioavailability in vivo. Furthermore, oximes turned out to be the only possible 
functionalization of the C-1 position of 2.1 (Scheme 2.13). A series of oximes 2.48-
2.52 were easily obtained by heating withanolide A or the derived epoxide 2.39 with 
the corresponding hydroxylamine hydrochlorides in pyridine at 70 °C for 24-48 h. 
2.3 Biological Evaluation 
The natural product 2.1 and several semi-synthetic derivatives were tested in order 
to determine their neuritogenic properties according to the previously published 
method.31b,60 Briefly, human SH-SY5Y neuroblastoma cells (ca. 4 x 104 cells/cm2) 
were grown on collagen I coated 24-well plates in minimal essential medium (MEM) 
with 5% fetal bovine serum (FBS). After incubation for 4 days in the presence of the 
corresponding compounds (1 µM, 0.1% DMSO), the cells were examined under a 
phase contrast microscope after fixation (5% formaldehyde in PBS buffer solution), 
stained (modified Giemsa stain), and the differentiated cells were counted. For each 
compound nine pictures from random areas of three different wells were taken. At 
least 500 cells were counted for each individual compound. The criterion for a 
differentiated cell was at least one neurite with a length of more than 50 µm. In 
control experiments DMSO (0.1%) was used as negative control. To obtain more 
accurate results for withanolide A, more than 1500 cells were evaluated.  
                                                
60  All cell-assays were performed by Dr. H. J. Jessen or P. Burch at the University of Basel. 
Analysis of the results was performed either by Dr. H. J. Jessen, R. Liffert or myself. 
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Figure 2.7. Neurite outgrowth induced by withanolide A (2.1), negative (DMSO) and 
positive (retinoic acid) controls in human SH-SY5Y cells in minimal essential medium 
(MEM) and Dulbecco’s modified Eagle medium (DMEM). Error bars denote SEM. For 
representive micrographs see Figure 2.7 D-F and G-I. 
Interestingly, when we used conditions published by Tohda et al.31b we were able 
to reproduce their results (DMSO vehicle 12% differentiated cells vs. withanolide A 
22%, data not shown). We then examined the same compounds on collagen-coated 
24-well plates to support adhesion of the cells under identical conditions. The vehicle 
control experiments (0.1% DMSO) displayed a dramatically different phenotype 
compared to withanolide A or retinoic acid (positive control) treated cells (Figure 
2.7). In the former case, we almost exclusively observed large cell aggregate 
formation with only few isolated cells. Withanolide A treated cells formed aggregates 
to a reduced extent, with many viable isolated cells that were often found to be 
differentiated (Figure 2.8). Finally, treatment with retinoic acid completely 
suppressed aggregate formation and led to fully differentiated phenotypes. We then 
incubated the cells in Dulbecco’s modified Eagle’s medium (DMEM, 10% FBS, 
antibiotics) in collagen-coated wells with the compounds and controls as 
recommended by the supplier. In these cases, the large difference obtained for 
negative control experiments in MEM compared to withanolide A (14% vs. 46%) was 
reduced to a non significant difference (28% vs. 32%).  
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Figure 2.8. Representative micrographs of the performed cell-assays (reffering to the 
conditions described in Figure 2.6). A, D, G withanolide A (1.1), B, E, H negative 
control, C, F, I positive control. A-C MEM, uncoated wells, D-F DMEM coated wells, 
G-I MEM, coated wells. Indicated scale bar = 250 µm. 
Also in rat cortical neurons, a reassessment of the neuritogenic activity has been 
proposed recently. In the presence of DMEM, isolated non-differentiated cells appear 
to be more viable, thus levelling the observed ratios. These experiments therefore 
suggest that the neuritogenic phenotype observed in SY5Y cells appears to be 
conditional related to medium (MEM vs. DMEM) or coating of the wells.  
Following these investigations, the results for the semi-synthetic derivatives are 
summarized in Figure 2.9. While it is difficult to draw quantitative conclusions from 
the biological assays as already mentioned, several facts became apparent: 
Compounds 2.36, 2.43, 2.45, and 2.48 showed similar activities when compared to 
withanolide A with regard to neurite outgrowth stimulating activity in SH-SY5Y 
cells. The compounds 2.39, 2.44, and 2.49-2.52 showed in fact less activity than 
withanolide A, to the extent that some compounds can be hardly distinguished from 
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the solvent control in these phenotypic assays. It appears that there is a correlation 
between the size of the attached group and their activity. For example, the 
hydroxylamine 2.48 shows increased activities than the corresponding and sterically 
more demanding oximes 2.49-2.52, what can also be attributed to the more non-polar 
nature of these compounds. The same trend was observed for allyl alcohol 2.43 and its 
acetate 2.44. Additionally, the chemically reactive enone moiety of withanolide A in 
the A ring might not be required for neuroactive properties, as the allylic alcohols 
2.36 and 2.43 retain activity. 
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Figure 2.9. Neurite outgrowth activity of DMSO blank, withanolide A and derivatives 
in human SH-SY5Y cells with MEM as cell-medium. Error bars denote SEM. 
Concerning the mechanism of action of 2.1, a recent study by Chan and co-
workers33 showed that this steroid lactone is able to modulate several secretase targets 
of relevance to neurodegeneration. Moreover, this study reported the docking of 
withanolide A into beta-secretase 1 (BACE1) suggesting enzyme inhibition by 
binding. We have evaluated the binding of withanolide A (2.1) against several 
proteases of potential relevance to neurodegenerative diseases (Table 2.1), however, 
in these assays withanolide A and derivatives 2.27 and 2.31 were found to be inactive 
up to a concentration of 100 µM.61 
Only very weak activity was found against plasmepsin I (compound 2.27) and 
plasmepsin I, II and IV (compound 2.31). While it remains feasible that withanolide A 
                                                
61  Enzymatic assays were carried out and evaluated by Dr. Solange Meyer, Actelion 
Pharmaceuticals Ltd. 
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is able to modulate the expression of BACE1, as demonstrated by Chan and 
coworkers,33 direct interaction of 2.1 with BACE1 as suggested appears very unlikely 
based on the values reported in this study. 
Table 2.1. Determined IC50 values (µM) of compounds 2.1, 2.27 and 2.31 against 
protease targets potentially relevant to neurodegenerative diseases (BACE and 
cathepsin (Cath)) and control proteases (plasmepsin (PM)). 
 
 
 
 
 
 
2.4 Conclusion 
In conclusion, we have developed the first successful synthesis of the pharma-
cologically important steroid withanolide A. Semi-synthetic investigations on the 
natural product provided essential understanding on its reactivity and successfully 
elaborated the synthetic route. Notable features of this synthesis include a highly 
diastereoselective Schenck-ene reaction, a minimal protecting group strategy 
exploiting the inherent reactivity pattern in the endgame and a Wharton transposition 
for the A ring formation. Furthermore, we have synthesized more than 15 derivatives 
of withanolide A directly from the isolated natural product. Consequently, we 
developed two new synthetic routes that allow the insertion of a hydroxyl group at 
C-3 and thereby opening the door for further functionalization. Both the β-hydroxy 
ketone 2.40 and the allylic alcohol 2.43 were synthesized in high yields and complete 
diastereoselectivity from 2.1. 
Biological studies of neurite outgrowth in human SH-SY5Y cells demonstrated the 
dependence of neuritogenic properties on the size rather than the functionality in the 
A ring of the evaluated compounds. Three compounds showed similar neurite 
outgrowth activity in cell assays than withanolide A itself. Further investigations 
towards the insertion of functional groups at C-3 of withanolide A could possibly give 
access to more potent candidates and allow for the manipulation of properties such as 
solubility or bioavailability. 
Comp. 
BACE1-
GST 
Cath D Cath E PM I PM II PM III 
2.1 >100 >100 >100 >100 >100 >100 
2.27 >100 >100 >100    67 ± 4 >100 >100 
2.31 >100 >100 >100    46 ± 14    52 ± 5    31 ± 7 
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3 DEVELOPMENT OF NITROCATECHOLS AS PHOTO-
LABILE SURFACE ANCHORS 
3.1 Introduction 
This chapter describes the development of a molecular surface modification 
platform based on nitrocatechols that allows for small molecule functionalization of 
TiO2 under mild aqueous conditions and efficient release triggered by light - therefore 
uncaging a small immobilized molecule cargo on demand.62 Altering a molecular 
surface with additional tailored properties and functionalities while maintaining the 
ones inherent in the bulk material has found applications in a wide variety of fields in 
modern surface coating technology.63 The combination of well designed and characte-
rized molecules as anchoring units or coating device with erratic surfaces is fast 
growing and very promising research field, despite the problems associated with the 
transfer of molecular understanding towards material science and the multiple 
techniques required to characterize this symbiosis. 
TiO2 
or 
SiO2
Anchoring
unit
PEG chain
 
Figure 3.1. Strategy for the conception of biocompatible antifouling surfaces (SiO2 or 
TiO2) using immobilized PEG chains. 
One famous application, which is of high importance for devices in medicinal 
environment, is the development of antifouling surfaces. The term biofouling 
characterizes the random absorption of proteins as well as microorganisms such as 
fungi or bacteria on surfaces and represents a major issue in hospitals.64 When 
                                                
62  R. Wehlauch, Master Thesis, Basel, 2012. 
63  Reviews: a) Q. Ye, F. Zhou, W. Liu, Chem. Soc. Rev. 2011, 40, 4244-4258; b) J. L. 
Dalsin, P. B. Messersmith, Mater. Today 2005, 8, 38-46. 
64  F. Brétagnol, A. Valsesia, G. Ceccone, P. Colpo, D. Gilliland, L. Ceriotti, M. Hasiwa, F. 
Rossi, Plasma Process. Polym. 2006, 3, 443-455. 
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exposed to sea- or freshwater containing microorgansims or protein solutions 
basically all surfaces suffer from biofouling. One promising strategy to prevent this is 
the immobilization of polymers e.g. water soluble polyethylene-glycol (PEG) on TiO2 
or glass surfaces, inhibiting the settlement of the microorganisms due to their 
dynnamic and flexible architecture.  
A central challenge remains the nature of the molecular anchor that links coating 
and surface. In this respect, catechols display unique properties due to their ability to 
strongly bind to metal oxides in aqueous media. Originally found in mussel adhesive 
proteins,65 L-DOPA or dopamine derived catechols were successfully used in surface 
modifications despite their sensitivity to oxidation.66 Additionally this biomimetic 
approach benefits from the fact that a single functional group - the catechol unit -
adjustable by external ambience as pH, ions or temperature regulates the reactivity of 
the anchor. The binding mode itself is strongly depended on environmental ions, 
leading to toughness by chelation of metal oxides and gaining robustness by oxidative 
cross-linking to form polymeric surface coating. Beneficial catechols allow to bind 
and unbind under water in a cooperative fashion, what is used by mussels to change 
locations. 
We have introduced a related anchoring catechol with electron-withdrawing 
substituents based on the iron chelator anachelin (3.1).67,68 This natural product was 
isolated from cyanobacteria and was shown to be essential for the iron uptake of these 
bacteria. Again, the catechol moiety was suspected to be responsible for this strong 
                                                
65  For recent examples: a) B. Geiseler, L. Fruk, J. Mater. Chem. 2012, 22, 735-741; b) A. S. 
Goldmann, C. Schödel, A. Walther, J. Yuan, K. Loos, A. H. E. Müller, Macromol. Rapid 
Commun. 2010, 31, 1608-1615. 
66  a) H. Zhao, J. H. Waite, J. Biol. Chem. 2006, 281, 26150-26158; b) H. Lee, N. F. Scherer, 
P. B. Messersmith, Proc. Natl. Acad. Sci. USA 2006, 103, 12999-13003; c) J. H. Waite, 
Nature Mater. 2008, 7, 8-9; d) H. Zeng, D. S. Hwang, J. N. Israelachvili, J. H. Waite, 
Proc. Natl. Acad. Sci. USA 2010, 107, 12850-12853; e) H. Lee, S. M. Dellatore, W. M. 
Miller, P. B. Messersmith, Science 2007, 318, 426-430; f) J. Moser, S. Punchihewa, P. P. 
Infelta, M. Grätzel, Langmuir 1991, 7, 3012-3018. 
67  S. Zürcher, D. Wäckerlin, Y. Bethuel, B. Malisova, M. Textor, S. Tosatti, K. Gademann, 
J. Am. Chem. Soc. 2006, 128, 1064-1065. 
68  a) A. E. Walsby, Br. Phycol. J. 1974, 9, 371-381; b) A. E. Walsby, Br. Phycol. J. 1974, 9, 
383-391; c) H. Breiderbeck, K. Taraz, H. Budzikiewicz, A. E. Walsby, Z. Naturforsch. C. 
Biosci. 2000, 55, 681-687; d) Y. Itou, S. Okada, M. Murakami, Tetrahedron 2001, 57, 
9093-9099; e) Y. Ito, K. Ishida, S. Okada, M. Murakami, Tetrahedron 2004, 60, 9075-
9080. 
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binding event. Iron as essential nutrition for microorganism is highly prevalent in 
nature but only as insoluble iron oxides. In order to obtain enough iron, cyanobacteria 
produce siderophores to chelate metals ions and make them bioavailable.  
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Figure 3.2. Structure of siderophore anacheline (3.1), surface anchoring moiety 
indicated in green. 
Using this knowledge, we were able to show that the affinity to bind to metal oxide 
surfaces in particularly to iron and titanium oxide, could lead to new innovative 
surface modifications based on the anachelin siderophore. Substitution of the natural 
side chain by a polymeric PEG chain led to protein-resistant surfaces (Figure 3.3), 
which remained stable to multiple washings. This surface alteration was achieved by 
an operationally simple dip-and-rinse procedure, incubating with TiO2 coated silicon 
wafers in catechol solution with a high salt buffer to achieve dense packing of the 
PEG chains.69 
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Figure 3.3. Design of antifouling surfaces consist of anachelin (3.2) or nitrocatechol 
(3.3) anchoring moiety and a biocompatible PEG chain. 
Furthermore, we also showed that the positively charged nitrogen substituent is 
essential for improved stability compared to the unsubstituted dopamine present in 
                                                
69  J.-Y. Wach, B. Malisova, S. Bonazzi, S. Tosatti, M. Textor, S. Zürcher, K. Gademann, 
Chem. Eur. J. 2008, 14, 10579-10584 
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mussels. A second-generation design consisted of nitrocatechols such as nitro-
dopamine (3.3) due to the ease of preparation,70 improved adhesion properties and 
stability towards oxidation. All these anchors have found widespread applications.71 
We have shown that such catechols can be used to functionalize surfaces with 
complex antibiotics (vancomycin) to generate anti–microbial surfaces and expose 
them to biofilm forming bacteria, which will be killed.72 
3.2 Concept of the Light-Tunable Anchors 
In addition to immobilization, the release of small molecules from a modified 
surface triggered by an external stimulus would be highly desirable. Potential 
applications would range from drug delivery, small molecule microarrays to selective 
probes in chemical biology.  
In particular in the latter area, such an approach would combine the well-known 
strategy of temporarily disabling the biological activity of a small molecule ('caging') 
with the possibility of controlled release on demand. This would allow for both high 
spatial control (through immobilization) and temporal control (through caging) of the 
biological activity of a small molecule, two key elements in chemical biology 
approaches.73,74 In here, we describe the development of such a molecular platform 
that allows for the spatio-temporal control of small molecule release. In particular, we 
propose a bio-inspired approach that leverages the presence of a catechol with the 
versatility of the nitrophenyl system (Figure 3.4).  
                                                
70  B. Malisova, S. Tosatti, M. Textor, K. Gademann, S. Zürcher, Langmuir 2010, 26, 4018-
4026 
71  a) S. Saxer, C. Portmann, S. Tosatti, K. Gademann, S. Zürcher, M. Textor, Macro-
molecules 2010, 43, 1050-1060; b) Review: K. Gademann, J. Kobylinska, J.-Y. Wach, T. 
M. Woods, Biometals 2009, 22, 595-604. 
72  J.-Y. Wach, S. Bonazzi, K. Gademann, Angew. Chem. Int. Ed. 2008, 47, 7123-7126. 
73  T. Tachikawa, Y. Asanoi, K. Kawai, S. Tojo, A. Sugimoto, M. Fujitsuka, T. Majima, 
Chem. Eur. J. 2008, 14, 1492-1498. 
74  X. Wang, S. Werner, T. Weiß, K. Liefeith, C. Hoffmann, RSC Adv. 2012, 2, 156-160. 
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Figure 3.4. Concept of the light induced surface release of carrier molecules for the 
photolabile NPP protecting group. 
Among the most commonly used photocleavable protecting groups are several 
nitrophenyl derivatives, including (2-nitrophenyl)ethyl (NPE) and (2-nitrophenyl)pro-
pyl (NPP) derivatives.75,76 However, upon inspection of the literature, we were 
surprised to find that no free nitrocatechols have been utilized as photocleavable 
groups and the surface functionalization and release properties of such systems have 
not been investigated.77 We have targeted both NPE and NPP systems 3.4 (n = 0) and 
3.5 (n = 1), respectively, and demonstrated that controlled bonding and release is 
achievable for the latter derivatives.  
3.3 Synthesis of the Caged Anchors 
3.3.1 NPE Derivatives 
The first target compound constituted for the 2-nitrophenyl ethyl derivative 3.4. 
Its synthesis started with the preparation of nitrocatechol 3.7 by nitration of commer-
cially available 3,4-(methylenedioxy)acetophenone (3.6) using HNO3 in acetic acid 
(Scheme 3.1). Subsequent treatment with AlCl3 at low temperature was followed by 
hydrolysis with concentrated HBr gave nitrocatechol 3.7 in satisfying yield. Catechol 
                                                
75  Reviews: a) G. Mayer, A. Heckel, Angew. Chem Int. Ed. 2006, 45, 4900-4921; b) D. 
Puliti, D. Warther, C. Orange, A. Specht, M. Goeldner, Biorg. Med. Chem. 2011, 19, 
1023-1029; c) D. Warther, S. Gug, A. Specht, F. Bolze, J.-F. Nicoud, A. Mourot, M. 
Goeldner, Biorg. Med. Chem. 2010, 18, 7753-7758; d) C. G. Bochet, J. Chem. Soc., Perkin 
Trans. 1 2002, 125-142. 
76 S. Walbert, W. Pfleiderer, U. E. Steiner, Helv. Chim. Acta 2001, 84, 1601-1611. 
77  Z. Shafiq, J. Cui, L. Pastor-Pérez, V. San Miguel, R. A. Gropeanu, C. Serrano, A. del 
Campo, Angew. Chem. Int. Ed. 2012, 51, 4332-4335. 
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3.7 was then protected as MOM ether and NaBH4 reduction furnished benzylic 
alcohol 3.8. In the context of this synthesis, it was found necessary to protect the 
catecholate OH groups, in order to prevent attachment of this compound to silica 
during chromatographic purification. The alcohol 3.8 was then attached to the 
fluorophore78 3.9 via Mitsunobu reaction in moderate yields. For the final coupling 
reaction was performed under exclusion of light to avoid decomposition of the formed 
product. During the isolation of the photolabile compound from the reaction mixture, 
it became already apparent that the uncaging process could be induced, when TLC 
plates were exposed to UV light at 366 nm (see videos on the enclosed CD for further 
information). The MOM protecting group were finally removed using aqueous TFA, 
leading to the NPE derivative 3.4. 
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Scheme 3.1. Preparation of NPE conjugate 3.4 for surface modification: a) HNO3, 
AcOH, 0 °C to RT, 2.5 h, 59%; b) AlCl3, DCE, -5 °C, 1 h, then 48% HBr, RT, 24 h, 
84%; c) MOMCl, K2CO3, MeCN, 0 °C to RT, 3 h, 87%; d) NaBH4, MeOH, 0 °C to RT, 
3.5 h, 99%; e) 3.9, PPh3, DIAD, THF, 0 °C to RT, over night, 41%; f) TFA, H2O, RT, 
46%. 
There are at least two fundamentally different pathways possible for the cleavage 
of such catechols from titania, either via (1) photocatalytic oxidation to the quinone or 
(2) via nitroaryl mediated bond cleavage.77 In order to identify the cleavage products 
and to delineate the role of the nitro substituent, we planed to prepare control 
compounds 3.10 (X = H) and 3.11 (X = F) lacking this substituent, where only 
photocatalytic oxidation to the quinone would be possible.  
                                                
78  F. Fringuelli, O. Piermatti, F. Pizzo, Synlett 2003, 2331-2334. 
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Scheme 3.2. Deprotection studies of fluorinated and unsubstituted catechols. 
We were surprised to discover that the deprotection of either 3.10 or 3.11 under a 
variety of conditions proved to be impossible, as only decomposition of the starting 
material and the free fluorophore could be detected. This could be explained by the 
formation of reactive quinone methides (3.14) by cleavage of the fluorophore at the 
benzylic position.79  
3.3.2 NPP Derivatives 
In order to circumvent the decomposition via the quinone methide pathway, we 
wanted to investigate the corresponding homologated propyl substituted nitrophenols 
3.5. Therefore, acetonide 3.16 was successfully prepared from catechol 3.15 by using 
2,2-dimethoxypropane and catalytic amounts of p-TsOH in refluxing benzene. 
Subsequent nitration of the acetonide with half-concentrated HNO3 afforded 3.16 in 
high yield. To our delight, these strongly acidic, aqueous conditions did not induce 
the deprotection of the acetonide group. A X-ray crystal structure of 3.16 was 
obtained, which in turn confirmed the correct installment position of the nitro group 
(Figure 3.5). The reverse synthetic order, first nitration followed by protection, failed as 
no acetonide formation could be detected. The crucial elongation reaction of 3.16 with 
paraformaldehyde and Triton B gave the desired product 3.17,80 even though only a 
moderate conversion was achieved (with 40% starting material 3.16 recovered). 
                                                
79  a) M. Sugumaran, V. Semensi, J. Biol. Chem. 1990, 266, 6073-6078; b) M. Sugumaran, V. 
Semensi, S. J. Saul, Arch. Inst. Biochem. Phys. 1988, 9, 269-281; c) M. Sugumaran in 
Biological Oxidation Systems, Vol. 1, Academic-Press, 1990, pp. 347-363. 
80  K. R. Bhushan, Org. Biomol. Chem. 2006, 4, 1857-1859. 
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Scheme 3.3. Preparation of NPP conjugate 3.5 for surface modification: a) 2,2-dime-
thoxypropane, cat. p-TsOH, benzene, reflux, overnight, b) HNO3, H2O, 0 °C to RT, 
1.5 h, 86% (over 2 steps); c) CH2O, Triton B in MeOH, 85 °C, 65 h, (80% brsm); d) i) 
triphosgene, Et3N, THF; 0 °C, 25 min, ii) 3.18, pyridine, CH2Cl2, 0 °C to RT, 1.5 h; e) 
TFA, H2O, RT, over night, 68% (over 2 steps).  
With the catechol protected as the acetonide, carbonate formation using 
triphosgene and triethylamine in THF led to the desired chloroformate in quantitative 
yield within 25 min at 0 °C.81 To prevent decomposition, the chloroformate was 
coupled immediately to coumarin 3.18 to afford the desired carbonate, which was 
subsequently deprotected to the target catechol 3.5 using neat TFA. 
O
O NO2
3.16   
Figure 3.5. Crystal structure of protected nitrocatechol 3.16 confirming the correct 
installment of the nitro group. 
In total, the preparation of 3.5 was achieved in five steps using only two 
purifications rendering 3.5 an easily accessible and attractive candidate for further 
investigations. In particular, we expect that the alcohol 3.17 could serve as an ideal 
starting point for the attachment of various cargo compounds by coupling chemistry.  
3.4 Evaluation of the Physical Properties  
The stability of the different caged compounds was then investigated using a 
variety of methods and assays. Gratifyingly, the NPP linker 3.5 was considerably 
                                                
81  a) G. H. McGall, A. D. Barone, M. Diggelmann, S. P. A. Fodor, E. Gentalen, N. Ngo, J. 
Am. Chem. Soc. 1997, 119, 5081-5090; b) A. Gautier, D. P. Nguyen, H. Lusic, W. An, A. 
Deiters, J. W. Chin, J. Am. Chem. Soc. 2010, 132, 4086-4088. 
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stable to hydrolysis in aqueous medium (MOPS buffer) at pH 5.5 in the dark for at 
least 72 h. This is contrast to the ethyl derivative 3.4, which displayed only limited 
stability. Photocleavage of catechol 3.5 was investigated by detection of the evolving 
fluorescence during the release of coumarin 3.18 to determine the half-life time of 3.5 
in aqueous solution (MOPS buffer) under near UV-irradiation. As expected, a rapid 
increase in fluorescence was detected during the first minutes of irradiation and the 
fluorescence maximum was identified at 454 nm. However, after approximately 
10 min, the detected fluorescence intensity was decreasing, indicating that photo-
bleaching or [2+2] addition of the coumarin 3.18 occurred, which could be confirmed 
by control experiments using solely the coumarine in solution.  
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Figure 3.6. A) Fluorescence spectra of 3.5 and 3.18 after certain irradiation times; B) 
Fluorescence emission intensity at 454 nm depending on the irradiation time at 366 nm 
of 3.2 as a 5·10-5 M solution in MOPS buffer; C) UV spectra of 3.5 and 3.18; D) Decay 
of 3.2 upon UV irradiation at 366 nm, determined by HPLC-MS. 
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Quantification by HPLC-MS determined the half-life time of 3.5 to be around 
12 min at a concentration of 5·10-5 M in buffer. This is an attractively short period for 
cleavage, since the light intensity of a simple laboratory UV-lamp is rather low 
(~ 20 mW⋅cm-2). 
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Scheme 3.4. Immobilization of nitrochatechol 3.5 on TiO2 microparticles to deliver 
Ti-3.5 and release of the cargo 3.18 upon irradiation. 
To evaluate the surface release properties, TiO2 particles (1.0-2.0 µm) were 
functionalized with nitrocatechol 3.5 in MOPS buffer at 55 °C according to pre-
viously developed conditions.82 After the incubation, the functionalized particles 
Ti-3.5 were washed three times with CH3CN, and HPLC analysis of the washing 
solutions determined only small amounts of fluorophore 3.18 and no free 3.5 present.  
 
                                                
82  a) J. Gomes, A. Grunau, A. Lawrence, L. Eberl, K. Gademann, Chem. Comm. 2013, 49, 
155-157; b) J. Gomes, ongoing PhD Thesis, Basel 2013. 
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Figure 3.7. Ti-3.5 (left) and negative control (uncoated TiO2 particles, right) in MOPS 
buffer upon UV irradiation; Release kinetics of 3.18 from Ti-3.5 upon UV irradiation 
at 366 nm in MOPS buffer. 
The release of the fluorescent cargo from the functionalized beads was investigated 
next. The functionalized TiO2 beads Ti-3.5 were suspended in MOPS buffer and the 
mixture was irradiated. Fluorescence became immediately visible (Figure 3.7A). 
Aliquots were taken after certain irradiation time intervals and analyzed by HPLC at 
366 nm. The obtained data demonstrates that no catechol 3.5 is present and the 
amount of 3.18 was increasing over the irradiation time (Figure 3.7B), providing 
evidence that photocleavage of surface-adsorbed nitrocatechol 3.5 and concomitant 
release of coumarin 3.18 has occured. In this reaction setup, a half-life time of ca. 
19 min was determined for the release of 3.18.  
 
foil
60 sec UV light
UV irradiation for 
indicated time
foil removed
Si-3.5
3.18
     
Figure 3.8. TLC plate coated with nitrocatechol 3.5 (Si-3.5) and irradiated for 60 sec at 
366 nm under a printed foil, after 10 sec exposure to UV light without foil, after 60 sec 
and after 180 sec UV irradiation at 366 nm (see videos).  
Qualitatively, these observations could be corroborated by the immobilization of 
3.5 on silica (Si-3.5, TLC plate) and controlled release under UV light (Figure 3.8A 
10 sec 
60 sec 
180 sec 
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and B; see videos on the enclosed CD for further information). In this simple 
application, a printed foil was used as template to generate the desired surface pattern, 
which could be unmasked by release of the fluorophore via irradiation. 
3.5 Conclusion and Outlook 
In conclusion, we have successfully developed a bio-inspired surface modification 
platform based on nitrocatechols that allows for the controlled release of small 
molecules under an external stimulus. Salient features of this method involve (1) ease 
of functionalization of TiO2 particles under an operationally simple dip-and-rinse 
procedure, (2) stability of the resulting functionalized particles to repeated washing 
and (3) rapid release of the small molecule cargo under an external stimulus, i.e. UV 
light. We think that this method displays advantages with regard to controlled release. 
This surface modification platform might find applications in drug delivery, as caged 
probes in chemical biology or for direct assays 'on chip'.  
The detailed photocleavage process and binding properties of the designed system 
need to be further investigated in detail. The effect of the tether bridging the 
coumarine and the caging group should also have an influence of the kinetic release of 
the cargo. Furthermore it is envisioned to use iron oxide particles instead of TiO2, so 
an additional handle for transport namely the magnetic field would be appropriate. 
Applications of the system to immobilize bioactive small molecules will be 
investigated in our group. 
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4 CAGED RETINOIDS AS PHOTOINDUCIBLE ACTIVA-
TORS: IMPLICATION FOR CELL DIFFERENTIATION 
4.1 Introduction 
Neurodegenerative disorders such as Alzheimer’s, Parkinson’s or Huntington’s 
disease are becoming more and more prevalent in our aging society as already 
discussed in the second chapter.83 In this respect, small molecules could give detailed 
insight into the progress of neurodegenerative diseases, regarding complex 
phenomena as plaque formation, loss of connectivity between synapses or neuron-
neuron communication.84 Additionally, treatment with a small molecule is a more 
convenient way to treat CNS injuries than with gene therapy or neurotrophins, since 
its use in principle could allow for simple oral administration.85 In our current 
research program directed towards neuropharmacological properties of such small 
molecules, we recently described the total syntheses of the neuroactive steroid 
withanolide A (Chapter 2) as well as several pyridone alkaloids of the militarinone 
type and evaluated their neuritogenic activity in different cell lines,86 aiming to 
control and direct neurite formation and navigate the axonal growth cones by an 
extrinsic guidance.87  
Related - signalling molecules, in particularly all-trans retinoic acid (ATRA, 4.1) 
are established by many pharmacological studies to initiate such a complex ‘growth 
program’ resulting in differentiation, neurite outgrowth and axonal elongation, and 
                                                
83  Review: A. Wimo, B. Winblad, H. Aguero-Torres, E. von Strauss, Alzheimer Dis. Assoc. 
Disord. 2003, 17, 63-67. 
84  Review: M. P. Mattson, Nature 2004, 430, 631-639. 
85  a) J. Corcoran, P.-L. So, R. D. Barber, K. J. Vincent, N. D. Mazarakis, K. A. 
Mitrophanous, S. M. Kingsman, M. Maden, J. Cell Sci. 2002, 115, 3779-3786; b) M. 
Agudo, P. Yip, M. Davies, E. Bradbury, P. Doherty, S. McMahon, M. Maden, J. Corcoran, 
Neurobiol. Disease 2010, 37, 147-155. 
86  a) H. J. Jessen, A. Schumacher, T. Shaw, A. Pfaltz, K. Gademann, Angew. Chem. Int. Ed. 
2011, 50, 4222-4226; b) H. J. Jessen, A. Schumacher, F. Schmid, A. Pfaltz, K. Gademann, 
Org. Lett. 2011, 13, 4368-4370; c) F. Schmid, H. J. Jessen, P. Burch, K. Gademann, Med. 
Chem. Commun. 2013, 4, 135-139; d) F. Schmid, ongoing PhD Thesis, Basel, 2013. 
87  B. M. Marsick, K. C. Flynn, M. Santiago-Medina, J. R. Bamburg, P. C. Letourneau, 
Devel. Neurobiol. 2010, 70, 565-588. 
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therefore represent a standard control substance. 88,89 Corcoran and Maden have 
examined that the vitamin A metabolite is critical for neurite regeneration and that its 
synthesis is regulated by the neurotrophin nerve growth factor (NGF) and vice 
versa.90  
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OCH3O2N
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4.1
4.2  
Figure 4.1. Structures of retinoic acid (ATRA, 4.1) and the caged analog (4.2) used by 
Jullien et al. in zebrafish embryos.91 
Recently, Jullien reported on photo-released ATRA in zebrafish embryos by one 
and two-photon excitation with UV light, to induce teratogens in the vertebrate 
(Figure 4.1).91 While the photo-regulation effect could be verified after passive 
diffusion into the cells, photo-isomerization and degradation of the light-sensitive 
polyene side chain of ATRA (4.2) were recognized as drawbacks, besides the lack of 
selectivity to one specific receptor.  
The use of selective agonists showed that RARβ agonists stimulate neurite 
outgrowth, proposing ATRA acting via RARβ2 in the outgrowth of neurites.92 The 
binding mode of ATRA can be rationalized from crystal structures of the ligand-
binding domain of RARs (or related RXRs, Figure 4.2)93 with different retinoids 
suggesting an attraction for the carboxylic acid moiety and inducing a ‘mouse-trap’ 
mechanism. Therefore an appropriate ligand should fulfil two criteria: 1) contain a 
                                                
88  V. Perissi, M. G. Rosenfeld, Nature 2005, 6, 542-554. 
89  Review: M. Clagett-Dame, E. M. McNeill, P. D. Muley, J. Neurobiol. 2006, 66, 739-756. 
90  J. Corcoran, M. Maden, Nat. Neurosci. 1999, 2, 307-308. 
91  P. Neveu, I. Aujard, C. Benbrahim, T. Le Saux, J.-F. Allemand, S. Vriz, D. Bensimon, L. 
Jullien, Angew. Chem. Int. Ed. 2008, 47, 3744-3746. 
92  J. Corcoran, B. Shroot, J. Pizzey, M. Maden, J. Cell Sci. 2000, 113, 2567-2574. 
93  a) P. Germain, S. Kammerer, E. Pérez, C. Peluso-Iltis, D. Tortolani, F. C. Zusi, J. Starrett, 
P. Lapointe, J.-P. Daris, A. Marinier, A. R. de Lera, N. Rochel, H. Gronemeyer, EMBO 
Rep. 2004, 5, 877-882; b) J.-P. Renaud, N. Rochel, M. Ruff, V. Vivat, P. Chambon, H. 
Gronemeyer, D. Moras, Nature 1995, 378, 681-689; c) A. R. de Lera, W. Bourguet, L. 
Altucci, H. Gronemeyer, Nature Drug Disc. Rev. 2007, 6, 811-820. 
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carboxylic acid functionality for the electrostatic attraction and 2) must not exceed a 
certain length to keep its agonistic properties.  
 
Figure 4.2. X-ray crystal structure of the related RXR binding domain, co-crystallized 
with RXR agonist (SR11237). (adapted by permission from Nature Drug Disc. Rev. 
2007, 6, 811-820). Upon binding of the agonistic ligand induced conformational 
change occurs to display a hydrophobic surface selectiv for short helical motif of 
LXXLL. L = leucine; X = any amino acid. 
Based on the third generation SAR study of Carpentier,94 we wanted to use 
retinoid 4.3 as a temporally tuneable activator for neurite outgrowth. Compound 4.3 
(Figure 2.2; RARα (695±248 nM), RARβ (21±6 nM), RARγ (72±2 nM)) has an 
attractive activity and selectivity profile towards RARβ as required. Further, the 
alcohol functionality in 4.3 offers the possibility to bind an adjustable protecting 
group to the agonist, thereby increasing the length and temporally inactivating its 
biological activity.95 Upon uncaging with an external stimulus, e.g. irradiation with 
UV light of a photolabile protecting group, the concentration of free ligand 4.3 should 
increase, postulated binding to RARβ should occur and thereupon lead to the active 
conformation of the protein, resulting in desired neurite outgrowth.  
                                                
94  a) B. Charpentier, J.-M. Bernardon, J. Eustache, C. Millois, B. Martin, S. Michel, B. 
Shroot, J. Med. Chem. 1995, 38, 4993-5006; b) B. Charpentier, Centre International de 
Recherches Dermatologiques Galderma, US-Patent: US5547983 A1, 1996, 1-18. 
95  K. H. Link, F. G. Cruz, H.-F. Ye, K. E. O’Reilly, S. Dowdell, J. T. Koh, Bioorg. Med. 
Chem. 2004, 12, 5949-5959. 
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Figure 4.3. Retinoids as agonists or non-agonists for RARβ. MeNPOC = [(α-methyl-2-
nitropiperonyl)oxy] carbonyl; Cbz = carboxybenzyl; Bn = benzyl. 
As photolabile protecting group the established [(α-methyl-2-nitropipero-
nyl)oxy]carbonyl (MeNPOC)96 was chosen, because its photochemical properties are 
well understood and its chemical stablility under physiological conditions. Similarly, 
free nitrocatechol allows the attachment of small molecules to a solid support 
(Ti-4.4), and thereby provides access to direct neurite outgrowth also in a spatially 
controllable fashion. This methodology was introduced in Chapter 3 in a proof-of-
concept study, using a caged fluorophore to investigate light mediated release 
properties from a solid support.77  
Herein, the development of caged retinoids as photoinducible activators to 
temporally and spatially control neurite outgrowth is presented. Release of the active 
agonist by UV irradiation leads to significant neurite outgrowth and confirmed the 
selectivity of the ATRA receptors. 
4.2 Results and Discussion 
4.2.1 Synthesis 
The synthesis of the caged retinoids 4.4 and 4.5 as well as control substances 4.6 
and 4.7 started from the known route to acid 4.3 by Carpentier and co-workers.94 For 
the introduction of the photolabile protecting group to the primary hydroxy group 
different strategies were investigated. Etherifications of the alcohol group of the 
methyl ester 4.8, a synthetic intermediate in the established 10 step sequence to 
                                                
96  J. H. Kaplan, B. Forbush III, J. F. Hoffman, Biochemistry 1978, 17, 1929-1935. 
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retinoid 4.3, with nitrophenyl derivatives was not successful under a variety of 
conditions (Williamson ether synthesis, glycosylation strategy using trichloro-
acetimidate, Lewis acid catalyzed etherification).97 Except for the benzylation under 
neutral conditions using BnOPT (4.9),98 which resulted in full conversion to the 
desired ether (Scheme 4.1), and upon hydrolysis with aqueous LiOH in THF, led to 
the free acid 4.7. 
OMe
O
HO
a,b
OH
O
O
4.8
4.7
N+BnO OTf
4.9
 
Scheme 4.1. Synthesis of control compound 4.7: a) 4.9, MgO, DCE, rfx, 95%; b) 
LiOH, H2O, THF, RT, quant.  
In order to circumvent problems associated with the etherification we used a 
protocol to introduce the photolabile MeNPOC group as its carbonate.99 Subsequent 
hydrolysis to set free acid 4.5 would cleave the carbonate linkage even by use of mild 
LiOH. So, we first formed the tert-butyl ester 4.10 by exposing acid 4.3 to DMF di-
tert-butyl acetal in a mixture of refluxing benzene and THF (Scheme 4.2). Due to the 
low solubility of this acid 4.3 only moderate conversion was accomplished, but a 
simple acid-base-extraction could re-isolate the remaining starting material.  
To reach the desired caged retinoid 4.5, tert-butyl ester 4.10 was added to a 
mixture of MeNPOC chloroformate in pyridine/ CH2Cl2 at 0 °C to yield the corres-
ponding carbonate in excellent 95% yield. Upon exposure to a mixture of trifluoro-
acetic acid 4.5 was obtained in quantitative yield as an off-white solid, decomposing 
at temperatures above 125 °C. All operations involving the light-sensitive MeNPOC 
 
                                                
97  V. J. Patil, Tetrahedron Lett. 1996, 37, 1481-1484. 
98  W. C. K. Poon, S. E. House, G. B. Dudley, Synlett 2005, 20, 3142-3144. 
99  G. H. McGall, A. D. Barone, M. Diggelmann, S. P. A. Fodor, E. Gentalen, N. Ngo, J. Am. 
Chem. Soc. 1997, 119, 5083-5090. 
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Scheme 4.2. Synthesis of caged retinoid 4.5: a) DMF di-tert-butyl acetal, benzene, 
THF, 90 °C, 23% (99% brsm); b) MeNPOC chloroformate, pyridine, CH2Cl2, 0 °C to 
RT, 95%; c) TFA, TIPS, CH2Cl2, RT, 99%. 
group were performed in the dark, although photo-deprotection was not detectable for 
short exposure to daylight. The same reaction sequence starting from ester 4.10 was 
used to synthesize benzyloxycarbonyl (Cbz) protected retinoid 4.6, as a non-agonistic 
control substance in 53% yield over two steps.  
a,b
4.10
4.4
c
OH
NO2
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O
O
O
O
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HO
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Scheme 4.3. Synthesis of the caged retinoid 4.4 and its immobilization on TiO2 surface 
to Ti-4.4: a) i) 3.15, triphosgene, Et3N, THF; 0 °C, 25 min; ii) 4.10, pyridine, CH2Cl2, 
0 °C to RT, 1.5 h; b) TFA, H2O, RT, over night, 42% (over 2 steps); c) TiO2, MOPS 
buffer, 50 °C, 4 h. 
Following our protocol for the immobilization of small molecules on metal oxide 
surfaces by an operationally simple dip-and-rinse procedure (Chapter 3), we 
examined the synthesis of nitrocatechol 4.4 (Scheme 4.3). Nitroarene alcohol 3.17 
was converted with triphosgene and triethylamine in 25 min at 0 °C to the chloro-
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formate in quantitative yield. Subsequently, the previously established conditions 
(pyridine, CH2Cl2 at 0 °C to room temperature) were used to generate the carbonate, 
containing small amounts of the homo-coupled nitrophenyl carbonate as an 
inseparable side-product. Exposure to TFA supplemented with a small amount of 
water gave finally access to the free catechol 4.4 as a yellow solid in moderate yield 
(42% over 2 steps) after reverse-phase HPLC purification.  
Immobilization on TiO2 microparticles (1.0-2.0 µm) to Ti-4.4 was accomplished 
by incubation of 4.4 in MOPS buffer at 50 °C for 4 h. After incubation, the 
functionalized particles Ti-4.4 were washed three times with CH3CN and once with 
MOPS buffer; HPLC analysis of the last washing solution determined no free agonist 
4.3. This synthesis demonstrated the versatility of the nitroarene alcohol 3.17 for 
subsequent chemical transformations. This simple combination of two functionalities 
in compound 3.17, namely the catechol unit and the simple nitroarene, allows for the 
caging on solid support and controlled release on demand by non-invasive UV light at 
366 nm.  
4.2.2 Studies on Photocleavage 
The ability of both photolabile compounds Ti-4.4 and 4.5 to liberate free agonist 4.3 
was investigated next by spectroscopic means (HPLC-MS and UV). First, it was 
demonstrated that both compounds were stable to the appropriate solvent environment 
over a period of at least 3 days incubation in the dark, and no free alcohol 4.3 could be 
detected by HPLC. 
Then, MeNPOC derivative 4.3 was irradiated with a common laboratory UV lamp 
(~20 mW⋅cm-2) at 366 nm in cell medium (minimal essential medium, MEM) in a 
24-well plate covered with a glass disk in order to filter off undesired short-wave 
radiation. Aliquots were taken after indicated irradiation time intervals and analysed 
by HPLC with the help of their UV absorption. The half-life could be determined for 
the cleavage of 4.3 in MEM with an irradiated surface area of approximately 2.5 cm2 
per 1 mL solvent volume to 8.3 min (Figure 4.4B). 
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Figure 4.4. A) Representative HPLC diagram for the cleavage process after 30 s 
irradiation: UV traces at 2 4 nm, retention times for retinoid 4.3 (tR = 15.484 min) and 
caged-retinoid 4.5 (tR = 19.374 min); minor peaks from 2 to 10 min derive from the cell 
medium (MEM); B) Uncaging process of retinoid 4.5 to 4.3 during exposure to UV 
light at 366 nm; cell medium, 24-well plate: volume = 1 mL, irradiated surface area = 
254.5 mm2. 
The uncaging properties of Ti-4.4 were determined in a similar setup. The 
incubated TiO2 particles Ti-4.4 were resuspended in cell medium in a 24-well plate 
and irradiated with a common UV lamp. Aliquots were taken after the indicated 
period and analysed by HPLC-MS. The HPLC analysis indicates release of free 
agonist 4.3 occurred in detectable quantities after 5 to 10 min of irradiation (HPLC 
traces and UV spectra). Longer exposure to 366 nm UV light for extended periods 
(1 h to 15 h) strongly increased the liberation of free agonist 4.3.  
OH
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Scheme 4.4. Cleavage of Ti-4.2 induced by UV irradiation at 366 nm to liberate 
agonist 1 from a solid support.  
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4.2.3 Investigations of the Neuritogenic Activity 
We then investigated the target and control compounds for their ability to induce 
neurite outgrowth in the human neuroblastoma SH-SY5Y cellular model.60 To 
achieve this goal, free alcohol 4.3, caged acid 4.5, carbonate 4.6 and ether 4.7 were 
evaluated in human SH-SY5Y cells according to the method described and optimized 
in Chapter 2.31b Briefly, cells were grown on collagen coated 24-well plates in 
minimum essential medium (MEM without an indicator) supplemented with 5% fetal 
bovine serum in the presence of the corresponding compounds (1 µM, 0.1% in 
DMSO) at 37°C in humidified atmosphere (CO2 content 5%). In control experiments, 
cells were treated with DMSO as a negative or ATRA as a positive control. After 
incubation for four days, cells were fixed, stained and examined under a phase 
contrast microscope. The differentiated cells from three random areas of the well were 
counted. In each experiment at least 500 cells were counted, except for DMSO and 
caged compound 4.5. Those having at least one neurite with a length of more than 50 
µm were counted as positive.  
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4.7 [1.0 µM] 
4.6 [1.0 µM] 
4.3 [0.01 µM] 
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Figure 4.5. A) Neurite outgrowth activity of ATRA, DMSO blank, retinoids 4.3, 4.6 
and 4.7 in human SH-SY5Y cells with MEM as cell-medium. Error bars denote SEM. 
B) Representative micrograph for retinoid 4.3 (0.1 µM).  
The results are summarized in Figure 4.5B and representative micrographs are 
given in the Appendices. The results of the experiments confirms our expectations 
that retinoid 4.3 acts as agonist and significantly induces neurite outgrowth down to a 
concentration as low as 0.1 µM, on a scale comparable to ATRA itself. The observed 
phenotypes (micrograph; Figure 4.5A) display the same characteristics as for ATRA: 
almost complete differentiation, indicated by formation of several long neurites for 
each individual cell, no aggregate formation and a high cell-density on the well 
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surface. Below a concentration of 0.1 µM retinoid 4.3 does not display significant 
activity. The control-compounds 4.6 and 4.7 (concentration = 1 µM) do not act as 
agonists and their phenotypes strongly resemble the one observed for vehicle 
(DMSO) as negative control. In addition, high cell aggregate formation complicates 
the evaluation and a low cell-density on the surface is observed. The low observed 
cell density can be explained by the removal of non-differentiated cells by washing 
before the fixation step. 
30 40 50 60 70
4.5 [0.1 µM] b
4.5 [1.0 µM] a
4.3 [0.1 µM] a
DMSO blank a
Amount of differentiated cells [%]
30 40 50 60 70
4.5 [1.0 µM] e
4.5 [1.0 µM] d
4.5 [0.1 µM] d
4.5 [1.0 µM] c
DMSO blank c
Amount of differentiated cells [%]
 
Figure 4.6. Neurite outgrowth activity of retinoid 4.3 (0.1 µM), DMSO blank and 
caged retinoid 4.5 (0.1 µM or 1.0 µM) in human SH-SY5Y cells with MEM as 
medium; A) without UV irradiation: a performed as control without UV irradiation; 
b incubated for 24 h, prewashed without irradiation; B) UV irradiation: c irradiated for 
60 s at 366 nm without prewash; d irradiated for 180 s at 366 nm without prewash; 
e irradiated for 180 s at 366 nm after incubation for 24 h prewash. Error bars denote 
SEM.  
A second assay based on the kinetics of the investigated uncaging process of 4.5 to 
4.3 was performed to temporally control neurite outgrowth. Again, the vehicle control 
experiment (0.1 % DMSO) displayed a completely different phenotype compared to 
cells treated with ATRA or 4.3. We almost exclusively observed large cell aggregates 
with only a few isolated, non-differentiated cells. The same picture could be drawn 
Without UV irradiation 
n 
UV irradiation 
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for the evaluation of caged retinoid 4.5, as long as no UV irradiation liberated the free 
agonist 4.3. This successful control experiment indicates that the caged compound 
does not act as agonist as required for the experiment-setup, as anticipated after the 
results of control compounds (Figure 4.6A).  
Upon UV irradiation of caged compound 4.5 for 60 or 180 s neurite outgrowth 
with familiar phenotypes was induced (Figure 4.6B). To simulate intracellular 
uncaging, cells were incubated for 24 h with caged retinoid 4.5, but prior to 
irradiation the cell medium was removed, cells were washed twice with fresh media 
and directly irradiated for 60 s. Again differentiation was the read-out as in the cases 
of no prewash before illumination.  
Ti-4.4 was not suitable for our assay conditions, as it did not allow us the visual 
elaboration of the neurite outgrowth due to a lack of background contrast from the 
TiO2 microparticles. In further studies a more convenient surface consistence based 
on biocompatible TiO2 should be investigated to proof our concept to navigate axonal 
growth cones by an extrinsic guidance on surface. 
4.3 Conclusion 
In summary we were able to show that retinoid 4.3 exhibits significant neurite 
outgrowth activities as anticipated for a RARβ agonist. For caged retinoid 4.5, as well 
as for the non-agonistic control compounds 4.6 and 4.7, no significant outgrowth 
could be determined in the cell assay. The controlled release of retinoid agonist 4.3 
from the caged precursor 4.5 was achieved using non-invasive UV light (366 nm) in 
cell-medium. As a result, neuron differentiation and neurite outgrowth could be 
temporally controlled by using our caged retinoid probes in solution. Furthermore, 
anchor 4.4 was successfully synthesized and the agonist was caged and immobilized 
on TiO2 particles (Ti-4.4). Although the release properties of Ti-4.4 have been 
investigated by spectroscopy, further studies should investigate if Ti-4.4 can direct 
neurite outgrowth on surfaces triggered by light under certain assay conditions or by 
carefully choosing an appropriate surface texture. 
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5 TOTAL SYNTHESES OF JBIR-02 AND RELATED 
PIERICIDINS 
5.1 Classification and Biological Activities of Piericidins 
Piericidins belong to a family of antibiotics that are produced dominantly by 
various Streptomyces strains. Piericidin A1 the prototypical exemplar was isolated in 
1963 from Streptomyces mobaraensis by Takahashi and co-workers (Figure 5.1).100 
The elucidation of the structure remained in those early days of NMR spectroscopy 
problematic,101 even though more and more members of the piericidin family were 
isolated.102 Additionally, the originally attributed configuration had to be reassigned 
several times103 and was not established until the first total synthesis of piericidin A1 
and B1 in 2005 by Boger and Schnermann.104  
N
OH
H3CO
OHH3CO
5.1  
Figure 5.1. Piericidin A1 (5.1) parent structure of the piericidin family. 
Still today, the isolation of novel piericidins remains an active field105 and multiple 
biological targets besides the long known inhibitory effects of electron transport 
chain106 attract the attention of researchers from various disciplines. Up to now more 
                                                
100  S. Tamura, N. Takahashi, S. Miyamoto, R. Mori, S. Suzuki, J. Nagatsu, Agr. Biol. Chem. 
1963, 27, 576-582. 
101  N. Takahashi, A. Suzuki, Y. Kimura, S. Miyamoto, Tetrahedron Lett. 1967, 21, 1961-
1964. 
102  S. Yoshida, K. Yoneyama, S. Shiraishi, A. Watanabe, N. Takahashi, Agr. Biol. Chem. 
1977, 41, 855-862. 
103  R. Jansen, G. Höfle, Tetrahedron Lett. 1983, 24, 5485-5486. 
104  a) M. J. Schnermann, D. L. Boger, J. Am. Chem. Soc. 2005, 127, 15704-15705; b) M. J. 
Schnermann, F. A. Romero, I. Hwang, E. Nakamura-Ogiso, T. Yagi, D. L. Boger, J. Am. 
Chem. Soc. 2006, 128, 11799-11807; c) M. J. Schnermann, PhD Thesis, La Jolla, 2008. 
105  K. A. Shaaban, E. Helmke, G. Kelter, H. H. Fiebig, H. Laatsch, J. Antibiot. 2011, 64, 205-
209. 
106  a) D. L. Nelson, M. M. Cox in Lehninger Principles of Biochemistry, Worth, 2000; 
Chapter 19; b) D. Voet, J. G. Voet in Biochemie, Wiley-VCH, 1994, pp. 527-545. 
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then twenty different piericidins have been isolated (Table 5.1),107 sharing some 
characteristics in their structural arrangement.  
Table 5.1. Core structures of the piericidin class. Natural products have been isolated 
(colorless), putative natural products (light grey) and natural products labeled with * 
have been synthesized by total synthesis.  
N
OH
H3CO R3
OR2H3CO
R1  
N
OH
H3CO R3
OR2H3CO
R1 O  
 R1 R2 R3  R1 R2 R3 
A1* H H Me C1 H H Me 
A2 Me H Me C2 Me H Me 
A3 H H i-Pr C3 H H i-Pr 
A4 Me H i-Pr C4 Me H i-Pr 
A5 H H Et C5 H H Et 
A6 Me H Et C6 Me H Et 
A7  H H C4H7 C7 H H C4H7 
A8 Me H C4H7 C8 Me H C4H7 
B1* H Me Me D1 H Me Me 
B2 Me Me Me D2 Me Me Me 
B3 H Me i-Pr D3 H Me i-Pr 
B4 Me Me i-Pr D4 Me Me i-Pr 
B5 H Me Et D5 H Me Et 
B6 Me Me Et D6 Me Me Et 
B7 H Me C4H7 D7 H Me C4H7 
B8 Me Me C4H7 D8 Me Me C4H7 
The compounds named A7 and A8 for systematic reasons in this table correspond to IT-143-A 
and IT-143-B.108 
Interestingly for each individual member novel biochemical properties were 
reported presumably due to a lack of material for a necessary comparisons of the 
individual compounds. Moreover, the implication from Table 5.1 is that the 
established structural motif is highly preserved in nature and in most cases only small 
                                                
107  G. P. Meier, Master Thesis, Basel, 2012. 
108  A. Urakawa, T. Sasaki, K.-I. Yoshida, T. Otani, Y. Lei, W. Yun, J. Antibiot. 1996, 49, 
1052-1055. 
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post-modifications in the biosynthesis lead to relatives of the parent natural product 
piericidin A1 (methylation of the secondary alcohol for class B and D or epoxidation 
of the adjacent double-bond for class C and D). More significant variations that have 
been isolated include (Figure 5.2) altered heterocycles (5.2 and 5.3), tailored (5.4) or 
glycosilated side chains (5.5) and the corresponding N-oxides of the pyridine moiety 
(5.6). 
N
OH
H3CO R
OH
5.2: R = C4H7
5.3: R = CH3
N
OH
H3CO
ORH3CO
5.4: R = H
5.5: R = OO CH3
HO
OH
OH
N
OH
H3CO
OCH3
H3CO
O
5.6  
Figure 5.2. Structures of some isolated variations of piericidins A1: JBIR-02 (5.2)109 
and Mer-A2026B (5.3),110 will be the object of the following total synthesis, 7-de-
methylpiericidin A1 (5.4),111 7-demethyl-3’-rhamnopiericidin A1 (5.5),111 piericidin B1 
N-oxide (5.6).112 
The prominent pharmaceutical feature of piericidins is their ability to mimic 
ubiquinone (CoQ, 5.7). Due to their high structural similarity, inhibition of complex I 
of the ubiquitous mitochondrial NADH dehydrogenase (Ki = 0.6-1.0 µM) is 
accomplished through which they exhibit their strong antimicrobial, antifungal and 
antitumor activities. Complex I, the first enzyme of the energy transducting enzymes 
in the electron transport chain is mainly responsible to build an electrochemical 
potential.  
                                                
109  J. Ueda, T. Togashi, S. Matukura, A. Nagai, T. Nakashima, H. Komaki, K. Anzai, S. 
Harayama, T. Doi, T. Takahashi, T. Natsume, Y. Kisu, N. Goshima, N. Nomura, M. 
Takagi, K. Shin-ya, J. Antibiot. 2007, 60, 459-462. 
110  a) K. Kominato, Y. Watanabe, S.-I. Hirano, T. Kioka, T. Terasawa, T. Yoshioka, K. 
Okamura, H. Tone, J. Antibiotics 1995, 48, 99-102; b) K. Kominato, Y. Watanabe, S.-I. 
Hirano, T. Kioka, T. Terasawa, T. Yoshioka, K. Okamura, H. Tone, J. Antibiot. 1995, 48, 
103-105. 
111  K. Kimura, H. Takahashi, N. Miyata, M. Yoshihama, M. J. Uramoto, J. Antibiot. 1996, 49, 
697-699. 
112  H. Nishioka, M. Imoto, T. Imaoka, T. Sawa, T. Takeuchi, K. Umezawa, J. Antibiot. 1994, 
47, 447-452. 
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The following reaction is catalyzed by complex I:  
NADH + H+ + CoQ + 4H+in → NAD+ + CoQH2 + 4H+out 
In this process, the complex translocates four protons facilitated by ubiquinone 
across the inner membrane, what creates a proton gradient used to produce ATP from 
ADP. Other famous natural inhibitors of the respiratory chain are rotenone (5.8), 
which was used as fishing poison in the 17th century 113  and members of the 
myxalamide family (5.9 and 5.10). 
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Figure 5.3. Structures of ubiquinone (coenzyme CoQ, 5.7) and further potent inhibitors 
of the electron transport chain in cells: rotenone (5.8) and myxalamide B (5.9, R = i-Pr) 
& D (5.10, R = Et). 
The symbiosis of beewolf digger wasps with certain strains of Streptomyces to 
incooperate piericidins into the larval cocoon of their offspring is a related 
phenomenon that recently caused much attention.114  
 
Figure 5.4. Left: Beewolf digger wasp secreting Streptomyces with their glands. Right: 
Fluorescently labeled symbiotic Streptomyces strains. (adapted by permission from 
Nat. Chem. Biol. 2010, 6, 261-263). 
                                                
113  C. Moretti, P. Grenand, J. Ethnopharmacol. 1982, 6, 139-160. 
114 a) J. Kroiss, M. Kaltenpoth, B. Schneider, M.-G. Schwinger, C. Hertweck, R. K. Maddula, 
E. Strohm, A. Svatos, Nat. Chem. Biol. 2010, 6, 261-263; b) S. Koehler, J. Doubsky, M. 
Kaltenpoth, Front. Zool., 2013, doi:10.1186/1742-9994-10-3. 
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The cooperative effect of this piericidin cocktail provides an astonishing vital 
defense against competitors such as fungi or bacteria that grow preferable in the warm 
and humid environment of the larvae. Female beewolves cultivate certain strains of 
Streptomyces in their unique antennal glands and administer them on top of the brood 
thereby creating an antimicrobial, antifungal coating. 
5.2 Biosynthetic Pathways for the Formation of Piericidins 
Taking in account these potent biological activities, investigations on the 
biosynthesis of piericidin were already performed as early as 1968. First, simple 
feeding experiments with 14C labeled propionate and acetate established the origin of 
the side chain pattern after degradation analysis.115 The arragenement follows the well 
investigated polketide pathway wherein malonyl-CoA or methyl malonyl-CoA is 
incooperated into the growing chain via acyl carrier proteins (ACPs). However, it 
remained unclear until last year how and when the aromatic core structure is formed. 
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Figure 5.5. Constitution of piericidin A1 (5.1) and its biosynthetic precursors, propio-
nate and acetate units are labeled red respectively blue. ACP = acyl carrier protein; 
PieD = polyketide synthase (PKS; here: amidotranferase); PieC = PKS (here: cyclase). 
In 2012 You and co-workers sequenced and identified several gen cluster located 
in Streptomyces piomogeues var. and revealed a pathway for the cyclisation to form 
                                                
115  N. Takahashi, Y. Kimura, S. Tamura, Tetrahedron Lett. 1968, 45, 4659-4662. 
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the pyridine ring.116 In their analysis the identification of all polyketide synthase 
(PKS) genes, responsible for the elongation of the side chain, as well as hydrolase, 
amidotransferase (PieD) and cyclase (PieC) could be verified and compared to 
existing gene clusters known from the biosynthesis of other natural products (Figure 
1.1). Post-modifications, involving the hydroxylation of the aromatic moiety (PieE) 
and the two O-methylation (PieB1 and PieB2) have not yet been completely clarified. 
Studies towards the origin of methyl groups (CH3O-) point towards S-adenosyl-
methionine (SAM) mediated methyl transfer (PieB1) which was earlier emphazised 
by 13C-enriched NMR studies,117,118 however the responsible gene cluster has not yet 
been isolated. 
5.3 Previous Synthetic Contributions  
The initial reports on the first synthesis of the piercidin structures date back to 
1977 when Schmidtchen and Rapoport accomplished natural product analogs 
featuring simplified side chains.119 For the construction of the heteroaromatic core 
they started from 3-amino-2-methylacrylonitrile (5.11) which was condensed with 
methoxyacetylchloride to acrylonitrile 5.12 (Scheme 5.1). Cyclisation of the enamide 
by NaH and methylation furnished aminopyridine 5.13. 
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H3CO Br
5.11 5.12 5.13 5.14  
Scheme 5.1. Synthesis of the heteroaromatic moiety by Rapoport et al.:119 a) methoxy-
acetyl chloride, n-BuLi, THF, 59%; b) NaH, dioxane/THF, 40%; c) (CH3)3OBF4, 
CH2Cl2, 69%; d) 4-NO2(C6H4)COCl, pyridine, 80%, e) Br2, NaOAc, AcOH, 68%; 
f) KOH, CH2OHCH2OH, 110 °C, 86%; g) NaNO2, AcOH, H2SO4, H2O, 0 °C, 84%; 
h) O-benzyldiisopropylisourea, 100 °C, 90%. 
To overcome stability problems associated with the diazotation and the 
bromination, pyridine 5.13 was first acetylated using nitrobenzoylchloride, sub-
                                                
116  Q. Liu, F. Yao, Y. H. Chooi, Q. Kang, W. Xu, Y. Li, Y. Shao, Y. Shi, Z. Deng, Y. Tang, 
D. You, Chemistry & Biology 2012, 19, 243-253. 
117  Y. Kimura, N. Takahashi, S. Tamura, Agric. Biol. Chem. 1969, 33, 1507-1516. 
118  M. Tanabe, H. Seto, J. Org. Chem. 1970, 35, 2087-2088. 
119  F. P. Schmidtchen, H. Rapoport, J. Am. Chem. Soc. 1977, 99, 7014-7019. 
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sequently brominated using Br2 in AcOH. Deacylation, diazotation and finaly 
protection as the benzylic hydroxypyridine ether 5.14 gave the coupling precursor. 
Although the overall yield for 8 steps is relatively high, this synthesis does not allow 
for different substitution pattern at the aromatic rings and the introduction of the 
4-hydroxy group was difficult to realize. 
O MsNCOOEt COOEt N COOEt
H3CO
H3CO
H3CO
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H3CO
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H3CO
H3CO
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a,b c
d-f
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5.15 5.16
5.17
5.185.19  
Scheme 5.2. Synthesis by Boger et al.:104 a) NH2OH⋅HCl, EtOH, 96%; b) MeSO2Cl, 
Et3N, CH2Cl2; c) tetramethoxyethene, toluene, 50 °C, 64% (over 2 steps); d) BF3⋅Et2O, 
CH2Cl2, 0 °C, 88%; d) DIBAlH, CH2Cl2, 92%; e) TIPSCl, imidazole, DMF, 95%; f) i) 
n-BuLi, THF; ii) B(OMe)3, AcOOH, H2O, 88%; g) TBAF, THF, 96%; h) CBr4, PPh3, 
CH2Cl2, 84%. 
In 2005, the Boger group reported the first total synthesis of piericidin A1, the 
prototypical member of the natural family itself.104 Their synthesis of the hetero-
aromatic core started with an inverse electron demanding Diels-Alder reaction of the 
formed sulfonylimine 5.16 with tetramethoxyethene (Scheme 5.2), a methodology 
developed by Boger group several years before.120 Lewis acid (BF3·Et2O) mediated 
aromatization of 5.17 was followed by DIBAlH reduction and silyl protection to 
afford pyridine 5.18. To introduce the 4-hydroxy function it was envisioned to use a 
directed lithiation-borylation-oxidation sequence, but additionally to the desired 
outcome a reverse Brook rearrangement of the TIPS group was observed. Therefore 
the obtained compound was exposed to TBAF prior to the formation of its benzyl 
bromide (5.19) under Appel conditions. 
 
                                                
120  a) D. L. Boger, K. C. Cassidy, S. J. Nakahara, J. Am. Chem. Soc. 1993, 115, 10733-
107041; b) D. L. Boger, O. Hüter, K. Mbiya, M. Zhang, J. Am. Chem. Soc. 1995, 117, 
839-849. 
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Scheme 5.3. Synthesis by Phillips et al.:121 a) i) n-BuLi, THF; ii) B(OMe)3, AcOOH, 
H2O, 70%; b) SEMCl, Ag2CO3, CH2Cl2, 97%; c) i) t-BuLi, hexane, -78 °C; ii) 
CBrCl2CBrCl2, THF, -78 °C, 82%; d) i) LiTMP, THF, -78 °C to -40 °C; ii) CH3I, -40 
°C, 85%, e) i) t-BuLi, THF, -78 °C; ii) Bu3SnCl, 96%. 
In 2006, Keaton and Phillips realized the synthesis of natural 7-demethylpiericidin 
A1 (5.4) containing the same aromatic motif (Scheme 5.3).121 They started from 
commericially available 2,3-dimethoxypyridine (5.20) which was converted to the 
4-hydroxypyridine 5.21 by the earlier mentioned lithiation-borylation-oxidation 
protocol. Afterwards, the free hydroxy group was protected selectively using Ag2CO3 
and SEMCl, which led to the next directed lithiation to introduce a bromine 
substituent with NBS as electrophile (5.22). The synthesis was completed by a 
halogen dance reaction,122 where the greater stability of the intermediate formed 
3-lithio-2-bromo-pyridine which was used to introduce the lacking methyl group. 
Substitution of the bromine by Bu3SnCl led to the final coupling precursor (5.23). 
This elegant route was later adapted by the Akita group in 2009 to finaly reward their 
efforts towards the natural piericidin A1 which they originally started in 1997 with the 
completion of the side chain.123  
The pyridinol synthesis of Lipshutz and Amorelli from 2009 (Scheme 5.4)124 was 
inspired by the chemistry of Takahashi in the early 1980s.125 Dieckmann cyclisation 
of the acylated aminotiglate 5.25 resulted in the formation of 4-hydroxypyridone 5.26 
which was PMB-deprotected by exposure to TFA at 110 °C. Specific silylation of the 
sterically more shielded 4-hydroxy-group in presence of the 2-hydroxy-group 
afforded surprisingly after methylation (Ag2CO3, CH3I) pyridine 5.27. Deprotonation 
at the benzylic position by the assistance of t-BuLi in THF at -78 °C, led after 
                                                
121 A. J. Phillips, K. A. Keaton, J. Am. Chem. Soc. 2006, 128, 408-409. 
122  For reviews on halogen dance reactions: a) V. Snieckus, Chem. Rev. 1990, 90, 879-933; b) 
J. F. Bunnett, Acc. Chem. Res. 1972, 5, 139-147; c) J. Froehlich in Progress in 
Heterocyclic Chemistry; Pergamon, 1994, pp. 1-35. 
123 a) R. Kikuchi, M. Fujii, H. Akita, Tetrahedron: Asymmetry 2009, 20, 1975-1983; b) M. 
Ono, N. Yoshida, Y. Kokubu, E. Sato, H. Akita, Chem. Pharm. Bull. 1997, 45, 1428-1434. 
124  B. H. Lipshutz, B. Amorelli, J. Am. Chem. Soc. 2009, 131, 1396-1397. 
125  S. Yoshida, Y. Nagao, N. Takahashi, Agric. Biol. Chem. 1980, 44, 2913-2920. 
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quenching with the electrophilic chlorine reagent CCl3CCl3 to the fully elaborated 
aromatic coupling partner 5.28.  
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Scheme 5.4. Lipshutz’ synthesis:124 a) methoxyacetyl chloride, pyridine, CH2Cl2, 73%; 
b) Na, EtOH, 71%; c) TFA, 110 °C, 86%; d) TBSCl, Et3N, CH2Cl2, 95%; d) Ag2CO3, 
CH3I, CH2Cl2, 90%; e) i) t-BuLi, hexane, 0 °C; ii) CCl3CCl3, THF, -78 °C, 82%. 
Obviously, after a closer look on these examples, the preparation of the pyridine 
moiety seems more challenging as originally anticipated. The unusual substitution 
pattern in combination with the typical problems of heterocyclic chemistry did not 
allow to synthesize this part of the molecule under five steps from commercially 
available precursors. For the construction of the side chain modern transformations 
developed in the last 10 to 15 years were necessary as shown in the following section. 
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Scheme 5.5. Total synthesis by Boger et al.:104 a) tiglic aldehyde, Bu2BOTf, DIPEA, 
CH2Cl2, 0 °C, 81%; b) H2NMeOMe⋅HCl, AlMe3, THF, 0 °C; c) TBSCl, imidazole, 
DMF, 66% (2 steps); d) DIBAlH, CH2Cl2, -78 °C, 60%; e) PO(OEt)2CHCH3COOEt, 
NaH; f) DIBAlH, THF, -78 °C, 72% (2 steps); g) (COCl)2, DMSO, CH2Cl2, -78 °C, 
99%; h) 5.32, KHMDS, DME, -78 °C, 60%; i) i) n-BuLi, THF, -78 °C; ii) Bu3SnCl, 
96%; j) 5.19, Pd2(dba)3, t-Bu3P, LiCl, dioxane, 70 °C, 74%; k) TBAF, THF, 50 °C, 
93%; l) PivCl, HSO4NBu4, NaOH, CH2Cl2, 92%; m) NaH, MeI, DMF, 78%; n) 
t-BuONa, MeOH, 60 °C, 88%. 
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The enantioselective side chain synthesis of piericidin A1 was first performed by 
Boger et al. (Scheme 5.5) as following:104 Acylated Evans auxiliary 5.29 was 
submitted to tiglic aldehyde (CHOCCH3CHCH3) in presence of Bu2BOTf to promote 
the anti-selective aldol reaction.126 The formed alcohol 5.30 was protected and further 
converted to the aldehyde (via the Weinreb amide), which was then elongated by a 
Horner-Wadsworth-Emmons (HWE) reaction. After additional redox manipulations 
the aldehyde 5.31 could be coupled via an (E)-selective Julia reaction with sulfone 
5.32, which upon lithium-halogen exchange followed by treatment with Bu3SnCl 
afforded the vinyl stannane 5.33. The final coupling was achieved using Fu’s catalyst 
system:127 Pd2(dba)3 and t-Bu3P in 74% yield. The natural product was finally 
obtained after desilylation and established the absolute configuration by the synthesis 
of the related piericidin B1 (5.34) due to its higher optical rotation (αD = -7.3° in 
MeOH, respectively αD = -1.1° in MeOH for piericidin A1). 
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Scheme 5.6. Rapoports synthesis of piericidin analogs:119 a) i) n-BuLi, THF, HMPA,  
-78 °C; ii) allyl bromide, THF, -78 °C, 60-68%; b) BuSNa, DMF, 80 °C, 60-70% (for 
n = 1, 2, 3).  
Rapoport studied alternative coupling strategies by using simple allylic bromides 
derived form prenol (5.35, n = 1), geraniol (5.36, n = 2) and farnesol (5.37, n = 3), 
with n-BuLi in a mixture of THF and HMPA at -78 °C (Scheme 5.6).119 This 
transformation was realized without detectable amount of isomerization of the allylic 
fragment (1H NMR analysis). Cleavage of the benzylic protecting group was 
accomplished by treatment with sodium butanthiolate at elevated temperatures to 
afford 5.38-5.40 as colorless oils in 40-60% yield over 2 steps.  
                                                
126  Y. Nakao, W. Y. Yoshida, Y. Takada, J. Kimura, L. Yang, S. L. Mooberry, P. J. Scheuer, 
J. Nat. Prod. 2004, 67, 1332-1340. 
127  A. F. Littke, G. Fu, J. Am. Chem. Soc. 2002, 124, 6343-6348. 
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Scheme 5.7. Total synthesis by Phillips et al.:121 a) ethynyl(diisopropyl)bromosilane, 
Et3N, DMAP, CH2Cl2, 78%; b) PdCl2(PPh3)2, CuI, Et3N, CH3CN, 87%; 
c) ClTi(Oi-Pr)3, i-PrMgCl, Et2O, 52%; d) HF⋅pyridine, THF, 84%; e) MeOOCOCl, 
pyridine, CH2Cl2, 97%; f) 5.23, Pd2(dba)3, LiCl, DMF, 55% (E:Z 2.5:1); g) TBAF, 
DMF, 75 °C, 70%. 
Next, the completed synthesis of the Phillips group is shown:121 Chiral allylic 
alcohol 5.41 (obtained from vinylmagnesium bromide addition to tiglic aldehyde 
followed by kinetic resolution) was silylated using ethynylbromosilane to 5.42 
(Scheme 5.7). Sonogashira-coupling with vinyl iodide 5.43 provided the precursor for 
the Ti(II)-mediated key step 5.44 - the eneyne cyclisation.128 Transformation of the 
TBDPS protected alcohol into its carbonate were performed to connect in a final 
Stille-coupling both entities in 55% yield with a E:Z ratio of 2.5:1, solely separable on 
silver coated HPLC columns. After TBAF cleavage the natural piericidin 5.4 was 
obtained in 9 linear steps for the longest sequence. 
Lipshutz synthesis of piericidin A1 was the second targeting the same natural 
product (Scheme 5.8).124 Key for his successful strategy was the Mukaiyama aldol 
reaction developed by Kobayashi and co-workers129 which will be discussed in the 
following part. The obtained alcohol 5.47 was TBS protected, converted first to the 
aldehyde (1 eq. DIBAlH at -78 °C) and then to the alkyne 5.48 by the Ohira-
Bestmann methodology. Hydrozirconation-iodination of eneyne 5.48 followed by 
propargyl coupling and cleavage of the TMS protecting group yielded alkyne 5.49. 
The crucial carboalumination was effected with AlMe3 and catalytic amounts of 
Cp2ZrCl2 and isobutylaluminiumoxane (IBAO). Then the vinylaluminium species was 
                                                
128  G. W. O’Neil, A. J. Phillips, Tetrahedron 2004, 45, 4253-4256. 
129  S. Shirokawa, M. Kamiyama, T. Nakamura, M. Okada, A. Nakazaki, S. Hosokawa, S. 
Kobayashi, J. Am. Chem. Soc. 2004, 126, 13604-13605. 
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in situ converted by addition of Ni catalyst and the heteroaromatic core 5.28 to the 
protected natural hydroxypyridine. This methodology developed in the Lipshutz 
laboratories130 was also used for the successful synthesis of related pyrone natural 
products (verticipyrone).131 Final cleavage with TBAF afforded piericidin A1 (5.1) in 
11 steps and an overall yield of 8% for the longest linear sequence. 
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Scheme 5.8. Total synthesis by Lipshutz et al.:124 a) tiglic aldehyde, TiCl4, CH2Cl2,  
-35 °C, 68%; b) TBSCl, imidazole, DMF, 92%; c) DIBAlH, CH2Cl2, -78 °C, 60%; 
d) dimethyl (1-diazo-2-oxopropyl)phosphonate, K2CO3, MeOH, 61%; e) i) Cp2ZrCl2, 
DIBAlH, THF, 0 °C; ii) I2, THF, -78 °C, 81%; f) TMS-propyne, n-BuLi, CuI, DMAP, 
THF, 0 °C; g) K2CO3, MeOH, 72% (2 steps); h) i) Cp2ZrCl2, AlMe3, IBAO, CH2Cl2; 
ii NiCl2(PPh3)2, n-BuLi, 5.28, THF, -50 to 0 °C; h) TBAF, THF, 60 °C, 58% (2 steps). 
Summarizing these achievements, the total synthesis of these complex natural 
products was made possible during the last ten years, when new synthetic methods for 
the stereoselective construction of the labile side chain were established and novel 
coupling startegies for merging both entities allowed for the final construction under 
mild conditions.  
5.4 Strategic Considerations and Goal of the Study 
5.4.1 Retrosynthetic Analysis 
As discussed in the previous section, two potential disconnections are reasonable 
for the synthesis of piericidins and dictate the following synthetic considerations: 
either the bond at C1’-C1 or the benzylic (C1-C2) bond has to be formed. The 
advantage of the C1-C2 disconnection for its facilitated installment - benzylic 
electrophiles can solely be attacked in a SN2 fashion, whereas in an allylic precursors 
                                                
130  B. H. Lipshutz, T. Butler, A. Lower, J. Servesko, Org. Lett. 2007, 9, 3737-3740. 
131  B. H. Lipshutz, B. Amorelli, Tetrahedron Lett. 2009, 50, 2144-2146. 
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both attacks a SN2 or a SN2’ are possible - is paid off later for the preparation of SAR 
libaries in which allylic precursors are easier accessible than their vinylic counterparts 
(Figure 5.6).  
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Figure 5.6. Retrosynthetic analysis of the 4’-demethoxy-piericidin structure. 
On the first glance the most difficult part of the synthesis appears to be the 
sensitive polyene side chain with its isolated 1,4-diene units from C1’ to C2 and C3 to 
C5. However the 4-hydroxypyridine or 4-pyridone ring with its ambident reactivity 
and its uncommon substitution pattern132 in combination with the final coupling of 
both elaborated parts represent the ‘mysterious’ challenge in the synthesis of these 
substrates. This synthetically delicate maneuver led in our investigation as well as in 
the published attempts from the Akita group to major problems.123 The side chain was 
envisioned to be constructed from small molecular entities allowing a more flexible 
route for further SAR investigations, implementing cross-coupling reactions for the 
terminal part and selective elongation strategies to build the polyene moiety. At last, 
the heteroaromatic core was proposed to come from a C-H activation-oxidation 
procedure to form 4-hydroxypyridines in one step from unfunctionalized pyridine 
precursors. 
5.4.2 Significance of the Proposed Project 
Interestingly, the piericidin JBIR-02 (5.2, Figure 5.7) derived from mycelium 
Streptomyces sp. ML55 (isolated from a soil sample collected in Taketomi Island, 
Japan)109 was reported to act as a nuclear export inhibitor by blocking the interaction 
between nuclear transport protein (CRM1) and the nuclear export signal of the cargo. 
Similarly, leptomycin and other nuclear export inhibitors can undergo a Michael-type 
addition of Cysteine-529 on the exportin CRM1. This well understood covalent 
                                                
132  M. Breugst, H. Mayr, J. Am. Chem. Soc. 2010, 132, 15380-15389. 
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modification inhibits binding between the nuclear export mediator (CRM1) of 
hundreds of proteins and the NES cargo.  
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Figure 5.7. Structures of isolated JBIR-02, 5.2 (R = C4H7) and Mer-A2026B, 5.3 (R = CH3). 
In the context of our program directed towards controlling protein transport in 
living cells, the pyridone polyene 5.2 was identified as a promising lead structure, 
despite its low activity (20 µM), caused by the loss of aromaticity when attacked  
covalently by a nucleophile. Still, 5.2 is a rather attractive target to find alternative 
heterocyclic derivatives, since members of the leptomycin family (e.g. anguino-
mycin A, 5.50, Figure 5.8)133 have been evaluated in clinical trials, but have failed in 
phase II due to unfavorable toxicity issues. 
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Figure 5.8. Structures of anguinomycin A (5.50) and militarinone D (5.51). 
In addition, we have synthesized natural pyridone polyenes of the militarinone type 
(5.51) with the goal to induce and understand neurite outgrowth.86,134 In the current 
approach we like to crosslink both aspects in terms of the identification of new 
biological targets for this phenomenon. Further, this synthesis should allow us to 
                                                
133  a) S. Bonazzi, S. Güttinger, I. Zemp, U. Kutay, K. Gademann, Angew. Chem. Int. Ed. 
2007, 46, 8707-8710; b) S. Bonazzi, O. Eidam, S. Güttinger, J.-Y. Wach, I. Zemp, U. 
Kutay, K. Gademann,  J. Am. Chem. Soc. 2010, 132, 1432-1442. 
134  Reviews on pyridone natural products: H. J. Jessen, K. Gademann, Nat. Prod. Rep. 2010, 
27, 1168-1185. 
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understand the role of the side chain length and substitution pattern for the 
recognition-processes. The combination of these structural features with the reported 
mechanism of action for these compounds lead to the hypothesis that small variations 
on the pyridone core could result in a large alteration of selectivity for biological 
targets.86,134,135  
As there are, to the best of our knowledge, no published reports on compounds 
lacking the 4'-methoxy group, we wanted to develop synthetic access to JBIR-02 and 
Mer-A2026B, which should also allow for the assignment of the unknown absolute 
and relative configuration of the two stereogenic centers of these compounds.  
5.5 Results and Discussion  
5.5.1 1st Generation Approach: Synthetic Investigations on Pyridones and 
Hydroxypyridines  
As pointed out in the retrosynthetic analyses the primary aim of this project was to 
find a suitable pyridine building block, functionalized at C1’, that allows the 
attachment of a fully elaborated side chain under mild conditions.  
N
H
OH
O ClClO
Cl
O
a
N
OCH3
H3CO Cl
b
5.52 5.53  
Scheme 5.9. Construction of the dimethylated pyridone: a) EtCN, neat, RT, 54%; b) 
Ag2CO3, MeI, CH2Cl2, hexane, RT, 34%.  
The investigations started with the formation of hydroxypyridone 5.52 in one step 
from ethyl nitrile and malonylchloride stirring with mechanical stirrer for three days 
(Scheme 5.9).136a The obtained brown solid could be easily purified by simple 
washing with CH2Cl2 to remove unreacted starting material. Then 5.52 was submitted 
to MeI and Ag2CO3 in order to obtain statistically the O,O-dimethylated hydroxy-
pyridone 5.53.136b  
                                                
135  K. Gademann, Current Drug Targets 2011, 12, 1574-1580. 
136  a) S. J. Davies, J. A. Elvidge, A. B. Foster, J. Chem. Soc. 1962, 3638-3644; b) J. Buck, J. 
P. Madeley, G. Pattenden, J. Chem. Soc. Perkin Trans. 1, 1992, 67-73. 
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Scheme 5.10. Attempts for the regioselective TBS protection: a) TIPSOTf, Et3N, 
hexane, DMSO, -78 °C to 0 °C, 40% (for 5.55); b) TBSCl, Et3N, CH2Cl2, DMSO, 80% 
(for 5.56); c) TBAF, KF or TFA. 
Attempts to selectively protect the 4-hydroxygroup of 5.52 with a TBS protecting 
group (5.54) as it was anticipated from the Lipshutz strategy124 were unsuccessful 
(Scheme 5.10). In contrast, the 2-hydroxy group was selectively protected when 5.52 
was treated with TBSOTf at -78 °C in a mixture of hexane/DMSO in presence of base 
which was verified by X-ray crystal structure analysis (5.55, not shown). Selective de-
protection methods (TBAF, Brønsted- or Lewis-acids) of the double TBS protected 
pyrone 5.56 to set free desired 4-mono-protected pyridone 5.54 were also unsuccesful 
(Scheme 5.10). 
Nevertheless, the dimethylated pyridone 5.53 was used to evaluate the finishing 
coupling strategy for the construction of the allyl-aryl fragment. A Stille-coupling, 
developed for unreactive arylchloride by Fu and co-workers (addition of CsF to 
facilitate the transmetallation)127 led to the formation of an undesired allene 5.58 in 
reasonable 68% yield (Scheme 5.11). The observed outcome of the reaction is in line 
with the one expected for a Hosomi-Sakurai reaction in which the propargylstannane 
5.57 gets activated by fluoride facilitating the tranfer of the attached residue.137  
We then inverted the coupling partners; the chloride subsituent was transformed by 
exposure to Me6Sn2, Pd(PPh3)4 and dppf in dioxane at 110 °C to the labile 2-pyridyl 
stannane 5.59.138 The propargylstannane 5.57 was substituted by geranylchloride to 
accomplish the desired allylic coupling127 in 41% yield (Scheme 5.11) without 
detectable E/Z-isomerization of the side chain (5.60). Nevertheless, the limited 
stability of the aryl precursor in combination with the undistinguishable double 
methylated hydroxy groups led us to abandoned this attempt on this early stage. 
                                                
137  N. Krause, A. S. K. Hashmi in Modern Allene Chemistry, Wiley-VCH, 2008, pp.1-37. 
138  G. R. Dick, E. M. Woerly, M. D. Burke, Angew. Chem. Int. Ed. 2012, 51, 2667-2672. 
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N
OCH3
H3CO SnMe3
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N
OCH3
H3CO
SnBu3
N
OCH3
H3CO
5.25
5.57
5.53a
c
5.58 5.59 5.60  
Scheme 5.11. Investigations on the final union of both entities: a) Pd(Pt-Bu3)2 
(10 mol %), CsF, dioxane, 100 °C, 68%; b) Pd(PPh3)4 (10 mol %), dppf (10 mol %), 
Me6Sn2, dioxane, 110 °C, 46%; c) geranylchloride, Pd(Pt-Bu3)2 (10 mol %), CuI, CsF, 
dioxane, 60 °C, 41%. 
5.5.2 2nd Generation Approach: Ortho-Functionalization of Pyridines 
In a second approach, it was envisioned to differentially protect both hydroxy 
groups directly from the beginning. Further, it was anticipated that the sensible 
organometallic species could be installed prior to the coupling by a methodology 
using dimethylaminoethanol as directing group for the ortho-lithiation of pyridines. 
NH3CO
CH3
NBr
CH3
5.61 5.62
N+H3CO
CH3
O-
NO2
NH3CO
CH3
OH
5.64
NH3CO
CH3
OTIPS
NH3CO
CH3
OTIPS
SnBu3
5.655.66
5.63
a b,c
d,e
fg
 
Scheme 5.12. Formation of the differently protected hydroxy-pyridone 5.66: a) NaH, 
MeOH, DMF, 100 °C, quant.; b) m-CPBA, CH2Cl2; c) HNO3 (fuming), H2SO4, 100 °C, 
3 h, 17% (2 steps); d) AcOH, Fe, 100 °C, 2 h; e) NaNO2, HNO3, H2O, 81% (2 steps); f) 
TIPSCl, Et3N, CH2Cl2, RT, 97%; g) i) DMEA (4 eq.), n-BuLi (8 eq.), hexane, 0 °C; ii) 
5.65, 0 °C, 1 h, iii) SnBu3Cl, THF, -78 °C to RT, 19%. 
The sequence started with the nucleophilic substitution of commercially available 
bromopyridine 5.61 with sodium methanolate at 100 °C (Scheme 5.12). Next the 
N-oxide was formed by addition of m-CPBA in CH2Cl2,139 or the methoxypyridine 
5.62 was directly treated with aqueous H2O2 and AcOH. Nitration of this compound 
was challenging, therefore the N-oxide was exposed to a 3:1 mixture of fuming HNO3 
                                                
139  J. M. Miller, J. Heterocycl. Chem. 1985, 22, 145-147. 
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and concentrated H2SO4 at 100 °C for 3 h.140 However, the yield of 5.63 (17% over 
both steps) was very low and the work-up and accordingly the purification of the 
polar nitropyridine-N-oxide was found to be difficult. The correct installment of the 
nitro group of 5.63 was confirmed by X-ray crystal structure analysis. The following 
reduction mediated by AcOH and iron powder at 100 °C and diazotation (NaNO2, 
HNO3, H2O) worked smoothly to afford 4-hydroxypyridine 5.64 in 81% yield over 
2 steps. Throughout these synthetic studies, exclusively the 4-hydroxypyridine 
tautomer, and not the 4-pyridone tautomer as reported for the natural JBIR-02 (5.2), 
was observed. The C-O bond lengths in the obtained X-ray crystal structure analysis 
of 5.64 support this observation. The C-OMe bond has a length of 135.3 pm likewise 
has the C-OH a length of 134.5 pm, which is rather long for a C=O double bond 
(typically around 120 pm) as required for a 4-pyridone. 
To prefunctionalize the heteroaromatic core for the subsequent allylic substitution, 
the directed lithiation strategy from Gros and Fort was adapted.141 Deprotonation of 
the ortho-position in pyridines is mediated by lithium dimethylaminoethoxide. The 
role of the amino group to chelate the lithium ion derived from n-BuLi, and the 
electron-rich alkoxy group enhances basicity, creating at the same time a sterically 
more hindered and less nucleophilic superbase. Additionaly, the nitrogen lone pair of 
the pyridine contributes to the stabilization of the lithium base accounting for the 
observed selectivity. Prior to the hydrogen-lithium exchange pyridine, 5.64 was 
protected as TIPS ether (5.65) and in a first screening exposed to the deprotonation 
conditions present in literature. The use of 4 eq. of the formed superbase was found to 
be the best compromise in terms of deprotonation time and concentration, what could 
be analysed by 1H NMR after quenching with D2O. Afterwards the lithiated hetero-
aromatic core was treated with 5 eq. of Bu3SnCl and stirring continued for further 
30 min at 0 °C. The choice of the used solvent, n-hexane and toluene had negligible 
effect on the reaction, as well as the temperature ranging from -20 °C until 10 °C.  
                                                
140  a) M. Tiecco, M. Tingoli, L. Testaferri, D. Chianelli, E. Wenkert, Tetrahedron 1986, 42, 
1475-1485; b) E. C. Taylor Jr, A. J. Crovetti, Org. Synth. 1963, 4, 654-655. 
141  a) H. K. Khartabil, P. C. Gros, Y. Fort, M. F. Ruiz-Lopez, J. Am. Chem. Soc. 2010, 132, 
2410-2416; For Reviews: b) P. Gros, Y. Fort, Eur. J. Org. Chem. 2002, 3375-3383; c) P. 
Gros, Y. Fort, Eur. J. Org. Chem. 2009, 4199-4209. 
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However, even when the reaction was succesfully performed, purification of the 
labile ortho-stannane 5.66 remained problematic (best yield 19%). Various column 
chromatography strategies were examined either on Alox or deactivated silica with 
solvents containing additional base or degased prior to use. This approach was there-
fore abandoned on this stage due to the low yielding nitration and the problematic 
ortho-functionalization. Furthermore the following Stille-coupling, when performed 
with the obtained stannane 5.66 afforded the protected piericidin precursor as an 
inseparable mixture of E:Z isomers (see Chapter 5.6, Scheme 5.21). So another 
strategy for the construction of the heteroaromatic motif had to be envisioned, 
focusing predominantly on the facilitated formation of 4-hydroxypyridines. 
5.5.3 3rd Generation Approach: Directed Bromine-Lithium Exchange 
Finally, the total synthesis started with the preparation of the protected bromo 
pyridinol 5.71 in 5 steps as shown in Scheme 5.13. Commercially available 2-bromo-
6-methoxypyridine (5.67) was converted to pyridinol 5.68 in 62% yield by a 
C-H activation reaction using [Ir(COD)Cl]2 and dppe in neat pinacolborane (pinBH, 
5 eq.) at 150 °C, followed by oxidation of the crude boronic acid intermediate with 
oxone in THF.142 Improving this protocol by replacing the catalyst to 2 mol % 
[Ir(COD)OMe]2, and the ligand to 4 mol % 4,4’-di-tert-butyl-2,2’-bipyridine (dtbpy) 
lead to a lower reaction temperature and a smaller amount of required pinBH (1.5 eq.) 
as the reaction was performed in hexane and improved the yield to 79%.143  
Subsequent treatment with excess of N-bromosuccinimide (NBS) afforded 
tribromopyridinol 5.69 in 92% yield, as all attempts to selectively mono-functionalize 
C2’ with different electrophilic bromination and iodination reagents (NBS, 1,1-di-
bromo-5,5-dimethylhydantoin (DBDMH) or I2 with catalytic amounts of CAN) were 
unsuccessful (Table 5.2).  
The best selectivity obtained for the C2’ functionalization was 57:43 in favor of the 
undesired regioisomer, when SEM protected pyridine 5.72 was subjected to NBS in 
CH3CN at room temperature. Analogous, 4-hydroxypyridine 5.68 was also protected 
as TIPS ether (5.73) or acetate (5.74) by standard conditions and evaluated for the 
                                                
142 R. E. Maleczka Jr., F. Shi, D. Holmes, M. R. Smith III, J. Am. Chem. Soc. 2003, 125, 
7792-7793. 
143  T. Ishiyama, Y. Nobuta, J. F. Hartwig, N. Miyaura, Chem. Commun. 2003, 2924-2925.  
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bromination reaction without effecting the selectivity. Additional investigations were 
performed with a smaller chloro substituted pyridinol instead of the bromo substituent 
without improving the selectivity.  
NH3CO Br NH3CO Br
OH
5.68
NH3CO Br
OSEM
BrBr
NH3CO Br
OH
BrBr
NH3CO Br
OSEM
CH3
5.71
5.705.69
4' 2'
4'
a b
5.67
c
d,ef or g or h
NH3CO Br
OR
5.72: R = SEM
5.73: R = TIPS
5.74: R = Ac
 
Scheme 5.13. Synthesis of the heteroaromatic intermediate 5.71. The positions labelled 
2' and 4' refer to the piericidin nomenclature: a) i) [Ir(COD)OMe]2 (2 mol %), dtbpy 
(4 mol %), HBpin, hexane, RT, ii) oxone, THF, H2O, RT, 79%; b) NBS, CH3CN, RT, 
92%; c) SEMCl, DIPEA, CH2Cl2, 0 °C to RT, 82%; d) i) n-BuLi, THF, -78 °C; ii) MeI, 
-78 °C to RT; e) i) n-BuLi, THF, -78 °C; ii) MeOH, -78 °C to RT, 67% (2 steps); 
f) TIPSCl, Et3N, CH2Cl2, 88%; g) SEMCl, Et3N, CH2Cl2, 88%; h) Ac2O, DMAP, Et3N, 
CH2Cl2, 84%.  
Selective O-SEM protection of the triple brominated pyridine 5.69 to direct the 
aromatic functionalization in the next steps was accomplished using SEMCl and 
DIPEA in CH2Cl2. The correct substitution pattern at the heteroaromatic ring was 
installed by sequential two-fold lithium-halogen exchange using n-BuLi in THF 
at -78 °C: (1) Trapping of the stabilized C2'-lithiated aryl species with MeI (for C2' 
substitution) followed by (2) protonation with MeOH (for the C4' position) completed 
the target fragment 5.71 with the correct substitution pattern in 67% yield over 
2 steps. Apparently, the donor capacity of the neighboring bromine is higher than the 
stabilizing effect of the methoxy group. This strategy was found to be superior to 
ortho-metalation, in which even bulky non-nucleophilic bases such as LDA or LiTMP 
resulted in nucleophilic substitution of the bromo substituent and could not be 
suppressed by varying the reaction conditions.  
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Table 5.2. Screening for the selective halogenation of position C2’. 
N
OR
H3CO Br N
OR
H3CO Br N
OR
H3CO Br N
OR
H3CO Br
X X X X
1 2 3
Conditions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Determined by 1H NMR of the crude product or the reaction mixture; b after 
purification by column chromatography. Pure products were analyzed by 1H NMR, 
13C NMR and UPLC-MS; c before work-up; when more then 1 eq. NBS was used 
double brominated side-product was obtained after evaporation of solvent. 
 Conditions 
Ratio of regio- 
isomersa 1:2:3 Conversion
a Yieldb 
R = H 1.1 eq. NBS, CH3CN 0:100:0 79%/ 60 h 63% 
 1.1 eq. NBS, MeOH 0:100:0 72%/ 16 h - 
 1.1 eq. NBS, CCl4 0:100:0 99%/ 16 h - 
 1 eq. DBDMH, THF 0:0:100 99%/ 19 h - 
 0.5 eq. DBDMH, THF 0:66:34 75%/ 18 h - 
 1 eq. I2, 0.1 CAN, CH3CN 0:31:69 99%/ 1.5 h 55% 
 0.5 eq. I2, 0.1 CAN, CH3CN 0:75:25 99%/ 1 h quant. 
 2 eq. I2, 0.1 CAN, CH3CN 0:0:100 99%/ 12 h quant. 
R = SEM 1.1 eq. NBS, CH3CN 42:57:0 78%/ 16 h 35% 
 1.5 eq. NBS, CH3CN, 60 °C 40:60:0c 99%/ 4 h - 
 1.1 eq. NBS, MeOH 0:100:0 75%/ 18 h - 
 1.1 eq. NBS, CCl4 - - / 18 h - 
 1.1 eq. NBS, CCl4, 75 °C - - / 5 h - 
 1.0 eq. Br2, NaOAc, AcOH 30:47:22 70%/ 1.5 h - 
 1 eq. DBDMH, THF Complex mixture 99%/ 19 h - 
 0.5 eq. I2, 0.1 CAN, CH3CN - - / 16 h - 
R = Ac 1.1 eq. NBS, CH3CN - - / 16 h - 
 1.1 eq. NBS, CH3CN, 90 °C - - / 16 h - 
R = TIPS 1.1 eq. NBS, CH3CN - - / 16 h - 
 1.1 eq. NBS, CH3CN, 90 °C - - / 16 h - 
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5.5.4 The Polyene Side Chain 
The polyene side chain synthesis was addressed next. As the configuration of both 
target compounds was unknown, we assumed the same absolute configuration as 
established for piericidin A1. The preparation of the side chain started with a 
vinylogous Mukaiyama aldol reaction developed by Kobayashi and co-workers.129,144 
This procedure allows to induce a high degree of asymmetric information in an 
acyclic system. The methyl group at the α-position stabilizes the planar conformation 
of the acyl residue on the one hand and excludes a free rotation of the chiral auxilliary 
(Figure 5.9), leading to the almost perpendicular arrangement of oxazolidin-2-one 
and the nucleophilic enolate. The aldehyde activated by the Lewis-acid approaches 
from the less hindered side to form a C-C bond and affords the observed stereogenic 
outcome. 
Me O
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Me
Me
Si
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E
H
Me
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Me OTBS
XN
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H
Me
O
H
R
Me OTBS
XN
Cl4TiMe
 
Figure 5.9. Mechanistic rational for Kobayashi’s Mukaiyama aldol.129 XN = Evans 
auxiliary. 
Instead of the more common Evans auxiliary, we planed to perfome the described 
transformation with the help of the bulkier, UV active Seebach’s auxiliary (5.72) 
which can be easiliy recovered and recycled by fash column chromatography once 
cleaved from the side chain. Acylation with 2-methyl-pentenoic acid was performed 
using pivalyl chloride to form in situ the unsymmetric anhydride which is attacked by 
the cyclic carbamate (Scheme 5.14). Due to the help of LiCl coordinating to the lone 
pairs of the anhydride increasing its electrophilic character 5.73 was obtained after 
stirring over night at room temperature in very good yield (89%). This method 
                                                
144  For recent examples and modifications of this methodology: a) I. Paterson, S. B. J. Kan, L. 
J. Gibson, Org. Lett. 2010, 12, 3724-3726; b) Y. Mukaeda, T. Kato, S. Hosokawa, Org. 
Lett. 2012, 14, 5298-5301; c) G. Symkenberg, M. Kalesse, Org. Lett. 2012, 14, 1608-
1611; d) K. Fujita, R. Matsui, T. Suzuki, S. Kobayashi, Angew. Chem. Int. Ed. 2012, 51, 
7271-7274; e) H. Tsukada, Y. Mukaeda, S. Hosokawa, Org. Lett. 2013, 15, 678-681. 
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displays significant advantages in terms of yield and handling compared to the regular 
use of acid chloride.  
OR
NO
O
Ph
Ph
O
NO
O
Ph
Ph
NHO
O
Ph
Ph
5.73
a b
5.72 5.74: R = TBS 
5.75: R = TMS  
Scheme 5.14. Attempts for the preparation of N,O-silyl ketene acetal starting from 
Seebach’s auxilliary: a) i) PivCl, Et3N, 2-methyl-pentenoic acid; ii) LiCl, auxilliary, 
THF, -45 °C to RT, 89%; b) i) KHMDS; ii) TBSCl or TMSCl, THF, -78 °C. 
Unfortunately all attemps to form the silyl ketene (5.74 or 5.75) acetal using 
TBSCl or TMSCl as protecting groups failed. This can be rationalized from the 
obtained X-ray crystal structure of the acylated auxiliary 5.73: The isopropyl group is 
pushed by both phenyl substituents of the auxilliary into the side chain thereby 
prohibiting the all planar arrangement for the desired product formation. Following 
the literature procedure usage of the smaller Evans auxilliary led to the formation of 
the desired TBS enolate (5.76).129 
O
H Br+
5.78 5.79
5.76
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O OTBS
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Scheme 5.15. Kobayashi’s vinylogous Mukaiyama aldol reaction: a) TiCl4, CH2Cl2,  
-35 °C, 18 h, 91%, dr > 50:1. 
Treatment of N,O-silyl ketene acetal 5.76 and bromoacrylate 5.78145 provided the 
desired hydroxyl imide 5.79 via a TiCl4 mediated C-C bond forming reaction with 
exclusive formation of one diastereomer (1H NMR > 50:1) in 91% yield (12-mmol 
scale). The relative and absolute configuration at C-9 and C-10 were established by 
                                                
145  Y. Murakami, M. Nakano, T. Shimofusa, N. Furuichi, S. Katsumura, Org. Biomol. Chem. 
2005, 3, 1372-1374. 
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the X-ray crystal structure analysis of the aldol product 5.79 (Scheme 5.15). The 
vinylogous Mukaiyama aldol reaction with the more complex substrate (2E,4E)-2,4-
dimethylhexa-2,4-dienal 5.77 as coupling partner, was not successful under the 
previously described conditions. This finding could be explained by the extended 
conjugation, transforming the dienal in a rather unreactive coupling partner towards 
nucleophilic attack.146 
Silylation of hydroxyl imide 5.79 with TBSOTf in the presence of 2,6-lutidine in 
CH2Cl2 at -78 °C, followed by the removal of the chiral auxiliary in a two-step 
process via reduction with NaBH4 and oxidation of the allylic alcohol with activated 
MnO2 afforded aldehyde 5.80 in 87% over 3 steps as our corporate building block 
(Scheme 5.16). Elongation to the unsaturated ester 5.81 was achieved by a Horner-
Wadsworth-Emmons (HWE) reaction applying a protocol developed by Masamune 
and Roush to avoid partial epimerization at C-9.147 Expanding the scope of this 
strategy, this transformation allowed the introduction of different residues at C-5 - as 
for example CH3 present in natural piericidins (IT-143-B)108 by changing the phos-
phonate coupling partner (5.82).  
5.79
NO
O O OH
Br
OTBS
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H
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OTBS
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MeO
5.81: R = H
5.82: R = CH3
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Scheme 5.16. Synthesis of the polyene side chain (part 1): a) TBSOTf, 2,6-lutidine, 
CH2Cl2, -78 °C to RT; b) NaBH4, THF, H2O, RT; c) MnO2, CH2Cl2, RT, 87% (3 steps); 
d) P(O)(OEt)2CH2COOMe, DBU, LiCl, CH3CN, 0 °C to RT, quant. (R = H) or 
P(O)(OEt)2CHCH3COOEt, DBU, LiCl, CH3CN, 0 °C to RT, 85%. 
Cross-coupling of vinyl bromide 5.81 (or 5.82) under Stille conditions 
(Pd(Pt-Bu3)2 (10 mol %), LiCl, NMP, 80 °C) with stannane 5.83, derived from 
commercially available E-2-bromo-2-butene by lithiation and quenching with 
Bu3SnCl, afforded tetraene 5.84 (or 5.85) in very good yield (Scheme 5.17). Under 
these conditions, isomerization of the terminal methyl group could be avoided 
(determined by NOE investigations). Using the opportunity to transform 
                                                
146  a) M. Bock, R. Dehn, A. Kirschning, Angew. Chem. Int. Ed. 2008, 47, 9134-9137; b) Y. 
Nakamura, H. Kiyota, B. J. Baker, S. Kuwahara, Synlett, 2005, 635-636. 
147  M. Blanchette, W. Choy, J. T. Davis, A. P. Essenfeld, S. Masamune, W. R. Roush, T. 
Sakai, Tetrahedron Lett. 1984, 25, 2183–2186. 
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vinylbromide 5.81 by transition metal catalysis into a number of natural piericidins, 
the vinylbromide was elongated at C-12 by Suzuki coupling (Pd(PPh3)4 (5 mol %), 
CH3B(OH)2, Cs2CO3, dioxane, H2O, 65 °C) to triene 5.86 in 69% yield. 
Bu3Sn
OTBSO
MeO
5.84: R = H
5.85: R = CH3
OTBSO
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5.86
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5.87-5.89
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Scheme 5.17. Synthesis of the polyene side chain (part 2): a) Pd(Pt-Bu3)2 (10 mol %), 
LiCl, NMP, 80 °C, 95% (R = H), 97% (R = CH3); b) Pd(PPh3)4 (5 mol %), CH3B(OH)2, 
Cs2CO3, dioxane, H2O, 65 °C, 69%; c) DIBAlH, CH2Cl2, -78 °C to 0 °C; d) Ac2O, 
DMAP, Et3N, CH2Cl2, 0 °C, 90% (R = H, R’ = C4H7, 2 steps), 80% (R = CH3, R’ = 
C4H7, 2 steps) and 95% (R’ = CH3, 2 steps); e) Pd(dba)2 (5 mol %), LiCl, DIPEA, 
NMP, 45 °C, 3 h, 90% (R = H, R’ = C4H7), 77% (R = CH3, R’ = C4H7) or 77% (R = 
CH3), for all cases E:Z = 5:1. 
DIBAlH reduction of esters 5.84-5.86 followed by acetylation produced the allylic 
acetates 5.87-5.89 as precursors for the first allylic substitution (90% for 5.87, 80% 
for 5.88 and 95% for 5.89 over 2 steps). In order to remove traces of AcOH, which 
led to significantly reduced yields, Ac2O was filtered through a small column of 
Al2O3 before use. Next allylic substitution using Pd(dba)2, LiCl, DIPEA and hydroxy 
stannane 5.90148 at 45 °C for 3 h delivered 5.91 (90%), 5.92 (77%) and 5.93 (77%) in 
a ratio of 5:1 as its E- and Z-isomers.  
5.5.5 Isomerization Along the Chain 
As the identification of the formed side product remained unknown at the 
beginning, bromide 5.95 was synthezised as a model compound via the same 
transformations: DIBAlH reduction, acetylation and allylic substitution (Scheme 
5.18). This time both isomers could be easily separated by chiral preparative HPLC 
                                                
148  J.-F. Betzer, F. Delaloge, B. Muller, A. Pancrazi, J. Prunet, J. Org. Chem. 1997, 62, 7768-
7780. 
82   CHAPTER 5 
 
(hexane/i-PrOH, 99.5:0.5 as solvent) and characterized by NOE experiments (Figure 
5.10 and Appendices).  
OTBS
Br
a,b
OTBS
BrHOAcO
c5.81
5.94 5.95  
Scheme 5.18. Synthesis of the vinyl bromide model: a) DIBAlH, CH2Cl2, -78 °C to 
0 °C; b) Ac2O, DMAP, Et3N, CH2Cl2, 0 °C, 83%; c) 5.90, Pd(dba)2 (5 mol %), LiCl, 
DIPEA, NMP, 45 °C, 3 h, 71%, E:Z 5:1. 
Surprisingly, the Stille-coupling performed at 45 °C did not solely answer the 
identity of the formed side product but itself is a rare example in which the reactivity 
of an allylic and a vinylic positon in a cross-coupling reaction are compared. 
Obviously, the allylic position is much more reactive towards the Stille-coupling 
conditions affording exclusively the allylic substitution products remaining the vinylic 
bromide untouched. 
Br
OTBSH3C
HO
CH3
(7Z)-isomer
Br
OTBS
CH3H3C
[Pd]
Br
OTBS
CH3H3C
[Pd]
OTBS
Br
CH3 CH3
HO
(7E)-isomer
5.90
Br
OTBSH3C
CH3
[Pd] 5.90
5.90
Bu3Sn
OH
7
8
7 8
1
4
1
4
14
 
Scheme 5.19. Plausible mechanism for the isomerization during allylic substitution 
with stannane 5.90. 
Interestingly, the isomerization could be observed at the olefinic linkage between 
C7-C8. A reasonable mechanism for the isomerization is shown in Scheme 5.19. 
Upon treatment with Pd catalyst and formation of the Pd-allyl-complex, isomerization 
of this complex along the chain is likely to occur. Due to the allylic strain of the 
adjacent methyl groups this complex could isomerize to the thermodynamically more  
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Figure 5.10. 1H NMR analysis of the isomerization during the second allylic 
substitution with a model substrate (vinyl bromide 5.95, crude E:Z ratio: 5:1). 
stable Z-olefin and react further with stannane 5.90 to afford (7Z)- 5.95. The E:Z-ratio 
could not be improved by exploring different reaction parameters such as catalyst, 
reaction time or temperature. 
5.5.6 Total Synthesis of JBIR-02 and Mer-A2026B 
Next, (7E)-allylic alcohols 5.91-5.93 were transformed to their corresponding 
carbonates 5.96-5.98 (CH3OCOCl, Et3N at 0 °C) thereby generating a suitable leaving 
group for the subsequent allylic substitution as shown in Scheme 5.20. The crucial 
connection of both moieties, the 4-hydroxypyridine core and the fully elaborated 
polyene chain, was realized after extensive experimentation on the Negishi cross-
coupling reaction and proved to be mild enough to avoid isomerization or 
decomposition.149 
The protected Br-pyridinol 5.23 or 5.71 was lithiated using n-BuLi in THF at  
-78 °C. After 10 min, ZnCl2 was added and the resulting mixture was allowed to 
warm to room temperature over 1 h to form a relatively stable 2-pyridylzinc 
                                                
149  E. Negishi, F. Liu in Handbook of Organopalladium Chemistry for Organic Synthesis, 
Wiley, 2002, pp. 551-589. 
(7E)-isomer 
(7Z)-isomer 
mixture of isomers 
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reagent,150 which was exposed to a freshly prepared mixture of carbonate 5.96-5.98 
and 5 mol % of Pd(PPh3)4, and warmed to 50 °C for 3 h to provide the protected 
natural products without detectable isomerization. Final deprotection of the succesful 
coupled polyenes was achieved by treatment with TBAF at elevated temperatures 
(70 °C, THF) to produce piericidin A1 (5.1, 29% over 3 steps), JBIR-02 (5.2, 57% 
over 3 steps) and Mer-A2026B (5.3, 60% over 3 steps) in good yields.  
OTBS
R'X
5.91-5.93, X = OH
5.96-5.98: X = OCOOCH3
NH3CO
OH
OH
R'
a
b,c
N
OSEM
H3CO Br
5.23 or 5.71
5.1-5.3
R
R
R''
R''
 
Scheme 5.20. Completion of the synthesis of piericidin A1 (5.1), JBIR-02 (5.2), 
Mer-A2026B (5.3): a) ClCOOCH3, Et3N, CH2Cl2, 0 °C, 30 min, quant.; b) i) 5.23 or 
5.71, n-BuLi, THF, -78 °C; ii) ZnCl2, THF, -78 °C to RT; iii) Pd(PPh3)4 (5 mol %), 
5.96 or 5.98, THF, 50 °C, 2 h, 69% (R’ = C4H7, R’’ = H) and 65% (R’ = CH3, R’’ = H), 
E:Z > 25:1; c) TBAF, THF, 70 °C, 30 min, 29% (over 2 steps, R’ = CH3, R’’ = OCH3), 
82% (R = H, R’ = C4H7) and 93% (R = H, R’ = CH3). 
The Negishi conditions proved superior to Sn based cross-coupling, in which 
significant isomerization was observed (Scheme 5.21), what was also observed by 
Phillips et al. during their synthesis of natural 7-demethyl-piericidin.121  
In the case of the Stille-coupling, the side chain was activated as its allyl chloride 
instead (Me2S, NCS in CH2Cl2 at 0 °C) and exposed to Pd(PPh3)4, LiCl in degased 
DMF at 45 °C. Except the low yield and selectivety this method lacked 
reproduceability mainly caused by the nature of the sensitive aromatic coupling 
partner. Purification of the desired E-isomers for the natural product was neither 
possible with silver coated silica nor with preparative HPLC. 
                                                
150  For selected 2-pyridylzinc reagents: a) M. R. Luzung, J. S. Patel, J. Yin, J. Org. Chem. 
2010, 75, 8330-8332; b) J. K. Klosterman, A. Linden, J. S. Siegel, Org. Biomol. Chem. 
2008, 6, 2755-2764; c) U. Kiehne, J. Bunzen, H. Staats, A. Lützen, Synthesis 2007, 1061-
1069; d) T. Sammakia, E. L. Stangeland, M. C. Whitcomb, Org. Lett 2002, 4, 2385-2388; 
e) F. Mongin, F. Trécourt, O. Mongin, G. Quéguiner, Tetrahedron 2002, 58, 309-314; f) S. 
A. Savage, A. P. Smith, C. L. Fraser, J. Org. Chem. 1998, 63, 10048-10051. 
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OTBS
X
5.91: X = OH
5.99: X = Cl
NH3CO
OTIPS
OTBS
a
b
N
OTIPS
H3CO SnBu3
5.66
5.2  
Scheme 5.21. Final Stille cross-coupling of stannane 5.66 and allylchloride 5.99: a) 
Me2S, NCS, CH2Cl2, 0 °C, quant.; b) Pd(dba)2 (10 mol %), PPh3, LiCl, DMF, 45 °C, 
45%, E:Z = 2.5:1 
5.5.7 Characterization 
The comparison of spectra of natural and synthetic samples was carried out next, in 
order to confirm the reported structures and to assign the absolute configuration. 
 
Figure 5.11. 1H NMR overlay of isolated (A) and synthetic (B) Mer-A2026B (5.3). 
B 
A 
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Table 5.3. NMR comparison of natural and synthetic Mer-A2026B (5.3). 
OH
NH3CO
OH
1
4 8
10
2'
5'
 
 Synthetic Mer-A2026B Natural Mer-A2026B110 
 1H NMR 13C NMR 1H NMR 13C NMR 
1 3.36 d (7.0) 29.8 3.36 d (6.9) NR 
2 5.31 m 130.0 5.32 t (7.0) NR 
3 - 136.4 - NR 
4 2.84 d (6.7) 42.9 2.83 d (7.0) 43.0 
5 5.58 dt (15.5, 7.0) 125.4 5.58 dt (15.4, 7.0) 125.8 
6 6.11 d (15.5) 136.5 6.10 d (15.4) 136.3 
7 - 135.8 - 135.7 
8 5.25 d (9.7) 133.8 5.24 d (9.9) 133.6 
9 2.69 m 36.8 2.69 m 36.9 
10 3.66 d (9.1) 82.8 3.64 d (9.2) 82.8 
11 - 135.5 - 135.6 
12 5.49 m 123.7 5.49 m 123.5 
13 1.63 d 13.0 1.63 d (7.0) 13.1 
1’ - NR - NR 
2’ - NR - NR 
3’ - NR - NR 
4’ 5.87 bs 92.4 5.93 s 92.4 
5’ - NR - NR 
3-Me 1.72 s 16.5 1.72 s 16.6 
7-Me 1.81 s 13.0 1.81 s 13.1 
9-Me 0.81 d (6.7) 17.2 0.81 d (6.6) 17.4 
11-Me 1.64 s 10.4 1.64 s 10.6 
2’-Me 2.03 9.9 2.03 s 10.1 
5’-OMe 3.81 55.0 3.79 s 54.6 
 1H NMR 400 MHz and 13C NMR 100 MHz in CDCl3; NR = could not be observed. 
The spectroscopic data of synthetic Mer-A2026B (5.3) were found to be identical 
in all respects (1H NMR, Figure 5.11, 13C NMR, UV spectra and optical rotation: 
[α]D = -1.1° (c = 0.11, MeOH), lit.[α]D = -1.07° (c = 0.36, MeOH)) to those reported 
in the literature for the natural product (Table 5.3). The same is true for piericidin A1 
which was identical to the spectra of the total syntheses of Boger,104 Lipshutz124 and 
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Akita123 and showed only one set of peaks indicating either the pyridone or 
hydroxypyridine tautomer is present. 
For JBIR-02 (5.2), confirmation of the structure proved to be more complex. At the 
beginning, several key signals of the aromatic core in the 1H NMR spectra (Figure 
5.12) displayed different chemical shifts when compared with the reported data of the 
isolated natural product (Table 5.4, indicated in red). Afterwards, the identity of 
natural and synthetic JBIR-02 was confirmed by 1H, 13C NMR and UHPLC measure-
ments by Dr. Izumikawa in the laboratories of Prof. Dr. Shin-ya (National Institute of 
Advanced Industrial Science and Technology) and later in our laboratories by 
1H NMR spectroscopy. In the 1H NMR of synthetic JBIR-02 was only one tautomer 
form observed when measured in Switzerland (CDCl3; Cambridge Isotope Lab. Inc.: 
DLM-7-100). Whereas when measured in Japan (CDCl3; Eurisotop: D007H) two 
tautomeric forms were detected in the synthetic sample and the spectra was in full 
agreement with the one from the isolated sample, what could be verified later by 
measuring the isolated natural product in Switzerland (with only one tautomer form 
visible).  
In the meantime the heterocyclic precursor (5.71) alone was exposed to the 
approved coupling conditions and SEM-deprotected afterwards to prove its structure 
by comparison with compound 5.64 an intermediate of the second generation 
approach for which we obtained a X-ray crystal structure analysis (Scheme 5.22). As 
both compounds were equivalent, methyl-group transfer as side reaction under the 
successful Negishi cross-coupling conditions could be ruled out and the present of the 
correct substitution pattern was confirmed. 
N
OSEM
H3CO Br
5.71
a,b
N
OH
H3CO
5.64  
Scheme 5.22. Confirmation of the structure of the heterocyclic motif: a) i) n-BuLi, 
THF, -78 °C; ii) ZnCl2, THF, -78 °C to RT; iii) MeOH; b) TBAF, THF, 70 °C, 30 min.  
The final proof of identical constitution of synthetic and natural samples of 
JBIR-02 was established by co-injection of both samples and analysis by UHPLC. 
Apparently, the amount of water or the amount of acid in the CDCl3 solution can lead 
to the observation of tautomerism and, therefore causes drastically different spectra. 
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Figure 5.12. 1H NMR overlay of isolated natural JBIR-02, 5.2 (A) and synthetic 5.2 
(B, both measured in the laboratory of Prof. Shin-ya at the National Institute of 
Advanced Industrial Science and Technology (AIST), Japan), natural 5.2 (C) and 
synthetic 5.2 (D, both measured in the University of Basel, Switzerland); most 
significant differences are indicated by red arrow symbols (in A and D). 
A 
B 
C 
D 
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Table 5.4. NMR comparison of natural and synthetic JBIR-02 (5.2); red frames 
indicated mismatches in the first obtained 1H NMR spectra of isolated (Japan) and 
synthesized (Switzerland) natural product. 
OH
NH3CO
OH
1
4 8
10
2'
5' 14
 
 Synthetic JBIR-02 Pyridone form109 Hydroxypyridine 
form109 
 1H NMR 13C NMR 1H NMR 13C NMR 1H NMR 13C NMR 
1 3.36 d (7.1) 30.6 3.54 d (6.9) 30.6 3.49 d (6.9) 35.1 
2 5.30 m 122.2 5.23 t (6.1) 121.5 b5.42 118.3 
3 - 135.8 - 139.9 - 135.8 
4 2.83 d (6.9) 42.9 2.81 d (6.8) 43.1 2.80 d (6.8) 43.2 
5 
5.58 dt 
(15.5, 7.0) 
125.9 
5.54 dt 
(15.7, 6.9) 
125.5 
5.60 dt (15.7, 
7.0) 
126.7 
6 6.11 d (15.5) 136.3 6.09 d (15.7) 136.7 6.10 d (15.4) 136.0 
7 - 135.7 - 135.6 - 136.1 
8 5.25 d (9.6) 133.6 5.26 d (9.8) 134.1 5.23 m 133.4 
9 2.71 ddq 36.9 2.71 ddq 37.1 2.71 ddq 37.2 
10 3.65 d (8.9) 83.3 3.66 d (8.8) 83.6 3.64 d (9.1) 83.5 
11 - 133.9 - 134.2 - 134.2 
12 5.84 s 132.8 5.84 s 132.9 5.84 s 132.8 
13 - 133.5 - 133.1 - 132.8 
14 5.41 q (6.8) 124.7 
5.41 qd 
(6.8, 1.2) 
124.9 
b5.41 qd  
(6.8,1.2) 
124.8 
15 1.68 d (6.8) 13.8 1.69 d (6.9) 13.8 1.69 d (6.9) 13.8 
1’ - NR - 148.0 - 159.2 
2’ - a113.4 - 115.9 - 116.7 
3’ - NR - 175.7 - 158.1 
4’ 5.92 bs 92.4 6.40 bs 92.2 6.50 bs 100.2 
5’ - a158.6 - 159.6 - 162.6 
3-Me 1.71 d (1.1) 16.8 1.74 d (1.2) 16.9 1.75 s 16.8 
7-Me 1.80 d (1.1) 13.3 1.79 d (1.2) 13.3 1.80 d (1.2) 13.3 
9-Me 0.85 d (6.7) 17.6 0.84 d (6.6) 17.7 0.84 d (6.6) 17.6 
11-Me 1.78 s 12.7 1.78 bs 12.7 1.78 bs 12.7 
13-Me 1.74 s 16.7 1.74 bs 16.7 1.74 bs 16.7 
2’-Me 2.03 10.3 2.04 s 10.1 2.14 s 10.8 
5’-OMe 3.79 54.7 3.85 s 56.3 3.91 s 53.8 
1H NMR 500 MHz and 13C NMR 125 MHz in CDCl3. 
a Low temperature (218 K) HMBC. b Overlap. NR = could not be observed. 
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Figure 5.13. UPLC traces of (A) a mixture of synthetic and isolated natural JBIR-02 
(5.2), (B) natural 5.2 and (C) synthetic 5.2 measured in the laboratory of Prof. Shin-ya 
(Tokyo, Japan). UPLC conditions: column: ACQUITY UPLC BEH C18; 1.7 mm, 
2.1 i.d. x 100 mm; flow rate: 0.4 ml/min; solvent: 50% MeCN (0.1% HCOOH).  
 
Figure 5.14. RP-HPLC (H2O:CH3CN) UV-trace and UV spectra of synthetic JBIR-02. 
A 
B 
C 
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Interestingly, the pyridone form of these piericidin analogs has been never observed 
by any other research group (see also X-ray crystal structure in Chapter 5.5.1, the 
related work of Boger and co-workers104 and the isolation and characterisation of 
natural piericidins105,108-112). The optical rotation ([α]D = -11.1° (c = 0.21, MeOH)) 
matched its literature value ([α]D = -13.0° (c = 0.88, MeOH)) and thereby allowed us 
to establish the absolute configuration as (9R,10R) for  5.2. 
5.5.8 SAR studies 
Having established conditions for the final coupling of the sensitive side chain with 
the heteroaromatic core we aimed to use further simplified side chain analogs to 
investigate whether the complexity - 2 chiral centers, 1,4-diene moiety - is necessary 
for its biological activity. For this purpose we used geranyl carbonate as side chain 
mimic and performed our developed Negishi cross-coupling with different 
heterocyclic cores (Scheme 5.23). TBAF mediated deprotection afforded two pierici-
din analogs, differing in the aromatic substitution pattern. 
N
OSEM
H3CO Br
5.71
N
OTIPS
H3CO Br
5.73
or a,b
N
OH
R
H3CO
5.100: R = H
5.101: R = CH3  
Scheme 5.23. Synthesis of simplified analogs using the Negishi cross-coupling 
strategy: a) i) 5.71 or 5.73, n-BuLi, THF, -78 °C; ii) ZnCl2, THF, -78 °C to RT; iii) 
Pd(PPh3)4 (5 mol %), geranyl carbonate, THF, 50 °C, 2 h, 42% (R = H) and 72% (R = 
CH3), E:Z > 25:1; c) TBAF, THF, 70 °C, 30 min, 98% (R = H) and 79% (R = CH3). 
In the future it is envisioned to create a library of different lengths similar to the 
one produced by Rapoport 40 years ago and evaluate the side chain recognition 
pattern. Biological evaluation for the obtained compounds (natural products as well as 
analogs) is currently carried out at Syngenta AG in Stein (Switzerland). 
5.6 Conclusion 
In conclusion, the first total syntheses of piercidin derivatives Mer-A2026B and 
JBIR-02 (longest linear sequence 12 steps, overall yield 28% for 5.2, respectively 
20% for 5.3) were developed and the absolute configuration could be established as 
(9R,10R). Further piericidin A1 5.1 – the prototype of the natural product family itself 
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was synthesized using the same strategy. Salient features of this efficient and 
convergent synthetic route are a highly diastereoselective Kobayashi-Mukaiyama 
aldol reaction, a C-H activation reaction in combination with an oxidation protocol for 
the preparation of the highly functionalized pyridine moiety and a final Negishi cross-
coupling reaction without isomerization of the labile side chain. Moreover, this 
approach opens up the stage for the synthesis of a number of piericidins by simply 
changing the coupling partner for the HWE reaction (C-5 analogs) or the 
organometallic species for the cross-coupling reaction (C-12 functionalization). 
Studies targeting these derivatives are underway in our laboratories.  
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6 ELECTRON-RICH BIPYRIDINES 
6.1 Introduction 
Inspired by the original bioactivities of piericidins as inhibitors of the respiratory 
chain, electron-rich 2,2’-bipyridine (bpy) systems also attracted our attention and 
were therefore investigated as model for the concerted proton coupled electron 
transfer (PCET).151  
Light driven water oxidation in the photosystem II is an ubiquitous reaction in 
plants producing not solely essential oxygen but also a proton gradient across the 
membrane from the stroma to the lumen responsible for the producion of ATP (eq 1). 
This oxygen-evolving complex with the active manganese cluster is still under 
controversial discussion since high-energetic X-ray beams could have altered its 
structural analysis; therefore speculations persist on its mechanism of action. 
Additional justification for the investigation of model bypyridine ligands originates 
from the catalytic water splitting, as this seems to be the most promising energy 
storage technology to create solar fuels: H2 from H2O (eq 2) respectively 
hydrocarbons from CO2 (eq 3).152 These processes of transferring light to energy 
might participate to solve our current and future energy problems. 
(1) 2 NADP+ + 2 H2O + 4 hν → 2 NADPH + O2 + 2 H+ 
(2) 2 H2O + 4 hν → 2 H2 + O2 
(3) 2 H2O + CO2 + 8 hν → CH4 + 2 O2  
Bipyridine are currently employed for a countless number of catalytic systems as 
selectivity and reactivity-regulating ligands.153 In particularly, electron-rich bipyridine 
systems have shown to exhibit good donor capacities by chelating a number of 
transition metal ions such as ruthenium, iron or iridium. As a result highly colored 
charge-transfer complexes can be found which have found application as sensors at 
present world. 
                                                
151  C. J. Gagliardi, A. K. Vannucci, J. J. Concepcion, Z. Chen, T. J. Meyer, Energy Environ. 
Sci. 2012, 5, 7704-7717. 
152  K. S. Joya, H. J. M. de Groot, Int. J. Hydrogen Energy 2012, 37, 8787-8799. 
153  O. Wenger, Chem. Rev. 2013, doi: 10.1021/cr300396p  
94  CHAPTER 6 
 
N N
HO
HO OH
OH
6.1
N N
HO OH
6.2  
Figure 6.1. Structure of prototypic 4,4’,5,5’-tetrahydroxy-2,2’-bipyridine (6.1) and of 
4,4’-dihydroxy-2,2’-bipyridine (6.2). 
In 2011, Paul and co-workers have extensively investigated the 4,4’-dihydroxy-
2,2’-bipyridine (6.2) by spectroscopical means either as a mixed-ligand system 
Ru(bpy)2(6.2)154a or as a complex Ru(6.2)3154b on its oxidation capacities (Figure 6.1). 
Significantly the influence of different protonation stages was found to alter the 
properties of the obtained complex. Elaboration of the electronic properties with 
cyclic voltammetry yields a reversible RuIII/II wave that shifts 1.43 V to lower energy 
upon deprotonation of the complex. 
N N
HO
HO OH
OH
N
N N
N
Ru
Ru(bpy)26.1
N N
O
O O
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Figure 6.2. PCET in Ru(bpy)2(6.1)-complexes 
On the other hand complex Ru(bpy)26.1 should allow the transfer of 4 protons 
coupled with 4 electrons in one single molecular entity. Similar to Ru(bpy)26.2 a pH 
dependency for Ru(bpy)26.1 is expected, which would allow to fine-tune the 
environment and optimize the desired PCET. 
6.2 Synthesis of Bipyridine Ligands 
In order to evaluate whether our developed cross-coupling conditions are feasible 
for the construction of bpy-systems, bromopyridine 5.67 was subjected to 
homocoupling conditions. As a result the desired product 6.3 was obtained in 91% 
                                                
154  a) S. Klein, W. G. Dougherty, W. S. Kassel, T. J. Dudley, J. J. Paul, Inorg. Chem. 2011, 
50, 2754-2763; b) M. J. Fuentes, R. J. Bognanno, W. G. Dougherty, W. J. Boyko, W. S. 
Kassel, T. J. Dudley, J. J. Paul, Dalton Trans. 2012, 41, 12514-12523. 
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yield (Scheme 6.1). 155  The formed 2,2’-bipyridines with their inherent strong 
chelating abilities was expected to affect the desired C-C bond formation by 
poisoning the Pd-catalyst. In this regard, the use of Negishi coupling reaction proved 
superior presumably because of the chelating effect of bipyridines to zinc ions thereby 
preventing the catalytic activity of the palladium.156 
NH3CO Br
N
N
H3CO
OCH3
a
6.35.67  
Scheme 6.1. Negishi cross-coupling reaction for the formation of bpy-system (6.3): a) 
i) n-BuLi, THF, -78 °C; ii) ZnCl2, THF, -78 °C to RT; iii) Pd(PPh3)4 (5 mol %), 5.67, 
THF, 50 °C, 2-4 h, 91%. 
Following these successful conditions were also applied for the synthesis of several 
electron-rich pyridines. Symmetrical bipyridine-systems were obtained in good yields 
(61% for 6.4; 64% for 6.5) starting from protected 4-hydroxypyridines 5.71 and 5.73. 
The bulkier methylated pyridine 5.73 did not influence the reaction outcome (Scheme 
6.2) and clean conversion was observed. The unsymmetrical dimer 6.6 was afforded 
only in poor 18% yield contaminated with both homocoupled products and 
debrominated starting material. 
N
OR1
H3CO Br
R
N
N
OR1
OR1H3CO
OCH3
R R
a
5.73: R = H, R1 = TIPS
5.71: R = CH3, R1 = SEM 6.4: R = H, R
1 = TIPS
6.5: R = CH3, R1 = SEM
6.6: R = H, CH3, R1 = SEM, TIPS
6.7: R = R1= H
c N N
HO OH
Ru
OCH3H3CO
Ru(bpy)26.7
2
b
bpybpy
 
Scheme 6.2. Synthesis of electron-rich bipyridines starting from heteroaromatic core of 
the piericidin syntheses (for clarity bpy ligand is indicated in grey): a) i) n-BuLi, 
THF, -78 °C; ii) ZnCl2, THF, -78 °C to RT; iii) Pd(PPh3)4 (5 mol %), 5.71 or 5.73, 
THF, 50 °C, 2-4 h, 61% (R1 = H), 64% (R1 = CH3) and 18% (R1 = H and CH3); b) 
TBAF, THF, 70 °C, 4-12 h, 75% (R1 = R2 = H); c) Ru(bpy)3Cl2, H2O. 
                                                
155  M. Tiecco, L. Testaferri, M. Tingoli, D. Chianelli, M. Montanucci, Synthesis 1984, 736-
738. 
156  J. K. Klostermann, A. Linden, J. S. Siegel, Org. Biomol. Chem. 2008, 6, 2755-2764. 
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Desilylation of 6.4 was achieved using TBAF in THF at elevated temperature to 
set free 6.7 as a colorless solid. Further studies in collaboration with the Wenger 
group (University Basel) should clarify, whether the electron-rich bpy-ligand 6.7 can 
easily substitute a dummy-ligand of the commercially available Ru(bpy)3 after 
deprotection or the inverse synthetical order, first coordination to metal ion followed 
by global desilylation is more convenient. 
Ru(bpy)26.7 could also be used as a probe for PCET to an acceptor system as it 
should allow in principle to transfer two protons and two electrons by oxidizing the 
bpy system. 
6.3 Conclusion and Outlook 
In future experiments, the 4,4’,5,5’-tetrahydroxy-2,2’-bypyridines 6.8 (Scheme 
6.3) will be synthesized in a similar manner. Key for this construction would be the 
regioselective exchange of the bromine at C-4’ (5.71b) with an electrophilic oxygen 
source, followed by protection and cross-coupling of both heteroaromatic moities. 
The Ru-complex could be obtained either by global desilylation and complexation to 
the transition metal or the inverse sequential order (coordination and deprotection) 
depending on the donor capacity of the bpy-ligand 6.8.  
N
OSEM
H3CO Br
Br 2 steps
N
OSEM
H3CO Br
SEMO 2 steps N N
HO OH
Ru
OCH3H3CO
Ru(bpy)26.8
HO OH
5.71b 6.8
2
bpy bpy
 
Scheme 6.3. Synthetic plan for the future installment of catecholic bypyridine ligands. 
With this system in hands, it is invisioned to investigate the concerted transfer of 
four protons and four electrons across this complex to an acceptor system. Potential 
application would range from artificial photosynthesis to improved energy storage 
devices. 
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7 CONCLUSION 
The present PhD thesis entitled Stereoselective Total Syntheses of Natural 
Piericidins, the Neurotogenic Steroid Withanolide A and the Development of 
Photolabile Surface Anchors should give a comprehensive impression on parts of the 
field of modern synthetic chemisry. The presented approaches may contribute to a 
certain extend for the understanding of complex biological phenomena such as cell 
differentiation, neurite outgrowth or nuclear export inhibition. 
The general motivation for this work is very much application-driven and inspired 
by problems addressed earlier in our research group. Similar in chess ‘if the student 
forces himself to examine all moves that smite, however absurd they may look at first 
glance, he is on the way to becoming a master of tactics.’ (C. Purdy, 1906-1979). 
Synthetic organic chemistry in particular enables us to perform successful research 
not before a lot of setbacks that lead to a higher frustration tolerance, a broader 
structural knowledge and a better understanding of the synthetic strategy. 
 
Chapter 2 described one of these targets in full detail with the first total synthesis 
of neurotogenic steroid withanolide A in which strategic considerations for the 
sequential order of the installation of the reactive enone moiety were the key for the 
succesful construction of the natural product. The synthesis was achieved starting 
from the commercially available pregnenolone by a Corey-Seebach homologation, a 
vinylogous aldol reaction, a singlet oxygen mediated Schenck ene-reaction and a 
Wharton transposition. In addition, semi-synthetic studies starting from the isolated 
natural product not only allowed to investigate the reactivity of different parts of the 
steroidal structure, but also resulted in the synthesis of 15 derivatives for further SAR 
studies. We then evaluated the neuritogenic activity of withanolide A in different cell 
lines, in which the shown phenotypes of neuronal differentiation in neuroblastoma 
cells supported the potential role of withanolide A in traditional Ayurvedic medicine 
where it is used as a tonic for the improvement of age-related cognitive disorders. 
Chapter 3 dealed with the evaluation of nitrocatechols as biomimetic surface 
anchors and photolabile protecting groups for the controlled release of small 
molecules under an external stimulus, UV light. This approach still holds the potential 
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for applications in drug delivery, as caged probes in chemical biology or for direct 
assays 'on chip'. Characteristics of this method involve the ease of functionalization of 
TiO2 under an operationally simple dip-and-rinse procedure. The stability of the 
resulting functionalized particles to repeated washing and a rapid release of the small 
molecule cargo under UV light stimulation at 366 nm was achieved.  
In Chapter 4 the UV light mediated release-strategy was also applied for retinoids 
as mediators for neurite outgrowth. The use of caged agonistic probes in solution 
resulted in temporally controllable neuron differentiation. The release properties of 
immobilized retinoids were subsequently investigated by spectroscopy. However, 
further studies are required to to clarify if we can direct neurite outgrowth on surfaces 
by the light-triggered release choosing an appropriate surface texture. 
The first total syntheses of piericidin derivatives Mer-A2026B and JBIR-02 to 
determine the previously unknown absolute configuration of both natural products as 
well as to confirm their reported biological properties was the subject of Chapter 5. 
Both natural products were obtained in enantiomerically pure in 12 steps and lead to 
the establishment of the absolute and relative configuration as (9R,10R). Salient 
features of this convergent synthetic route are a highly diastereoselective Kobayashi-
Mukaiyama aldol reaction, an efficient C-H activation reaction in combination with 
an oxidation protocol for the preparation of the functionalized 4-hydroxy-pyridine 
moiety and a final Negishi cross-coupling reaction merging both subunits without 
isomerization of the sensitive side chain.  
Finally, this strategy paved the way for the convenient synthesis of electron-rich 
bipyridine ligands by submitting the heteroaromatic coupling partner to the developed 
Negishi cross-coupling conditions in Chapter 6. These ligands could potentially find 
applications in the future as probes of PCET in artificial photosynthesis systems. 
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8 EXPERIMENTAL PART 
8.1 General Methods and Materials 
Chemicals were purchased from ABCR, Acros, Alfa Acer, or Sigma-Aldrich and 
used without further purification if not otherwise reported. Solvents for work-up and 
chromatography were distilled from technical quality. Amine bases were distilled 
prior to use by Dieckmann distillation. Solvents used for chemical transformations 
were either puriss. quality or dried by filtration through activated aluminum oxide 
under nitrogen (H2O content < 10 ppm, Karl-Fischer titration). Reactions involving 
air or moisture sensitive reagents or intermediates were performed under argon in 
glassware which had been heat gun dried under high vacuum. Concentration under 
reduced pressure was performed by rotary evaporation at 40 °C. Yields refer to 
purified, dried and spectroscopically pure compounds.  
Analytical thin layer chromatography (TLC) was performed on Merck silica 
gel 60 F254 plates (0.25 mm thickness) precoated with fluorescent indicator. The 
developed plates were examined under UV light (254 nm or 366 nm) and stained with 
aqueous KMnO4/Na2CO3 solution or Seebach’s stain (Ce(SO4)2, phosphomolybdic 
acid, H2SO4 in H2O) followed by heating.  
Flash chromatography was performed using silica gel 60 (230-240 mesh) from 
Fluka using a forced flow eluant at 0.3-0.5 bar pressure.  
All 1H and 13C NMR spectra were recorded either using Bruker Avance 400 MHz 
(1H) & 101 MHz (13C) or Bruker Avance DRX 500 MHz (1H) & 126 MHz (13C) 
spectrometer at RT. Chemical shifts (δ-values) are reported in ppm, spectra were 
calibrated related to solvent’s residual proton chemical shift (CHCl3, δ = 7.26; 
d4-MeOD, δ = 4.78, 3.35; d6-DMSO, δ = 2.50) and solvent’s residual carbon chemical 
shift (CDCl3, δ = 77.16; d4-MeOD, δ = 49.30; d6-DMSO, δ = 39.52), multiplicity is 
reported as follows: s = singlet, br. s = broad singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet or unresolved and coupling constant J in Hz.  
IR spectra were recorded using a Varian 800 FT-IR ATR Spectrometer. The 
absorptions are reported in cm–1.  
Optical rotations [α]D were measured at the sodium D line using a 1 mL cell with a 
1 dm path length on a Jasco P-2000 digital polarimeter and the concentration c is 
100  EXPERIMENTAL PART 
 
given in g/100 mL and the used solvent is MeOH or CHCl3.  
Melting points (M.p.) were determined using a Büchi B-545 apparatus in open 
capillaries and are uncorrected.  
HPLC purification was performed on a Dionex HPLC with a UV-detector using a 
Chiralpak IA column with isocratic solvent mixture of n-hexane:i-PrOH 99.5:0.5, 
with a flowrate of 5 mL/min, 25 °C, UV = 254 nm, if not further specified in the 
Experimental Part. 
UPLC reaction control was performed on a Agilent 1290 Infinity. 
Mass spectra (HRMS ESI) were recorded by the Mass spectrometric Service of the 
University of Bern on a Sciex QSTAR Pulsar mass spectrometer or by H. Nadig at the 
University of Basel on a Bruker maXis 4G using electrospray ionization in both cases. 
X-ray analyses: Data collections for both crystal structures were performed at low 
temperature (123 K) using Mo-Ka radiation on a Bruker KappaAPEX diffractometer. 
Integration of the frames and data reduction was carried out using APEX2.157 The 
structures were solved by direct methods using SIR92.158 All non-hydrogen atoms 
were refined using anisotropically by full-matrix least squares on F using 
CRYSTALS.159 Hydrogen atoms were placed in calculated positions by means of the 
“riding” model.  
Labeling of compounds was organized as following: All compound mentioned in 
the theoretical part were indexed with a number (e.g. Chapter 1 - 1.X, Chapter 2 - 
2.X etc.). Intermediates that are not mentioned in the theoretical part, but in the 
Experimental Part referring to compounds mentioned in the theoretical part are 
either labeled with Xa (afore in the synthetic order) or Xb (later on). 
Reaction indicated with 51,62 and 107 were performed and characterized by 
51 Raphael Liffert, 62 Robin Wehlauch or 107 Gregor P. Meier. 
 
                                                
157  Bruker Analytical X-ray Systems, Inc., 2006. Apex2, Version 2 User Manual, M86-
E01078, Madison, WI. 
158  A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, M. C. Burla, G. Polidori, M. 
Camalli, J. Appl. Cryst. 1994, 27, 435-436. 
159  P. W. Betteridge, J. R. Carruthers, R. I. Cooper, K. Prout, D. J. Watkin, J. Appl. Cryst. 
2003, 36, 1487. 
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8.2 List of Abbreviations, Acronyms and Symbols 
Ac acetyl 
AcOH acetic acid 
AD Alzheimer disease 
aq. aqueous 
ATRA all-trans retinoic acid 
Bn benzyl 
Bn-OPT benzyloxypyridinium triflate 
brsm based on recovered starting material 
bpy  2,2’-bipyridine  
c concentration 
CAN    ceric ammonium nitrate 
cath     human cathepsin 
Cbz carboxybenzyl 
CH2Cl2 dichloromethane 
CHCl3 chloroform 
COD 1,5-cyclooctadiene 
δ chemical shift 
d doublet 
D deuterium 
DBDMH 1,1-dibromo-5,5-dimethylhydantoin 
DBU 1,8-diazabicyclo[5.4.0]undec-7-en 
DCE 1,2-dichloroethane 
DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD diethyl azodicarboxylate 
DIAD diisopropyl azodicarboxylate 
DIPEA N,N-diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DME dimethoxyethane 
DMEM Dulbecco’s modified Eagle’s medium 
DMF dimethylformamide 
DMP Dess-Martin periodinane 
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DMPU 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DMSO dimethyl sulfoxide 
L-DOPA  3,4-dihydroxyphenylalanine 
dppf 1,1'-bis(diphenylphosphino)ferrocene 
dr diastereomeric ratio 
DMS dimethyl sulfide 
DSC  N,N’-disuccinimidy carbonate 
dtbpy 4,4’-di-tert-butyl-2,2’-bipyridine 
EDC 1-(3-dimetylaminopropyl)-3-ethylcarbodiimid 
ee enantiomeric excess 
ESI electrospray ionization 
Et ethyl 
Et3N triethylamine  
Et2O diethyl ether 
EtOAc ethyl acetate 
EtOH ethanol 
eq. equivalent 
FTIR Fourier transform infrared spectroscopy 
HBpin  pinacolborane 
HMPA hexamethylphosphoramide 
HOBt    1-hydroxybenzotriazol 
HPLC high-performance liquid chromatography 
HRMS high-resolution mass spectrometry 
IBX 2-iodoxybenzoic acid 
Imd imidazole 
J coupling constant 
LDA lithium diisopropylamide 
LHMDS lithium bis(trimethylsilyl)amide 
m multiplet 
m-CPBA meta-chloroperoxybenzoic acid 
M.p. melting point 
Me methyl 
MeNPOC-Cl 5’-(α-methyl-2-nitropiperonyl) oxycarbonyl chloride 
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MeOH methanol 
MEM minimal essential medium 
MOM methoxymethyl 
NBS N-bromosuccinimide 
NCS N-chlorosuccinimide 
NGF nerve growth factor 
NIS N-iodosuccinimide 
NMO N-methylmorpholine N-oxide 
NMR nuclear magnetic resonance spectroscopy 
NMP N-methyl-2-pyrrolidon 
NOE nuclear Overhauser effect  
NPE (2-nitrophenyl)ethyl 
NPP (2-nitrophenyl)propyl 
Oxone 2 KHSO5·KHSO4·K2SO4 
PCC pyridinium chlorochromate 
PCET  proton coupled electron transfer  
PDC pyridinium dichromate 
Ph phenyl 
PPh3 triphenylphosphine 
PM  plasmepsin 
PMB para-methoxybenzyl 
ppm parts per million 
pTsOH para-toluenesulfonic acid 
q quartet 
RAR retinoic acid receptor 
Rf retention factor 
Rt retention time 
RT room temperature 
s singlet 
sat. saturated 
SEM 2-(trimethylsilyl)ethoxymethyl 
t triplet 
TBAF tetrabutylammonium fluoride 
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TBAH tetrabutylammonium hydroxide 
TBHP tert-butyl hydroperoxide 
TBS tert-butyldimethylsilyl 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIPS triisopropylsilyl 
TLC thin layer chromatography 
TPAP tetrapropylammonium perruthenate 
TPP  meso-tetraphenylporphyrin 
Triton B  benzyltrimethylammonium hydroxide 
UPLC ultra high-performance liquid chromatography 
UV ultraviolet 
ν wavenumber 
 
Units of measure (except Å for Angstrom) and their standard unit prefixes were used 
in accordance with the international system of units (SI), together with the respective 
prefixes for the type of physical quantity. 
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8.3 Withanolide A 
8.3.1 Total Synthesis of Withanolide A  
Dithian (2.7):37 To a cold (-10 °C) solution of 1,3-dithiane (8.900 g, 0.074 mol, 
2.0 eq.) in dry THF (65 mL) was added n-BuLi (1.6 M, 
47.0 mL, 2.05 eq.) slowly and the reaction was stirred at 
-10 °C for 2 h. The mixture was then cooled to -78 °C 
and a cold (0 °C) solution of TBS protected pregneno-
lone (15.943 g, 0.037 mol, 1.0 eq.) in dry THF (100 mL) was added slowly via 
syringe and the resulting mixture stirred at -78 °C for 5 h then allowed to warm 
slowly to RT and stirred for a further 18 h. The reaction was quenched with sat. 
aqueous NH4Cl, then extracted with Et2O, the combined organics were washed with 
H2O, dried over MgSO4 and concentrated to afford an off-white solid (dr 15:1). The 
crude material was recrystallised from hot EtOAc/hexane (ca. 1:1) affording the 
dithian 2.7 as a colorless solid (16.986 g, 0.031 mol, 84%).  
 
Rf = 0.36 (hexane:EtOAc 9:1). 1H NMR (400 MHz, CDCl3) δ = 5.31 (m, 1H), 4.14 
(s, 1H), 3.48 (m, 1H), 2.90 (m, 4H), 1.44 (s, 3H), 1.00 (s, 3H), 0.89 (s, 9H), 0.87 (s, 
3H), 0.05 (s, 6H).  
 
Analytical according to reference: B. B. Shingate, B. G. Hazra, V. S. Pore, R. G. 
Gonnade, M. Bhadbhade, Tetrahedron 2007, 63, 5622-5635. 
 
 
Hydroxy aldehyde (2.7b): To a stirred solution of dithian 2.7 (10.794 g, 
19.591 mmol, 1.0 eq.) in CH2Cl2/H2O (10:1, 150 mL) was 
added N-chlorosuccinimide (5.363 g, 40.161 mmol, 
2.05 eq.) in portions. The reaction mixture was stirred at 
RT for 2 h, then quenched with Na2S2O3/NaHCO3 
solution (1:1, 100 mL) and the aqueous phase extracted with Et2O. The combined 
organic layers were washed with H2O, dried over Na2SO4 and concentrated to a white 
solid. The residue was purified by flash column chromatography (pentane:Et2O 10:1) 
and afforded aldehyde 2.7 as a colorless solid (6.624 g, 14.375 mmol, 73%). 
H
HH
TBSO
S
SHO
H
H
HH
TBSO
O
HO
H
H
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M.p.: 199-201 °C. Rf = 0.6 (hexane:EtOAc 4:1). Optical rotation: [α]D = -56.8° (c = 
0.45, CHCl3). FTIR ν = 3375, 2936, 2858, 1728, 1470, 1385, 1358, 1254, 1080, 887, 
868, 837, 772 cm-1. 1H NMR (500 MHz, CDCl3) δ = 9.56 (s, 1H), 5.31-5.30 (m, 1H), 
3.51-3.44 (m, 1H), 3.25 (s, 1H), 2.29-2.24 (m, 1H), 2.18-2.12 (m, 2H), 1.98-1.95 (m, 
1H), 1.81-1.75 (m, 2H), 1.73-1.62 (m, 3H), 1.57-1.42 (m, 6H), 1.35 (s, 3H), 1.32-1.25 
(m, 1H), 1.22-1.13 (m, 1H), 1.07-1.02 (m, 2H), 1.00 (s, 3H), 0.96-0.91 (m, 1H), 0.88 
(s, 9H), 0.79 (s, 3H), 0.05 (s, 6H). 13C NMR (126 MHz, CDCl3) δ = 203.7, 141.8, 
121.0, 79.7, 72.7, 56.7, 55.6, 50.3, 43.4, 42.9, 40.2, 37.5, 36.7, 32.2, 31.9, 31.6, 26.1, 
24.3, 23.1, 22.3, 21.1, 19.6, 18.4, 14.0, -4.4. HRMS ESI calc. for C28H47O3Si [M-H]-: 
459.3294, found: 459.3303. 
 
 
MOM protected aldehyde (2.8): To a cold (0 °C) solution of NaI (671 mg, 
4.479 mmol, 4 eq., dried under high vacuum at 100 °C for 
6 h) in dry DME (5 mL) was added freshly distilled 
MOMCl (451 mg, 5.599 mmol, 5 eq.) upon which a 
yellow suspension formed. The mixture was allowed to 
warm to RT and stirred for 10 minutes. This mixture was then added slowly via 
syringe to a cold (0 °C) solution of aldehyde 2.7b (516 mg, 1.120 mmol, 1 eq.) and 
DIPEA (956 mg, 6.159 mmol, 5.5 eq.) in dry DME and the reaction mixture heated at 
reflux for 18 h. The reaction mixture was allowed to cool to RT and quenched with 
Na2CO3 solution (1M, 10 mL) and then extracted with Et2O. The combined organic 
layers were washed with H2O, dried over Na2SO4, filtered and concentrated to afford 
an orange solid. The crude material was subjected to flash chromatography on silica 
(hexane:EtOAc, 9:1) and concentrated to give protected aldehyde 2.8 (540 mg, 
1.070 mmol, 94%) as an off-white solid.  
 
M.p. : 131-132 °C. Rf = 0.8 (pentane:EtOAc, 4:1). Optical rotation: [α]D = -16.3° 
(c = 1.11, CHCl3). FTIR: ν = 2931, 1727, 1462, 1380, 1252, 1080, 1033, 869, 838, 
776, 671 cm-1. 1H NMR (400 MHz, CDCl3) δ = 9.69 (s, 1H), 5.33-5.28 (m, 1H), 4.84 
(d, J = 7.3 Hz, 1H), 4.61 (d, J = 7.3 Hz, 1H), 3.52-3.42 (m, 1H), 3.41 (s, 3H), 2.31-
2.21 (m, 1H), 2.19-2.07 (m, 2H), 2.01-1.91 (m, 1H), 1.90-1.77 (m, 2H), 1.73-1.60 (m, 
4H), 1.58-1.41 (m, 7H), 1.36 (s, 3H), 1.27-1.09 (m, 3H), 0.99 (s, 3H), 0.88 (s, 9H), 
H
HH
TBSO
O
MOMO
H
H
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0.77 (s, 3H), 0.05 (s, 6H). 13C NMR (101 MHz, CDCl3) δ = 205.3, 141.7, 121.0, 92.0, 
85.7, 72.7, 58.5, 56.2, 55.9, 50.2, 43.5, 42.9, 40.0, 37.5, 36.7, 32.2, 31.9, 31.6, 26.0, 
24.1, 22.0, 21.0, 19.5, 18.8, 18.3, 14.7, -4.5. Elementary Analyses calc. for 
C30H52O4Si: C = 71.38, H = 10.38, found: C = 71.60, H = 10.24. 
 
 
Lactone (2.26): A solution of ethyl 2,3-dimethylbut-2-enoate 2.24 (384 mg, 
2.70 mmol, 2.7 eq.) and DMPU (2.5 mL, distilled 
freshly over CaH2) in THF (2.5 mL) was added 
dropwise to a solution of LiHMDS (3.0 mL 1.0 M in 
THF, 3.0 mmol, 3 eq.) in THF (2.5 mL) at -78 °C and 
the mixture was stirred for 1.5 h at that temperature. A 
solution of protected aldehyde 2.8 (0.5 g, 1.0 mmol, 1 eq.) in THF (3.0 mL) was then 
added dropwise and the resulting mixture was stirred at -78 °C for 6 h. The 
temperature of the reaction mixture was allowed to increase to RT overnight. Then, 
the reaction was quenched by addition of saturated NH4Cl solution. The mixture was 
extracted with Et2O. The combined organic layers were washed with sat. aqueous 
NaCl solution, dried over Na2SO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (pentane:Et2O 3:1) to give 
lactone 2.26 (as a 93:7 mixture of diasteroisomers; 518 mg, 0.862 mmol, 87%) as 
colorless foam.  
 
Rf = 0.3 (pentane:EtOAc 7:1). Optical rotation: [α]D = +19.4° (c = 0.44, CHCl3). 
FTIR: ν = 2931, 1714, 1463, 1381, 1318, 1253, 1083, 1016, 889, 836, 775, 670 cm-1. 
1H NMR (500 MHz, CDCl3) δ = 5.32-5.29 (m, 1H), 4.97 (d, J = 6.6 Hz, 1H), 4.82 (d, 
J = 6.6 Hz, 1H), 4.25 (dd, J = 13.3, 3.3 Hz, 1H), 3.51-3.44 (m, 1H), 3.37 (s, 3H), 
2.53-2.44 (m, 1H), 2.29-2.22 (m, 1H), 2.18-2.10 (m, 2H), 2.02-1.96 (m, 3H), 1.93 (s, 
3H), 1.86 (s, 3H), 1.84-1.67 (m, 4H), 1.65-1.45 (m, 7H), 1.39 (s, 3H), 1.35-1.27 (m, 
2H), 1.07-1.00 (m, 2H), 0.99-0.96 (m, 3H), 0.88 (s, 9H), 0.86 (s, 3H), 0.05 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ = 166.3, 148.9, 141.8, 122.0, 121.1, 92.8, 82.3, 80.0, 
72.7, 56.8, 56.4, 54.5, 50.2, 43.1, 42.9, 40.3, 37.5, 36.7, 32.2, 32.2, 31.9, 31.5, 26.1, 
24.1, 22.0, 21.0, 20.6, 19.5, 18.4, 18.0, 13.9, 12.6, -4.5. Elementary Analyses calc. 
for C36H60O5Si: C = 71.95, H = 10.06, found: C = 72.04, H = 9.86. 
H H
H
H
MOMO
TBSO
O O
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Hydroxy lactone (2.27): To a solution of lactone 2.26 (143 mg, 238 µmol) in THF 
(10 mL) was added 6 M aqueous HCl (2 mL) and the 
resulting solution was stirred for 3 h until TLC indicated 
full conversion. NaHCO3 solution was added, the 
aqueous phase was extracted by CH2Cl2, dried over 
Na2SO4 and subjected to flash chromatography (pentane: 
EtOAc, 2:1) to yield hydroxy lactone 2.27 (92 mg, 208 µmol, 87%) as a colorless 
solid. An analytical sample was recrystallized from EtOAc for X-ray analysis.  
 
M.p. : 243-245 °C. Rf = 0.3 (pentane:EtOAc 2:1). Optical rotation: [α]D = +16.7° 
(c = 0.62, CHCl3). FTIR: ν = 3406, 2935, 1696, 1438, 1383, 1320, 1190, 1135, 1059, 
955, 833, 756, 667 cm-1. 1H NMR (500 MHz, CDCl3) δ = 5.38 – 5.31 (m, 1H), 4.23 
(dd, J = 13.3, 3.4 Hz, 1H), 3.62-3.46 (m, 1H), 2.49-2.41 (m, 1H), 2.34-2.19 (m, 3H), 
2.16-2.09 (m, 1H), 2.07-2.02 (m, 1H), 2.01-1.97 (m, 1H), 1.95 (s, 3H), 1.94-1.91 (m, 
1H), 1.89 (s, 3H), 1.87-1.80 (m, 2H), 1.66-1.60 (m, 1H), 1.56-1.42 (m, 8H), 1.28 (s, 
3H), 1.25-1.04 (m, 3H), 1.01 (s, 3H), 0.99-0.88 (m, 2H), 0.87 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ = 166.3, 149.1, 141.0, 122.1, 121.7, 81.1, 75.4, 71.9, 57.0, 54.8, 50.2, 
43.1, 42.4, 40.2, 37.4, 36.6, 31.9, 31.8, 31.6, 31.5, 24.0, 22.2, 21.1, 20.9, 20.7, 19.5, 
13.8, 12.6. Elementary Analyses calc. for C28H42O4: C = 75.98, H = 9.56, found: C = 
75.91, H = 9.42. X-ray crystal structure is given in the appendices section. 
 
8.3.2 Semisynthetic Studies on Synthetic Precursors of Withanolide A 
Acetate (2.31): To a solution of diol 2.27 (12 mg, 27 µmol, 1 eq.) in CH2Cl2 (2 mL) 
was added Et3N (50% in CH2Cl2; 22 µL, 71 µmol, 
3eq.), DMAP (0.3 mg, 3 µmol, 0.1 eq.) and Ac2O 
(10 µL, 98 µmol, 4 eq.) and the resulting mixture was 
stirred at RT over night. The mixture was quenched by 
addition of 0.1 M HCl solution and extracted using 
CH2Cl2. The organic layers were dried over Na2SO4, evaporated and subjected to 
flash chromatography (pentane:EtOAc 4:1) to yield acetate 2.31 (11.2 mg, 23 µmol, 
85%) as a colorless solid. 
H H
H
H
OH
HO
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Rf = 0.2 (EtOAc:hexane:CHCl3 8:1:1). Optical rotation: [α]D = +38.5° (c = 0.41, 
CHCl3). FTIR: ν = 2940, 1711, 1440, 1379, 1319, 1245, 1132, 1032, 918, 758, 
631 cm-1. 1H NMR (500 MHz, CDCl3) δ = 5.37 (d, J = 4.4 Hz, 1H), 4.66-4.54 (m, 
1H), 4.22 (dd, J = 13.3, 3.4 Hz, 1H), 2.47-2.38 (m, 1H), 2.34-2.27 (m, 2H), 2.24 (s, 
1H), 2.15-2.09 (m, 1H), 2.03 (s, 3H), 2.01-1.97 (m, 1H), 1.95 (s, 3H), 1.93-1.79 (m, 
6H), 1.67-1.41 (m, 10H), 1.29 (s, 3H), 1.25-1.09 (m, 4H), 1.02 (s, 3H), 0.87 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ = 170.82, 166.37, 165.72, 151.42, 149.19, 139.95, 
122.67, 122.21, 81.21, 75.46, 74.14, 57.03, 54.89, 50.19, 43.26, 40.29, 38.32, 37.21, 
36.80, 31.99, 31.78, 31.50, 27.98, 24.08, 22.21, 21.69, 21.11, 21.10, 20.81, 19.55, 
13.82, 12.71. HRMS ESI calc. for C30H45O5 [M-H]+: 485.3262 found: 485.3254. 
 
 
Acid (2.33): To a solution of diol 2.27 (23 mg, 52 µmol, 1eq.) in CH2Cl2 (2 mL) was 
added Et3N (50% in CH2Cl2; 44 µL, 
156 µmol, 3 eq.), DMAP (3 mg, 3 µmol, 
0.1 eq.) and succinic anhydride (21 mg, 
208 µmol, 4 eq.) and the resulting mixture 
was stirred at RT for 1 h. The mixture was 
quenched by addition of 0.1 M HCl solution and extracted using CH2Cl2. The organic 
layers were dried over Na2SO4, evaporated and subjected to flash chromatography 
(CH2Cl2:MeOH 10:1 + 1% TFA) to yield acid 2.33 (11.2 mg, 23 µmol, 85%) as a 
colorless solid. 
 
M.p.: 200-202 °C. Rf = 0.2 (CH2Cl2:MeOH 10:1 + 1% TFA). Optical rotation: 
[α]D = +24.3° (c = 0.24, CHCl3). FTIR: ν = 3476, 2934, 1727, 1664, 1386, 1325, 
1156, 1012, 890, 826, 635 cm-1. 1H NMR (500 MHz, CDCl3) δ = 6.94 (bs, 1H), 5.36 
(d, J = 4.1 Hz, 1H), 4.66-4.58 (m, 1H), 4.23 (dd, J = 13.3, 3.4 Hz, 1H), 3.70 (s, J = 
4.7, 1H), 2.72-2.56 (m, 5H), 2.49-2.33 (m, 1H), 2.31 (d, J = 7.8 Hz, 2H), 2.13 (dd, J = 
17.4, 2.6 Hz, 1H), 2.10-2.03 (m, 1H), 1.95 (s, 3H), 1.88 (s, 3H), 1.80-1.35 (m, 10H), 
1.28 (s, 3H), 1.02 (s, 4H), 0.87 (s, 3H). 13C NMR (126 MHz, CDCl3) δ = 177.55, 
171.80, 166.75, 149.53, 139.74, 122.62, 122.00, 81.22, 75.39, 74.57, 56.87, 54.73, 
50.01, 43.16, 40.16, 38.05, 37.01, 36.70, 31.89, 31.67, 31.39, 29.34, 29.05, 27.76, 
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23.97, 22.08, 21.02, 20.94, 20.73, 19.43, 13.73, 12.53. HRMS ESI calc. for 
C32H46O7Na [M-Na]+: 565.3136 found: 565.3144. 
 
 
Nitrocatechol hybrid (2.34): To a solution of acid 2.33 (42 mg, 77 µmol, 1 eq.) in 
dry CH3CN (2 mL) was added 
N,N’-disuccinimidy carbonate 
(22 mg, 81 µmol, 1.05 eq.) ar RT 
to form a white suspension. After 
5 min pyridine (9.5 µL, 
116 µmol, 1.5 eq.) was added at 
RT to form again a clear solution and stirring was continued for 6 h at RT, until TLC 
indicated full conversion. To the reaction mixture was added 0.2 M aqueous HCl, and 
the aqueous phase was extracted with CH2Cl2. The organic layer was dried over 
Na2SO4, evaporated to afford a colorless solid, which was dissolved in DMSO/THF 
(1:1, 2 mL). To this mixture was added nitro dopamine sulfate (21 mg, 43 µmol, 
0.55 eq.) and Et3N (55 mL, 387 µmol, 5 eq.) and stirring continued at RT over night. 
The mixture was quenched by addition of water and extracted using EtOAc. The 
organic layers were dried over Na2SO4, evaporated and subjected to flash 
chromatography (CH2Cl2:MeOH 10:1) and reverse phase HPLC to yield catechol 2.34 
(8 mg, 11 µmol, 14%) as a orange oil. 
 
M.p.: 140-170 °C (decomposition). Rf = <0.1 (EtOAc). Optical rotation: [α]D = 
+2.9° (c = 1.10, CHCl3). FTIR: ν = 3362, 2942, 2696, 1527, 1437, 3883, 1288, 1192, 
1052, 888, 769 cm-1. 1H NMR (400 MHz, CDCl3) δ = 9.14 (bs, 1H), 7.63 (s, 1H), 
6.81 (s, 1H), 6.48 (t, J = 5.9 Hz, 1H), 5.33 (d, J = 4.4 Hz, 1H), 4.56-4.53 (m, 1H), 
4.24 (dd, J = 13.3, 3.4 Hz, 1H), 3.59 (dd, J = 12.7, 6.4 Hz, 2H), 3.08 (t, J = 6.7 Hz, 
2H), 2.65 (t, J = 6.4 Hz, 2H), 2.52-2.48 (m, 2H), 2.43-2.05 (m, 8H) 1.96 (s, 3H), 1.89 
(s, 3H), 1.80-1.02 (m, 10H), 1.27 (s, 2H), 0.99 (s, 3H), 0.84 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ = 173.22, 173.01, 166.68, 149.68, 143.63, 141.14, 139.54, 
128.11, 122.82, 121.97, 118.20, 112.67, 81.16, 75.41, 75.16, 56.87, 54.77, 50.01, 
43.01, 40.57, 40.05, 38.09, 37.01, 36.64, 32.76, 31.84, 31.58, 31.34, 31.07, 30.89, 
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29.86, 27.79, 23.92, 22.14, 20.97, 20.81, 19.40, 13.76, 12.58. HRMS ESI calc. for 
C40H54O10N2Na+ [M-Na]+: 745.3671 found: 745.3686. 
 
 
Dansyl hybrid (2.35): To a solution of acid 2.33 (23 mg, 42 µmol, 1 eq.) in dry 
CH3CN/DMF (5:1, 2.5 mL) was 
added sequentially Et3N (21 µL, 
148 µmol, 3.5 eq.), 1-hydroxy-
benzotriazole (7 mg, 51 µmol, 
1.2 eq.), EDC (10 mg, 51 µmol, 
1.2 eq.) and dansyl amine (17 mg, 51 µmol, 1.2 eq.) and the resulting mixture stirred 
over night, until TLC indicated complete conversion. The volatiles were removed at 
HV, then 0.1 M aqueous HCl was added and the aqueous layer was extracted with 
EtOAc. The organic layer was dried over Na2SO4, evaporated and subjected to flash 
chromatography (CH2Cl2:MeOH 40:1) to afford catechol 2.35 (26 mg, 30 µmol, 71%) 
as yellow solid. 
 
M.p.: 141-143 °C. Rf = 0.3 (CH2Cl2:MeOH 40:1). 1H NMR (400 MHz, CDCl3) δ = 
8.53 (d, J = 8.5 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 8.23 (d, J = 7.3 Hz, 1H), 7.59-7.50 
(m, 2H), 7.18 (d, J = 7.5 Hz, 1H), 5.73 (t, J = 5.6 Hz, 1H, NH), 5.34 (d, J = 4.1 Hz, 
1H, NH), 5.00 (t, J = 6.0 Hz, 1H), 4.59 (d, J = 8.5 Hz, 1H), 4.22 (dd, J = 13.3, 3.4 Hz, 
1H), 3.09 (dd, J = 12.5, 6.4 Hz, 2H), 2.88 (m, 8H), 2.63 (t, J = 6.9 Hz, 2H), 2.42 (t, 
J = 6.6 Hz, 2H), 2.30 (d, J = 7.7 Hz, 2H), 1.95 (s, 3H), 1.88 (s, 3H), 2.30-1.00 (m, 
27H), 1.28 (s, 3H), 1.00 (s, 3H), 0.86 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 
172.71, 171.73, 170.58, 166.29, 152.10, 149.16, 139.76, 135.00, 130.45, 129.99, 
129.76, 129.66, 128.45, 123.35, 122.58, 122.05, 118.93, 115.29, 109.71, 81.10, 75.32, 
74.44, 56.89, 54.76, 50.02, 45.55, 43.12, 43.05, 40.15, 39.13, 38.15, 37.02, 36.67, 
31.86, 31.65, 31.36, 31.22, 30.05, 28.98, 28.89, 27.82, 23.96, 23.42, 22.09, 20.96, 
20.69, 19.42, 13.71, 12.59. HRMS ESI calc. for C49H70O8N3S+ [M-H]+: 860.4878 
found: 860.4887. 
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8.3.3 Semisynthetic Studies on Withanolide A 
Isolation Procedure of Withanolide A (2.1): The dried Ashwagandha roots (1.5 kg) 
were placed in a large column and percolated with MeOH 
(3 L) several times. The MeOH extracts were concentrated 
from 3 L to 1 L under reduced pressure and then washed 
with pentane (3 x 250 mL). The MeOH extracts were then 
carefully concentrated under reduced pressure affording a 
thick brown oil, which was suspended in EtOAc (300 mL), washed with H2O 
(3 x 200 mL), dried over MgSO4 and concentrated to a brown oil (4.39 g). The crude 
material was purified by silica gel chromatography using a graduated eluent system 
(40% to 100% EtOAc/pentane at intervals of 10%, 1.5 column lengths of 
eluent/fraction) and each fraction was collected in an Erlenmeyer and concentrated 
separately and analyzed by HPLC and TLC. Withanolide A was found to be present 
in the 70% and 80% fractions. These two fractions were combined and purified by 
column chromatography (CH2Cl2:MeOH 40:1) affording withanolide A 2.1 (340 mg, 
0.722 mmol, 0.025% from mass of dried roots) as an off-white solid.  
 
M.p.: 287-289 °C. Rf = 0.5 (EtOAc:hexane:CHCl3 8:1:1). Optical rotation: [α]D = 
+86.8° (c = 1.15, CHCl3). UV: 228.5 nm. 1H NMR (400 MHz, CDCl3) δ = 6.58 (ddd, 
J = 10.1, 5.0, 2.1 Hz, 1H), 5.83 (dd, J = 10.2, 2.2 Hz, 1H), 4.20 (dd, J = 13.3, 3.4 Hz, 
1H), 3.31 (s, 1H), 3.16 (s, 1H, OH), 3.04 (d, J = 3.9 Hz, 1H), 2.76-2.62 (m, 2H), 2.51 
(dd, J = 18.8, 5.1 Hz, 1H), 2.44-2.33 (m, 2H), 2.20-1.99 (m, 3H), 1.95 (s, 3H), 1.88 (s, 
3H), 1.85-1.72 (m, 2H), 1.61-1.33 (m, 7H), 1.31 (s, 3H), 1.17 (s, 3H), 0.95 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ = 203.3, 166.2, 149.0, 139.8, 129.1, 122.1, 81.1, 75.2, 
73.4, 57.4, 56.5, 54.5, 52.0, 51.1, 44.0, 40.5, 36.9, 35.7, 35.2, 31.8, 23.3, 21.9, 21.9, 
21.2, 20.7, 14.9, 13.9, 12.6. HPLC/MS: Rt = 48.9 min, m/z (ES+) 493.2 (MNa+). 
 
Analytical data according to reference: S. S. Subramanian, P. D. Sethi, E. Glotter, I. 
Kirson, D. Lavie, Phytochemistry 1971, 10, 685-688. 
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Allylic alcohol (2.36): To a cold solution (0 °C) of withanolide A (30 mg, 64 µmol, 
1 eq.) in CHCl3/MeOH (1.5 mL; 1:2) was added 
CeCl3⋅7 H2O (47.5 mg, 128 µmol, 2 eq.). After 5 min NaBH4 
(24.1 mg, 640 µmol, 10 eq.) was added over a period of 4 h 
in 5 portions until TLC indicated full conversion. The 
reaction was quenched by addition of saturated NH4Cl 
solution, extracted with CH2Cl2, dried over Na2SO4 and evaporated. The crude 
product was subjected to flash chromatography (EtOAc:pentane 6:4) to yield allylic 
alcohol 2.36 (24.3 mg, 48 µmol, 75%) as a colorless solid. An analytical sample was 
recrystallized from EtOAc for X-ray analysis.  
 
M.p.: 255-257 °C. Rf = 0.6 (EtOAc:hexane:CHCl3 8:1:1). Optical rotation: [α]D = 
+112.2° (c = 0.40, CHCl3). FTIR: ν = 3480, 2944, 1703, 1384, 1290, 1217, 1132, 
1028, 910, 784 cm-1. 1H NMR (400 MHz, CDCl3) δ = 5.89 (d, J = 9.9 Hz, 1H), 5.72-
5.66 (m, 1H), 4.18 (dd, J = 13.0, 3.7 Hz, 1H), 3.52 (s, 1H), 3.51 (s, 1H), 3.43 (s, 1H), 
3.31-3.27 (m, 1H), 2.95 (d, J = 3.8 Hz, 1H), 2.40 (s, 1H), 2.35-1.95 (m, 6H), 1.92 (s, 
3H), 1.85 (s, 3H), 1.84-1.72 (m, 3H), 1.63-1.31 (m, 7H), 1.28 (s, 3H), 0.93 (s, 3H), 
0.75 (s, 3H). 13C NMR (126 MHz, CDCl3) δ = 166.2, 148.9, 129.8, 124.2, 122.2, 
81.1, 75.2, 71.4, 70.8, 58.0, 57.5, 54.5, 52.0, 44.3, 40.3, 40.1, 35.7, 34.9, 34.7, 31.7, 
23.2, 22.1, 21.2, 20.7, 20.3, 15.3, 13.8, 12.6. HRMS ESI calc. for C28H40O6Na 
[M-Na]+: 495.2717 found: 495.2704. X-ray crystal structure is given in the 
appendix. 
 
 
Alcohol (2.37):51 Allylic alcohol 2.36 (10.0 mg, 0.021 mmol, 1.0 eq.) and Crabtree’s 
catalyst (0.34 mg, 2 mol%) were dissolved in CH2Cl2 
(0.2 mL) in a small vial. The vial was placed in an autoclave 
and the mixture was stirred at RT for 2 h under a H2 
atmosphere (10 bar). The solvent was removed, the residue 
filtered through a short pad of silica (EtOAc) and evaporated 
to yield alcohol 2.37 (10.0 mg, 0.021 mmol, quant.) as a colorless solid.  
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M.p. = 251 °C (decomposed). Rf = 0.74 (EtOAc). Optical rotation: [α]D = +46.4° 
(c = 0.5, CHCl3). FTIR: ν = 3578, 3464, 3362, 2938, 1717, 1445, 1381, 1316, 1103, 
1021, 949, 913, 854, 757, 687 cm−1. 1H NMR (400 MHz, CDCl3) δ = 4.49 (d, J = 
10.7 Hz, 1H), 4.21 (dd, J = 13.3, 3.5 Hz, 1H), 3.58-3.51 (m, 1H), 3.50 (d, J = 1.2 Hz, 
1H), 3.28 (dd, J = 3.9, 2.4 Hz, 1H), 2.90 (d, J = 3.9 Hz, 1H), 2.43-2.31 (m, 2H), 2.18-
2.00 (m, 4H), 1.95 (s, 3H), 1.89 (s, 3H), 1.86-1.33 (m, 15H), 1.31 (s, 3H), 0.94 (s, 
3H), 0.80 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 166.14, 148.89, 122.19, 81.15, 
75.24, 72.37, 72.07, 58.52, 57.80, 54.48, 52.00, 44.50, 40.25, 40.22, 35.39, 35.24, 
32.53, 31.79, 28.81, 23.13, 22.17, 21.25, 20.69, 19.89, 16.06, 15.86, 13.88, 12.62. 
UPLC/MS: Rt = 2.015 min, m/z (ES+) 971.5 (2M + Na+). 
 
 
Amine (2.38): To a solution of acyl chloride (80 mg, 317 µmol, 5 eq.) in CH2Cl2 
(1 mL) was added a solution of diol 2.36 
(30 mg, 64 µmol, 1 eq.) CH2Cl2 (1 mL) and 
DIPEA (55µL, 317 µmol, 5 eq.). The 
reaction mixture was stirred over night, but 
no conversion was monitored by TLC. So 
AgNO3 (27 mg, 160 µmol, 2.5 eq.) was added and a white precipitate occurred. The 
reaction mixture was quenched by addition of aqueous 0.1 M HCl, extracted by 
CH2Cl2. The crude product was subjected to flash chromatography (CH2Cl2:MeOH 
50:1) to afford Boc-protected amine as a colorless solid. 
 
1H NMR (400 MHz, CDCl3) δ = 5.97-5.78 (m, 2H), 4.81 (d, J = 3.8 Hz, 1H), 4.20 
(dd, J = 13.3, 3.4 Hz, 1H), 3.27 (d, J = 1.9 Hz, 1H), 3.09 (d, J = 7.1 Hz, 1H), 2.98 (d, 
J = 3.7 Hz, 1H), 2.49-2.19 (m, 6H), 2.00-1.00 (m, 24H), 1.95 (s, 3H), 1.88 (s, 3H), 
1.42 (s, 9H), 1.29 (s, 3H), 0.94 (s, 3H), 0.86 (s, 3H). 
 
Boc protected amine was dissolved in CH2Cl2 (2 mL) and exposed to TFA (10 eq., as 
50% solution in CH2Cl2) to afford after removal of all volatiles amine 2.38 (30 mg, 
43 µmol, 68%) as its trifluoroacetate.  
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M.p. : 127-128 °C (decomposition). Rf = <0.1 (EtOAc). Optical rotation: [α]D = 
+91.6° (c = 0.28, MeOH). FTIR: ν = 2936, 2624, 2072, 1984, 1680, 1387, 1176, 
1128, 806, 629 cm-1. 1H NMR (400 MHz, d4-MeOD) δ = 5.94-5.75 (m, 2H), 4.74 (d, 
J = 4.6 Hz, 1H), 4.26 (dd, J = 13.2, 3.4 Hz, 1H), 3.25 (s, 1H), 3.00-2.87 (m, 2H), 
2.67-2.55 (m, 1H), 2.43-2.17 (m, 6H), 2.00-1.00 (m, 24H), 1.99 (s, 3H), 1.85 (s, 3H), 
1.25 (s, 3H), 0.90 (s, 3H), 0.88 (s, 3H). 13C NMR (126 MHz, d4-MeOD) δ = 174.84, 
168.56, 153.00, 129.90, 125.01, 121.93, 82.71, 76.06, 73.21, 70.35, 58.03, 57.27, 
55.57, 53.25, 44.60, 41.81, 40.78, 40.53, 36.80, 36.43, 36.00, 34.99, 32.03, 28.03, 
26.68, 25.39, 23.93, 23.35, 21.74, 20.84, 20.49, 16.00, 14.48, 12.41. HRMS ESI calc. 
for C34H52O7N [M-H]+: 586.3738 found: 586.3743. 
 
 
Epoxy ketone (2.39):51 To a solution of withanolide A (100 mg, 0.21 mmol, 1.0 eq.) 
and TBHP (5.5 M in decane, 100 µL, 0.55 mmol, 2.6 eq.) 
in CH2Cl2 (1.3 mL) was added dropwise TBAF (1 M in 
THF, 425 µL, 0.43 mmol, 2 eq.) and the mixture was 
stirred at RT for 15 h. The reaction was then diluted with 
water and extracted with CH2Cl2. The organic layer was 
dried over Na2SO4 and concentrated under reduced pressure. The residue was purified 
by flash column chromatography (EtOAc/pentane, 2:1 to pure EtOAc) to give epoxy 
ketone 2.39 (78.4 mg, 0.16 mmol, 76%) as a colorless solid. 
 
M.p. = 285 °C (decomposed). Rf = 0.37 (EtOAc). Optical rotation: [α]D = +107.1° 
(c = 0.5, CHCl3). FTIR: ν = 3476, 2967, 2924, 1981, 1706, 1517, 1468, 1382, 1318, 
1221, 1187, 1141, 1107, 1069, 1009, 952, 897, 852, 815, 757. 648 cm−1. 1H NMR 
(400 MHz, CDCl3) δ = 4.17 (dd, J = 13.3, 3.5 Hz, 1H), 3.61-3.54 (m, 1H), 3.29 (d, J = 
3.4 Hz, 1H), 3.26-3.18 (m, 2H), 2.94 (d, J = 3.8 Hz, 1H), 2.54-2.41 (m, 2H), 2.42-
2.29 (m, 2H), 2.23 (dd, J = 15.9, 2.4 Hz, 1H), 2.14-1.97 (m, 3H), 1.94 (s, 3H), 1.87 (s, 
3H), 1.84-1.21 (m, 12H), 1.10 (s, 3H), 0.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 
203.68, 166.10, 148.97, 122.06, 81.09, 75.15, 70.75, 56.36, 54.43, 53.44, 52.77, 
52.09, 51.67, 43.86, 40.23, 35.17, 34.84, 33.32, 31.77, 23.26, 21.87, 21.50, 21.21, 
20.66, 13.76, 13.50, 12.56. HRMS ESI calc. for C28H39O7+ [M+H]+: 487.2690, 
found: 487.2689. 
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β-Hydroxy ketone (2.40):51 To a solution of (PhSe)2 (96.2 mg) in EtOH (1.0 mL) 
was added NaBH4 (23.3 mg) and acetic acid (10 µL). 
The stock solution was stirred for 10 min at RT and then 
added (0.2 mL, 0.123 mmol, 3 eq.) to a solution of 
epoxy ketone 2.39 (20 mg, 0.041 mmol, 1.0 eq.) in 
CH2Cl2 (0.2 mL). The resulting yellow mixture was 
stirred at RT for 1 h, then diluted with CH2Cl2 and washed with saturated brine. The 
organic phase was dried over NaSO4, concentrated and subjected to flash column 
chromatography (EtOAc) to yield β-hydroxy ketone 2.40 (16 mg, 0.033 mmol, 80%) 
as a colorless solid.  
 
M.p. = 275-276 °C. Rf = 0.37 (EtOAc). Optical rotation: [α]D = +148.2° (c = 0.36, 
CHCl3). FTIR: ν = 3478, 2924, 1707, 1388, 1142, 1008, 897, 814, 759, 649 cm−1. 
1H NMR (400 MHz, CDCl3) δ = 4.40-4.33 (m, 1H), 4.20 (dd, J = 13.3, 3.5 Hz, 1H), 
4.16-4.07 (m, 1H), 3.46 (d, J = 2.0 Hz, 1H), 3.30 (dd, J = 3.9, 2.2 Hz, 1H), 3.14 (dd, 
J = 8.1, 6.1 Hz, 1H), 3.10 (d, J = 3.9 Hz, 1H), 2.56-2.26 (m, 4H), 2.19-1.99 (m, 4H), 
1.96 (s, 3H), 1.89 (s, 3H), 1.86-1.78 (m, 1H), 1.77-1.67 (m, 1H), 1.66-1.34 (m, 7H), 
1.31 (s, 3H), 1.27-1.20 (m, 1H), 1.19 (s, 3H), 0.94 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ = 210.33, 166.13, 148.91, 122.21, 81.14, 75.21, 68.92, 57.57, 56.40, 54.53, 
53.73, 51.95, 47.20, 44.32, 40.42, 38.49, 35.53, 34.83, 31.83, 23.23, 22.02, 21.65, 
21.26, 20.72, 16.02, 13.98, 12.63. HRMS ESI calc. for C28H41O7+ [M+H]+: 489.2847, 
found: 489.2837. 
 
 
Acetate (2.41):51 To a solution of β-hydroxy ketone 2.40 (10 mg, 0.021 mmol, 1 eq.) 
in CH2Cl2 (0.3 mL) was added acetic anhydride 
(9.6 µL, 0.102 mmol, 5 eq.), DMAP (2.5 mg, 
0.021 mmol, 1 eq.), and Et3N (29 µL, 0.210 mmol, 
10 eq.). The colorless solution was stirred at RT for 
45 min, then quenched with 0.1 M HCl and 
extracted with CH2Cl2. The organic phase was dried over Na2SO4 and evaporated. 
The residue was purified by column chromatography (pentane/EtOAc 1:2) affording 
acetate 2.41 (8.4 mg, 0.016 mmol, 78%) as a colorless solid.  
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M.p. = 237-238 °C. Rf = 0.51 (EtOAc). Optical rotation: [α]D = +69.5° (c = 0.42, 
CHCl3). FTIR: ν = 3518, 3470, 2956, 2932, 1703, 1380, 1282, 1144, 1026, 900, 813, 
758, 651 cm−1. 1H NMR (400 MHz, CDCl3) δ = 5.49-5.41 (m, 1H), 4.20 (dd, J = 
13.3, 3.5 Hz, 1H), 3.29 (dd, J = 4.0, 2.0 Hz, 1H), 3.16 (d, J = 2.0 Hz, 1H), 3.01 (d, J = 
3.9 Hz, 1H), 2.98 (dd, J = 9.6, 7.3 Hz, 1H), 2.59 (dd, J = 16.9, 4.9 Hz, 1H), 2.51 (ddd, 
J = 15.6, 7.3, 2.1 Hz, 1H), 2.45-2.36 (m, 2H), 2.15-1.98 (m, 4H), 2.07 (s, 3H), 1.95 (s, 
3H), 1.89 (s, 3H), 1.86-1.79 (m, 1H), 1.77-1.70 (m, 1H), 1.58-1.21 (m, 8H), 1.31 (s, 
3H), 1.08 (s, 3H), 0.94 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 208.89, 170.79, 
166.12, 148.90, 122.19, 81.13, 75.20, 73.17, 67.58, 57.50, 56.59, 54.54, 52.54, 51.94, 
44.11, 43.06, 40.43, 37.93, 35.72, 34.90, 31.83, 23.31, 21.99, 21.82, 21.48, 21.23, 
20.71, 15.00, 13.90, 12.62. UPLC/MS: Rt = 1.785 min, m/z (ES+) 1061.5 (2M + Na+). 
 
 
Tetraol (2.42):51 To a solution of β-hydroxy ketone 2.40 (30 mg, 0.061 mmol, 1 eq.) 
in CHCl3/MeOH (1.0 mL, 1:1) was added NaBH4 
(9.5 mg, 0.246 mmol, 4 eq.). After stirring for 1 h at RT 
the reaction mixture was quenched with 0.1 M HCl 
solution. Saturated aqueous Rochelle’s solution (40 mL) 
and EtOAc (40 mL) were added to the mixture and 
stirred for 1 h. Then the layers were separated and the aqueous was extracted with 
EtOAc. The combined organic layers were dried over Na2SO4 and evaporated. The 
residue was purified by column chromatography (CH2Cl2/MeOH, 25:1) to yield 
tetraol 2.42 (19.5 mg, 0.040 mmol, 65%) as a colorless solid.  
 
M.p. = 234-235 °C. Rf = 0.22 (CH2Cl2/MeOH, 25:1). Optical rotation: [α]D = 
+38.0° (c = 0.27, CHCl3). FTIR: ν = 3551, 2943, 1705, 1440, 1382, 1305, 1106, 
1093, 910, 843, 746 cm−1. 1H NMR (400 MHz, CDCl3) δ = 4.21 (dd, J = 13.3, 
3.5 Hz, 1H), 4.18-4.12 (m, 1H), 3.85 (s, 1H), 3.78 (d, J = 10.7 Hz, 1H), 3.67 (d, J = 
9.0 Hz, 1H), 3.62 (ddd, J = 10.7, 4.4, 2.0 Hz, 1H), 3.33 (dd, J = 3.9, 2.3 Hz, 1H), 2.98 
(d, J = 3.8 Hz, 1H), 2.44-2.33 (m, 2H), 2.31-2.23 (m, 1H), 2.18-1.99 (m, 6H), 1.95 (s, 
3H), 1.89 (s, 3H), 1.87-1.74 (m, 3H), 1.66-1.28 (m, 10H), 0.95 (s, 3H), 0.77 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 166.11, 148.88, 122.20, 81.11, 75.21, 73.98, 71.90, 
66.82, 58.23, 57.93, 54.46, 51.93, 44.46, 40.69, 40.10, 38.44, 36.89, 35.15, 31.77, 
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23.13, 22.16, 21.22, 20.70, 19.91, 16.40, 13.88, 12.62. UPLC/MS: Rt = 1.612 min, 
m/z (ES+) 981.6 (2M + H+). 
 
 
Allylic alcohol (2.43):51 A solution of epoxy ketone 2.39 (100 mg, 0.21 mmol, 1 eq.) 
in MeOH/CH2Cl2 (4.0 mL, 1:1) was cooled to 0 °C, and 
hydrazine hydrate (100 µl, 2.1 mmol, 10 eq.) was added 
dropwise. After stirring for 15 min, AcOH (50 µL) was 
added dropwise and the reaction mixture was stirred for 
additional 15 min at 0 °C. Then the reaction mixture was 
allowed to come to RT and stirred for 3 h. The slightly yellow solution was diluted 
with CH2Cl2 and quenched with saturated aqueous NaHCO3. The mixture was 
extracted with CH2Cl2, dried over Na2SO4 and concentrated under reduced pressure. 
The residue was subjected to flash column chromatography (EtOAc/pentane, 1:1 to 
2:1) to give allylic alcohol 2.43 (59 mg, 0.13 mmol, 61%) as a colorless solid. An 
analytical sample was recrystallized from EtOAc for X-ray analysis. 
 
M.p. = 248-249 °C. TLC: Rf = 0.51 (EtOAc). Optical rotation: [α]D = -7.0° (c = 0.5, 
CHCl3). FTIR: ν = 3495, 2939, 1700, 1384, 1318, 1092, 1029, 895, 748, 644 cm−1. 
1H NMR (400 MHz, CDCl3) δ = 5.87-5.80 (m, 2H), 4.20 (dd, J = 13.3, 3.5 Hz, 1H), 
4.16-4.09 (m, 1H), 3.35 (d, J = 11.2 Hz, 1H), 3.33-3.28 (m, 1H), 3.22 (d, J = 1.6 Hz, 
1H), 3.09 (d, J = 3.8 Hz, 1H), 2.45-2.25 (m, 3H), 2.21-2.00 (m, 4H), 1.95 (s, 3H), 
1.89 (s, 3H), 1.87-1.74 (m, 2H), 1.68-1.54 (m, 2H), 1.52-1.34 (m, 5H), 1.31 (s, 3H), 
1.29-1.20 (m, 1H), 0.95 (s, 3H), 0.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 
166.13, 148.91, 132.74, 128.48, 122.21, 81.13, 75.21, 70.14, 64.81, 57.93, 57.57, 
54.45, 51.80, 44.35, 40.85, 40.23, 38.61, 36.35, 35.50, 31.85, 23.16, 22.21, 21.27, 
21.16, 20.72, 13.87, 12.62. HRMS ESI calc. for C28H41O6+ [M+H]+: 473.2898, 
found: 473.2890. X-ray crystal structure is given in the appendices section. 
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Acetate (2.44):51 To a solution of allylic alcohol 2.43 (6 mg, 0.013 mmol, 1 eq.) in 
CH2Cl2 (0.1 mL) was added acetic anhydride (4.8 µL, 
0.052 mmol, 4 eq.), DMAP (0.16 mg, 0.001 mmol, 
0.1 eq.), and Et3N (5.4 µL, 0.039 mmol, 3 eq.). The 
colorless solution was stirred at RT for 45 min, then 
quenched with 0.1 M HCl and extracted with CH2Cl2. 
The organic phase was dried over Na2SO4 and evaporated. The residue was purified 
by column chromatography (pentane/EtOAc, 1:1) affording acetate 2.44 (5.7 mg, 
0.011 mmol, 87%) as a colorless solid.  
 
M.p. = 245-246 °C. TLC: Rf = 0.60 (EtOAc). Optical rotation: [α]D = -4.3° (c = 
0.29, CHCl3). FTIR: ν = 3502, 2922, 2324, 1718, 1462, 1374, 1310, 1248, 1139, 
1100, 1015, 970, 891, 813, 754 cm−1. 1H NMR (400 MHz, CDCl3) δ = 6.07 (dd, J = 
10.2, 1.7 Hz, 1H), 5.75-5.69 (m, 1H), 5.45-5.39 (m, 1H), 4.20 (dd, J = 13.4, 3.5 Hz, 
1H), 3.31 (dd, J = 3.8, 2.4 Hz, 1H), 3.08 (d, J = 1.6 Hz, 1H), 3.05 (d, J = 3.8 Hz, 1H), 
2.47-2.30 (m, 3H), 2.10 (s, 3H), 2.19-2.00 (m, 4H), 1.95 (s, 3H), 1.89 (s, 3H), 1.87-
1.75 (m, 2H), 1.68-1.51 (m, 2H), 1.42 (m, 5H), 1.32 (s, 3H), 1.26-1.19 (m, 1H), 0.96 
(s, 3H), 0.92 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 170.99, 166.13, 148.87, 
136.29, 124.39, 122.22, 81.14, 75.22, 67.89, 65.88, 57.68, 57.26, 54.38, 51.81, 44.37, 
40.77, 40.32, 37.15, 36.15, 35.40, 31.91, 23.16, 22.19, 21.67, 21.33, 21.13, 20.71, 
20.61, 13.83, 12.62. HRMS ESI calc. for C30H43O7+ [M+H]+: 515.3003, found: 
515.2987. 
 
 
Allylic alcohol (2.45):51 A stirred mixture of allylic alcohol 2.43 (10.0 mg, 
0.021 mmol, 1.0 eq.), 4-nitrobenzoic acid (14.4 mg, 
0.085 mmol, 4.0 eq.) and PPh3 (21.1 mg, 0.080 mmol, 
3.8 eq.) in CH2Cl2 (0.2 mL) was cooled to 0 °C. To the 
cold solution was added DEAD (17.1 mg, 0.095 mmol, 
4.5 eq.), and the mixture was stirred at RT overnight. 
The solvent was removed under reduced pressure and the residue subjected to flash 
column chromatography (pentane/EtOAc, 1:1) to yield the 4-nitrobenzoate (8.7 mg, 
0.014 mmol, 66%) as a yellowish solid.  
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Rf = 0.79 (EtOAc, 1:1). 1H NMR (400 MHz, CDCl3) δ = 8.33-8.17 (m, 5H), 6.03 (dd, 
J = 10.3, 1.8 Hz, 1H), 5.98-5.91 (m, 1H), 5.77–5.70 (m, 1H), 4.21 (dd, J = 13.3, 
3.5 Hz, 1H), 3.33 (dd, J = 3.8, 2.5 Hz, 1H), 3.17 (d, J = 1.5 Hz, 1H), 3.08 (d, J = 
3.8 Hz, 1H), 2.57-2.46 (m, 1H), 2.46-2.31 (m, 2H), 2.28-1.98 (m, 5H), 1.96 (s, 3H), 
1.89 (s, 3H), 1.87-1.77 (m, 2H), 1.52-1.34 (m, 6H), 1.32 (s, 3H), 1.12 (s, 3H), 0.97 (s, 
3H). 
 
To a solution of 4-nitrobenzoate (8.7 mg, 0.014 mmol, 1 eq.) in THF/CH2Cl2 (0.4 mL, 
1:1) was added 5% aqueous NaOH solution (0.2 mL) and TBAH solution (7 µL, 1 M 
in methanol) and the mixture was stirred at RT for 2 h. The mixture was then diluted 
with CH2Cl2 and washed with 1 M HCl and water. The organic phase was dried over 
Na2SO4, evaporated and the residue subjected to flash column chromatography 
(EtOAc) to yield allylic alcohol 2.45 (5.0 mg, 0.011 mmol, 76%) as a colorless solid.  
 
M.p. = 240 °C (decomposed). Rf = 0.27 (pentane/EtOAc, 1:1). Optical rotation: 
[α]D = +39.1° (c = 0.25, CHCl3). FTIR: ν = 3475, 2925, 1696, 1453, 1384, 1139, 
1098, 1061, 1022, 923, 817, 763, 610 cm−1. 1H NMR (400 MHz, CDCl3) δ = 5.85 
(dd, J = 10.3, 1.8 Hz, 1H), 5.67 (ddd, J = 10.1, 2.8, 1.1 Hz, 1H), 4.75-4.63 (m, 1H), 
4.20 (dd, J = 13.4, 3.5 Hz, 1H), 3.30 (dd, J = 3.8, 2.5 Hz, 1H), 3.10 (d, J = 1.6 Hz, 
1H), 3.06 (d, J = 3.9 Hz, 1H), 2.46-2.24 (m, 3H), 2.19-1.98 (m, 4H), 1.95 (s, 3H), 
1.89 (s, 3H), 1.86-1.72 (m, 3H), 1.68-1.52 (m, 3H), 1.50-1.33 (m, 5H), 1.31 (s, 3H), 
1.05 (s, 3H), 0.95 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 166.15, 148.91, 133.69, 
128.84, 122.21, 81.15, 75.22, 71.52, 66.75, 57.92, 57.73, 54.43, 51.79, 44.42, 41.01, 
40.28, 39.87, 36.02, 35.34, 31.88, 23.13, 22.71, 22.19, 21.29, 20.75, 20.71, 13.87, 
12.62. HRMS ESI calc. for C28H41O6+ [M+H]+: 473.2898, found: 473.2885. 
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Alcohol (2.47):51 Allylic alcohol 2.43 (5.0 mg, 0.011 mmol, 1.0 eq.) and Crabtree’s 
catalyst (0.17 mg, 2 mol%) were dissolved in CH2Cl2 
(0.1 mL) in a small vial. The vial was placed in an 
autoclave and the mixture was stirred at RT for 2.5 h 
under a H2 atmosphere (10 bar). The solvent was 
removed, the residue filtered through a short pad of 
silica (EtOAc) and evaporated to yield alcohol 2.47 (5.0 mg, 0.011 mmol, quant.) as a 
colorless solid.  
 
M.p. = 205-206 °C. TLC: Rf = 0.52 (EtOAc). Optical rotation: [α]D = +19.1° (c = 
0.36, CHCl3). FTIR: ν = 3475, 2922, 1705, 1382, 1142, 1102, 1024, 895, 855, 811, 
759, 652 cm−1. 1H NMR (400 MHz, CDCl3) δ = 4.53 (d, J = 9.7 Hz, 1H), 4.21 (d, J = 
9.8 Hz, 1H), 4.04-3.93 (m, 1H), 3.35 (s, 1H), 3.31-3.24 (m, 1H), 2.95 (d, J = 3.8 Hz, 
1H), 2.46-2.31 (m, 2H), 2.17 (s, 1H), 2.14-1.97 (m, 3H), 1.95 (s, 3H), 1.92-1.90 (m, 
1H), 1.89 (s, 3H), 1.85-1.65 (m, 5H), 1.50 (t, J = 9.5 Hz, 1H), 1.44-1.33 (m, 3H), 1.30 
(s, 3H), 1.28-1.04 (m, 5H), 0.92 (s, 3H), 0.81 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ = 166.15, 148.94, 122.19, 81.10, 75.23, 71.60, 67.11, 58.07, 57.92, 54.48, 51.83, 
44.31, 40.25, 38.44, 38.23, 37.94, 35.15, 31.78, 29.25, 24.29, 23.08, 22.22, 21.16, 
20.72, 20.18, 14.56, 13.87, 12.62. HRMS ESI calc. for C28H43O6+ [M+H]+: 475.3054, 
found: 475.3042. 
 
 
General Procedure A for oxime ethers 2.48-2.52 
To a solution of withanolide A (1 eq.) in pyridine was added the hydroxylamine 
hydrochloride (2 eq.) and the mixture was heated at 70 °C for the indicated time. The 
solvent was removed under high vacuum, and the residue dissolved in CH2Cl2. 
Saturated aqueous NH4Cl solution was added and the aqueous phase was extracted 
with CH2Cl2. The organic phase was dried over Na2SO4, evaporated, and the residue 
subjected to flash column chromatography to yield oxime ethers 2.48-2.52 as 
colorless solids. 
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Hydroxylamine (2.48):51 Following General Procedure A: Withanolide A (20 mg, 
0.04 mmol, 1 eq.) in pyridine (0.50 mL), hydroxylamine 
hydrochloride (5.9 mg, 0.08 mmol, 2 eq.), 70 °C for 20 h. 
Additional hydroxylamine hydrochloride (3.0 mg, 
0.04 mmol, 1 eq.), 70 °C for 5 h, flash column chromato-
graphy (pentane/EtOAc, 1:1), 58% yield.  
 
M.p. = 180-181 °C. Rf = 0.55 (EtOAc). Optical rotation: [α]D = +175.0° (c = 0.69, 
CHCl3). FTIR: ν = 3417, 2922, 2360, 1691, 1382, 1290, 1023, 907, 815, 750, 
645 cm−1. 1H NMR (400 MHz, CDCl3) δ = 7.19 (s, 1H), 6.75 (ddd, J = 10.3, 2.9, 
1.2 Hz, 1H), 6.02 (ddd, J = 10.3, 4.7, 2.5 Hz, 1H), 4.21 (dd, J = 13.3, 3.5 Hz, 1H), 
3.30 (dd, J = 4.0, 2.1 Hz, 1H), 3.01 (d, J = 3.9 Hz, 1H), 2.98 (d, J = 1.5 Hz, 1H), 2.73-
2.66 (m, 1H), 2.53-2.33 (m, 4H), 2.17-2.08 (m, 1H), 2.03-1.97 (m, 1H), 1.95 (s, 3H), 
1.88 (s, 3H), 1.87-1.77 (m, 2H), 1.64-1.32 (m, 8H), 1.30 (s, 3H), 1.08 (s, 3H), 0.96 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ = 166.21, 159.55, 149.01, 131.00, 122.12, 
117.81, 81.14, 75.24, 71.42, 57.43, 56.82, 54.61, 52.39, 45.37, 44.02, 40.52, 37.42, 
36.70, 35.43, 31.79, 23.33, 22.85, 22.07, 21.15, 20.72, 15.98, 14.07, 12.61. HRMS 
ESI calc. for C28H40NO6+ [M+H]+: 486.2850, found: 486.2839. 
 
 
Methyloxime (2.49):51 Following General Procedure A: Withanolide A (10 mg, 
0.02 mmol, 1 eq.) in pyridine (0.25 mL), methoxylamine 
hydrochloride (3.6 mg, 0.04 mmol, 2 eq.), 70 °C for 3 h. 
Additional methoxylamine hydrochloride (1.8 mg, 
0.02 mmol, 1 eq.), 70 °C for 2 d, flash column chromato-
graphy (pentane/EtOAc, 1:1), 58% yield (as an inseparable 
diastereomeric mixture).  
 
M.p. = 157-158 °C. Rf = 0.81 (EtOAc). Optical rotation: [α]D = +217.1° (c = 0.18, 
CHCl3). FTIR: ν = 3500, 2937, 2325, 1702, 1463, 1381, 1289, 1187, 1130, 1046, 
896, 829, 733, 683, 614 cm−1. 1H NMR (400 MHz, CDCl3) δ = 6.67-6.60 (m, 1H), 
6.01-5.94 (m, 1H), 4.21 (dd, J = 13.3, 3.5 Hz, 1H), 3.87 and 3.84 (s, 3H), 3.30 (dd, 
J = 4.0, 2.1 Hz, 1H), 3.00 (d, J = 3.9 Hz, 1H), 2.95 (d, J = 1.5 Hz, 1H), 2.93-2.85 (m, 
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1H), 2.51-2.30 (m, 4H), 2.17-1.98 (m, 3H), 1.95 (s, 3H), 1.89 (s, 3H), 1.87-1.77 (m, 
1H), 1.67-1.34 (m, 8H), 1.32 (s, 3H), 1.12 and 1.07 (s, 3H, diastereomers), 0.97 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ = 166.19, 157.97, 148.89, 130.78, 122.19, 
118.30, 81.17, 75.25, 71.31, 61.81, 57.46, 56.86, 54.60, 52.36, 45.19, 44.02, 40.63, 
37.41, 36.74, 35.41, 31.87, 23.38, 22.74, 22.02, 21.24, 20.71, 16.10, 14.00, 12.62. 
HRMS ESI calc. for C29H42NO6+ [M+H]+: 500.3007, found: 500.2996. 
 
Allyloxime (2.50): Following General Procedure A: Withanolide A (50 mg, 
0.11 mmol, 1 eq.) in pyridine (1.25 mL), O-allyl-
hydroxylamine hydrochloride (23.3 mg, 0.21 mmol, 
2 eq.), 70 °C for 14 h. Additional O-allylhydroxyl-
amine hydrochloride (11.7 mg, 0.11 mmol, 1 eq.), 
70 °C for 14 h, flash column chromatography 
(pentane/EtOAc, 1:1), 72% yield.  
 
M.p. = 117-118 °C. Rf = 0.75 (EtOAc). Optical rotation: [α]D = +218.3° (c = 0.24, 
CHCl3). FTIR: ν = 3506, 2925, 1702, 1382, 1289, 1131, 1097, 1025, 906, 826, 
664 cm−1. 1H NMR (400 MHz, CDCl3) δ = 6.73-6.62 (m, 1H), 6.03-5.90 (m, 2H), 
5.27-5.20 (m, 1H), 5.17-5.11 (m, 1H), 4.61-4.45 (m, 2H), 4.20 (dd, J = 13.3, 3.5 Hz, 
1H), 3.29 (dd, J = 4.0, 2.1 Hz, 1H), 2.99 (d, J = 3.9 Hz, 1H), 2.94 (s, 1H), 2.89-2.79 
(m, 1H), 2.51-2.28 (m, 4H), 2.18-1.97 (m, 4H), 1.94 (s, 3H), 1.88 (s, 3H), 1.88-1.74 
(m, 2H), 1.60-1.38 (m, 5H), 1.31 (s, 3H), 1.29-1.23 (m, 1H), 1.06 (s, 3H), 0.96 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ = 166.16, 158.08, 148.88, 134.84, 130.73, 
122.13, 118.43, 117.22, 81.15, 75.20, 74.86, 71.29, 57.43, 56.82, 54.55, 52.35, 45.27, 
44.01, 40.57, 37.37, 36.74, 35.38, 31.83, 23.34, 22.74, 21.99, 21.21, 20.68, 16.07, 
13.97, 12.59. HRMS ESI calc. for C31H44NO6+ [M+H]+: 526.3163, found: 526.3148. 
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Benzyloxime (2.51):51 Following General Procedure A: Withanolide A 1 (10 mg, 
0.02 mmol, 1 eq.) in pyridine (0.25 mL), O-benzyl-
hydroxylamine hydrochloride (6.8 mg, 0.04 mmol, 
2 eq.), 70 °C for 14 h. Additional O-benzylhydroxyl-
amine hydrochloride (3.4 mg, 0.02 mmol, 1 eq.), 
70 °C for 14 h, flash column chromatography 
(pentane/EtOAc, 2:1), 63% yield (as an inseparable diastereomeric mixture).  
 
M.p. = 106-107 °C. Rf = 0.79 (EtOAc). Optical rotation: [α]D = +174.0° (c = 0.37, 
CHCl3). FTIR: ν = 3485, 2922, 2361, 1703, 1455, 1381, 1289, 1212, 1131, 1095, 
1019, 906, 815, 753, 698, 613 cm−1. 1H NMR (400 MHz, CDCl3) δ = 7.39-7.27 (m, 
5H), 6.75-6.68 (m, 1H), 6.01-5.93 (m, 1H), 5.16-5.01 (m, 2H), 4.26-4.17 (m, 1H), 
3.32-3.27 (m, 1H), 3.00 (d, J = 3.9 Hz, 1H), 2.95 (d, J = 1.4 Hz, 1H), 2.84-2.77 (m, 
1H), 2.52-2.29 (m, 4H), 2.17-1.98 (m, 3H), 1.96 (s, 3H), 1.90 (s, 3H), 1.85-1.74 (m, 
2H), 1.63-1.36 (m, 6H), 1.33 (s, 3H), 1.32-1.29 (m, 1H), 1.08 and 1.05 (s, 3H, 
diastereomers), 0.96 and 0.95 (s, 3H, diastereomers). 13C NMR (101 MHz, CDCl3) 
δ = 166.18, 158.33, 148.90, 138.50, 130.76, 128.33, 128.30, 127.65, 122.20, 118.64, 
81.18, 75.99, 75.26, 71.35, 57.46, 56.86, 54.60, 52.40, 45.33, 44.06, 40.63, 37.41, 
36.77, 35.43, 31.88, 23.36, 22.77, 22.04, 21.25, 20.72, 16.10, 14.02, 12.64. HRMS 
ESI calc. for C35H46NO6+ [M+H]+: 576.3320, found: 576.3323. 
 
 
Epoxy allyloxime (2.52):51 To a solution of epoxy ketone 2.39 (5 mg, 0.01 mmol, 
1 eq.) in pyridine (0.15 mL) was added O-
allylhydroxylamine hydrochloride (2.3 mg, 0.02 mmol, 
2 eq.) and the mixture was heated at 70 °C for 7 h. The 
solvent was removed under high vacuum, and the residue 
dissolved in CH2Cl2. Saturated NH4Cl solution was added 
and the aqueous phase was extracted with CH2Cl2. The organic phase was dried over 
Na2SO4, evaporated, and the residue subjected to flash column chromatography 
(pentane:EtOAc, 4:6) to yield the allylhydroxylamie 2.52 (2.7 mg, 0.005 mmol, 49%) 
as a colorless solid.  
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M.p. = 109-110°C. Rf = 0.54 (EtOAc). Optical rotation: [α]D = +126.7° (c = 0.16, 
CHCl3). FTIR: ν = 3495, 2922, 2362, 1704, 1462, 1383, 1315, 1261, 1096, 1006, 
919, 805, 754, 665 cm−1. 1H NMR (400 MHz, CDCl3) δ = 6.08-5.89 (m, 1H), 5.33-
5.23 (m, 1H), 5.22-5.14 (m, 1H), 4.67-4.56 (m, 2H), 4.20 (dd, J = 13.3, 3.7 Hz, 1H), 
3.93 (d, J = 3.7 Hz, 1H), 3.51 (t, J = 3.2 Hz, 1H), 3.24-3.10 (m, 1H), 2.94 (s, 1H), 
2.90 (d, J = 3.8 Hz, 1H), 2.63 (d, J = 11.6 Hz, 1H), 2.47-2.30 (m, 2H), 2.22-2.00 (m, 
5H), 1.95 (s, 3H), 1.89 (s, 3H), 1.76-1.63 (m, 3H), 1.46 (d, J = 19.6 Hz, 6H), 1.32 (s, 
3H), 1.04 (s, 3H), 0.96 and 0.92 (s, 3H, diastereomers). 13C NMR (101 MHz, CDCl3) 
δ = 166.05, 155.33, 148.77, 134.37, 122.04, 117.63, 81.03, 75.29 and 75.11 
(diastereomers), 70.35, 56.28, 55.69, 54.36, 52.17, 51.86, 46.97, 46.03, 43.87 and 
43.79 (diastereomers), 40.22 and 40.07 (diastereomers), 35.74, 35.70, 35.30, 33.85, 
31.74, 29.70, 23.21, 21.96 and 21.87 (diastereomers), 21.17, 20.58, 15.40, 13.75, 
12.48. HRMS ESI calc. for C31H44NO7+ [M+H]+: 542.3112, found: 542.3099. 
 
 
Neurotogenic properties: SH-SY5Y cells (obtained from DSMZ, Germany) were 
cultured in minimal essential medium (MEM without phenol red (GIBCO, 
Invitrogen)) containing 5% fetal bovine serum (FBS, GIBCO, Invitrogen) with and 
Ala-Gln (406 mg/L, BioReagent, Sigma). All experiments were conducted under 
strictly sterile conditions and exclusion of light. Passage numbers 3 to 9 were used for 
the experiments. Cells were plated either on collagen coated 24-well plates (Iwaki, 
Asahi Glass Co., Japan). After incubating in the dark for three days at 37 °C in 
humidified atmosphere (CO2 content 5%) in the presence of the compounds, e.g. 
withanolide A (0.1 or 1 µM), vehicle solution (DMSO, 0.1%, negative control) or 
ATRA (1 µM, positive control, Sigma-Aldrich), cells were examined under a phase 
contrast microscope (Leica, Germany). Cells were examined in three randomly 
chosen areas per well. More than 500 cells were examined and ranked positive, if they 
possess a neurite with more than 50 µM length (double cell diameter). Large cell 
aggregates were not counted. The ratio of neurite positive cells to total cells was 
calculated. Error bars are given as SEM. 
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8.4 Release on Demand: Nitrocatechols 
1-(4,5-dihydroxy-2-nitrophenyl)ethanone (3.7): Sublimed AlCl3 (3.65 g, 
27.38 mmol, 3 eq.) was added to 10 mL of cold (-5 °C), dry 1,2-di-
chloroethane. Then a solution of methylen protected nitro-
actophenone81 (1.91 g, 9.13 mmol, 1 eq.) in 1,2-dichloroethane (9 mL) 
was added dropwise. The reaction was stirred at -5 to +5 °C for 1 h, then poured into 
cold HBr (48%; 25 mL) and stirred at RT over night. The reaction mixture was 
diluted with water, extracted with Et2O and dried over Na2SO4. The solvent was 
evaporated to yield 3.7 as a green brown adhesive solid (1.86 g, 9.41 mmol, 84 %).  
 
M.p. = 148-149 °C. Rf = 0.1 (pentane: Et2O 2:1). FTIR: ν = 3405, 3121, 2802, 2662, 
1669, 1593, 1503, 1441, 1291, 1189, 1107, 1011, 964, 893, 798, 754, 670 cm-1. 
1H NMR (400 MHz, DMSO-d6) δ = 10.75 (s, 1H), 10.44 (s, 1H), 7.45 (s, 1H), 6.87 
(s, 1H), 2.41 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ = 199.32, 151.39, 146.64, 
137.27, 130.42, 113.68, 111.09, 29.88. HRMS ESI calc. for C8H7O5NNa+ [M-Na]+: 
220.0216, found: 220.0216. 
 
 
MOM protected catechol (3.7b): To a stirred solution of catechol 3.7 (1.325 g, 
6.72 mmol, 1.0 eq.) and K2CO3 (4.644 g, 33.6 mmol, 5.0 eq.) in 
CH3CN (50 mL) at 0 °C was dropwisely added MOMCl (1.69 mL, 
22.2 mmol, 3.3 eq.). After 5 minutes the cooling bath was removed 
and stirring was continued at RT for 3 h. The brown mixture was diluted with Et2O, 
washed with water and brine and dried over Na2SO4. The solvent was evaporated and 
the resulting solid triturated in pentane to afford 3.7b (1.658 g, 5.81 mmol, 87%) as a 
pale yellow solid.  
 
M.p. = 84-85 °C. Rf = 0.4 (pentane/Et2O 1:1). FTIR: ν = 2937, 2832, 2307, 1701, 
1575, 1518, 1332, 1272, 1153, 1080, 989, 917, 785, 618 cm-1. 1H NMR (400 MHz, 
CDCl3) δ = 7.91 (s, 1H), 7.11 (s, 1H), 5.32 (s, 2H), 5.32 (s, 2H), 3.53 (s, 3H), 3.52 (s, 
3H), 2.50 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 199.51, 152.05, 147.46, 139.45, 
HO
HO
O
NO2
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133.48, 113.10, 112.01, 95.48, 95.32, 56.79, 56.66, 30.30. Elementary Analysis calc. 
for C12H15NO7: C = 50.53, H = 5.30, N = 4.91, found: C = 50.66, H = 5.13, N = 5.09. 
 
 
Benzylic alcohol (3.8): To a stirred solution of acetophenone 3.7b (255.0 mg, 
0.894 mmol, 1.0 eq.) in methanol (2.5 mL) at 0 °C was added 
NaBH4 (33.8 mg, 0.894 mmol, 1.0 eq.) and after 5 minutes at 0 °C 
stirring was continued at RT for 3.5 h. The mixture was quenched 
with a saturated, aqueous NH4Cl solution and extracted with CH2Cl2. The combined 
organic layers were washed with brine, dried over Na2SO4 and evaporated under 
reduced pressure to afford alcohol 3.8 (254.6 mg, 0.886 mmol, 99%) as a pale yellow 
solid.  
 
M.p. = 67-68 °C. FTIR: ν = 3284, 2932, 2829, 2072, 1577, 1515, 1328, 1262, 1151, 
1080, 995, 947, 916, 845, 795, 715 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.84 (s, 
1H), 7.56 (s, 1H), 5.48 (q, J = 6.3 Hz, 1H), 5.34 (s, 2H), 5.28 (s, 2H), 3.52 (s, 6H), 
1.55 (d, J = 6.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 151.95, 145.71, 141.03, 
137.49, 113.38, 113.13, 95.64, 95.20, 65.72, 56.81, 56.62, 24.25. HRMS ESI calc. 
for C12H17O7NNa+ [M-Na]+: 310.0897, found: 310.0892. 
 
 
3-Cyano-7-hydroxycoumarin (3.9):62 A mixture of 2,4-dihydroxybenzaldehyde 
(2.072 g, 15.0 mmol, 1.0 eq.), malononitrile (1.239 g, 18.8 mmol, 
1.3 eq.) and 0.05 M aqueous NaHCO3 (75 mL) was stirred at RT 
for 5 h. Conc. HCl (2.8 mL) was added and the mixture was heated to 90 °C for 2 h. 
After cooling to RT the resulting precipitate was filtered off, washed with water and 
dried in vacuo to afford coumarin 3.9 (2.397 g, 12.8 mmol, 85%) as an orange-red 
solid.  
 
M.p. = 257-260 °C (lit. 273-275 °C). 1H NMR (400 MHz, DMSO-d6) δ = 11.33 (s, 
1H), 8.79 (s, 1H), 7.65 (d, J = 8.6 Hz, 1H), 6.90 (dd, J = 8.6, 2.2 Hz, 1H), 6.79 (d, J = 
2.2 Hz, 1H).  
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Analytical data are in agreement with the reported literature: F. Fringuelli, O. 
Piermatti, F. Pizzo, Synthesis 2003, 15, 2331-2334. 
 
 
Benzylic ether (3.4a):62 To a stirred solution of alcohol 3.8 (100 mg, 0.348 mmol, 
1 eq.), coumarin 3.9 (130 mg, 0.696 mmol, 2.0 eq.) 
and PPh3 (182 mg, 0.696 mmol, 2 eq.) in THF 
(2.0 mL) at 0 °C and under exclusion of light was 
slowly added DIAD (138 µL, 0.696 mmol, 2 eq.). After 5 min the cooling bath was 
removed and stirring was continued at RT overnight. The reaction mixture was 
concentrated under reduced pressure and the oily resin was subjected to repeated flash 
chromatography (CH2Cl2:MeOH 200:1 to pentane:EtOAc 3:1 to 1:1) to afford ether 
3.4a (65 mg, 0.142 mmol, 41 %) as a yellow oil. 
 
Rf = 0.5 (pentane/EtOAc 1:1). FTIR: ν = 2982, 2940, 1733, 1688, 1605, 1519, 1374, 
1337, 1246, 1153, 1107, 1092, 1049, 1002, 923, 853, 793, 760, 639, 609 cm-1. 
1H NMR (400 MHz, CDCl3) δ = 8.12 (s, 1H), 7.97 (s, 1H), 7.44 (d, J = 8.8 Hz, 1H), 
7.36 (s, 1H), 6.91 (dd, J = 8.7, 2.3 Hz, 1H), 6.73 (d, J = 2.2 Hz, 1H), 6.27 (q, J = 
6.2 Hz, 1H), 5.30-5.17 (m, 4H), 3.52 (s, 3H), 3.39 (s, 3H), 1.75 (d, J = 6.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 163.68, 157.00, 156.80, 152.47, 151.39, 146.47, 
140.64, 133.14, 130.77, 114.89, 114.08, 113.32, 112.77, 111.49, 103.66, 99.42, 95.62, 
95.26, 73.10, 56.80, 56.71, 23.28. HRMS ESI calc. for C22H21O9N2+ [M-H]+: 
457.1242, found: 457.1231. 
 
 
Catechol (3.4):62 To a stirred solution of ether 3.4a (24 mg, 52.6 µmol) in CHCl3 
(0.5 mL) was added TFA (0.15 mL) at 0 °C and the 
mixture was stirred overnight at RT under exclusion of 
light. Volatiles were removed under reduced pressure 
and the residue was subjected to preparative reversed-phase HPLC (CH3CN:H2O 5% 
to 100%, over 33 min, Rt = 17.2 min) to afford catechol 3.4 (9 mg, 24.4 µmol, 46%).  
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M.p. = 109-111 °C. FTIR: ν = 3354, 2238, 1713, 1599, 1525, 1504, 1435, 1376, 
1329, 1290, 1245, 1156, 1133, 1077, 1045, 1000, 892, 860, 806, 762. 1H NMR 
(400 MHz, DMSO-d6) d = 8.79 (s, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.57 (s, 1H), 6.99 
(dd, J = 8.8, 2.4 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J = 2.5 Hz, 1H), 6.17 (q, J = 6.1 Hz, 
1H), 1.64 (d, J = 6.1 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) d = 162.88, 157.60, 
156.14, 153.04, 152.25, 144.95, 137.97, 131.83, 130.62, 114.98, 114.41, 112.38, 
112.27, 111.66, 102.61, 97.99, 72.39, 22.82. UPLC-MS ESI for C18H13O7N2+ 
[M-H]+: 369.1, found: 369.1. 
 
 
Acetonide (3.15b):62 A solution of ethylcatechol 3.15 (0.993 g, 7.19 mmol, 1.0 eq.), 
2,2-dimethoxypropane (1.78 mL, 14.5 mmol, 2.0 eq.) and p-toluene-
sulfonic acid (14 mg, 72.4 µmol, 1 mol %) in benzene (26 mL) was 
refluxed overnight. After cooling to RT the solution was poured into saturated 
aqueous NaHCO3 solution followed by extraction with Et2O. The combined organic 
extracts were washed with water, dried over Na2SO4 and evaporated to afford crude 
acetonide 3.15b (1.679 g) as a yellowish oil which could be used without further 
purification. To obtain an analytical sample of 3.15b the crude product was subjected 
to flash chromatography (pentane + 1% Et3N).  
 
Rf = 0.6 (pentane). FTIR: ν = 2965, 2934, 2873, 1496, 1445, 1377, 1228, 1156, 982, 
837, 808, 658, 627 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.65-6.58 (m, 3H), 2.56 (q, 
J = 7.6 Hz, 2H), 1.66 (s, 6H), 1.20 (t, J = 7.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ = 147.49, 145.43, 137.68, 119.87, 117.56, 108.36, 108.01, 28.80, 25.99, 16.14.  
 
 
Acetonide (3.16):62 Crude acetonide 3.15b (ca. 1.7 g) was cooled to 0 °C and slowly 
added a cold solution of conc. HNO3 (4.18 mL) in H2O (4.18 mL) 
resulting in a brown mixture. The cooling bath was removed after 
5 min and stirring was continued at RT for 1.5 h. The mixture was cautiously poured 
into saturated aqueous NaHCO3 solution followed by extraction with Et2O. The 
combined organic extracts were washed with water, dried over Na2SO4 and 
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evaporated to afford nitroaryl compound 3.16 (1.381 g, 6.18 mmol, 86% over 2 steps) 
as a yellow solid.  
 
M.p. = 56-59 °C. Rf = 0.3 (pentane). FTIR: ν = 2988, 2938, 2877, 1615, 1519, 1492, 
1416, 1379, 1331, 1250, 1215, 981, 876, 631 cm-1. 1H NMR (400 MHz, CDCl3) δ = 
7.39 (s, 1H), 6.64 (s, 1H), 2.88 (q, J = 7.4 Hz, 2H), 1.71 (s, 6H), 1.26 (t, J = 7.4 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ = 151.76, 145.98, 142.30, 136.26, 120.81, 
109.72, 105.59, 27.23, 26.03, 15.18. HRMS ESI calc. for C11H13O4NNa+ [M-Na]+: 
246.0737, found: 246.0738.  
 
 
Alcohol (3.17):62 Acetonide 3.16 (0.700 g, 3.14 mmol, 1.0 eq.) and paraformaldehyde 
(1.883 g, 62.7 mmol, 20 eq.) were dissolved in benzyl-
trimethylammonium hydroxide (6.41 mL, 14.1 mmol, 4.5 eq., 
40 wt. % solution in MeOH) and the mixture was heated to 85 °C 
for 65 h in a sealed flask. After cooling to RT the mixture was poured into 0.1 M 
aqueous HCl followed by extraction with CH2Cl2. The combined organic extracts 
were washed with water, dried over Na2SO4 and evaporated. The residue was 
subjected to flash chromatography (pentane/EtOAc 3:2 to 1:1, 1% Et3N) to afford 
alcohol 3.17 (324 mg, 1.28 mmol, 41%, 80% brsm) as a yellow oil.  
 
Rf = 0.3 (pentane/EtOAc 3:2). FTIR: ν = 3335, 2988, 2927, 2878, 1519, 1493, 1379, 
1335, 1256, 1214, 1033, 978, 872, 822, 759 cm-1. 1H NMR (400 MHz, CDCl3) δ = 
7.24 (s, 1H), 6.44 (s, 1H), 3.81-3.70 (m, 2H), 3.67-3.59 (m, 1H), 1.71 (s, 6H), 1.27 (d, 
J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 151.68, 146.12, 143.94, 134.86, 
121.03, 106.67, 105.31, 68.20, 36.55, 26.10, 17.84. HRMS ESI calc. for 
C12H15O5NNa+ [M-Na]+: 276.0842, found: 276.0842. 
 
 
Methyl 7-hydroxycoumarin-3-carboxylate (3.18):62 A solution of 2,4-dihydroxy-
benzaldehyde (4.000 g, 29.0 mmol, 1.0 eq.), dimethyl malonate 
(5.000 g, 37.9 mmol, 1.3 eq.) and piperidine (0.7 mL, 
7.03 mmol, 0.2 eq.) in methanol (25 mL) was heated at 90 °C. After 6 h the mixture 
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was allowed to cool to RT, the yellow precipitate was filtered off, washed with water 
and dried in vacuo to afford coumarin 3.18 (3.101 g, 14.1 mmol, 49%) as a yellow 
solid.  
 
M.p. = 255-260 °C. 1H NMR (400 MHz, DMSO-d6) δ = 11.09 (s, 1H), 8.69 (s, 1H), 
7.75 (d, J = 8.6 Hz, 1H), 6.84 (dd, J = 8.6, 2.2 Hz, 1H), 6.72 (d, J = 2.1 Hz, 1H), 3.79 
(s, 3H).  
 
Analytical data are in agreement with the reported literature: H. Valizadeh, S. 
Vaghefi, Syn. Comm. 2009, 39, 1666-1678. 
 
Carbonate (3.5a):62 A solution of triphosgene (183 mg, 0.616 mmol, 1.4 eq.) in THF 
(0.82 mL) was cooled to 0 °C and a solution 
of alcohol 3.17 (130 mg, 0.513 mmol, 1.2 eq.) 
and Et3N (71 µL, 0.513 mmol, 1.2 eq.) in 
THF (0.82 mL) dropwisely added. After stirring for 25 min at 0 °C, the mixture was 
filtered and volatiles were removed in vacuo without heating to afford the desired 
chloroformate in approximately quantitative yield (as indicated by 1H NMR spectro-
scopy, see 8.4). 
Chloroformate was redissolved in CH2Cl2 (1.3 mL) and slowly added to a solution of 
coumarin 3.18 (94 mg, 0.428 mmol, 1.0 eq.) in pyridine (1.3 mL) at 0 °C. After 
20 min the ice bath was removed and stirring was continued for another 60 min. The 
mixture was poured into water and subsequently extracted with CH2Cl2. The 
combined organic extracts were dried over Na2SO4 and evaporated to afford crude 
carbonate 3.5a (300 mg, contaminated mainly with pyridine) as a brown oil which 
was used without further purification. Exposure to light was avoided as much as 
possible during the entire procedure.  
 
1H NMR (400 MHz, CDCl3) δ = 8.56 (s, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.29 (s, 1H), 
7.23 (d, J = 2.0 Hz, 1H), 7.19 (dd, J = 8.5, 2.2 Hz, 1H), 6.77 (s, 1H), 4.48-4.34 (m, 
2H), 3.99-3.91 (m, 1H), 3.96 (s, 3H), 1.73 (s, 3H), 1.72 (s, 3H), 1.37 (d, J = 7.0 Hz, 
3H).  
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Catechol (3.5):62 Crude carbonate 3.5a (ca. 300 mg) was added TFA (3.0 mL) and 
the mixture was stirred at rt under the exclusion 
of light. Since after 14 h 1H NMR analysis did 
not show complete conversion of the starting 
material, water (0.6 mL) and TFA (1.5 mL) was added and stirring was continued for 
another 24 h so 1H NMR indicated full conversion. Volatiles were removed in vacuo 
without heating and the residue was subjected to preparative, reversed-phase HPLC 
(CH3CN 1% to 50%, 15 min; 50% to 100%, 3.6 min) to afford nitrocatechol 3.5 
(145 mg, 0.290 mmol, 68% over 2 steps) as a yellow solid.  
 
M.p. = >65 °C (decomposed). FTIR: ν = 3367, 3090, 2959, 1754, 1616, 1525, 1289, 
1206, 1166, 1027, 957, 800, 773 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 10.31 (s, 
1H), 9.98 (s, 1H), 8.81 (s, 1H), 7.98 (d, J = 8.6 Hz, 1H), 7.39 (d, J = 2.2 Hz, 1H), 7.38 
(s, 1H), 7.27 (dd, J = 8.5, 2.2 Hz, 1H), 6.93 (s, 1H), 4.42-4.31 (m, 2H), 3.86-3.77 (m, 
1H), 3.83 (s, 3H), 1.27 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ = 
163.04, 155.68, 155.27, 154.68, 151.96, 151.11, 148.59, 144.02, 140.47, 131.53, 
130.05, 118.40, 116.75, 116.02, 114.27, 111.98, 109.39, 72.64, 52.47, 32.24, 17.52. 
HRMS ESI calc. for C21H17O11NNa+ [M-Na]+: 482.0694, found: 482.0696. 
 
 
Surface Modifications: Test tubes (5 mL) were cleaned with piranha solution (conc. 
H2SO4 and 30% H2O2 3:1), rinsed with Millipore water and oven-dried (120 °C). 
Portions of TiO2 particles (10 mg, rutile, 1.0-2.0 µm) were suspended in toluene 
(3 mL), sonicated for 20 min at 35 °C, centrifuged (4500 rpm, 3 min) and the solvent 
decanted. This washing was repeated with i-PrOH and the particles were oven-dried 
(120 °C) overnight. To the TiO2 particles (20 mg) were added MOPS buffer (3 mL) 
and 3.5 (2.5 mg, dissolved in a few drops of DMSO), followed by sonication for 
2 min and subsequent incubation at 50 °C for 4 h under exclusion of light. During 
incubation TiO2 particles were re-suspended with a syringe every 15 min. The 
mixture was centrifuged (4500 rpm, 4 min), the particles were washed with CH3CN 
(3 x 3 mL) and MOPS buffer (3 mL), centrifugation after each washing to yield off-
white Ti-3.5. Ti-3.5 particles were re-suspended in 6 mL of cell medium (MEM), 
1 mL of the yellow suspension was added to each well of a 24-well plate and 
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irradiated (irradiated surface area = 254.5 mm3). The complete mixture of a well was 
taken after the indicated time, filtered and subjected to HPLC analysis, showing the 
qualitatively release of 3.18 from surface bond Ti-3.5. 
 
 
Kinetic Measurements: Applying a Falcon® 24 well plate, wells were loaded with 
millipore water (1 mL) and a 1 mM solution of 3.5 in CH3CN (50 µL) was added. On 
a sheet of aluminum foil the plate was positioned under a laboratory UV lamp and 
irradiation at 366 nm was performed with a distance of approximately 3.5 cm between 
the lamp and the sample solutions. After the indicated irradiation-periode the entire 
solution of one well at a time was filtered and subjected to UPLC analysis. Substance 
ratios (between caged 3.5 and the released coumarin 3.18) were determined by 
integration of their respective peaks in the UV trace recorded at 254 nm. 
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8.5 Caged Retinoids as Photoinducible Activators 
Triflate (4.8aa): To a solution of substituted phenol94 (825 mg, 2.00 mmol, 1.0 eq.) 
in CH2Cl2 (8.0 mL) was added pyridine (0.49 mL, 
6.00 mmol, 3.0 eq.) and DMAP (2.44 mg, 20.0 µmol, 
1 mol %). The yellow mixture was cooled to -78 °C 
followed by dropwise addition of triflic anhydride 
(0.40 mL, 2.40 mmol, 1.2 eq.). After stirring for 2 h TLC did not show full 
conversion. Hence, another portion of triflic anhydride (0.2 mL, 1.19 mmol, 0.6 eq.) 
was added to the red mixture and stirring was continued for 2 h. The reaction mixture 
was quenched with water and extracted with CH2Cl2. The combined organic layers 
were washed with water, dried over Na2SO4 and evaporated. The crude material was 
subjected to flash column chromatography (pentane:CH2Cl2 2:3) to afford triflate 
4.8aa as a pale yellow solid (1.014 g, 1.86 mmol, 93%).  
 
Rf = 0.6 (pentane:CH2Cl2 2:3). M.p. = 186–187 °C. 1H NMR (400 MHz, CDCl3) δ = 
8.64 (s, 1H), 8.11 (dd, J = 8.6, 1.7 Hz, 1H), 8.05-8.03 (m, 2H), 7.95 (d, J = 8.7 Hz, 
1H), 7.77-7.74 (m. 2H), 7.59 (dd, J = 8.6, 2.4 Hz, 1H), 7.47 (d, J = 8.6 Hz, 1H), 4.00 
(s, 3H), 2.16 (s, 9H), 1.82 (s, 6H).  
 
All analytical data were in agreement with reference: B. Charpentier, J.-M. 
Bernardon, J. Eustache, C. Millois, B. Martin, S. Michel, B. Shroot, J. Med. Chem. 
1995, 38, 4993-5006. 
 
 
Olefin (4.8a): Allyltributylstannane (500 µL, 1.61 mmol, 1.2 eq.), triflate 4.8aa 
(732 mg, 1.34 mmol, 1.0 eq.) and dried LiCl 
(114 mg, 2.68 mmol, 2.0 eq.) were suspended in 
DMF (4.6 mL) and DMSO (2 mL) and heated until a 
clear yellow solution was obtained. The mixture was 
degassed applying the freeze-thaw technique. Pd(PPh3)2Cl2 (18.8 mg, 26.7 µmol, 0.02 
eq.) was added and the stirred mixture was heated to 100 °C for 3.5 h. The reaction 
mixture was poured into ice water followed by extraction with Et2O. The combined 
OMe
O
TfO
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O
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organic extracts were washed with brine, dried over Na2SO4 and evaporated. The 
solid brown residue was subjected to flash column chromatography (pentane: CH2Cl2 
3:2) to afford olefin 4.8a as a colorless solid (583 mg, 1.34 mmol, 99%).  
 
Rf = 0.3 (pentane:CH2Cl2 3:2). M.p. = 135-136 °C. FTIR: ν = 2902, 2678, 1921, 
1712, 1632, 1434, 1287, 1219, 1183, 1095, 978, 903, 808, 747 cm-1. 1H NMR 
(400 MHz, CDCl3) δ = 8.63 (s, 1H), 8.08 (dd, J = 8.6, 1.6 Hz, 1H), 8.05 (s, 1H), 8.01 
(d, J = 8.6 Hz, 1H), 7.94 (d, J = 8.6 Hz, 1H), 7.82 (dd, J = 8.5, 1.7 Hz, 1H), 7.70 (d, 
J = 1.9 Hz, 1H), 7.52 (dd, J = 7.9, 1.9 Hz, 1H), 7.31 (d, J = 7.9 Hz, 1H), 6.04 (ddt, J = 
16.3, 10.2, 6.1 Hz, 1H), 5.13 (dd, J = 10.1, 1.6 Hz, 1H), 5.08 (dd, J = 17.0, 1.7 Hz, 
1H), 4.00 (s, 3H), 3.84 (d, J = 6.1 Hz, 1H), 2.17 (s, 9H), 1.82 (s, 6H). 13C NMR 
(101 MHz, CDCl3) δ = 167.44, 148.43, 141.6, 138.75, 138.29, 138.25, 136.02, 
133.47, 131.65, 130.98, 129.89, 128.49, 127.29, 126.71, 125.75, 125.66, 125.42, 
124.82, 116.10, 52.36, 42.40, 38.68, 38.17, 37.00, 29.34. HRMS ESI calc. for 
C31H33O2: 437.2470, found: 437.2475. 
 
 
Alcohol (4.8): To a solution of 4.8a (518 mg, 1.19 mmol, 1.0 eq.) in THF (2.4 mL) at 
0 °C was added 9-BBN (0.5 M solution in THF; 
4.74 mL, 2.37 mmol, 2.0 eq.). After 1 h the cooling 
bath was removed and stirring was continued for 
2 h. As TLC did not indicate full conversion 
another portion of 9-BBN (0.5 M solution in THF; 2.00 mL, 1.00 mmol, 0.8 eq.) was 
added and again stirring was continued for 16 h. The mixture was cooled to 0 °C and 
subsequently quenched by addition of 1 M aqueous NaOH (3.0 mL) and 30% H2O2 
(2.4 mL). After 20 min the cooling bath was removed and stirring was continued for 
3 h. The mixture was diluted with water and extracted with CH2Cl2. The combined 
organic extracts were washed with water, dried over Na2SO4 and evaporated. The 
crude material was subjected to flash column chromatography (pentane:Et2O 1:1) to 
afford alcohol 4.8 as a colorless solid (436 mg, 959 µmol, 81%).  
 
Rf = 0.3 (pentane:Et2O 1:1). M.p. = 175–176 °C. FTIR: ν = 3306, 2904, 1717, 1629, 
1450, 1281, 1218, 1097, 1056, 991, 916, 882, 814, 751 cm-1. 1H NMR (400 MHz, 
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CDCl3) δ = 8.62 (s, 1H), 8.08 (dd, J = 8.6, 1.7 Hz, 1H), 8.05 (s, 1H), 8.01 (d, J = 
8.6 Hz, 1H), 7.93 (d, J = 8.7 Hz, 1H), 7.82 (dd, J = 8.5, 1.8 Hz, 1H), 7.69 (d, J = 
1.9 Hz, 1H), 7.52 (dd, J = 7.9, 1.9 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 3.99 (s, 3H), 
3.83 (t, J = 6.3 Hz, 2H), 3.13-3.09 (m, 2H), 2.17 (s, 9H), 2.01-1.94 (m, 2H), 1.82 (s, 
6H). 13C NMR (101 MHz, CDCl3) δ = 167.45, 148.25, 141.66, 140.86, 137.96, 
136.03, 132.79, 131.64, 130.98, 129.89, 128.48, 127.27, 126.70, 125.74, 125.69, 
125.38, 124.89, 63.18, 52.37, 42.47, 38.28, 37.01, 36.33, 30.70, 29.38.  
 
 
Acid (4.3): To a solution of 4.8 (10 mg, 22.0 µmol, 1.0 eq.) in THF (0.4 mL) was 
added LiOH (0.1 M solution in H2O; 0.44 mL, 
44.0 µmol, 2.0 eq.) and the resulting clear solution 
was stirred for 16 h at rt. The mixture was acidified 
with 0.1 M aqueous HCl to pH ~5 and extracted 
with Et2O. The combined organic extracts were thoroughly washed with water, dried 
over Na2SO4 and evaporated to afford acid 4.3 as a colorless solid (10 mg, 22.0 µmol, 
quant.).  
 
Rf < 0.1 (pentane:Et2O 2:5). M.p. = 241-243 °C. 1H NMR (400 MHz, DMSO-d6) δ = 
13.04 (s, 1H), 8.61 (s, 1H), 8.25 (s, 1H), 8.17 (d, J = 8.7 Hz, 1H), 8.09 (d, J = 8.7 Hz, 
1H), 7.99 (dd, J = 8.6, 1.6 Hz, 1H), 7.90 (dd, J = 8.6, 1.7 Hz, 1H), 7.65 (d, J = 1.8 Hz, 
1H), 7.59 (dd, J = 7.9, 1.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 3.55 (m, 2H), 3.02-2.98 
(m, 2H), 2.12 (s, 9H), 1.78 (s, 6H).  
 
Analytical data according to afore mentioned reference. 
 
 
tert-Butyl ester (4.10): A solution of acid 4.3 (220 mg, 0.499 mmol, 1 eq.) and 
N,N-dimethylformamide di-tert-butyl acetal 
(358 µL, 1.498 mmol, 3 eq.) in benzene-THF (1:1, 
2 mL) was refluxed for 3 h. The mixture was 
washed with 5% aqueous Na2CO3, dried over 
Na2SO4 and evaporated. The residue was purified by flash column chromatography 
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(pentane:Et2O 1:1) to give ester 4.10 as a colorless solid (57 mg, 0.115 mmol, 23.0 %, 
respectively 99% based on recovered starting material). 
 
M.p. = 77-78 °C. Rf = 0.3 (pentane: Et2O 1:1). FTIR: ν = 3412, 2924, 2855, 2361, 
1735, 1514, 1461, 1376, 1166, 1033, 824, 765, 622 cm-1. 1H NMR (400 MHz, 
CDCl3) δ = 8.54 (s, 1H), 8.06-8.01 (m, 2H), 7.99 (d, J = 8.5 Hz, 1H), 7.90 (d, J = 
8.6 Hz, 1H), 7.80 (dd, J = 8.5, 1.8 Hz, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.52 (dd, J = 7.9, 
1.9 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 3.83 (q, J = 6.0 Hz, 2H), 3.16-3.06 (m, 2H), 
2.17 (s, 9H), 2.03-1.93 (m, 2H), 1.82 (s, 6H), 1.66 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ = 166.12, 148.20, 141.30, 140.75, 138.02, 135.81, 132.76, 131.66, 130.54, 
129.81, 129.16, 128.22, 126.49, 125.84, 125.64, 125.33, 124.87, 81.27, 63.18, 42.47, 
38.28, 37.02, 36.34, 30.70, 29.38, 28.44. HRMS ESI calc. for C34H40O2Na: 
519.2867, found: 519.2870. 
 
 
Carbonate (4.4a): A solution of triphosgene (21.3 mg, 0.07 mmol, 1.4 eq.) in THF 
(0.4 mL) was cooled to 0 °C and 
a solution of alcohol 3.17 
(15.3 mg, 0.06 mmol, 1.2 eq.) 
and Et3N (11 µL, 0.07 mmol, 
1.2 eq.) in THF (0.3 mL) 
dropwisely added. After stirring for 25 min at 0 °C, the mixture was filtered over 
Celite and all volatiles were removed in vacuo to afford the desired chloroformate in 
approximately quantitative yield as indicated by 1H NMR spectroscopy. 
 
1H NMR (400 MHz, CDCl3) δ = 7.30 (s, 1H), 6.74 (s, 1H), 4.44 (d, J = 6.1 Hz, 2H), 
3.89 (m, 1H), 1.73 (s, 3H), 1.72 (s, 1.72), 1.36 (d, J = 7.0 Hz, 3H). 
  
The chloroformate was redissolved in CH2Cl2 (0.5 mL) and slowly added to a 
solution of tert-butyl ester 4.10 (25 mg, 0.05 mmol, 1 eq.) in pyridine (0.3 mL) at 
0 °C. After 20 min the ice bath was removed and stirring was continued for another 
60 min. The mixture was poured into water and subsequently extracted with CH2Cl2. 
The combined organic extracts were dried over Na2SO4 and evaporated to afford a 
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brown oil (28 mg) which was subjected to flash column chromatography 
(pentane:Et2O 1:1 + Et3N) to afford carbonate 4.4a (24 mg, 0.028 mmol, 58%) as a 
orange solid with homocoupled nitrocarbonate as an inseparable side-product. 
Exposure to light was avoided as much as possible during the entire procedure.  
 
Rf = 0.2 (pentane:Et2O 1:1). FTIR: ν = 2910, 2361, 1745, 1629, 1521, 1379, 1257, 
1162, 1098, 978, 875, 820 cm-1. 1H NMR (400 MHz, CDCl3) δ = 8.55 (s, 1H), 8.06-
8.01 (m, 2H), 7.99 (d, J = 8.6 Hz, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.79 (dd, J = 8.5, 
1.7 Hz, 1H), 7.68 (d, J = 1.8 Hz, 1H), 7.52 (dd, J = 7.9, 1.8 Hz, 1H), 7.27-7.29 (d and 
s, 2H), 6.78 (s, 1H), 4.27-4.22 (m, 4H), 3.91-3.79 (m, 1H), 3.14-3.06 (m, 2H), 2.14 (s, 
9H), 2.05 (dd, J = 10.7, 5.3, 2H), 1.81 (s, 6H), 1.71 (s, 9H), 1.66 (s, 9H), 1.35 (d, J = 
6.9, 3H). 13C NMR (63 MHz, CDCl3) δ = 166.10, 155.36, 151.65, 148.27, 146.37, 
143.57, 141.26, 139.97, 138.25, 135.81, 133.60, 132.68, 131.69, 130.54, 129.82, 
129.22, 128.23, 126.48, 125.86, 125.70, 125.36, 124.93, 121.12, 106.86, 81.24, 68.16, 
65.98, 42.44, 38.23, 36.97, 33.58, 32.18, 30.61, 29.84, 29.37, 28.43, 15.41. HRMS 
ESI calc. for C47H53NO9Na (M-Na+): 798.3613, found: 798.3627. 
 
 
Acid (4.4): To carbonate 4.4a (23 mg) was added TFA (1.0 mL) and H2O (0.1 mL) 
and the mixture was stirred at RT 
under the exclusion of light for 
16 h. Volatiles were removed in 
vacuo without heating and the 
residue was subjected to prepara-
tive, reversed-phase HPLC (CH3CN/H2O 1% to 50%, over 15 min, then 50% to 
100%, over 3.6 min; without UV detector) to afford nitrocatechol 4.4 (14.5 mg, 
0.021 mmol, 42% over two steps) as a yellow solid.  
 
Rf < 0.1 (EtOAc). FTIR: ν = 3394, 2907, 2361, 2350, 1630, 1523, 1409, 1265, 1174, 
1043, 788 cm-1. 1H NMR (400 MHz, DMSO) δ = 8.61 (s, 1H), 8.25 (s, 1H), 8.17 (d, 
J = 8.8 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.99 (dd, J = 8.6, 1.6 Hz, 1H), 7.90 (dd, J = 
8.6, 1.7 Hz, 1H), 7.64 (d, J = 1.7 Hz, 1H), 7.60 (dd, J = 8.0, 1.7 Hz, 1H), 7.38 (s, 1H), 
7.32 (d, J = 8.0 Hz, 1H), 6.89 (s, 1H), 4.17-4.23 (m, 4H), 3.80-3.67 (m, 1H), 2.98-
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3.03 (m, 2H), 2.07 (s, 9H), 1.91 (bs, 2H), 1.74 (s, 6H), 1.23 (d, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ = 167.48, 154.54, 151.20, 147.59, 143.94, 140.32 (2), 
139.98, 136.95, 135.37, 132.60, 131.19, 130.41, 130.22, 129.88, 128.46, 127.98, 
126.02, 125.54, 124.75, 124.68, 124.57, 114.10, 111.91, 71.16, 67.50, 41.57, 37.47, 
32.39, 31.63, 29.75, 28.57, 17.71. HRMS ESI calc. for C40H41NO9Na+ (M-Na+): 
702.2674, found: 702.2671. 
 
 
Carbonate (4.5a): The tert-butyl ester 4.10 (20.0 mg, 0.040 mmol, 1 eq.) was 
dissolved in 0.15 mL pyridine under 
argon and then cooled to 0 °C. A 
solution of MeNPOC-Cl (30.9 mg, 
0.120 mmol, 3 eq.) in 0.2 mL of dry 
CH2Cl2 was then added dropwise. 
After 30 min, the solution was allowed to reach rt and stirred for 75 min. Then the 
solvent was evaporated. The crude material was taken up in Et2O and washed with 
saturated aqueous NH4Cl and water. The organic phase was dried over Na2SO4, 
evaporated and subjected to flash column chromatography (pentane:Et2O 4:1) to 
afford 4.5a as a yellowish solid (28.2 mg, 0.038 mmol, 95%).  
 
M.p. = 80-81 °C. Rf = 0.7 (pentane: Et2O 1:1). FTIR: ν = 2907, 2361, 1746, 1708, 
1628, 1524, 1484, 1391, 1259, 1162, 1036, 984, 931, 880, 817, 737 cm-1. 1H NMR 
(400 MHz, CDCl3) δ = 8.55 (s, 1H), 8.06-8.02 (m, 2H), 7.99 (d, J = 8.6 Hz, 1H), 7.90 
(d, J = 8.7 Hz, 1H), 7.79 (dd, J = 8.5, 1.6 Hz, 1H), 7.69 (d, J = 1.7 Hz, 1H), 7.54-7.50 
(m, 2H), 7.28 (d, J = 5.1 Hz, 1H), 7.10 (s, 1H), 6.31 (q, J = 6.4 Hz, 1H), 6.11 (dd, J = 
7.1, 1.0 Hz, 2H), 4.32-4.18 (m, 2H), 3.13-3.05 (m, 2H), 2.16 (s, 9H), 2.09-1.99 (m, 
2H), 1.83 (s, 6H), 1.68 (d, J = 1.6 Hz, 3H), 1.66 (s, 9H). 13C NMR (101 MHz, CDCl3) 
δ = 166.08, 154.33, 152.62, 148.24, 147.47, 141.75, 141.19, 139.82, 138.27, 135.78, 
135.18, 132.61, 131.67, 130.53, 129.83, 129.21, 128.21, 126.45, 125.86, 125.72, 
125.35, 124.93, 105.90, 105.38, 103.23, 81.26, 72.14, 68.22, 42.43, 38.22, 36.98, 
32.10, 30.52, 29.36, 28.43, 22.26. HRMS ESI calc. for C44H47NO9+ (M-Na)+: 
756.3143, found: 756.3123. 
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Acid (4.5): Carbonate 4.5a (28.2 mg, 0.038 mmol, 1 eq.) was added into a mixture of 
20% TFA, 5% TIPS in CH2Cl2 
(0.4 mL) and stirred at RT for 2 h. 
The solvent was evaporated and the 
residue purified by flash column chro-
matography (pentane: Et2O 1:1) to give 4.5 as a yellowish solid (25.5 mg, 
0.038 mmol, 99 %).  
 
M.p. = 127 °C (decomposed). Rf = 0.2 (pentane: Et2O 1:1). FTIR: ν = 3417, 2905, 
2851, 2656, 2565, 2325, 2111, 1994, 1745, 1682, 1628, 1523, 1483, 1423, 1392, 
1337, 1257, 1224, 1185, 1142, 1064, 1034, 983, 930, 877, 815, 758, 726, 684, 
613 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 13.05 (s, 1H), 8.61 (s, 1H), 8.26 (s, 
1H), 8.18 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.6 Hz, 1H), 7.99 (dd, J = 8.6, 1.7 Hz, 1H), 
7.90 (dd, J = 8.6, 1.9 Hz, 1H), 7.65 (d, J = 2.1 Hz, 1H), 7.63-7.57 (m, 2H), 7.32 (d, 
J = 8.1 Hz, 1H), 7.17 (s, 1H), 6.24 (d, J = 5.3 Hz, 2H), 6.04 (q, J = 6.4 Hz, 1H), 4.25-
4.15 (m, 2H), 3.05-2.96 (m, 2H), 2.09 (s, 9H), 1.97-1.86 (m, 2H), 1.79 (m, 6H), 1.60 
(d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, DMSO-d6, HMBC/HMQC) δ = 167.2, 
153.5, 152.0, 147.3, 147.1, 141.4, 140.1, 139.7, 136.7, 135.1, 133.1, 132.4, 131.0, 
130.1, 129.7, 128.3, 127.5, 125.9, 125.4, 124.6, 124.5, 124.4, 105.5, 104.5, 103.5, 
70.9, 67.5, 41.3, 37.2, 36.0, 31.4, 29.5, 28.4, 21.1. HRMS ESI calc. for C40H39NO9- 
(M-H)-: 676.2552, found: 676.2565. 
 
 
Cbz carbonate (4.6a): The tert-butyl ester 7 (16.0 mg, 0.032 mmol, 1 eq.) was 
dissolved in 0.11 mL pyridine under argon and 
then cooled to 0 °C. A solution of CbzCl 
(16.5 mg, 0.097 mmol, 3 eq.) in 0.2 mL of dry 
CH2Cl2 was then added dropwise. After 30 min, 
the solution was allowed to reach rt and stirred for 2.5 h. TLC still indicated starting 
material, therefore additional CbzCl (16.5 mg, 0.097 mmol, 3 eq.) in 0.2 mL of dry 
CH2Cl2 was added dropwise and the reaction mixture was stirred over night. The 
solvent was evaporated and the crude material was taken up in Et2O, washed with 
saturated aqueous NH4Cl and water. The organic phase was dried over Na2SO4, 
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evaporated and subjected to flash column chromatography (pentane:Et2O 4:1) to 
afford 4.6a as a colorless solid (12.0 mg, 0.019 mmol, 59 %).  
 
Rf = 0.9 (pentane: Et2O 1:1). 1H NMR (500 MHz, CDCl3) δ = 8.55 (s, 1H), 8.05-8.02 
(m, 2H), 7.99 (d, J = 8.7 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.79 (dd, J = 8.6, 1.8 Hz, 
1H), 7.68 (d, J = 2.0 Hz, 1H), 7.51 (dd, J = 7.9, 1.9 Hz, 1H), 7.43-7.33 (m, 5H), 7.28 
(d, J = 7.9 Hz, 1H), 5.19 (s, 2H), 4.31 (t, J = 6.1 Hz, 2H), 3.13-3.09 (m, 2H), 2.14 (s, 
9H), 2.10-2.04 (m, 2H), 1.80 (s, 6H), 1.66 (s, 9H). 
 
 
Cbz protected acid (4.6): Carbonate 4.6a (12.0 mg, 0.019 mmol, 1 eq.) was added 
into a mixture of 20% TFA, 5% TIPS in CH2Cl2 
(0.2 mL) and stirred at RT for 2 h. The solvent was 
evaporated and the residue purified by flash 
column chromatography (pentane:Et2O 1:1) to 
afford 4.6 as a colorless solid (10.0 mg, 0.017 mmol, 89 %).  
 
M.p. = 204-205 °C. Rf = 0.3 (pentane: Et2O 1:1, 1% TFA). FTIR: ν = 3446, 2907, 
1744, 1672, 1472, 1426, 1251, 1140, 1007, 971, 895, 817, 741, 689 cm-1. 1H NMR 
(500 MHz, DMSO-d6) δ = 13.06 (s, 1H), 8.61 (s, 1H), 8.26 (s, 1H), 8.18 (d, J = 
8.8 Hz, 1H), 8.09 (d, J = 8.9 Hz, 1H), 7.99 (dd, J = 8.6, 1.7 Hz, 1H), 7.91 (dd, J = 8.6, 
1.8 Hz, 1H), 7.65 (d, J = 1.9 Hz, 1H), 7.61 (dd, J = 7.9, 1.9 Hz, 1H), 7.41-7.36 (m, 
5H), 7.34 (d, J = 8.0 Hz, 1H), 5.16 (s, 2H), 4.27 (t, J = 5.9 Hz, 2H), 3.08-2.99 (m, 
2H), 2.08 (s, 9H), 2.01-1.90 (m, 2H), 1.81-1.68 (m, 6H). 13C NMR (126 MHz, 
DMSO-d6) δ = 167.2, 154.4, 147.5, 140.1, 139.8, 136.7, 135.4, 135.2, 132.5, 130.9, 
130.1, 129.8, 128.4, 128.3, 128.2, 127.9, 127.6, 125.9, 125.4, 124.6, 124.5, 124.4, 
68.7, 67.4, 41.4, 37.3, 36.0, 31.5, 29.5, 28.3. HRMS ESI calc. for C38H38O3- (M-H)-: 
573.2646, found: 573.2654. 
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Benzyl ether (4.7a): A mixture of Bn-OPT 4.9 (15.4 mg, 0.044 mmol, 2 eq.), MgO 
(40.3 mg, 0.044 mmol, 2 eq.) and methyl 
ester 4.8 (10 mg, 0.022 mmol, 1 eq.) in 
CH2Cl2 (0.1 mL) was heated at 80 °C over 
night. The reaction mixture was filtered 
through Celite, and the filtrate was concentrated under reduced pressure. The residue 
was subjected to flash column chromatography (pentane: Et2O 10:1) and afforded 
benzyl ether 4.7a as a colorless solid (11 mg, 0.021 mmol, 95%). 
 
Rf = 0.7 (pentane: Et2O 3:1). FTIR: ν = 3732, 2905, 2850, 2361, 1719, 1629, 1453, 
1362, 1287, 1219, 1097, 1028, 911, 800, 753, 630 cm-1. 1H NMR (400 MHz, CDCl3) 
δ = 8.62 (s, 1H), 8.08 (dd, J = 8.6, 1.7 Hz, 1H), 8.05 (s, 1H), 8.00 (d, J = 8.6 Hz, 1H), 
7.93 (d, J = 8.6 Hz, 1H), 7.82 (dd, J = 8.5, 1.8 Hz, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.51 
(dd, J = 7.9, 1.9 Hz, 1H), 7.42-7.29 (m, 6H), 4.58 (s, 2H), 3.99 (s, 3H), 3.65 (t, J = 
6.0 Hz, 2H), 3.17-3.08 (m, 2H), 2.20-2.11 (m, 9H), 2.06-1.96 (m, 2H), 1.83-1.77 (m, 
6H). 13C NMR (101 MHz, CDCl3) δ = 167.45, 148.30, 141.72, 141.12, 138.80, 
137.87, 136.04, 132.78, 131.63, 130.98, 129.87, 128.49, 128.47, 127.66, 127.63, 
127.26, 126.72, 125.73, 125.63, 125.36, 124.84, 73.09, 70.45, 52.36, 42.41, 38.27, 
36.99, 33.44, 31.18, 29.39. 
 
 
Acid (4.7): To a solution of 4.7a (11.0 mg, 0.020 mmol, 1 eq.) in THF (0.5 mL) was 
added LiOH (0.1 M solution in H2O; 
0.40 mL, 0.040 mmol, 2 eq.). The solution 
was stirred over night, acidified with 0.1 M 
HCl to pH 2 and extracted with Et2O. The 
combined organic phases were washed with water, dried over Na2SO4 and evaporated 
to afford 4.7 as a colorless solid (11.0 mg, 0.020 mmol, quant.).  
 
M.p. = 243-244 °C. Rf = <0.1 (pentane:Et2O 1:2). FTIR: ν = 3391, 2910, 2851, 2680, 
2558, 1680, 1627, 1475, 1453, 1346, 1291, 1221, 1103, 1027, 927, 918, 816, 
737 cm-1. 1H NMR (400 MHz, DMSO-d6) δ = 13.04 (s, 1H), 8.61 (s, 1H), 8.25 (s, 
1H), 8.17 (d, J = 8.6 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 7.99 (dd, J = 8.5, 1.8 Hz, 1H), 
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7.90 (dd, J = 8.7, 2.0 Hz, 1H), 7.65 (s, 1H), 7.59 (dd, J = 7.7, 2.0 Hz, 1H), 7.41-7.27 
(m, 6H), 4.52 (s, 2H), 3.60 (t, J = 5.7 Hz, 2H), 3.09-3.02 (m, 2H), 2.15-2.04 (m, 9H), 
1.94-1.84 (m, 2H), 1.76-1.69 (m, 6H). HRMS ESI calc. for C37H38O3- (M-H)-: 
529.2748, found: 529.2747. 
 
 
Kinetic measurements of cleavage: 24-Well plates were filled with 4.5 (1 µM) in cell 
medium (MEM) or CH3CN/MeOH (1:1) and irradiated under a common laboratory 
UV lamp at 366 nm (~ 20 mW cm-2) with a distance of approximately 3.5 cm between 
the lamp and the sample solutions for the indicated time (irradiated surface area = 
254.5 mm3). Afterwards samples were filtered through syringe filter and submitted for 
HPLC analysis. 
 
 
Surface modifications and kinetic measurements of surface release: As already 
reported in section 8.3. 
 
 
Neuritogenic properties: Cells were treated in the same manner as already reported in 
section 8.2. 
Additionally, In order to determine if ligand was deprotected inside cells, SH-SY5Y 
cells were incubated for 24 h at 37 °C in presence of active agonist 4.3 and its photo-
caged analogue 4.5. The cells were then washed twice with afore mentioned medium 
and replaced with ligand free medium. Immediately after the medium was changed, 
the cells were irradiated for 60 s and 180 s at 366 nm to liberate the free agonist. The 
cells were further allowed to incubate for three days and examined as described in the 
previous section. 
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8.6 JBIR-02 and Related Piericidins  
8.6.1 Synthesis of the Heterocyclic Core (1st Generation Approach) 
Pyridone (5.52): Malonylchloride (25.00 g, 170 mmol, 1.4 eq.) and propionitrile 
(6.53 g, 119 mmol, 1 eq.) were stirred under argon with a mechanical 
stirrer for 3 days at RT. The obtained solid was diluted with water and 
extensively washed with CH2Cl2 in order to remove unreacted starting 
material. The aqueous phase was then lyophilized to afford pyridone 5.52 (9.70 g, 
61 mmol, 51%) as a beige solid. 
 
M.p. = 302-303 °C. Rf = <0.05 (EA). 1H NMR (400 MHz, d6-DMSO) δ = 11.12 (bs, 
1H, OH), 6.13 (s, 1H), 3.76 (bs, 1H, OH or NH), 2.00 (s, 3H). 
 
Analytical data according to reference : S. J. Davies, J. A. Elvidge, A. B. Foster, J. 
Chem. Soc. 1962, 3638-3644. 
 
 
Dimethoxy pyridine (5.53): A mixture of pyridone 5.52 (100 mg, 0.6 mmol, 1 eq.) 
and Ag2CO3 (114 mg, 1.9 mmol, 3 eq.) was suspended in hexane 
(20 ml). Methyl iodide (1.6 ml, 3.57 g, 3.1 mmol, 5 eq.) was 
added and the mixture was stirred at RT during 36 h, then heated to 
reflux during 1 h. After cooling, CH2Cl2 (20 ml) was added and the mixture was 
stirred vigorously. Remaining solids were filtered and the filtrate was evaporated. The 
residue subjected to flash column chromatography (pentane:Et2O 25:1 + 1% Et3N) to 
afford dimethoxy pyrdine 5.53 (34 mg, 0.18 mmol, 32%) as a colorless solid. 
 
M.p. = 92-93.5 °C. Rf = 0.4 (pentane:Et2O 10:1). 1H NMR (400 MHz, CDCl3) δ = 
6.12 (s, 1H), 3.90 (s, 3H), 3.83 (s, 3H), 2.14 (s, 3H). 
 
Analytical data according to reference: J. Buck, J. P. Madeley, G. Pattenden, J. Chem. 
Soc. Perkin Trans. 1 1992, 67-73. 
 
N
H
O
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Pyridyl stannane (5.59): LiCl (20 mg, 0.45 mmol, 3 eq.) was fuse-dried in a 
Schlenck flask. Then pyridine 5.53 (30 mg, 0.15 mmol, 1 eq.), 
Pd(PPh3)4 (8.8 mg, 0.008 mmol, 5 mol %), dppf (8.7 mg, 
0.015 mmol, 10 mol %) were added and dried under high-vacuum. 
Dry dioxane (0.5 mL) was added and finally hexamethylditin (60 mg, 0.18 mmol, 
1.2 eq.) with a Hamilton-syringe. The solution was deoxygenated using the freeze-
thaw method, and then stirred at 110 °C for 22 h. The orange solution was cooled to 
RT, water was added extracted with Et2O and washed with water. The aqueous phase 
was extracted twice with Et2O, the combined organic extracts were dried over Na2SO4 
and concentrated in vacuo. The crude orange oil was subjected to flash column 
chromatography Al2O3 (pentane) to afford stannyl pyridine 5.59 (22 mg, 0.069 mmol, 
46%) as colorless oil contaminated wit PPh3O. 
  
Rf = 0.8 (pentane:Et2O 100:1). 1H NMR (400 MHz, CDCl3) δ = 6.06 (s, 1H), 3.92 (s, 
3H), 3.78 (s, 3H), 2.14 (s, 3H), 0.34 (m, 9H). 13C NMR (101 MHz, CDCl3) δ = 
168.03, 164.39, 163.40, 124.07, 90.77, 54.97, 53.18, 14.82, 8.36. 
 
 
8.6.2 Synthesis of the Heterocyclic Core (2nd Generation Approach) 
2-Methoxy pyridine (5.62): To a solution of NaH (60% dispersion in mineral oil; 
2.44 g, 28.4 mmol, 2 eq.) in dry DMF (30 mL) was added 2-bromo-
5-methylpyridine 5.61 (5.24 g, 14.2 mmol, 1 eq.) in small portions. 
Then a solution of dry MeOH (5 mL) in DMF (10 mL) was added slowly (1 h) 
through the reflux condenser. The resulting suspension was further heated at 100 °C 
for 48 h. The mixture was cooled to RT, water was carefully added, extracted with 
Et2O and washed with water. The aqueous phase was extracted twice with Et2O, the 
combined organic extracts were dried over Na2SO4 and concentrated in vacuo to 
afford the volatile 2-methoxy pyridine (5.36 g, 70% purity (Et2O remaining), 
14.2 mmol, quant.) as colorless oil.  
 
Rf = 0.9 (EA). 1H NMR (400 MHz, CDCl3) δ = 7.96 (dd, J = 1.5, 0.7 Hz, 1H), 7.38 
(dd, J = 8.2, 2.2 Hz, 1H), 6.65 (d, J = 8.4 Hz, 1H), 3.90 (s, 3H), 2.24 (s, 3H).  
NH3CO
CH3
NH3CO
OCH3
CH3
SnMe3
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Analytical according to reference: P. M. Hatton, S. Sternhell, Aust. J. Chem. 1993, 46, 
149-152. 
 
 
Pyridine-N-oxide (5.62b): To a solution of 2-methoxy pyridine 5.61 (1.00 g, 
8.12 mmol, 1 eq.) in 10 mL of AcOH was added H2O2 (30% in H2O) 
at RT and the mixture was stirred at 75 °C for 24 h until reaction 
control by 1H NMR indicated full conversion. The excess AcOH 
was removed under reduced pressure, the residue was diluted with H2O and 
concentrated again. The residual mixture is cooled to 0 °C and NaOH (40%) is added 
slowly. The strong alkaline solution was extracted using CH2Cl2, dried over Na2SO4 
and evaporated to dryness to afford N-oxide 5.62b (740 mg, 5.3 mmol, 66%) as a 
colorless crystalline solid, which was used in the next step without further 
purification.  
 
M.p. = 107-108 °C. Rf = 0.5 (EA). FTIR: ν = 3047, 2171, 1632, 1528, 1442, 1325, 
1272, 1133, 1000, 882, 771, 711 cm-1. 1H NMR (400 MHz, CDCl3) δ = 8.12 (s, 1H), 
7.11 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 8.5 Hz, 1H), 4.04 (d, J = 1.5 Hz, 3H), 2.25 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ = 156.16, 143.92, 139.64, 129.11, 110.52, 59.15, 
17.62. HRMS ESI calc. for C7H10NO2+ [M-H]+: 140.0706, found: 140.0707. 
 
 
Nitropyridine (5.63): N-oxide 5.62b (4.00 g, 28.7 mmol) was added to cooled (0 °C) 
conc. H2SO4 (5 mL). To this solution was added a mixture of 
fuming HNO3 and conc. H2SO4 (3:1, 5 mL). The mixture is then 
heated to 100 °C for 3 h (Fume hood! Aqueous NaOH for gas 
adsorption). The yellow mixture is cooled to 5°C and added dropwise onto crushed 
ice carbonate. Extraction using CHCl3 yielded an orange solid which was subjected to 
flash column chromatography (CH2Cl2:MeOH 20:1) to afford nitropyridine 5.63 as 
yellow crystals (710 mg, 3.9 mmol, 13%).  
 
M.p. = 191.5-196.5 °C (decomposition). Rf = 0.05 (EA). FTIR: ν = 3053, 2473, 
1612, 1562, 1506, 1458, 1299, 1220, 1057, 982, 890, 805, 753, 662 cm-1. 1H NMR 
N+H3CO
CH3
O-
NO2
N+H3CO
CH3
O-
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(400 MHz, CDCl3) δ = 8.21 (s, 1H), 7.64 (s, 1H), 4.14 (s, 3H), 2.56 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 157.71, 143.53, 141.98, 123.96, 103.37, 58.18, 17.62. HRMS 
ESI calc. for C7H9N2O4+ [M-H]+: 185.0557, found: 185.0552. X-Ray crystal 
structure is given in the appendices section. 
 
 
Aminopyridine (5.63b): To a solution of 5.63 (710 mg, 3.86 mmol, 1 eq.) in AcOH 
(22 mL) was added Fe-powder (1.50 g, 27 mmol, 7 eq.) and the 
brownish suspension was heated to 100 °C for 2 h until reaction 
control by 1H NMR indicated full conversion. The crude mixture 
was neutralized using aqueous sat. NaHCO3 solution and further basified using 
aqueous NH3 solution. The alkaline solution (pH 10) was extracted using Et2O, dried 
over Na2SO4 and evaporated to dryness to afford aniline 5.63b (450 mg, 3.24 mmol, 
84%) as colorless crystalline solid, which was used in the next step without further 
purification.  
 
M.p. = 108.5-109.5°C. Rf = 0.35 (EA). FTIR: ν = 3464, 3313, 3169, 2933, 1610, 
1567, 1497, 1460, 1403, 1317, 1219, 1026, 932, 841, 743 cm-1. 1H NMR (400 MHz, 
CDCl3) δ = 7.70 (s, 1H), 5.96 (s, 1H), 4.00 (bs, 2H), 3.86 (s, 3H), 2.04 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 164.37, 153.64, 146.61, 112.30, 93.11, 53.19, 
13.44. HRMS ESI calc. for C7H10N2O+ [M-H]+: 139.0866, found: 139.0866. 
 
 
4-Hydroxypyridine (5.64): To a cold (0°C) solution of 5.63b (200 mg, 1.45 mmol, 
1 eq.) in half conc. HNO3 (5 mL) was added NaNO2 (599 mg, 
8.68 mmol, 6 eq.) in 5 mL H2O, so the solution turned immediately 
yellowish. Stirring was continued over night at RT. Then the 
reaction was poured into sat. aqueous NaHCO3 solution (pH 7) and extracted with 
EtOAc to afford hydroxypyridine 5.64 (201 mg, 1.45 mmol, quant.) as colorless 
crystals.  
 
M.p. = 152-153 °C. Rf = 0.25 (EA). FTIR: ν = 3484, 3311, 3173, 2361, 1638, 1570, 
1499, 1403, 1321, 1221, 1030, 993, 776 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.54 
NH3CO
CH3
NH2
NH3CO
CH3
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(s, 1H), 6.12 (s, 1H), 3.84 (s, 3H), 2.09 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 
172.74, 162.52, 140.06, 118.71, 94.56, 54.85, 13.07. HRMS ESI calc. for C7H10NO2+ 
[M-H]+: 140.0706, found: 140.0705. X-Ray crystal structure is given in the 
appendices section. 
 
 
TIPS-protected hydroxy pyridine (5.65): To a cold (0 °C) suspension of pyridone 
5.64 (395 mg, 2.84 mmol, 1.0 eq.) in dry CH2Cl2 (15 mL) was added 
Et3N (574 mg, 0.8 mL, 5.68 mmol, 2 eq.) and TIPSOTf (942 mg, 
2.98 mmol, 1.05 eq.) and allowed to come to RT and stirring was 
continued for 3 h until TLC indicated full conversion. Water was added to quench the 
reaction. The aqueous phase was extracted with Et2O, washed with water and the 
combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The 
crude oil was subjected to flash column chromatography (pentane:Et2O 50:1 + Et3N) 
to afford TIPS protected hydroxy pyridine 5.65 as a colorless oil (790 mg, 2.67 mmol, 
94%).  
 
Rf = 0.15 (pentane:Et2O 50:1). FTIR: ν = 2946, 2868, 2361, 1609, 1492, 1391, 1252, 
1189, 884, 631 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.82 (s, 1H), 6.13 (s, 1H), 3.88 
(s, 3H), 2.10 (s, 3H), 1.38-1.25 (m, 3H), 1.11 (d, J = 7.4 Hz, 18H). 13C NMR 
(101 MHz, CDCl3) δ = 164.45, 163.35, 147.19, 119.06, 98.90, 53.37, 18.05, 13.36, 
12.97. HRMS ESI calc. for C16H30NO2Si+ [M-H]+: 296.2040, found: 296.2039. 
 
 
Stannane pyridine (5.66): To a cold (0 °C) solution of N,N-dimethylaminoethanol 
(0.8 mL, 8 mmol) in dry toluene (10 mL) was added dropwise 
n-BuLi (1.6 M in hexane; 10 mL, 16 mmol). The stock solution 
was stirred 30 min at 0 °C getting a clear yellow 0.4 M solution. 
1.27 mL (3 eq.) of this solution was added to a second Schlenk tube followed by 
addition of TIPS-protected hydroxy pyridine 5.65 (50 mg, 0.17 mmol, 1 eq.) in dry 
toluene (0.9 mL) and stirring at 0 °C was continued for 1 h. 1H NMR (D2O quench) 
indicated full deprotonation. The solution was cooled to -78 °C and SnBu3Cl (165 mg, 
0.51 mmol, 3 eq.) in dry THF (0.7 mL) was added dropwise. After 30 min the 
NH3CO
CH3
OTIPS
NH3CO
CH3
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SnBu3
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reaction was allowed to warm to RT and quenched with H2O. The aqueous phase was 
extracted with Et2O, washed with water and the combined organic extracts were dried 
over Na2SO4 and concentrated in vacuo. The crude orange oil was subjected to flash 
column chromatography (pentane:Et2O 50:1 + Et3N) to afford stannane 5.66 (10 mg, 
0.02 mmol, 10%) as colorless oil.  
 
Rf = 0.9 (pentane:Et2O 50:1 + Et3N). FTIR: ν = 2926, 2361, 1575, 1457, 1418, 1384, 
1153, 1017, 961, 881, 750, 689 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.01 (s, 1H), 
3.88 (s, 3H), 2.15 (s, 3H), 1.60-1.52 (m, 6H), 1.37-1.27 (m, 9H), 1.11-1.09 (m, 24H), 
0.87 (t, J = 7.3 Hz, 9H). 13C NMR (101 MHz, CDCl3) δ = 170.24, 163.00, 161.50, 
126.75, 97.70, 53.20, 29.36, 27.55, 18.13, 15.97, 13.86, 13.05, 10.82. HRMS ESI 
calc. for C28H55NO2SiSn+ [M-H]+: 586.3097, found: 586.3097. 
 
 
8.6.3 Synthesis of the Heterocyclic Core (3rd Generation Approach) 
4-Hydroxy-pyridine (5.68): A dry 50 mL Schlenck tube was filled with 
[Ir(COD)OMe]2 (16.9 mg, 0.03 mmol, 2 mol %), dtbpy (13.8 mg, 
0.05 mmol, 4 mol %) and filled with argon. To this heterogeneous 
mixture pinacolborane (204 mg, 1.55 mmol, 1.2 eq.) and 2-bromo-6-
methoxypyridine (5.67, 97%, 250 mg, 1.29 mmol, 1 eq.) in n-hexane (2.5 mL) was 
added and the orange solution stirred further at rt for 3 h. Reaction control by 
1H NMR after 3 h indicated ca. 95% conversion The resulting mixture was diluted 
with THF (10 mL) and aqueous Oxone (872 mg, 1.42 mmol, 1.1 eq.; in 10 mL H2O) 
was added slowly under vigorous stirring. After 10 min at rt, the reaction mixture was 
quenched with sat. aqueous NaHSO3 solution, sat. aqueous NaCl solution and 
extracted with EtOAc. The aqueous phase was extracted with EtOAc, washed with 
water and the combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. The crude solid was subjected to flash column chromategraphy 
(pentane:EtOAc 4:1) to afford 4-hydroxy-pyridine 5.68 (208 mg, 1.02 mmol, 79%) as 
colorless solid. 
 
BrNH3CO
OH
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M.p. = 148-149 °C. TLC: Rf = 0.5 (CH2Cl2:EtOAc 10:1). FTIR: ν = 2884, 2654, 
2507, 1554, 1455, 1406, 1346, 1256, 1200, 1153, 1045, 980, 796, 647 cm-1. 1H NMR 
(400 MHz, DMSO) δ = 11.07 (s, 1H, OH), 6.64 (d, J = 1.7 Hz, 1H), 6.12 (d, J = 
1.7 Hz, 1H), 3.77 (s, 3H). 13C NMR (101 MHz, DMSO) δ = 167.50, 164.61, 138.45, 
109.68, 94.92, 53.76. HRMS ESI calc. for C6H7O2NBr+ [M-H]+: 203.9655, found: 
203.9659. 
 
Dibromo-pyridone (5.68b): To a solution of pyridone 5.68 (50 mg, 0.25 mmol, 
1 eq.) in CH3CN (1.5 mL) was added NBS (48 mg, 0.27 mmol, 
1.1 eq.) and stirred in the dark over the weekend at RT. 1H NMR after 
70 h indicated formation of a new compound. All volatiles were 
removed in vacuo and the crude orange oil subjected to flash column chromatography 
(CH2Cl2) to afford dibromo pyridone 5.68b (55 mg, 0.19 mmol, 79%) as colorless 
solid. 
 
Rf = 0.3 (CH2Cl2). FTIR: ν = 3479, 2874, 1579, 1366, 1139, 1085, 1030, 940, 855, 
772 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.80 (s, 1H), 4.00 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 161.51, 160.31, 137.79, 110.00, 93.62, 55.48. HRMS MS 
calc. for C6H6Br2NO2+ [M-H]+ = 280.8760, found: 280.8758. 
 
 
SEM protected 4-pyridone (5.72): To a suspension of 4-pyridone 5.68 (50 mg, 
0.25 mmol, 1 eq.) in CH2Cl2 was added DIPEA (52 µL, 0.37 mmol, 
1.5 eq.) to form a clear-yellow solution. Then SEMCl (49 mg, 
0.29 mmol, 1.2 eq.) was added in a single portion and the resulting 
mixture stirred at RT for 3 h, until TLC indicated full conversion. The reaction was 
quenched by sequential addition of sat. aqueous NaHCO3 solution, sat. aqueous NaCl 
solution and extracted with CH2Cl2. The aqueous phase was extracted with CH2Cl2, 
washed with water and the combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. The crude orange oil was filtered through a plug of silica 
(CH2Cl2) to afford SEM protected 4-hydroxypyridine 5.72 (72 mg, 0.22 mmol, 88%) 
as colorless oil.  
 
BrNH3CO
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Rf = 0.7 (CH2Cl2). FTIR: ν = 2952, 2898, 1595, 1551, 1462, 1387, 1174, 1087, 1047, 
984, 914, 694, 651, 622 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.78 (d, J = 1.8 Hz, 
1H), 6.31 (d, J = 1.8 Hz, 1H), 5.20 (s, 2H), 3.91 (s, 3H), 3.72 (dd, J = 8.8, 7.9 Hz, 
2H), 1.00-0.89 (m, 2H), 0.00 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 166.67, 
165.16, 139.20, 110.16, 95.72, 92.73, 67.21, 54.36, 18.16, -1.30. HRMS ESI calc. for 
C12H20BrNO3SiNa+ [M-Na]+ = 356.0289, found: 356.0288. 
 
 
TIPS protected 4-pyridone (5.73): To a suspension of 4-pyridone 5.68 (150 mg, 
0.74 mmol, 1 eq.) in CH2Cl2 was added Et3N (0.21 mL, 1.47 mmol, 
2.0 eq.) to form a clear-yellow solution. Then TIPSCl (145 mg, 
0.75 mmol, 1.02 eq.) was added in a single portion and the resulting 
mixture stirred at RT for 3 h, until TLC indicated full conversion. The solvent was 
evaporated and the crude oil filtered through a short plug of silica to afford TIPS 
protected 4-pyridone 5.73 (257 mg, 0.65 mmol, 88%) as colorless oil. 
 
Rf = 0.8 (CH2Cl2). FTIR: ν = 2946, 2868, 1588, 1541, 1440, 1388, 1256, 1178, 1119, 
1043, 974, 863, 750, 695, 654 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.63 (d, J = 
1.8 Hz, 1H), 6.12 (d, J = 1.8 Hz, 1H), 3.90 (s, 3H), 1.36-1.21 (m, 3H), 1.09 (d, J = 
7.2 Hz, 18H). 13C NMR (101 MHz, CDCl3) δ = 166.01, 165.23, 139.28, 114.03, 
99.73, 54.27, 17.92, 12.74. HRMS ESI calc. for C15H27O2NBrSi+ [M+H]+: 360.0989, 
found: 360.0984. 
 
 
2,3,5-Tribromo-4-pyridone (5.69): To a solution of 4-hydroxypyridine 5.68 
(670 mg, 3.28 mmol, 1 eq.) in dry acetonitrile (12 mL) was added 
NBS (1227 mg, 3.28 mmol, 2.1 eq.) in a single portion and stirred for 
5 h at rt in the dark until reaction control by 1H NMR or UPLC 
indicated full conversion. The reaction mixture was poured in sat. aqueous Na2S2O3 
solution and extracted with EtOAc, washed with water and the combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo. The crude solid was 
subjected to flash column chromatography (pentane: EtOAc 4:1 + 1% TFA) to afford 
tribromo pyridine 5.69 as colorless solid. (1088 mg, 3.01 mmol, 92 %).  
BrNH3CO
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M.p. = 153-155 °C. Rf = 0.3 (strong tailing, pentane:EtOAc 4:1 + 1% TFA). FTIR: 
ν = 3438, 2958, 1559, 1468, 1370, 1290, 1178, 1106, 1056, 950, 870, 703, 646 cm-1. 
1H NMR (400 MHz, DMSO) δ = 3.87 (s, 3H). 13C NMR (101 MHz, DMSO) δ = 
160.85, 158.94, 138.41, 105.58, 93.65, 55.12. HRMS ESI calc. for C6H5O2NBr3+ 
[M-H]+: 359.7865, found: 359.7870. 
 
 
SEM-protected pyridine (5.70): To a cold (0 °C) solution of pyridine 5.69 (200 mg, 
0.55 mmol, 1 eq.) in dry CH2Cl2 was added DIPEA (137 µL, 107 mg, 
0.83 mmol, 1.5 eq.) and SEMCl (115 mg, 0.69 mmol, 1.2 eq.). The 
mixture was slowly allowed to reach rt; when reaction control by TLC 
indicated full conversion the reaction mixture was filtered through a short plug of 
silica using CH2Cl2 + 1% Et3N as solvent to afford SEM-protected pyridine 5.70 as 
colorless oil (223 mg, 0.453 mmol, 82%).  
 
Rf = 0.7 (CH2Cl2). FTIR: ν = 2952, 1552, 1459, 1369, 1291, 1249, 1077, 889, 835, 
705, 631 cm-1. 1H NMR (400 MHz, CDCl3) δ = 5.33 (s, 2H), 4.00 (s, 3H), 3.96 (m, 
2H), 1.00 (m, 2H), 0.04 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 161.82, 159.90, 
139.77, 111.67, 101.70, 98.40, 68.87, 55.78, 18.20, -1.26. HRMS ESI calc. for 
C12H18O3NBr3Si+ [M-X]+: 492.0737, found: 433.8240. 
 
 
2,5-Dibromo-3-methylpyridine (5.71a): To a cold (-78 °C) solution of tribromo-
pyridine 5.70 (220 mg, 0.45 mmol, 1.0 eq.) in dry THF (3 mL) was 
added dropwisely n-BuLi (280 µL, 0.45 mmol, 1.0 eq., as a 1.6 M 
solution in cyclohexane). After stirring for 10 min at -78 °C to the 
deep orange solution was added MeI (635 mg, 4.47 mmol, 10 eq.) and the mixture 
further stirred at this temperature. After another 15 min the mixture was allowed to 
reach rt within 1 h and quenched by addition of sat. aqueous Na2S2O3 solution. The 
aqueous phase was extracted with Et2O, washed with water and the combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo. The crude solid was 
subjected to flash column chromatography (pentane: Et2O 100:1 + 1% Et3N) to afford 
dibromo-pyridine 5.71a as colorless oil. (151 mg, 0.35 mmol, 79%).  
BrNH3CO
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Rf = 0.7 (pentane:Et2O 10:1). FTIR: ν = 2953, 1574, 1528, 1466, 1389, 1302, 1249, 
1170, 1076, 1016, 959, 907, 858 cm-1. 1H NMR (400 MHz, CDCl3) δ = 5.19 (s, 2H), 
3.98 (s, 3H), 3.90 (m, 2H), 2.31 (s, 3H), 0.99 (m, 2H), 0.04 (s, 9H). 13C NMR 
(101 MHz, CDCl3) δ = 163.05, 158.96, 140.02, 123.69, 100.82, 98.22, 68.40, 55.29, 
18.30, 16.20, -1.30. HRMS ESI calc. for C13H22O3NBr2Si+ [M-H]+: 425.9730, found: 
425.9728. 
 
 
2,5-Dibromo-pyridine (5.72b): Following the procedure for 3-methylpyridine 5.70b: 
Tribromo-pyridine 5.70b (500 mg, 1.02 mmol, 1.0 eq.) in dry THF 
was treated with n-BuLi (635 µL, 1.02 mmol, 1.0 eq., as a 1.6 M 
solution in cyclohexane) and MeOH (412 µL, 10.20 mmol, 10 eq.) to 
afford dibromo-pyridine 5.72b (350 mg, 0.85 mmol, 83%) as colorless oil. 
 
Rf = 0.3 (pentane: Et2O 100:1). FTIR: ν = 2953, 1578, 1536, 1362, 1141, 1082, 1031, 
984, 894, 854, 692 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.94 (s, 1H), 5.31 (s, 2H), 
4.00 (s, 3H), 3.81-3.75 (m, 2H), 0.98-0.93 (m, 2H), 0.01 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ = 162.87, 160.99, 137.66, 108.90, 94.96, 93.55, 67.63, 55.41, 18.13, -1.29. 
HRMS MS calc. for C12H20Br2NO3Si+ [M-H]+ = 411.9574, found: 411.9572. 
 
 
2-Bromo-3-methylpyridine (5.71): Following the procedure for 3-methyl pyridine 
5.70b: Dibromo-pyridine 5.70b (173 mg, 0.41 mmol, 1.0 eq.) in dry 
THF (3 mL) was treated with n-BuLi (0.25 mL, 0.41 mmol, 1.0 eq., 
as a 1.6 M solution in cyclohexane) and MeOH (0.16 mL, 
4.05 mmol, 10 eq.) to afford bromo-pyridine 5.71 (120 mg, 0.35 mmol, 85%) as 
colorless oil. 
 
Rf = 0.7 (pentane:Et2O 10:1). FTIR: ν = 2953, 1598, 1555, 1473, 1408, 1358, 1249, 
1206, 1160, 1094, 1053, 1012, 917, 760, 693 cm-1. 1H NMR (400 MHz, CDCl3) δ = 
6.38 (s, 1H), 5.23 (s, 2H), 3.88 (s, 3H), 3.72 (m, 2H), 2.18 (s, 3H), 0.94 (m, 2H), 0.00 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ = 164.38, 162.68, 140.89, 117.29, 94.24, 
BrNH3CO
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92.94, 67.10, 54.06, 18.14, 14.53, -1.30. HRMS ESI calc. for C13H23O3NBrSi+ 
[M-H]+: 348.0625, found: 348.0625. 
 
 
4-Hydroxy-pyridine (5.64): To a cold (-78 °C) solution of 5.71 (25.8 mg, 74 µmol, 
1 eq.) in dry THF (1 mL) was added n-BuLi (74 µL, 74 µmol, 
1.0 eq., as a 1.6 M solution in cyclohexane). After stirring for 
10 min at -78 °C ZnCl2 (89 µL, 89 µmol, 1.2 eq., as a 1.0 M solution 
in THF) was added and the mixture allowed to come to rt. Then the H2O was added 
and the reaction mixture was extracted with EtOAc to afford SEM protected 
4-hydroxypyridine as colorless oil.  
 
1H NMR (400 MHz, CDCl3) δ = 7.81 (s, 1H), 6.39 (s, 1H), 5.25 (s, 2H), 3.89 (s, 3H), 
3.71-3.75 (m, 2H), 2.09 (s, 3H), 0.93-0.97 (m, 2H), 0.00 (s, 9H). 
 
The crude oil was dissolved in dry THF (1 mL), TBAF (0.37 mL, 370 µmol, 5.0 eq., 
as a 1.0 M solution in THF) was added and the mixture was heated to 70 °C for 3 h, 
until TLC monitoring indicated full conversion. The brown solution was allowed to 
come to RT, 1 M HCl was added, the aqueous phase was extracted with EtOAc, 
washed with water and the combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. The crude solid was subjected to flash column chromatography 
(pentane:EtOAc 3:1) to afford 4-hydroxypyridine 5.64 (8 mg, 58 µmol, 77%) as 
colorless solid.  
 
M.p. = 152-153 °C. Rf = 0.25 (EA). 1H NMR (400 MHz, CDCl3) δ = 7.54 (s, 1H), 
6.12 (s, 1H), 3.84 (s, 3H), 2.09 (s, 3H).  
 
Analytical data according to compound 5.64. 
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8.6.4 Synthesis of the Polyene Side Chain 
Bromo acrylate (5.78aa): To a solution of methyl methacrylate (4.90 g, 48.5 mmol, 
1 eq.) in CCl4 (10 mL) was slowly added bromine (7.74 g, 48.5 mmol, 
1 eq.) in 5 mL of CCl4 at 0 °C. After stirring at rt for 3 h, DBU 
(11.06 g, 72.7 mmol, 1.5 eq.) was added dropwise at 0 °C and the 
solution stirred over night, therby allowing to come to RT. The mixture was acidified 
to pH 2-3 with aqueous 1 M HCl, and the organic layers were separated. The aqueous 
layer was extracted with Et2O, and the combined layers were washed with sat. 
aqueous NaCl solution (3 times) to afford after removal of solvent bromo acrylate 
5.78aa (8.20 g, 45.8 mmol, 95%) as yellowish oil, which was used without any 
further purification in the next step. 
 
Rf = 0.8 (pentane:Et2O 4:1). 1H NMR (400 MHz, CDCl3)  = 7.50 (s, 1H), 3.75 (s, 
3H), 1.99 (s, 3H). 
 
All analytical according to reference: X. Li, X. Zeng, Tetrahedron Lett. 2006, 47, 
6839-6842. 
 
 
Allyl alcohol (5.78a): To a suspension of LiAlH4 (1.17 g, 30.7 mmol, 1.00 eq.) in 
Et2O (60 mL) at 0 °C was added a solution of ester 5.78aa (5.50 g, 
30.7 mmol, 1.00 eq.) in Et2O (50 mL) and the resulting mixture was stirred 
for 1 h at RT. The mixture was cooled to 0 °C followed by addition of 
MeOH, water and HCl (2M aqueous solution). Saturated aqueous Rochelle's solution 
was added and the mixture was stirred at RT for 12 h. The resulting clear mixture was 
extracted with Et2O and washed with water and brine. The combined organic layers 
were dried over Na2SO4 and concentrated under reduced pressure to afford the allyl 
alcohol 5.78a (4.37 g, 29.0 mmol, 94%) as colorless oil.  
 
Rf = 0.2 (pentane:Et2O 4:1). 1H NMR (400 MHz, CDCl3) δ = 6.23-6.21 (m, 1H), 4.06 
(s, 2H), 2.21 (s, 1H, OH), 1.81-1.80 (m, 3H).  
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Analytical data according to reference: Y. Murakami, M. Nakano, T. Shimofusa, N. 
Furuichi, S. Katsumura, Org. Biomol. Chem. 2005, 3, 1372-1374. 
 
 
Aldehyde (5.78): To a suspension of MnO2 (7.65 g, 88.0 mmol, 11.1 eq.) in CH2Cl2 
(20 mL) was added allyl alcohol 5.78a (1.20 g, 7.95 mmol, 1.00 eq.) and 
stirred at RT for 12 h. The black suspension was filtered through a plug 
of celite and carefully evaporated to afford the volatile aldehyde 5.78 
(0.89 g, 5.96 mmol, 75%) as colorless oil.  
 
Rf = 0.7 (CH2Cl2). 1H NMR (400 MHz, CDCl3)  = 9.49 (s, 1H), 7.43 (q, J = 1.3 Hz, 
1H), 1.90 (d, J = 1.3 Hz, 3H).  
 
Analytical data according to reference: Y. Murakami, M. Nakano, T. Shimofusa, N. 
Furuichi, S. Katsumura, Org. Biomol. Chem. 2005, 3, 1372-1374. 
 
 
Imide (5.76a): To a cold (-40 °C, acetonitrile/dry ice) solution of 2-methyl-2-
pentenoic acid (1.59 g, 13.9 mmol, 1.2 eq.) and Et3N (5.17 mL, 
36.2 mmol, 3.2 eq.) in dry THF (80 mL) was added dropwise 
trimethylacetyl chloride (1.80 mL, 14.6 mmol, 1.25 eq.). The 
resulting white slurry was stirred for 1.5 h at -40 °C. Then flame 
dried LiCl (0.68 g, 16.0 mmol, 1.4 eq.) and (R)-(+)-4-Isopropyl-2-oxazolidinone 
(1.50 g, 11.6 mmol, 1 eq.; Rf = 0.05 (pentane:Et2O, 1:1)) were added in a single 
portion. The cooling bath was removed and the reaction mixture was allowed to stir at 
RT over night until TLC-control indicated full conversion. The reaction was quenched 
with first MeOH, then saturated aqueous NH4Cl solution. The aqueous phase was 
extracted with Et2O, washed with saturated NaHCO3 solution, saturated NaCl solution 
and water, dried over Na2SO4 and concentrated in vacuo. The residue was purified by 
column chromatography (pentane:Et2O 3:1) to yield imide 5.76a as colorless oil 
(2.17 g, 9.61 mmol, 83 %).  
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Rf = 0.8 (pentane:Et2O 1:1). Optical rotation: [α]D = -29.7° (c = 0.56, CHCl3). 
1H NMR (400 MHz, CDCl3 δ = 6.01 (tq, J = 7.2 Hz, J = 1.3 Hz, 1H), 4.47-4.42 (m, 
1H), 4.42 (t, J = 8.9 Hz, 1H), 4.12-4.08 (m, 1H), 2.34-2.25 (m, 1H), 2.18-2.09 (m, 
2H), 1.83 (s, 3H), 0.98 (t, J = 7.6 Hz, 3H), 0.85 (t, J = 6.4 Hz, 6H).  
 
Analytical data according to reference: S. Shirokawa, M. Kamiyama, T. Nakamura, 
M. Okada, A. Nakazaki, S. Hosokawa, S. Kobayashi, J. Am. Chem. Soc. 2004, 126, 
13604-13605. 
 
 
TBS enol (5.76): To a solution of imide 5.76a (1000 mg, 4.44 mmol, 1 eq.) in dry 
THF (30 mL) at -78°C was added NaHMDS (1M solution in THF; 
6.67 mL, 6.67 mmol, 1.5 eq.) and the resulting mixture was stirred for 
1.5 h at -78 °C. Then TBSCl (2000 mg, 13.3 mmol, 3 eq.) in 10 mL dry 
THF was added and stirred another 30 min. Quenching by addition of 
first MeOH, then NH4Cl at -78 °C, extraction with Et2O afforded a colorless oil which 
was further purified by flash column chromatography (pentane: Et2O 6:1) to afford 
TBS enol 5.76 as colorless oil (1497 mg, 4.41 mmol, 99%).  
 
Rf = 0.6 (pentane:Et2O, 3:1). Optical rotation: [α]D = +23.6° (c = 0.65, CHCl3). 
1H NMR (400 MHz, CDCl3 δ = 6.21 (d, J = 16.0 Hz, 1H), 5.63 (dq, J = 13.4, 6.6 Hz, 
1H), 4.32 (t, J = 8.7 Hz, 1H), 4.12 (t, J = 8.4 Hz, 1H), 4.02-3.96 (m, 1H), 1.97-1.89 
(m, 1H), 1.79-1.77 (m, 6H), 0.98 (s, 9H), 0.93 (s, 3H), 0.91 (s, 3H), 0.19 (s, 3H), 0.14 
(s, 3H).  
 
Analytical data according to reference: S. Shirokawa, M. Kamiyama, T. Nakamura, 
M. Okada, A. Nakazaki, S. Hosokawa, S. Kobayashi, J. Am. Chem. Soc. 2004, 126, 
13604-13605.  
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Allylic alcohol (5.79): To a cold (-78 °C) solution of aldehyde 5.78 (7.430 g, 
25.90 mmol, 2 eq.; Rf = 0.5 (pentane:EtOAc, 7:3)) in dry 
CH2Cl2 (70 mL) was added TiCl4 (1 M solution in CH2Cl2, 
13.60 mL, 13.60 mmol, 1.05 eq.) and the resulting orange 
solution stirred for 5 min. Then a solution of TBS enol 5.76 
(4.863 g, 12.90 mmol, 1 eq.; Rf = 0.8 (pentane:EtOAc, 7:3)) in dry CH2Cl2 (60 mL) 
was added dropwise via additional funnel into the reaction mixture and further stirred 
at -35 °C (cryostate) for 18 h to form a yellow solution. The mixture was quenched by 
addition of pyridine (5 mL), Rochelle solution and NaHCO3 solution (20 mL) and 
allowed to come to RT until a clear solution was formed. The aqueous layer was 
extracted with Et2O, dried over Na2SO4 and evaporated to yield a yellow oil, then 
subjected to flash column chromatography (pentane:EtOAc 7:3) to afford allylic 
alcohol 5.79 as colorless foamy oil. (4.712 g, 11.90 mmol, 92%). An analytical 
sample was recrystallized from EtOAc/n-hexane for X-ray analysis. 
 
M.p. = 73-75 °C. Rf = 0.3 (pentane:EtOAc, 7:3). Optical rotation: [α]D = +9.3° (c = 
0.48, CHCl3). FTIR: ν = 3395, 3301, 3134, 2972, 2324, 1786, 1663, 1431, 1394, 
1303, 1223, 1119, 1015, 966, 901, 777, 712 cm-1. 1H NMR (400 MHz, CDCl3) δ = 
6.15 (d, J = 1.1 Hz, 1H), 5.65 (dd, J = 10.3, 1.5 Hz, 1H), 4.52 (ddd, J = 9.0, 5.6, 
4.6 Hz, 1H), 4.29 (t, J = 9.0 Hz, 1H), 4.13 (dd, J= 9.1, 5.6 Hz, 1H), 3.73 (dd, J = 9.2, 
2.2 Hz, 1H), 3.50 (d, J = 2.3 Hz, 1H, OH), 2.70 (ddq, J = 10.3, 9.2, 6.7 Hz, 1H), 2.29 
(ddq, J = 7.0, 7.0, 4.6 Hz, 1H), 1.91 (d, J = 1.5 Hz, 3H), 1.79 (d, J = 1.3 Hz, 3H), 0.87 
(d, J = 5.3 Hz, 3H), 0.86 (d, J = 5.2 Hz, 1H), 0.79 (d, J = 6.7, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 171.41, 154.73, 141.36, 140.46, 132.60, 106.30, 80.28, 63.68, 
58.25, 38.12, 28.57, 18.00, 16.15, 15.34, 14.26, 14.24. HRMS ESI calc. for 
C16H25BrNO4+ [M-H]+: 374.0950, found: 374,0961. X-Ray structure is given in the 
appendices section. 
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Imide (5.79b): To a cold (-78 °C) solution of alcohol 5.79 (5.360 g, 14.30 mmol, 
1 eq.; Rf = 0.3 (pentane:EtOAc, 7:3)) and 2,6-lutidine 
(3.34 ml, 28.6 mmol, 3 eq.) in dry CH2Cl2 (150 mL) was 
added TBSOTf (4.28 ml, 18.60 mmol, 1.3 eq.) in dry CH2Cl2 
(20 mL). The solution was allowed to reach rt and further stirred for 1 h at RT before 
being quenched with aqueous NaHCO3 solution (50 mL), NH4Cl solution and water. 
Extraction with Et2O and evaporation yielded a colorless oil which was subjected to 
flash column chromatography (pentane:Et2O 4:1) to afford imide 5.79b as colorless 
oil (7.118 g, 13.87 mmol, 97%).  
 
 
Rf = 0.8 (pentane: EtOAc 7:3). Optical rotation: [α]D = -3.1° (c = 0.28, CHCl3). 
FTIR: ν = 2960, 2857, 1785, 1684, 1463, 1386, 1298, 1204, 1077, 1007, 860, 775, 
713 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.14 (s, 1H), 5.84 (dd, J = 9.8, 1.4 Hz, 
1H), 4.47 (dt, J = 8.9, 4.6 Hz, 1H), 4.30 (t, J = 8.8 Hz, 1H), 4.18 (dd, J = 9.0, 4.9 Hz, 
1H), 3.91 (d, J = 6.7 Hz, 1H), 2.68 (ddq, J = 9.8, 6.8, 6.8 Hz, 1H), 2.38 (ddq, J = 7.0, 
7.0, 4.3 Hz, 1H), 1.92 (d, J = 1.4 Hz, 3H), 1.76 (d, J = 1.2 Hz, 3H), 0.91 (m, J = 7.9, 
3.2 Hz, 9H), 0.85 (s, 9H), 0.04 (s, 3H), -0.02 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ = 171.74, 153.49, 142.99, 140.07, 131.88, 105.20, 80.55, 63.58, 58.48, 37.94, 25.87, 
15.20, 15.01, 14.40, -4.73, -5.00. HRMS ESI calc. for C22H39BrNO4Si+ [M-H]+: 
488.1826, found: 488.1817. 
 
 
Allylic alcohol (5.80a): To a solution of imide 5.79b (2.500 mg, 4.97 mmol, 1 eq.; 
Rf = 0.4 (CH2Cl2, UV active)) in THF/H2O (5:1, 50 mL) at rt was 
added NaBH4 (950 mg, 24.90 mmol, 5eq.) in small portions. The 
reaction mixture was stirred in the dark for 12 h, two times 
addition of additional NaBH4 (1 eq.), before being cooled to 0 °C and quenched with 
0.1 M HCl. The aqueous phase was extracted with Et2O, washed with water and the 
combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The 
crude oil was subjected to flash column chromatography (pentane:DCM 3:1) to afford 
alcohol 5.80a as colorless oil (1.700 g, 4.67 mmol, 94%).  
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Rf = 0.3 (DCM, not UV active). Optical rotation: [α]D = +12.5° (c = 0.87, CHCl3). 
FTIR: ν = 3326, 2929, 2857, 1791, 1630, 1461, 1377, 1253, 1078, 1007, 940, 864, 
775, 714, 671 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.08 (s, 1H), 5.22 (dd, J = 9.7, 
1.3 Hz, 1H), 4.00 (d, J = 6.2 Hz, 2H), 3.80 (d, J = 7.2 Hz, 1H), 2.59 (ddq, J = 9.6, 7.2, 
6.8 Hz, 1H), 1.75 (d, J = 1.2 Hz, 3H), 1.67 (d, J = 1.3 Hz, 3H), 0.85 (s, 9H), 0.82 (d, 
J = 6.8 Hz, 3H), -0.00 (s, 3H), -0.03 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 143.48, 
135.30, 128.97, 104.52, 81.24, 69.16, 37.00, 25.82, 18.24, 17.53, 15.10, 14.22, -4.67, 
-4.95. HRMS ESI calc. for C16H32BrO2Si+ [M-H]+: 363.1713, found: 363.1703. 
 
 
Aldehyde (5.80): To a suspension of MnO2 (8.200 g, 94.00 mmol, 30 eq.) in CH2Cl2 
(125 mL) was added alcohol 5.80a (1.700 g, 4.68 mmol, 1 eq.; 
Rf = 0.3 (CH2Cl2)) and stirred over night. The black suspension 
was filtered through a plug of celite and evaporated to yield 5.80 without further 
purification as colorless oil (1.655 g, 4.59 mmol, 98%).  
 
Rf = 0.8 (DCM). Optical rotation: [α]D = +21.4° (c = 0.78, CHCl3). FTIR: ν = 2956, 
2858, 2416, 2257, 1687, 1462, 1256, 1077, 1007, 836, 775, 715, 672 cm-1. 1H NMR 
(400 MHz, CDCl3) δ = 9.40 (s, 1H), 6.32 (dd, J = 9.9, 1.3 Hz, 1H), 6.16 (s, J = 
0.7 Hz, 1H), 3.95 (d, J = 7.1 Hz, 1H), 2.89 (ddq, J = 9.9, 7.1, 6.8 Hz, 1H), 1.80-1.73 
(m, 6H), 0.94 (d, J = 6.8 Hz, 3H), 0.83 (s, 9H), 0.00 (s, 3H), -0.03 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 195.39, 156.61, 142.62, 139.72, 105.54, 80.73, 38.45, 25.77, 
18.20, 16.65, 15.02, 9.70, -4.62, -5.00. UPLC-MS ESI calc. for C16H29BrO2Si+ 
[M-H]+: 360.1, found: 360.1.  
 
 
Ester (5.81): To a cold (0 °C) solution of Methyl diethylphosphonoacetate (182 mg, 
0.87 mmol, 2.5 eq.) in CH3CN (2 mL) was added DBU 
(114 µl, 0.76 mmol, 2.2 eq.) and stirred for 10 min. Then 
LiCl (44 mg, 1.04 mmol, 3 eq.) was added and the 
solution allowed to further stir at rt. Then aldehyde 5.80 (125 mg, 0.35 mmol, 1 eq.; 
Rf = 0.8 (CH2Cl2)) was added in CH3CN (2 mL) and the resulting solution stirred over 
night (12 h) until 1H NMR control indicated full conversion of the reaction. The 
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reaction mixture was quenched with 0.1M HCl, NH4Cl solution. The aqueous phase 
was extracted with Et2O, washed with water and the combined organic extracts were 
dried over Na2SO4 and concentrated in vacuo. The crude oil was subjected to flash 
column chromatography (CH2Cl2) to afford ester 5.81 as colorless oil (144 mg, 
0.35 mmol, quant.).  
 
Rf = 0.8 (CH2Cl2). Optical rotation: [α]D = +40.8° (c = 0.77, CHCl3). FTIR: ν = 
2929, 2857, 1720, 1623, 1461, 1377, 1310, 1253, 1168, 1077, 1014, 862, 776, 
714 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.31 (dd, J = 15.7, 0.6 Hz, 1H), 6.10 (d, 
J = 1.7 Hz, 1H), 5.80 (d, J = 15.5 Hz, 1H), 5.70 (d, J = 9.9 Hz, 1H), 3.85 (d, J = 
6.9 Hz, 1H), 3.75 (s, 3H), 2.72 (ddq, J = 9.9, 6.9, 6.8 Hz, 1H), 1.75 (dd, J = 11.4, 
1.2 Hz, 6H), 0.87 (d, J = 6.8 Hz, 3H), 0.82 (s, 9H), -0.04 (d, J = 6.5 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ = 168.16, 149.93, 144.48, 143.07, 133.24, 115.69, 
105.04, 80.99, 51.61, 38.23, 25.80, 18.17, 17.24, 15.06, 12.80, -4.71, -4.94. HRMS 
ESI calc. for C19H34BrO3Si+ [M-H]+: 417.1455, found: 417.1456.  
 
 
Ester (5.82):107 To a solution of 2-(diethoxyphosphoryl)-propionic acid ethyl ester 
(528 mg, 0.48 mL, 2.22 mmol, 4.00 eq.) in CH3CN 
(0.4 mL) at 0 °C was added DBU (294 mg, 0.29 mL, 
1.94 mmol, 3.50 eq.). The resulting mixture was stirred for 
10 min and LiCl (70.5 mg, 1.66 mmol, 3.00 eq.) was added. After 10 min stirring a 
solution of aldehyde 5.80 (206 mg, 0.56 mmol, 1.00 eq.) in CH3CN (0.5 mL) was 
added dropwise. The mixture was allowed to come to RT and stirred at ambient 
temperature for 6 h until 1H NMR showed complete conversion. The resulting yellow 
solution was quenched using saturated aqueous NH4Cl solution and extracted with 
Et2O. The combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure. The resulting oil was purified by column 
chromatography (pentane:Et2O 40:1) to afford ester 5.82 (199 mg, 0.45 mmol, 81%) 
as colorless oil.  
 
Rf = 0.3 (pentane:Et2O 40:1). Optical rotation: [α]D +36.4° (c = 0.84, CHCl3). 
FTIR: ν = 3890, 2932, 2358, 2109, 1706, 1628, 1462, 1378, 1251, 1008, 861, 776, 
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631 cm-1. 1H NMR (500 MHz, CDCl3) δ = 7.09 (s, 1H), 6.10 (s, 1H), 5.43 (d, 
J = 9.8 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.86 (d, J = 6.3 Hz, 1H), 2.67 (ddq, J = 9.8, 
6.8, 6.7 Hz, 1H), 1.99 (d, J = 1.4 Hz, 3H), 1.82 (d, J = 1.3 Hz, 3H), 1.75 (d, 
J = 1.2 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H), 0.89 (d, J = 6.8 Hz, 3H), 0.85 (s, 
9H), 0.01 (s, 3H), -0.04 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 169.35, 143.22, 
143.02, 138.36, 132.51, 125.70, 104.78, 80.94, 60.73, 37.77, 25.84, 18.22, 17.67, 
16.93, 15.45, 14.46, 14.23, -4.64, -4.98. HRMS ESI calc. for C21H38O3BrSi+ [M-H]+: 
445.1768, found: 445.1760. 
 
 
Stannane (5.83): To a cold (-50 °C) solution of (E)-2-Bromo-2-butene (95% purity; 
392 mg, 2.76 mmol, 1.25 mmol) in dry THF (5 mL) was added dropwise 
t-BuLi (as a 1.9 M solution in pentane, 2.16 mL, 3.45 mmol, 1.55 eq.) and 
further stirred at this temperature until the yellow color of the solution disappears 
(1 h). Then SnBu3Cl (0.60 mL, 2.21 mmol, 1 eq.) was added as a solution in dry THF 
(1.5 mL) and slowly allowed to reach rt and stirred another 12 h at rt. To this white 
suspension was added water to obtain a clear organic layer. The aqueous phase was 
extracted with Et2O, washed with water and the combined organic extracts were dried 
over Na2SO4 and concentrated in vacuo to yield a light yellow oil which was further 
purified by flash column chromatography on Al2O3 (pentane) to afford stannane 5.83 
as colorless oil (720 mg, 2.21 mmol, 95%).  
 
Rf = 0.9 (pentane). FTIR: ν = 2922, 2853, 1902, 1615, 1461, 1377, 1291, 1181, 1073, 
1001, 872, 802, 664 cm-1. 1H NMR (400 MHz, CDCl3) δ = 5.68-5.43 (m, 1H), 1.75 
(dd, J = 1.8, 1.1 Hz, 3H), 1.62 (dd, J = 6.4, 1.0 Hz, 3H), 1.46-0.75 (m, 27H). 
13C NMR (101 MHz, CDCl3) δ = 138.92, 134.86, 29.35, 27.58, 18.82, 14.01, 13.86, 
9.18. Elementary Analyses calc. for C16H34Sn: calc.: C = 55.68, H = 9.93, Sn = 
34.39; found: C = 55.47, H = 9.68. 
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Ester (5.84): LiCl (136 mg, 3.21 mmol, 3 eq.) was dried in a Schlenk tube with a 
Bunsen burner. A solution of ester 5.81 (460 mg, 
1.070 mmol, 1 eq.; Rf = 0.20 (pentane:Et2O 40:1)) and 
stannane 5.83 (480 mg, 1.390 mmol, 1.3 eq.) in dry 
NMP (5 mL) was added and the mixture was degassed by the freeze-thaw procedure 
(cooled in liquid N2 until solution freezes, high vacuum; allowed to reach rt still high 
vacuum, then Argon; this procedure was repeated 3 times). Then Pd(t-Bu3P)2 (54 mg, 
0.107 mmol, 10 mol %) was added and the orange solution stirred 10 min at rt then 
1.5 h at 80 °C. The mixture was cooled to RT, Et2O was added and the crude black 
suspension filtered before washing with H2O. The aqueous phase was extracted with 
Et2O, washed with water and the combined organic extracts were dried over Na2SO4 
and concentrated in vacuo. The crude oil was subjected to flash column 
chromatography (pentane:Et2O 40:1) to afford ester 5.84 as colorless oil (400 mg, 
1.017 mmol, 95%) together with trace impurities which could not be separated by 
column chromatography. For analytical purposes a sample was purified using HPLC.  
 
Rf = 0.25 (pentane:Et2O 40:1). Optical rotation: [α]D = -7.8° (c = 0.18, CHCl3). 
FTIR: ν = 2955, 1722, 1622, 1460, 1378, 1308, 1252, 1168, 1067, 774, 631 cm-1. 
1H NMR (500 MHz, CDCl3) δ = 7.33 (d, J = 15.6 Hz, 1H), 5.79 (s, 1H), 5.76 (s, 1H), 
5.74 (s, 1H), 5.34 (q, J = 6.8 Hz, 1H), 3.75 (s, 3H), 3.71 (d, J = 7.4 Hz, 1H), 2.72 
(ddq, J = 9.9, 6.9, 6.8 Hz, 1H), 1.77 (d, J = 1.1 Hz, 3H), 1.71 (s, 3H), 1.69 (d, J = 
1.1 Hz, 3H), 1.67 (d, J = 6.8 Hz, 3H), 0.85 (d, J = 6.8 Hz, 3H), 0.82 (s, 9H), -0.04 (s, 
3H), -0.05 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 168.29, 150.41, 146.43, 135.40, 
133.15, 132.62, 131.46, 124.16, 115.07, 83.64, 51.54, 38.36, 25.89, 18.21, 17.39, 
16.67, 13.77, 13.08, 12.81, -4.46, -4.89. HRMS ESI calc. for C23H40O3NaSi+ [M-H]+: 
415.2639, found: 415.2642.  
 
 
Ester (5.85):107 To a solution of ester 5.82 (172 mg, 374 µmol, 1.00 eq.) and stannane 
5.83 (194 mg, 562 µmol, 1.50 eq.) in NMP (8.0 mL) 
was added flame-dried LiCl (31.7 mg, 749 µmol, 
2.00 eq.). This mixture was degassed three times by 
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freeze-thaw procedure. Pd(Pt-Bu3)2 (19.1 mg, 37.4 µmol, 0.10 eq.) was added and the 
resulting orange mixture was stirred at 80 °C for 6 h until TLC indicated full 
conversion. The resulting black suspension was filtered and washed with Et2O. Water 
was added and the mixture was extracted with Et2O. The combined organic layers 
were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. 
The resulting yellow oil was purified by column chromatography (pentane:Et2O 
100:1) to afford the olefin 5.85 (153 mg, 363 µmol, 97%) as colorless oil. For 
analytical purposes a sample was further purified by HPLC. 
 
Rf = 0.2 (pentane:Et2O 100:1). Optical rotation: [α]D = -9.2° (c = 0.06, CHCl3). 
FTIR: ν = 2926, 2856, 2362, 1708, 1462, 1377, 1248, 1112, 1014, 735, 623 cm-1. 
1H NMR (500 MHz, CDCl3) δ = 7.11 (s, 1H), 5.75 (s, 1H), 5.49 (d, J = 9.8 Hz, 1H), 
5.34 (q, J = 6.9 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.72 (d, J = 6.9 Hz, 1H), 2.67 (ddq, 
J = 9.8, 6.8, 6.8 Hz, 1H), 2.00 (d, J = 1.3 Hz, 3H), 1.84 (d, J = 1.2 Hz, 3H), 1.71 (d, 
J = 3.1 Hz, 3H), 1.70 (s, 3H), 1.67 (d, J = 6.9 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H), 
0.86 (d, J = 6.7 Hz, 3H), 0.84 (s, 9H), -0.02 (s, 3H), -0.05 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ = 169.45, 143.24, 140.32, 135.42, 133.10, 131.68, 130.78, 
124.90, 123.88, 83.30, 60.45, 37.59, 25.69, 18.02, 17.57, 16.75, 16.45, 14.19, 13.95, 
13.64, 13.23,-4.76, -5.03. HRMS ESI calc. for C25H44O3NaSi+ [M-Na]+: 443.2953, 
found: 443.2944. 
 
 
Ester (5.86): A solution of ester 5.81 (475 mg, 0.97 mmol, 1 eq.), MeB(OH)2 (88 mg, 
1.45 mmol, 1.5 eq.) and Cs2CO3 (946 mg, 2.90 mmol, 
3 eq.) in dioxane (5 mL) and 0.1 mL H2O was degassed by 
the freeze-thaw procedure. Then Pd(PPh3)2 (56 mg, 
0.05 mmol, 5 mol %) was added and the orange solution stirred 10 min at RT then 5 h 
at 65 °C. The mixture was cooled to RT, Et2O was added and the crude black 
suspension filtered before washing with H2O. The aqueous phase was extracted with 
Et2O, washed with water and the combined organic extracts were dried over Na2SO4 
and concentrated in vacuo. The crude oil was subjected to flash column 
chromatography (pentane:Et2O 40:1) to afford ester 5.86 as colorless oil (238 mg, 
OTBS
MeO
O
EXPERIMENTAL PART  165 
 
0.67 mmol, 69%) together with trace impurities which could not be separated by 
column chromatography.  
 
Rf = 0.3 (pentane:Et2O 40:1). FTIR: ν = 3629, 2955, 1722, 1622, 1459, 1308, 1252, 
1168, 1056, 775, 630 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.32 (dd, J = 15.6, 
0.5 Hz, 1H), 5.82-5.70 (m, 2H), 5.35 (q, J = 6.4 Hz, 1H), 3.75 (s, 3H), 3.70 (d, J = 
7.6 Hz, 1H), 2.74- 2.62 (m, 1H), 1.77 (d, J = 1.1 Hz, 3H), 1.58 (dd, J = 6.7, 0.9, 3H), 
1.55 (s, 3H), 0.81-0.78 (m, 12H), -0.07 (s, 3H), -0.09 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ = 168.29, 150.44, 146.68, 136.86, 135.82, 132.50, 132.21, 121.86, 114.98, 
114.23, 107.15, 83.20, 77.48, 77.16, 76.84, 72.54, 51.51, 38.21, 25.85, 18.18, 17.26, 
13.06, 12.75, 11.03, -4.63, -4.94. HRMS ESI calc. for C20H37O3Si+ [M-H]+: 
353.2506, found: 353.2509. 
 
 
Allylic alcohol (5.87a): To a solution of ester 5.84 (107 mg, 0.27 mmol, 1 eq.) in dry 
CH2Cl2 (2.5 mL) was added at -78 °C DIBAH (1 M 
solution in hexane, 0.81 mL, 0.81 mmol, 3 eq.) and the 
solution was stirred at -78 °C until TLC indicated full 
conversion (0.5 h). The reaction mixture was then quenched by dropwise addition of 
first MeOH, Rochelle’s solution and Et2O and warmed to rt and stirred until both 
layers became clear solutions. The aqueous phase was extracted with Et2O, washed 
with water and the combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo to afford alcohol 5.87a (96 mg, 0.27 mmol, quant.) as colorless 
oil, which was used without further purification in the next step. For analytical 
purposes a sample was purified using HPLC.  
 
Rf = 0.2 (pentane:Et2O 4:1). Optical rotation: [α]D = -17.5° (c = 0.12, CHCl3). 
FTIR: ν = 3361, 2927, 2856, 2316, 1717, 1566, 1456, 1362, 1255, 1079, 1061, 1036, 
838, 774 cm-1. 1H NMR (500 MHz, CDCl3) δ = 6.25 (dd, J = 15.6, 0.6 Hz, 1H), 5.75-
5.67 (m, 2H), 5.38-5.31 (m, 2H), 4.20 (s, 2H), 3.67 (d, J = 7.5 Hz, 1H), 2.71-2.62 (m, 
1H), 1.75 (d, J = 1.2 Hz, 3H), 1.71 (s, 3H), 1.69 (d, J = 1.2 Hz, 3H), 1.67 (d, J = 
6.8 Hz, 3H), 0.82 (m, 12H), -0.04 (s, 3H), -0.05 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ = 137.86, 137.47, 135.90, 133.28, 132.63, 131.08, 125.07, 123.91, 83.91, 64.28, 
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37.78, 25.93, 18.24, 17.76, 16.70, 13.77, 13.11, -4.48, -4.86. HRMS ESI calc. for 
C22H40O2NaSi+ [M-Na]+: 387.2690, found: 387.2691.  
 
 
Allyl alcohol (5.88a):107 Following the reported procedure for 5.87a: Ester 5.85 
(92.7 mg, 220 µmol, 1.00 eq.) in dry CH2Cl2 (4.0 mL) 
was treated with DIBAL (1M solution in hexane, 
661 µL, 661 µmol, 3.0 eq.) to afford the allyl alcohol 
5.88a (81.0 mg, 214 µmol, 97%) as colorless oil. For analytical purposes a sample 
was further purified by HPLC. 
 
Rf = 0.2 (pentane :Et2O 4:1). Optical rotation: [α]D = +5.53° (c = 0.13, CHCl3). 
FTIR: ν = 3336, 2929, 2856, 2361, 1460, 1377, 1252, 1069, 1033, 887, 836, 775, 
669 cm-1. 1H NMR (500 MHz, CDCl3) δ = 5.86 (s, 1H), 5.74 (s, 1H), 5.33 (q, 
J = 6.8 Hz, 1H), 5.19 (d, J = 9.7 Hz, 1H), 4.04 (s, 2H), 3.70 (d, J = 6.7 Hz, 1H), 
2.62 (ddq, J = 9.7, 6.9, 6.8 Hz, 1H), 1.82 (d, J = 1.3 Hz, 3H), 1.75 (d, J = 1.3 Hz, 3H), 
1.70 (d, J = 3.0 Hz, 3H), 1.70 (s, 3H), 1.67 (d, J = 6.9 Hz, 3H), 0.85 (d, J = 6.8 Hz, 
3H), 0.85 (s, 9H), -0.02 (s, 3H), -0.05 (s, 3H). 13C NMR (126 MHz, CDCl3) δ = 
135.85, 134.67, 133.81, 133.17, 131.50, 130.56, 130.05, 123.70, 83.47, 69.74, 37.30, 
25.67, 18.01, 17.83, 15.27, 17.15, 16.43, 13.45, 13.20, -4.68, -5.18.  
 
 
Allylic alcohol (5.89a): Following the reported procedure for 5.87a: Ester 5.86 
(255 mg, 0.72 mmol, 1 eq.) in dry CH2Cl2 (10 mL) was treated 
with DIBAH (1 M solution in hexane, 2.2 mL, 2.17 mmol, 3eq.) 
to yield alcohol 5.89a (225 mg, 0.69 mmol, 95%) as colorless 
oil together with trace impurities which could not be separated by column 
chromatography.  
 
Rf = 0.2 (pentane:Et2O 4:1). FTIR: ν = 3313, 2928, 2857, 1249, 1056, 963, 860, 835, 
773, 669, 630 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.25 (d, J = 15.6 Hz, 1H), 5.70 
(dt, J = 15.6, 6.2 Hz, 1H), 5.38-5.28 (m, 2H), 4.19 (d, J = 6.0 Hz, 2H), 3.66 (d, J = 
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7.6 Hz, 1H), 2.68-2.58 (m, 1H), 1.74 (s, 3H), 1.61-1.56 (m, 3H), 1.55 (d, J = 1.0 Hz, 
3H), 1.26 (s, 1H, OH), 0.81 (s, 9H), 0.77 (d, J = 6.8 Hz, 3H), -0.06 (s, 3H), -0.08 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ = 138.11, 137.52, 137.26, 132.50, 124.98, 
121.39, 118.28, 92.42, 83.47, 64.29, 37.63, 25.90, 18.23, 17.66, 13.08, 11.09,  
-4.63, -4.89. HRMS ESI calc. for C19H36O2SiNa+ [M-Na]+: 347.2377, found: 
347.2380. 
 
 
Allylic alcohol (5.94a): Following the reported procedure for 5.87a : Ester 5.81 
(150 mg, 0.36 mmol, 1 eq.) in dry CH2Cl2 (5 mL) was treated 
with DIBAL-H (1.08 mL, 1.08 mmol, 3 eq., 1 M solution in 
hexane, mL, mmol, 3 eq.) to yield alcohol 5.94a (135 mg, 0.35 mmol, 97%) as 
colorless oil.  
 
Rf = 0.2 (pentane:Et2O 4:1). Optical rotation: [α]D = +25.0° (c = 0.70, CHCl3). 
FTIR: ν = 3307, 2956, 2928, 2857, 1629, 1255, 1081, 1004, 964, 861, 836, 775, 
631 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.24 (d, J = 16.2 Hz, 1H), 6.08 (d, J = 
0.6 Hz, 1H), 5.73 (dt, J =15.6, 6.1 Hz, 1H), 5.29 (d, J = 9.7 Hz, 1H), 4.20 (t, J = 
5.6 Hz, 2H), 3.82 (d, J = 6.9 Hz, 1H), 2.67 (dq, J = 9.6, 6.8 Hz, 1H), 1.74 (d, J = 
1.1 Hz, 6H), 1.25 (s, 1H, OH), 0.84 (m, 12H), -0.03 (s, 3H), -0.05 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 143.39, 136.86, 135.94, 133.33, 125.69, 104.56, 81.14, 64.07, 
37.66, 25.81, 18.17, 17.57, 15.13, 13.07, -4.75, -4.94. HRMS ESI calc. for 
C18H33BrO2SiNa+ [M-Na]+ = 411.1325, found: 411.1330. 
 
 
Allylic acetate (5.87): To a cold (0 °C) solution of alcohol 5.87a (88 mg, 0.24 mmol, 
1 eq.) in dry CH2Cl2 (1.0 mL) was added DMAP (3 mg, 
0.02 mmol, 0.1 eq.) distilled Et3N (68 µl, 0.48 mmol, 2 eq.) 
and Ac2O (28 µl, 0.30 mmol, 1.25 eq.; purified by filtration 
over basic Alox) and the resulting mixture was further stirred at 0 °C for 0.5 h. The 
reaction was quenched by addition of sat. aqueous NaHCO3 solution. The aqueous 
phase was extracted with Et2O, washed with water and the combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo. The crude oil was 
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subjected to flash column chromatography (pentane:Et2O 50:1) to afford acetate 5.87 
as colorless oil (95 mg, 0.24 mmol, 97%). For analytical purposes a sample was 
purified using HPLC.  
 
Rf = 0.8 (pentane:Et2O 4:1). Optical rotation: [α]D = -12.8° (c = 0.4, CHCl3). FTIR: 
ν = 2929, 2857, 1741, 1452, 1378, 1027, 860, 835, 631 cm-1. 1H NMR (400 MHz, 
CDCl3) δ = 6.29 (d, J = 15.6 Hz, 1H), 5.72 (s, 1H), 5.61 (dt, J = 15.5, 6.8 Hz, 1H), 
5.39-5.28 (m, 2H), 4.61 (m, 2H), 3.67 (d, J = 7.5 Hz, 1H), 2.72-2.61 (m, 1H), 2.07 (s, 
3H), 1.74 (d, J = 0.7, 3H), 1.71 (s, 3H), 1.68 (m, 6H), 0.82 (m, 12H), -0.04 (s, 3H),  
-0.06 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 171.09, 140.33, 138.82, 135.83, 
133.26, 132.48, 131.14, 123.94, 119.69, 83.88, 65.77, 37.81, 25.91, 21.22, 18.24, 
17.67, 16.69, 13.77, 13.09, 13.01, -4.48, -4.89. HRMS ESI calc. for C24H42O3NaSi+ 
[M-Na]+: 429.2795, found: 429.2793. 
 
 
Acetate (5.88):107 Following the reported procedure for 5.87: Alcohol 5.88a 
(73.2 mg, 193 µmol, 1.0 eq.) in dry CH2Cl2 (4.0 mL) was 
treated with DMAP (4.72 mg, 38.6 µmol, 0.20 eq.), Et3N 
(39.1 mg, 54.3 µL, 386 µmol, 2.00 eq.) and Ac2O (24.7 mg, 
22.7 µL, 241 µmol, 1.25 eq.) in CH2Cl2 (0.5 mL) to afford acetate 5.88 as colorless 
oil (67.0 mg, 159 µmol, 82%).  
 
Rf = 0.8 (pentane:Et2O 4:1). Optical rotation: [α]D = +4.40° (c = 0.09, CHCl3). 
FTIR: ν = 2929, 2857, 2361, 1741, 1649, 1451, 1375, 1228, 1063 1023, 836, 775, 
669 cm-1. 1H NMR (500 MHz, CDCl3) δ = 5.88 (s, 1H), 5.74 (s, 1H), 5.33 (q, 
J = 6.8 Hz, 1H), 5.21 (d, J = 9.7 Hz, 1H), 4.49 (s, 2H), 3.69 (d, J = 6.9 Hz, 1H), 
2.62 (ddq, J = 9.6, 6.9, 6.8 Hz, 1H), 2.08 (s, 3H), 1.80 (d, J = 1.3 Hz, 3H), 1.75 (d, 
J = 1.2 Hz, 3H), 1.71 (s, J = 1.0 Hz, 3H), 1.70 (d, J = 1.2 Hz, 3H), 1.67 (d, J = 6.8 Hz, 
3H), 0.85 (s, 9H), 0.84 (d, J = 6.7 Hz, 3H), -0.02 (s, 3H), -0.05 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ = 171.01, 135.40, 135.32, 133.24, 133.08, 131.20, 130.62, 
128.72, 123.73, 83.48, 71.03, 37.36, 25.67, 20.90, 18.07, 17.74, 17.02, 16.42, 15.54, 
13.47, 13.15, -4.72, -5.24.  
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Allylic acetate (5.89): Following the reported procedure for 5.87: Alcohol 5.89a 
(204 mg, 0.63 mmol, 1 eq.) in dry CH2Cl2 (7.5 mL) was treated 
with DMAP (8 mg, 0.06 mmol, 0.1 eq.), Et3N (177 µL, 
1.27 mmol, 2 eq.) and Ac2O (922 µL, 0.79 mmol, 1.2 eq.) to 
yield acetate 5.89 (231 mg, 0.63 mmol, quant.) as colorless oil together with trace 
impurities which could not be separated by column chromatography.  
 
Rf = 0.8 (pentane:Et2O 4:1). FTIR: ν = 2925, 2857, 1740, 1232, 1228, 964, 840, 669, 
631 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.29 (d, J = 15.6 Hz, 1H), 5.60 (dt, J = 
15.5, 6.7 Hz, 1H), 5.40-5.29 (m, 2H), 4.66-4.56 (m, 2H), 3.66 (d, J = 7.7 Hz, 1H), 
2.68-2.57 (m, 1H), 2.06 (s, 3H), 1.73 (d, J = 1.1 Hz, 3H), 1.60-1.56 (m, 3H), 1.54 (d, 
J = 1.0 Hz, 3H), 0.81 (s, 9H), 0.77 (d, J = 6.8 Hz, 3H), -0.06 (s, 3H), -0.09 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 171.09, 140.38, 139.06, 137.20, 132.36, 121.45, 
119.60, 83.44, 65.78, 37.66, 25.89, 21.22, 18.23, 17.58, 13.07, 12.97, 
11.08, -4.62, -4.92. HRMS ESI calc. for C21H38O3SiNa+ [M-Na]+: 389.2482, found: 
389.2487. 
 
 
Acetate (5.94): Following the reported procedure for 5.87: Alcohol 5.94a 
(15 mg, 38 µmol, 1 eq.) in dry CH2Cl2 (1 mL) was treated with 
DMAP (5 mg, 4 µmol, 0.1 eq.), Et3N (11 µL, 77 µmol, 2 eq.) 
and Ac2O (22 µL, 48 µmol, 1.5 eq., as 30% solution in 
CH2Cl2) to yield acetate 5.94 (14.3 mg, 33 µmol, 86%) as a colorless oil.  
 
Rf = 0.8 (pentane:Et2O 4:1). Optical rotation: [α]D = +17.8° (c = 0.50, CHCl3). 
FTIR: ν = 2929, 2857, 1738, 1647, 1377, 1225, 1077, 1025, 963, 835, 775, 669, 
632 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.31 (d, J = 15.6 Hz, 1H), 6.11 (s, 1H), 
5.66 (dt, J = 15.5, 6.7 Hz, 1H), 5.35 (d, J = 9.7 Hz, 1H), 4.69-4.59 (m, 2H), 3.85 (d, 
J = 7.0 Hz, 1H), 2.70 (dq, J = 9.6, 6.9 Hz, 1H), 2.10 (s, 3H), 1.77 (m, 6H), 0.86 (m, 
12H), -0.00 (s, 3H), -0.02 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 171.06, 143.37, 
139.85, 137.01, 133.18, 120.35, 104.64, 81.14, 65.62, 37.72, 25.82, 21.21, 18.20, 
17.52, 15.12, 12.99, -4.72, -4.95. HRMS ESI calc. for C20H35O3BrSiNa+ [M-Na]+: 
453.1429, found: 453.1431. 
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Vinyl stannane (5.90): To a suspension of CuCN (358 mg, 4 mmol, 2 eq.) in dry 
THF (16 mL) was added n-BuLi (1.6 M solution in hexane; 5.25 mL, 
8.4 mmol, 4.2 eq.) at -78 °C. This mixture was stirred 10 min at -40 °C 
to become a clear solution. Then Bu3SnH (2445 mg, 8.4 mmol, 4.2 eq.) 
was added to the mixture at -78 °C. The mixture was stirred until a yellow solution 
was obtained, then warmed to -40 °C for 10 min and cooled again to -78 °C. Dry 
MeOH (2 mL) was added at -78 °C and the temperature was warmed to -10 °C for 
5 min to form a brown solution. Then the brown solution was cooled again to -78 °C 
and 2-butin-1-ol (97%; 145 mg, 2 mmol, 1 eq.) in 2 mL dry THF was added, and 
slowly warmed to 10 °C overnight. MeOH was added to quench the reaction 
at -20 °C, then H2O and Et2O. The aqueous phase was extracted with Et2O, washed 
with water and the combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. 1H NMR of the crude mixture indicated the formation of a 
single product. The crude oil was subjected to flash column chromatography (SiO2, 
pentane:Et2O 4:1 + Et3N) to afford stannane 5.90 as colorless oil (620 mg, 1.72 mmol, 
86%).  
 
Rf = 0.3 (pentane:Et2O 4:1). 1H NMR (400 MHz, CDCl3) δ = 5.75 (ddd, J = 6.1, 4.2, 
2.1 Hz, 1H), 4.25 (t, J = 5.5 Hz, 2H), 2.00-1.79 (m, 3H), 1.56-1.41 (m, 6H), 1.31 (m, 
6H), 0.89 (m, 15H).  
 
Analytical data were in full agreement with literature: J.-F. Betzer, F. Delaloge, B. 
Muller, A. Pancrazi, J. Prunet, J. Org. Chem. 1997, 62, 7768-7780. 
 
 
Allyl alcohol (5.91): To a solution of allyl acetate 5.87 (250 mg, 0.63 mmol, 1 eq.) 
and stannane 5.90 (250 mg, 0.69 mmol, 1.1 eq.) in 
dry NMP (1.0 mL) was added flame dried LiCl 
(107 mg, 2.52 mmol, 4 eq.). The suspension was 
degased using the freeze-thaw procedure; DIPEA (138 mg, 178 µl, 1.07 mmol, 
1.7 eq.) was added and finally Pd(dba)2 (36.2 mg, 0.06 mmol, 10 mol %) to give a 
black suspension, which was stirred at 45 °C for 3 h (until TLC indicated full 
conversion). Water was added to stop the reaction. The aqueous phase was extracted 
SnBu3
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with Et2O, washed with water and the combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo. The crude oil was subjected to flash column 
chromatography (pentane:Et2O 7:1) to afford allyl alcohol 5.91 as colorless oil 
(241 mg, 0.55 mmol, 88%) as a 5:1 mixture of E:Z isomers. Separated by HPLC 
(column: IA (l = 25 cm; ∅ = 1 cm), solvent: hexane: i-PrOH 99.5:0.5, 25 °C, flow: 
6 mL/min, 2 mg/100 µL; Rt = 28 min).  
 
Rf = 0.2 (pentane:Et2O 4:1). Optical rotation: [α]D = -40.5° (c = 1.00, CHCl3). FTIR 
ν = 3350, 2928, 2316, 1670, 1444, 1385, 1251, 1066, 1006, 882, 775 cm-1. 1H NMR 
(500 MHz, CDCl3) δ = 6.06 (dd, J = 15.5, 0.6 Hz, 1H), 5.71 (s, 1H), 5.49 (t, J = 
7.3 Hz, 1H), 5.47-5.43 (m, 1H), 5.34 (q, J = 6.8 Hz, 1H), 5.20 (d, J = 9.7 Hz, 1H), 
4.17 (d, J = 7.1 Hz, 2H), 3.64 (d, J = 7.8 Hz, 1H), 2.78 (d, J = 7.1 Hz, 2H), 2.70-2.61 
(m, 1H), 1.73 (d, J = 1.2 Hz, 3H), 1.71 (s, 3H), 1.69 (d, J = 1.2 Hz, 3H), 1.68 (s, 3H), 
1.66 (s, 3H), 0.82 (s, 9H), 0.80 (d, J = 6.8 Hz, 3H), -0.04 (s, 3H), -0.06 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 139.58, 137.45, 136.00, 135.79, 133.31, 133.13, 
131.09, 124.11, 123.83, 123.80, 84.14, 59.65, 43.12, 37.57, 25.93, 18.25, 17.75, 
16.69, 16.45, 13.76, 13.21, 12.99, -4.49, -4.88. HRMS ESI calc. for C26H46O2NaSi+ 
[M+H]+: 441.3159, found: 441.3157. 
 
 
Allyl alcohol (5.92):107 Following the reported procedure for 5.91: Acetate 5.88 
(64.8 mg, 154 µmol, 1.00 eq.) in dry NMP 
(0.25 mL) was treated with stannane 5.90 (66.8 
mg, 185 µmol, 1.20 eq.), LiCl (26.1 mg, 
616 µmol, 4.00 eq.), DIPEA (46 µL, 262 µmol, 1.7 eq.) and Pd(dba)2 (17.7 mg, 30.8 
µmol, 0.20 eq.) to afford allyl alcohol 5.92 (51.6 mg, 119 µmol, 77%) as colorless oil. 
Separated by HPLC (column: IA (l = 25 cm; ∅ = 1 cm), solvent: hexane: i-PrOH 
99.5:0.5, 25 °C, flow: 5 mL/min, 2 mg/100 µL; Rt = 32 min). 
 
Rf = 0.2 (pentane:Et2O 4:1). Optical rotation: [α]D = -15.4° (c = 0.08, CHCl3). 
FTIR: ν = 3727, 3336, 2929, 2858, 2361, 1448, 1380, 1521, 1067, 1022, 837, 775, 
670 cm-1. 1H NMR (500 MHz, CDCl3) δ = 5.72 (s, 1H), 5.66 (s, 1H), 5.47 (t, 
HO
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J = 6.9 Hz, 1H), 5.34 (q, J = 6.8 Hz, 1H), 5.10 (d, J = 9.7 Hz, 1H), 4.18 (dd, J = 5.9, 
5.9 Hz, 2H), 3.66 (d, J = 7.3 Hz, 1H), 2.70 (s, 2H), 2.60 (ddq, J = 9.6, 6.9, 6.8 Hz, 
1H), 1.73 (d, J = 1.3 Hz, 3H), 1.70 (d, J = 3.2 Hz, 3H), 1.70 (s, 3H), 1.68 (d, 
J = 1.3 Hz, 3H), 1.66 (s, 3H), 1.60 (s, 3H), 1.11 (dd, J = 5.5, 5.5 Hz, 1H, OH), 0.84 (s, 
9H), 0.83 (d, J = 6.8 Hz, 3H), -0.02 (s, 3H), -0.05 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ = 138.23, 135.82, 133.77, 133.18, 132.04, 131.69, 131.61, 130.62, 124.98, 
123.59, 83.81, 59.55, 51.13, 37.38, 25.78, 18.04, 17.86, 17.44, 17.24, 17.18, 15.60, 
13.48, 13.11, -4.86, -5.11 HRMS ESI calc. for C27H48O2NaSi+ [M-Na]+: 455.3316, 
found: 455.3322.  
 
 
Allylic alcohol (5.93): Following the reported procedure for 5.91: Acetate 5.89 
(180 mg, 0.49 mmol, 1 eq.) in dry NMP (0.5 mL) was 
treated with stannane 5.90 (195 mg, 0.54 mmol, 
1.1 eq.), LiCl (83 mg, 1.96 mmol, 4 eq.), DIPEA 
(138 µL, 108 mg, 0.84 mmol, 1.7 eq.) and Pd(dba)2 (28 mg, 0.05 mmol, 10 mol %) to 
yield acetate 5.93 as colorless oil (143 mg, 0.38 mmol, 77%) as a 5:1 mixture of E:Z 
isomers. Separated by HPLC (column: IC (l = 25 cm; ∅ = 3 cm), solvent: hexane: 
i-PrOH 99.5:0.5, 25 °C, flow: 6 mL/min, 10 mg/100 µL; Rt = 48 min).  
 
Rf = 0.2 (pentane:Et2O 4:1). Optical rotation: [α]D = -14.3° (c = 0.43, CHCl3). 
FTIR: ν = >3100, 2926, 2855, 1454, 1378, 1248, 1056, 860, 835, 774, 631 cm-1. 
1H NMR (400 MHz, CDCl3) δ = 6.06 (d, J = 15.5 Hz, 1H), 5.52-5.41 (m, 2H), 5.32 
(q, J = 6.4 Hz, 1H), 5.19 (d, J = 9.7 Hz, 1H), 4.21-4.13 (m, 2H), 3.63 (d, J = 7.9 Hz, 
1H), 2.78 (d, J = 7.1 Hz, 2H), 2.66-2.56 (m, 1H), 1.72 (s, 3H), 1.66 (s, 3H), 1.59 (s, 
3H), 1.56 (d, J = 7.6 Hz, 3H), 0.80 (s, 9H), 0.76 (d, J = 6.8 Hz, 3H), -0.06 (s, 
3H), -0.09 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 139.42, 137.46, 137.36, 136.02, 
133.01, 124.06, 123.96, 121.36, 83.71, 59.64, 43.12, 37.42, 25.91, 18.24, 17.67, 
16.46, 13.19, 13.06, 10.98, -4.63, -4.91. HRMS ESI calc. for C23H42O2SiNa+ 
[M-Na]+: 401.2846, found: 401.2849. 
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Allylic alcohol (5.95): Following the reported procedure for 5.91: Acetate 5.94 
(24 mg, 59 µmol, 1 eq.) in dry NMP (0.5 mL) was 
treated with stannane 5.90 (23 mg, 65 µmol, 0.1 eq.), 
LiCl (10 mg, 236 µmol, 4 eq.), DIPEA (16 µL, 
100 µmol, 1.7 eq.) and Pd(dba)2 (3 mg, 6 µmol, 
10 mol %) to yield acetate 5.95 (17 mg, 41 µmol, 
71%) as a colorless oil in a 5:1 ratio of E/Z-isomers. 
Separated by HPLC (column: IA (l = 25 cm; ∅ = 1 cm), solvent: hexane: i-PrOH 
99.5:0.5, 25 °C, flow: 5 mL/min, 2 mg/100 µL; Rt (E) = 23 min, Rt (Z) = 19 min). 
 
Rf = 0.2 (pentane:Et2O 4:1). E-5.95-isomers: Optical rotation: [α]D = +4.8° (c = 
0.10, CHCl3). FTIR: ν = 3311, 2929, 1633, 1460, 1080, 1032, 778, 630 cm-1. 
1H NMR (400 MHz, CDCl3) δ = 6.05 (m, 2H), 5.55-5.42 (m, 2H), 5.17 (d, J = 9.7 Hz, 
1H), 4.17 (s, 2H), 3.79 (d, J = 7.3 Hz, 1H), 2.79 (d, J = 7.1 Hz, 2H), 2.71-2.60 (m, 
1H), 1.74 (d, J = 1.2, 3H), 1.72 (s, 3H), 1.66 (s, 3H), 0.82 (m, 12H), -0.03 (s, 
3H), -0.05 (s, 3H). Z-5.95-isomers: 1H NMR (600 MHz, CDCl3) δ = 6.41 (d, J = 
15.9 Hz, 1H), 6.07 (s, 1H), 5.63 (dt, J = 15,4 7.2 Hz, 1H), 5.46 (t, J = 6.9 Hz, 1H), 
5.04 (d, J = 9.7 Hz, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.77 (d, J = 7.3 Hz, 1H), 2.82 (d, J = 
7.1 Hz, 2H), 2.80-2.70 (m, 1H), 1.79 (s, 3H), 1.75 (d, J = 0.9 Hz, 3H), 1.68 (s, 3H), 
0.82 (s, 9H), 0.81 (d, J = 6.9 Hz, 3H), -0.03 (s, 3H), -0.05 (s, 3H). HRMS ESI calc. 
for C22H39O2BrNaSi+ [M-Na]+: = 465.1795, found: 465.1794, 
 
 
Allylic carbonate (5.96): To a cold (0 °C) solution of alcohol 5.91 (21.5 mg, 
51 µmol, 1 eq.) in dry CH2Cl2 (2.5 mL) was 
added pyridine (12.3 µL, 154 µmol, 3 eq.) 
and methyl chloroformate (77 µL, 77 µmol, 
1.5 eq., as a 1 M solution in CH2Cl2). After 45 min reaction time TLC indicated full 
conversion and saturated NH4Cl solution was added. The aqueous phase was 
extracted with CH2Cl2, washed with water and the combined organic extracts were 
dried over Na2SO4 and concentrated in vacuo. The crude carbonate 5.96 (24.5 mg, 
51 µmol, 99%) was directly used without any further purification in the next step.  
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Rf = 0.8 (CH2Cl2). Optical rotation: [α]D = -36.2° (c = 0.61, CHCl3). FTIR: ν = 
2928, 2856, 1749, 1443, 1383, 1259, 1066, 942, 881, 835, 775 cm-1. 1H NMR 
(400 MHz, CDCl3) δ = 6.06 (d, J = 15.5 Hz, 1H), 5.71 (s, 1H), 5.50-5.38 (m, 2H), 
5.34 (q, J = 6.7 Hz, 1H), 5.20 (d, J = 9.7 Hz, 1H), 4.67 (d, J = 7.2 Hz, 2H), 3.78 (s, 
3H), 3.64 (d, J = 7.8 Hz, 1H), 2.80 (d, J = 7.0 Hz, 2H), 2.70-2.60 (m, 1H), 1.76-1.60 
(m, 15H), 0.82 (s, 9H), 0.80 (d, J = 6.8 Hz, 3H), -0.04 (s, 3H), -0.06 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 156.03, 142.75, 137.70, 136.00, 135.94, 133.31, 
133.10, 131.09, 123.84, 123.67, 118.35, 84.12, 64.91, 54.81, 43.06, 37.57, 25.91, 
18.24, 17.74, 16.70, 16.68, 13.76, 13.21, 12.99, -4.49, -4.89.  
 
Allylic carbonate (5.97): Following the reported procedure for 5.96: Alcohol 5.92 
(10.0 mg, 23 µmol, 1 eq.) in dry CH2Cl2 
(1.5 mL) was treated with pyridine (6 µL, 
69 µmol, 3 eq.) and methyl chloroformate (34 µL, 34 µmol, 1.5 eq., as a 1 M solution 
in CH2Cl2) to yield carbonate 5.97 (10.4 mg, 23 µmol, 99%) as colorless oil. 
 
Rf = 0.8 (CH2Cl2). Optical rotation: [α]D = -8.3° (c = 0.52, CHCl3). 1H NMR 
(400 MHz, CDCl3) δ = 5.72 (s, 1H), 5.66 (s, 1H), 5.42 (t, J = 7.7 Hz, 1H), 5.34 (dd, 
J = 13.5, 6.8 Hz, 1H), 5.09 (d, J = 9.7 Hz, 1H), 4.68 (d, J = 7.1 Hz, 2H), 3.78 (s, 3H), 
3.66 (d, J = 7.3 Hz, 1H), 2.71 (s, 2H), 2.65-2.55 (m, 1H), 1.72 (d, J = 1.2 Hz, 3H), 
1.71-1.68 (m, 9H), 1.67 (d, J = 1.2 Hz, 3H), 1.64 (s, 3H), 0.84 (s, 9H), 0.83 (d, J = 
7.1 Hz, 3H), -0.03 (s, 3H), -0.05 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 156.03, 
141.82, 136.06, 134.07, 133.35, 132.23, 132.04, 131.89, 130.82, 123.77, 119.53, 
83.99, 64.95, 54.82, 51.26, 37.55, 25.95, 18.28, 18.00, 17.62, 17.42, 16.71, 15.92, 
13.78, 13.25, -4.42, -4.92. 
 
 
Allylic carbonate (5.98): Following the reported procedure for 5.96: Alcohol 5.93 
(12.4 mg, 33 µmol, 1 eq.) in dry CH2Cl2 (1 mL) 
was treated with pyridine (8 µL, 98 µmol, 3 eq.) 
and methyl chloroformate (49 mg, 49 µmol, 
1.5 eq., as a 1 M solution in CH2Cl2) to yield carbonate 5.98 (14.2 mg, 33 µmol, 99%) 
as colorless oil.  
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Rf = 0.8 (CH2Cl2). Optical rotation: [α]D = -12.6° (c = 0.71, CHCl3). FTIR: ν = 
2956, 2858, 1749, 1677, 1602, 1519, 1443, 1342, 1252, 1087, 940, 835, 780, 
678 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.05 (dd, J = 15.5, 0.5 Hz, 1H), 5.49-5.37 
(m, 2H), 5.32 (q, J = 6.7 Hz, 1H), 5.19 (d, J = 9.7 Hz, 1H), 4.66 (d, J = 7.2 Hz, 2H), 
3.78 (s, 3H), 3.63 (d, J = 7.9 Hz, 1H), 2.79 (d, J = 7.0 Hz, 2H), 2.66-2.56 (m, 1H), 
1.72 (d, J = 1.2 Hz, 3H), 1.70 (s, 3H), 1.58 (dd, J = 6.7, 0.8 Hz, 3H), 1.55 (s, J = 
1.0 Hz, 3H), 0.80 (s, 9H), 0.76 (d, J = 6.8 Hz, 3H), -0.07 (s, 3H), -0.09 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 156.02, 142.74, 137.72, 137.35, 136.17, 132.97, 
123.57, 121.36, 118.34, 83.70, 64.91, 54.80, 43.05, 37.42, 25.89, 18.23, 17.65, 16.68, 
13.18, 13.06, 10.97, -4.64, -4.93.  
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8.6.5 Completion of the Synthesis – Cross-Coupling Strategies 
Dimethoxy pyridine (5.60): A solution of 5.59 (47 mg, 0.11 mmol, 1.25 eq.) and 
geranyl chloride (15 mg, 0.08 mmol, 1 eq.) in dry DMF 
(1.0 mL) was added to CsF (33 mg, 0.22 mmol, 2.5 eq.), 
CuI (3.3 mg, 0.018 mmol, 0.2 eq.) and Pd(t-Bu3P)2 
(4.4 mg, 0.008 mmol, 10 mol %), degased (3 x) and stirred at 60 °C over night. After 
30 min reaction time the mixture became black. The mixture was cooled to RT and 
Et2O was added. The aqueous phase was extracted with Et2O, washed with water (3 x) 
and the combined organic extracts were dried over Na2SO4 and concentrated in vacuo. 
The crude orange oil was subjected to flash column chromatography (pentane:Et2O 
50:1 to 25:1 + Et3N) to afford dimethoxy-pyridine 5.60 (12 mg, 0.04 mmol, 41%) as 
colorless oil.  
 
Rf = 0.2 (pentane:Et2O 25:1). FTIR: ν = 2944, 1584, 1463, 1361, 1205, 1147, 1059, 
822 cm-1. 1H NMR (500 MHz, CDCl3) δ = 6.04 (s, 1H), 5.38-5.31 (m, 1H), 5.07 
(dddd, J = 8.3, 5.6, 2.8, 1.4 Hz, 1H), 3.89 (s, 3H), 3.79 (s, 3H), 3.40 (d, J = 6.8 Hz, 
2H), 2.10-1.98 (m, 4H), 2.03 (s, 3H), 1.75 (d, J = 0.9 Hz, 3H), 1.65 (d, J = 1.0 Hz, 
3H), 1.57 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 166.1, 162.7, 156.6, 135.8, 131.3, 
124.2, 121.3, 112.9, 89.0, 55.2, 53.1, 39.6, 34.7, 26.5, 25.5, 17.5, 16.3, 9.8. HRMS 
ESI calc. for C18H28NO2+ [M-H]+: 290.2115, found: 290.2117. 
 
 
TIPS protected pyridone (5.101’a): A suspension of stannane 5.66 (15 mg, 26 µmol, 
1.0 eq.) and geranyl chloride (5 mg, 28 µmol, 1.1 eq.) in 
dry DMF (0.2 mL) was degassed three times. To the 
orange mixture was added flame dried LiCl (3.5 mg, 
77 µmol, 3 eq.) and Pd2(dba)3 (2.4 mg, 3 µmol, 0.1 eq.), degassing repeated (another 
3 x) and the mixture was heated to 80 °C to afford a clear yellow solution. Stirring at 
this temperature was continued until TLC indicated full conversion (ca. 3 h), the 
mixture was cooled to RT and Et2O was added. The aqueous phase was extracted with 
Et2O, washed with water (3 x) and the combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo. The crude orange oil was subjected to flash 
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column chromatography (pentane:Et2O 50:1) to afford protected pyridone 5.101’a 
(8 mg, 18 µmol, 72%) as colorless oil.  
 
Rf = 0.2 (pentane:Et2O 50:1). FTIR: ν = 2921, 2361, 1595, 1468, 1395, 1263, 1192, 
1156, 909, 737, 631 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.01 (s, 1H), 5.35 (dd, J = 
6.8, 5.7 Hz, 1H), 5.08 (dd, J = 9.5, 4.0 Hz, 1H), 3.86 (s, 3H), 3.40 (d, J = 6.8 Hz, 2H), 
2.07 (s, 7H), 1.75 (s, 3H), 1.65 (s, 3H), 1.58 (s, 3H), 1.31 (m, 3H), 1.10 (d, J = 7.4 Hz, 
18H). 13C NMR (101 MHz, CDCl3) δ = 163.29, 162.58, 157.62, 135.86, 131.47, 
124.47, 121.52, 115.79, 96.37, 53.24, 39.86, 35.36, 26.81, 25.81, 18.12, 17.80, 16.57, 
13.04, 11.04. HRMS ESI calc. for C26H46NO2Si+ [M+H]+: 432.3292, found: 
432.3283. 
 
 
Protected JBIR-02 (5.2’a): A suspension of stannane 5.66 (16 mg, 38 µmol, 1.0 eq.) 
and allyl chloride 5.99 (16.6 mg, 38 µmol, 
1.0 eq.) in dry DMF (0.2 mL) was 
degassed three times. To the orange 
mixture was added flame dried LiCl 
(3 mg, 75 µmol, 2 eq.) and Pd2(dba)3 (2.3 mg, 4 µmol, 10 mol %.), degassing repeated 
(another 3 x) and the mixture was heated to 80 °C to afford a clear yellow solution. 
Stirring at this temperature was continued until TLC indicated full conversion (ca. 3 
h), the mixture was cooled to RT and Et2O was added. The aqueous phase was 
extracted with Et2O, washed with water (3 x) and the combined organic extracts were 
dried over Na2SO4 and concentrated in vacuo. The crude orange oil was subjected to 
flash column chromatography (pentane:Et2O 50:1) and to HPLC (SiO2; hexane:i-
PrOH 99.5:0.5) to afford protected JBIR-02 5.2’a (13 mg, 19 µmol, 49%) as 
inseparable mixtures of (E:Z = ca. 3:2) isomers.  
 
Rf = 0.6 (pentane:Et2O 10:1). HRMS ESI for C42H74NO3Si2+ [M+H]+: 696.5202, 
found: 696.5195. 
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Protected JBIR-02 (5.2a): To a cold (-78 °C) solution of pyridine 5.71 (21 mg, 
60 µmol, 1.2 eq.) in dry THF (0.5 mL) 
was added n-BuLi (40 µL, 65 µmol, 
1.2 eq., as a 1.6 M solution in cyclo-
hexane) dropwisely. The color of the 
reaction mixture changed to light orange. After 10 min at -78 °C ZnCl2 (75 µL, 
75 µmol, 1.5 eq., as a freshly prepared 1.0 M solution in THF) was added, stirred 
10 min at -78 °C and allowed to come to RT and stirred at rt for 45 min to yield a 
clear solution. 1H NMR (quench with H2O and D2O) indicated formation of the 
desired pyridinylzinc reagent. In a separate flask was added Pd(PPh3)4 (3 mg, 3 µmol, 
5 mol-%) to a solution of carbonate 5.96 (24 mg, 50 µmol, 1.0 eq.) in dry THF 
(0.5 mL), and the orange solution was transferred slowly to the ArZnCl solution at 
0 °C to form a colorless solution. After 5 min the mixture was removed from the ice-
bath and further stirred at 50 °C for 3 h (until TLC indicated full conversion). Water 
was added to stop the reaction. The aqueous phase was extracted with Et2O, washed 
with water and the combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. The crude oil was subjected to flash column chromatography 
(pentane:Et2O 50:1 + Et3N) to afford protected JBIR-02 5.2a as colorless oil (23 mg, 
35 µmol, 69%).  
 
Rf = 0.6 (pentane:Et2O 10:1). Optical rotation: [α]D = -24.3° (c = 0.22, CHCl3). 
FTIR: ν = 2954, 1597, 1470, 1345, 1252, 1192, 1155, 1068, 994, 783, 630 cm-1. 
1H NMR (600 MHz, CDCl3) δ = 6.27 (s, 1H), 6.05 (d, J = 15.5 Hz, 1H), 5.71 (s, 1H), 
5.48 (dt, J = 15.2, 7.0 Hz, 1H), 5.40 (td, J = 6.8, 1.2 Hz, 1H), 5.34 (q, J = 6.9 Hz, 1H), 
5.22 (s, 2H), 5.17 (d, J = 9.7 Hz, 1H), 3.87 (s, 3H), 3.75-3.71 (m, 2H), 3.64 (d, J = 
7.8 Hz, 1H), 3.42 (d, J = 6.9 Hz, 2H), 2.77 (d, J = 6.9 Hz, 2H), 2.68-2.61 (m, 1H), 
2.06 (s, 3H), 1.73 (s, 3H), 1.71 (d, J = 1.2 Hz, 3H), 1.71 (s, 3H), 1.69 (d, J = 1.2 Hz, 
3H), 1.67 (d, J = 6.8 Hz, 3H), 0.97-0.93 (m, 2H), 0.81 (s, 9H), 0.79 (d, J = 6.7 Hz, 
3H), 0.00 (s, 9H), -0.05 (s, 3H), -0.06 (s, 3H). 13C NMR (151 MHz, CDCl3) δ = 
164.00, 162.84, 157.04, 136.72, 136.06, 135.37, 135.31, 133.33, 133.28, 131.05, 
125.29, 123.81, 122.04, 113.52, 92.64, 92.08, 84.17, 66.73, 53.35, 43.41, 37.55, 
35.16, 25.91, 18.23, 18.15, 17.77, 16.70, 16.58, 13.77, 13.25, 12.98, 10.49, -1.28,  
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-4.51, -4.89. HRMS ESI calc. for C39H68O4NSi2+ [M+H]+: 670.4681, found: 
670.4674. 
 
Protected Mer-A2026B (5.3a): Following the reported procedure for 5.2a: Pyridine 
5.71 (19 mg, 54 µmol, 1.25 eq.) was treated 
with n-BuLi (35 µL, 59 µmol, 1.35 eq., as a 
1.6 M solution in cyclohexane), ZnCl2 (65 µL, 
65 µmol, 1.5 eq., as a 1.0 M solution in THF), carbonate 5.98 (19 mg, 44 µmol, 1 eq.) 
and Pd(PPh3)4 (2.5 mg, 2 µmol, 5 mol-%) in dry THF (0.5 mL) to afford protected 
Mer-A2026B 5.3a (18 mg, 28 µmol, 66%) as colorless oil.  
 
Rf = 0.6 (pentane:Et2O 10:1). Optical rotation: [α]D = -11.1° (c = 0.35, CHCl3). 
FTIR: ν = 2954, 2856, 1598, 1471, 1381, 1345, 1249, 1058, 859, 835, 774, 631 cm-1. 
1H NMR (400 MHz, CDCl3) δ = 6.27 (s, 1H), 6.04 (d, J = 15.5 Hz, 1H), 5.47 (dt, J = 
15.5, 7.0 Hz, 1H), 5.40 (t, J = 6.8 Hz, 1H), 5.31 (q, J = 6.3 Hz, 1H), 5.22 (s, 2H), 5.16 
(d, J = 9.7 Hz, 1H), 3.87 (s, 3H), 3.76-3.68 (m, 2H), 3.62 (d, J = 7.9 Hz, 1H), 3.42 (d, 
J = 6.8 Hz, 2H), 2.77 (d, J = 7.0 Hz, 2H), 2.65-2.55 (m, 1H), 2.06 (s, 3H), 1.73 (s, 
3H), 1.71 (d, J = 0.9 Hz, 3H), 1.58 (d, J = 7.0 Hz, 3H), 1.55 (s, 3H), 0.98-0.91 (m, 
2H), 0.79 (s, 9H), 0.75 (d, J = 6.8 Hz, 3H), 0.00 (s, 9H), -0.07 (s, 3H), -0.09 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 164.01, 162.85, 157.05, 137.41, 136.76, 135.52, 
135.37, 133.16, 125.20, 122.04, 121.30, 113.51, 92.64, 92.10, 83.74, 66.73, 53.34, 
43.40, 37.41, 35.16, 25.90, 18.23, 18.15, 17.68, 16.60, 13.21, 13.06, 10.99, 
10.49, -1.28, -4.65, -4.92. HRMS ESI calc. for C36H64O4NSi2+ [M+H]+: 630.4360, 
found: 630.4368. 
 
 
Piericidin A1 (5.1): Following the reported procedure for 5.2a: 5.23 (9.0 mg, 
24 µmol, 1.3 eq.) was treated with n-BuLi 
(16 µL, 25 µmol, 1.35 eq., as a 1.6 M solution 
in cyclohexane), ZnCl2 (28 µL, 28 µmol, 
1.5 eq., as a 1.0 M solution in THF), carbonate 5.98 (8 mg, 18 µmol, 1.0 eq.) and 
Pd(PPh3)4 (0.9 mg, 1 µmol, 5 mol %) in dry THF (0.5 mL) to afford protected 
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piericidin A1 5.1a (ca. 8 mg) as colorless oil as a inseparable 1:1 mixture with 
dehalogenated pyridone.  
 
Rf = 0.7 (CH2Cl2). 1H NMR (400 MHz, CDCl3) δ = 6.05 (d, J = 15.5 Hz, 1H), 5.48 
(dt J = 14.9, 7.6 Hz, 1H), 5.41 (dd, J = 6.9, 5.7 Hz, 1H), 5.31 (q, J = 6.6 Hz, 1H), 5.28 
(s, 2H), 5.17 (d, J = 9.7 Hz, 1H), 3.94 (s, 3H), 3.83-3.79 (m, 2H), 3.78 (s, 3H), 3.62 
(d, J = 7.9 Hz, 1H), 3.38 (d, J = 6.9 Hz, 2H), 2.77 (d, J = 7.0 Hz, 2H), 2.66-2.54 (m, 
1H), 2.15 (d, J = 0.7, 3H), 2.12 (s, 3H), 1.72 (s, 3H), 1.71 (d, J = 1.1 Hz, 3H), 1.57 (d, 
J = 5.6 Hz, 3H), 1.55 (d, J = 1.0 Hz, 3H), 0.99-0.94 (m, 2H), 0.80 (s, 9H), 0.75 (d, J = 
6.8 Hz, 3H), 0.01 (s, 9H), -0.07 (s, 3H), -0.09 (s, 3H). 
 
The crude material was directly subjected to deprotection with TBAF: Following the 
reported procedure for 5.2a: A mixture of pyridine and protected piericidin 5.2a (ca. 
8.0 mg) was treated with TBAF (110 µL, as a 1.0 M solution in THF) in dry THF 
(0.8 mL) to afford the natural product piericidin A1 5.1 (2.3 mg, 5 µmol, 29%, over 
2 steps) as light-yellow oil. 
 
Rf = 0.4 (hexane EtOAc 1:1). Optical rotation: [α]D = -0.5° (c = 0.1, MeOH); Lit.: 
[α]D = +1.0° (c = 0.1, MeOH). UV: λMeOH = 273, 236, 203 nm. FTIR: ν = 3400, 
2923, 2854, 1586, 1468, 1412, 1190, 1125, 776, 630 cm-1. 1H NMR (400 MHz, 
CDCl3) δ = 6.19 (br s, 1H), 6.09 (d, J = 15.0 Hz, 1H), 5.61 (dt, J = 15.4, 7.0 Hz, 1H), 
5.48 (dd, J = 6.8, 2.1 Hz, 1H), 5.41 (dt, J = 6.9, 1.2, 1H), 5.21 (d, J = 9.7 Hz, 1H), 
3.95 (s, 3H), 3.85 (s, 3H), 3.62 (d, J = 9.1 Hz, 1H), 3.37 (s, 3H), 2.79 (d, J = 7.0 Hz, 
1H), 2.72-2.63 (m, 1H), 2.09 (s, 3H), 1.80 (d, J = 1.2 Hz, 3H), 1.75 (s, 3H), 1.64 (s, 
3H), 1.62 (s, 3H), 0.80 (d, J = 6.7 Hz, 3H). HRMS ESI calc. for C25H38O4N+ [M-H]+: 
416.2795, found: 416.2800. 
 
Analytical data (except optical rotation) according to reference: M. J. Schnermann, D. 
L. Boger, J. Am. Chem. Soc. 2005, 127, 15704-15705. 
 
 
 
EXPERIMENTAL PART  181 
 
TIPS protected pyridone (5.100a): Following the reported procedure for 5.2a: 
Pyridine 5.73 (37 mg, 103 µmol, 1.0 eq.) was treated 
with n-BuLi (70 µL, 113 µmol, 1.1 eq., as a 1.6 M 
solution in cyclohexane), ZnCl2 (123 µL, 123 µmol, 
1.2 eq., as a 1.0 M solution in THF), geranyl carbonate (26 mg, 123 µmol, 1.2 eq.) 
and Pd(PPh3)4 (6 mg, 5 µmol, 5 mol-%) in dry THF (0.5 mL) to afford TIPS protected 
pyridone 5.100a (18 mg, 43 µmol, 42%) as colorless oil. 
 
Rf = 0.6 (pentane:Et2O 10:1). FTIR: ν = 2945, 2868, 1598, 1454, 1408, 1362, 1262, 
1158, 1056, 1009, 882, 784, 688 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.29 (d, J = 
1.9 Hz, 1H), 6.02 (d, J = 1.9 Hz, 1H), 5.42 (td, J = 7.3 Hz, 1.2, 1H), 5.12 (t, J = 
6.8 Hz, 1H), 3.89 (s, 3H), 3.36 (d, J = 7.3 Hz, 2H), 2.14-2.03 (m, 4H), 1.70 (s, 3H), 
1.68 (d, J = 0.7 Hz, 3H), 1.60 (s, 3H), 1.30-1.19 (m, 3H), 1.09 (d, J = 7.2 Hz, 18H). 
13C NMR (101 MHz, CDCl3) δ = 165.53, 165.44, 160.48, 137.41, 131.59, 124.40, 
121.21, 108.52, 97.54, 53.51, 39.89, 36.71, 26.89, 25.83, 17.99, 17.80, 16.44, 12.81. 
HRMS ESI calc. for C25H44NO2Si+ [M+H]+: 418.3136, found: 418.3132. 
 
 
SEM protected pyridone (5.101a): Following the reported procedure for 5.2a: 
Pyridine 5.71 (21 mg, 60 µmol, 1.0 eq.) was treated with 
n-BuLi (45 µL, 72 µmol, 1.2 eq., as a 1.6 M solution in 
cyclohexane), ZnCl2 (90 µL, 90 µmol, 1.5 eq., as a 1.0 M 
solution in THF), geranyl carbonate (26 mg, 121 µmol, 2.0 eq.) and Pd(PPh3)4 (4 mg, 
3 µmol, 5 mol %) in dry THF (0.5 mL) to afford SEM protected pyridone 5.101a 
(18 mg, 44 µmol, 74%) as colorless oil. 
 
Rf = 0.6 (pentane:Et2O 10:1). FTIR: ν = 2951, 2844, 1596, 1469, 1409, 1345, 1249, 
1192, 1064, 991, 834, 758, 667 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.27 (s, 1H), 
5.34 (t, J = 6.8 Hz, 1H), 5.22 (s, 2H), 5.08 (t, J = 6.8 Hz, 1H), 3.88 (s, 3H), 3.73 (t, J = 
8.3 Hz, 2H), 3.41 (d, J = 6.8 Hz, 2H), 2.12-1.99 (m, 7H), 1.75 (s, 3H), 1.65 (s, 3H), 
1.58 (s, 3H), 0.95 (t, J = 8.3 Hz, 2H), 0.00 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 
164.00, 162.84, 157.23, 135.97, 131.46, 124.46, 121.44, 113.50, 92.62, 92.03, 66.71, 
NO
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53.34, 39.86, 35.17, 26.81, 25.81, 18.14, 17.80, 16.57, 10.43, -1.29. HRMS ESI calc. 
for C23H40NO3Si+ [M-H]+: 406.2772, found: 406.2769. 
 
 
8.6.6 Deprotection  
JBIR-02 (5.2): To a solution of protected JBIR-02 5.2a (23 mg, 34 µmol, 1.0 eq.) in 
dry THF (0.5 mL) was added TBAF 
(170 µL, 172 µmol, 5.0 eq., as a 1.0 M 
solution in THF) and the brown solution 
was heated to 70 °C for 3.5 h until UPLC indicated no further conversion. The 
solution was cooled to rt, EtOAc was added and washed with H2O. The aqueous 
phase was extracted three times with EtOAc and the combined organic extracts were 
dried over Na2SO4 and concentrated in vacuo. The crude orange oil was subjected to 
flash column chromatography (hexane:EtOAc 3:1 to 1:1) to afford JBIR-02 5.2 as 
colorless solid (12.1 mg, 28 µmol, 82%).  
 
Rf = 0.4 (hexane:EtOAc 1:1). Optical rotation: [α]D = -11.1° (c = 0.21, MeOH); Lit.: 
[α]D = -13.0° (c = 0.88, MeOH). UV: λCH3CN = 199, 241 nm. λMeOH = 240, 223, 
202 nm. FTIR: ν = 3249, 2922, 2859, 1597, 1489, 1452, 1399, 1231 cm-1. 1H NMR 
(500 MHz, CDCl3) δ = 6.11 (d, J = 15.5 Hz, 1H), 5.92 (bs, 1H), 5.84 (s, 1H), 5.58 (dt, 
J = 15.5, 7.0 Hz, 1H), 5.41 (q, J = 6.8 Hz, 1H), 5.30 (m, 1H), 5.25 (d, J = 9.6 Hz, 1H), 
3.79 (s, 3H), 3.65 (d, J = 8.9 Hz, 1H), 3.36 (d, J = 7.1 Hz, 2H), 2.83 (d, J = 6.9 Hz, 
2H), 2.71 (ddq like, 1H), 2.03 (s, 3H), 1.80 (d, J = 1.1 Hz, 3H), 1.78 (s, 3H), 1.74 (s, 
3H), 1.71 (d, J = 1.1 Hz, 3H), 1.68 (d, J = 6.8 Hz, 3H), 0.85 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ = 158.6, 136.3, 135.8, 135.7, 133.9, 133.6, 133.5, 
132.8, 125.9, 124.7, 122.2, 113.4, 92.4, 83.3, 54.7, 42.9, 36.9, 30.6, 17.6, 16.8, 16.7, 
13.8, 13.3, 12.7, 10.3, (C1’ and C3’ not detected; C2’ and C5’ detected by low 
temperature 318K HMBC). HRMS ESI calc. for C27H40NO3+ [M+H]+: 425.3003, 
found: 426.2997. 
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Mer-A2026B (5.3): Following the reported procedure for 5.2: Protected Mer-A2026B 
5.2a (14.0 mg, 22 µmol, 1 eq.) was treated 
with TBAF (110 µL, 110 mmol, 5.0 eq., as a 
1.0 M solution in THF) in dry THF (0.8 mL) 
to afford the natural product Mer-A2026B 5.3 (8.0 mg, 21 µmol, 93%) as light-yellow 
oil.  
 
Rf = 0.4 (hexane EtOAc 1:1). Optical rotation: [α]D = -1.1° (c = 0.105, MeOH); Lit. 
[α]D = -1.07° (c = 0.36, MeOH). UV: λCH3CN = 201, 235, 272 nm. λMeOH = 238, 223, 
202 nm. FTIR: ν = 3340, 2924, 2856, 1599, 1489, 1456, 1399, 965 cm-1. 1H NMR 
(500 MHz, CDCl3) δ = 6.11 (d, J = 15.5 Hz, 1H), 5.87 (bs, 1H), 5.58 (dt, J = 15.5, 
7.0 Hz, 1H), 5.31 (m, 1H), 5.25 (d, J = 9.7 Hz, 1H), 3.81 (s, 3H), 3.66 (d, J = 9.1 Hz, 
1H), 3.36 (d, J = 7.0 Hz, 2H), 2.84 (d, J = 6.7 Hz, 2H), 2.69 (ddq like, 1H), 2.03 (s, 
3H), 1.81 (s, 3H), 1.72 (s, 3H), 1.64 (s, 3H), 1.63 (d, 3H), 0.81 (d, J = 6.7 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ = 136.5, 136.4, 135.8, 135.5, 133.8, 130.0, 125.4, 
123.7, 92.4, 82.8, 55.0, 42.9, 36.8, 29.8, 17.2, 16.5, 13.0, 13.0, 10.4, 9.9, (C1’, C2’, 
C4’ and C3’ not detected). HRMS ESI calc. for C24H36O3N+ [M+H]+: 386.2690, 
found: 386.2687. 
 
 
4-Hydroxy-pyridine (5.100): Following the reported procedure for 5.2: Protected 
Piericidin 5.100a (18.0 mg, 43 µmol, 1 eq.) was treated 
with TBAF (86 µL, 86 mmol, 2.0 eq., as a 1.0 M 
solution in THF) in dry THF (0.8 mL) to afford 
4-hydroxy-pyridine 5.100 (11 mg, 42 µmol, 98%) as light-yellow oil. 
 
Rf = 0.4 (hexane EtOAc 1:1). FTIR: ν = 2916, 2674, 1612, 1489, 1361, 1229, 1152, 
1073, 988, 841 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.23 (d, J = 1.9 Hz, 1H), 5.93 
(d, J = 1.9 Hz, 1H), 5.30 (td, J = 7.3, 1.2 Hz, 1H), 5.07 (t, J = 6.8 Hz, 1H), 3.82 (s, 
3H), 3.29 (d, J = 7.3 Hz, 2H), 2.16-1.97 (m, 4H), 1.67 (d, J = 0.6 Hz, 3H), 1.65 (s, 
3H), 1.59 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 163.12, 139.50, 131.94, 124.07, 
119.22, 108.19, 93.03, 54.89, 39.78, 34.06, 26.62, 25.80, 17.84, 16.38 (C1’ and C3’ 
not detected). HRMS ESI calc. for C16H24NO2+ [M-H]+: 262.1802, found: 262.1802. 
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4-Hydroxy-pyridine (5.101): Following the reported procedure for 5.2: Protected 
piericidin 5.101a (13.0 mg, 32 µmol, 1 eq.) was treated 
with TBAF (64 µL, 64 mmol, 2.0 eq., as a 1.0 M 
solution in THF) in dry THF (0.8 mL) to afford the title 
compound 5.101 (7.0 mg, 25 µmol, 79%) as light-yellow oil. 
 
Rf = 0.4 (hexane EtOAc 1:1). FTIR: ν = 2927, 1613, 1534, 1490, 1451, 1382, 1261, 
1231, 1192, 1141, 1083, 831, 695 cm-1. 1H NMR (500 MHz, CDCl3) δ = 5.96 (s, 1H), 
5.24 (dd, J = 7.2 Hz, 6.2, 1H), 5.06 (dd, J = 4.7, 3.3 Hz, 1H), 3.81 (s, 3H), 3.38 (d, J = 
7.2 Hz, 2H), 2.17-2.08 (m, 4H), 2.02 (s, 3H), 1.70 (s, 3H), 1.67 (s, 3H), 1.60 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 159.56, 132.34, 123.74, 118.02, 92.34, 55.39, 46.03, 
39.73, 26.45, 25.79, 17.88, 16.49, 10.13, 8.77 (C1’, C2’, C4’ and C3’ not detected). 
HRMS ESI calc. for C17H26NO2+ [M-H]+: 276.1958, found: 276.1959. 
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8.7 Bipyridine Ligands 
6,6’-Dimethoxy-2,2’-bipyridine (6.3): To a cold (-78 °C) solution of 2-bromo-6-
methoxypyridine 5.67 (70 mg, 0.36 mmol, 1 eq.) in dry THF 
(2 mL) was added n-BuLi (250 µL, 0.39 mmol, 1.1 eq., as a 
1.6 M solution in cyclohexane). The reaction mixture turned 
orange and the solution was stirred for 10 min at this temperature. Then ZnCl2 
(450 µL, 0.45 mmol, 1.25 eq., as a 1.0 M solution in THF) was added and the solution 
slowly allowed to reach RT to form a white suspension. Then a solution of 2-bromo-
6-methoxypyridine (70 mg, 0.36 mmol, 1 eq.) and Pd(PPh3)4 (21 mg, 0.02 mmol, 
5 mol %) in dry THF (2 mL) at RT was added and the mixture (orange-white 
suspension) stirred further at 50 °C for 6 h to form an orange solution, until TLC 
reaction control indicated full conversion (UV active at 366 nm). The reaction 
mixture was quenched by addition of sat. aqueous NH4Cl solution, EDTA solution 
and extracted with EtOAc. The aqueous phase was extracted with EtOAc, washed 
with water and the combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. The crude oil was subjected to flash column chromatography 
(CH2Cl2 to CH2Cl2:MeOH 50:1) to afford dimethoxy-2,2’-bipyridine 6.3 (71 mg, 
0.33 mmol, 91%) as colorless crystals.  
 
M.p. = 120-121 °C. Rf = 0.5 (CH2Cl2, strong tailing). 1H NMR (400 MHz, CDCl3) 
δ = 8.01 (dd, J = 7.4, 0.7 Hz, 2H), 7.68 (dd, J = 8.1, 7.5 Hz, 2H), 6.75 (dd, J = 8.2, 
0.7 Hz, 2H), 4.04 (s, 6H). 
 
Analytical data according to reference: M. Tiecco, L. Testaferri, M. Tingoli, D. 
Chianelli, M. Montanucci, Synthesis 1984, 736-738. 
 
 
TIPS protected 2,2’-bipyridine (6.4): Following the reported procedure for 6.3: 
Pyridine 5.73 (75 mg, 202 µmol, 1.0 eq.) in dry THF (2 mL) was 
treated with n-BuLi (139 µL, 222 µmol, 1.1 eq., as a 1.6 M 
solution in cyclohexane), ZnCl2 (252 µL, 252 µmol, 1.25 eq., as 
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a 1.0 M solution in THF), pyridine 5.73 (75 mg, 202 µmol, 1.0 eq.) and Pd(PPh3)4 
(11 mg, 10 µmol, 5 mol %) in dry THF (2 mL) to afford TIPS protected 2,2’-
bipyridine 6.4 (92 mg, 123 µmol, 61%) as colorless oil. 
 
Rf = 0.5 (CH2Cl2, strong tailing). FTIR: ν = 2945, 2867, 1583, 1463, 1418, 1378, 
1275, 1172, 1047 881, 824, 633 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.61 (d, J = 
2.0 Hz, 2H), 6.22 (d, J = 2.0 Hz, 2H), 3.99 (s, 6H), 1.32 (sep, J = 7.2, 6H), 1.13 (d, 
J = 7.3, 36H). 13C NMR (101 MHz, CDCl3) δ = 165.78, 165.29, 154.44, 107.66, 
100.71, 53.40, 18.04, 12.81. HRMS ESI calc. for C30H53O4N2Si2+ [M-H]+: 561.3538, 
found: 561.3545. 
 
 
SEM protected 2,2’-bipyridine (6.5): Following the reported procedure for 6.3: 
Pyridine 5.71 (40 mg, 115 µmol, 1.0 eq.) in dry THF (1.5 mL) 
was treated with n-BuLi (79 µL, 126 µmol, 1.1 eq., as a 1.6 M 
solution in cyclohexane), ZnCl2 (144 µL, 144 µmol, 1.25 eq., as 
a 1.0 M solution in THF), pyridine 5.71 (40 mg, 115 µmol, 1.0 
eq.) and Pd(PPh3)4 (7 mg, 6 µmol, 5 mol %) in dry THF (2 mL) to afford SEM 
protected 2,2’-bipyridine 6.5(40 mg, 75 µmol, 64%) as colorless oil. 
 
Rf = 0.5 (CH2Cl2:MeOH 50:1, strong tailing). FTIR: ν = 2947, 2867, 1584, 1463, 
1379, 1191, 1174, 1055, 834, 693, 631 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.44 (s, 
2H), 5.29 (s, 4H), 3.88 (s, 6H), 3.76 (dd, J = 8.9, 7.8 Hz, 4H), 1.93 (s, 6H), 1.00-0.92 
(m, 4H), 0.02 (s, 18H). 13C NMR (101 MHz, CDCl3) δ = 164.44, 162.99, 154.70, 
132.31, 132.21, 132.08, 128.70, 128.58, 115.37, 94.05, 92.67, 66.84, 53.65, 18.17, 
11.32, -1.26. HRMS ESI calc. for C26H45O6N2Si2+ [M-H]+: 537.2811, found: 
537.2815. 
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Unsymmetrical protected 2,2’-bipyridine (6.6): Following the reported procedure 
for 6.3: Pyridine 5.71 (40 mg, 115 µmol, 1.0 eq.) in dry THF 
(1.5 mL) was treated with n-BuLi (79 µL, 126 µmol, 1.1 eq., as 
a 1.6 M solution in cyclohexane), ZnCl2 (144 µL, 144 µmol, 
1.25 eq., as a 1.0 M solution in THF), pyridine 5.73 (41 mg, 
115 µmol, 1.0 eq.) and Pd(PPh3)4 (7 mg, 6 µmol, 5 mol %) in dry THF (2 mL) to 
afford unsymmetrical protected 2,2’-bipyridine 6.6 (11 mg, 20 µmol, 18%) as 
colorless oil. 
 
Rf = 0.5 (CH2Cl2:MeOH 50:1, strong tailing). FTIR: ν = 2947, 2867, 1585, 1565, 
1401, 1379, 1250, 1176, 1158, 1061, 983, 834, 632 cm-1. 1H NMR (400 MHz, 
CDCl3) δ = 7.11 (d, J = 2.0 Hz, 1H), 6.45 (s, 1H), 6.21 (d, J = 2.0 Hz, 1H), 5.29 (s, 
2H), 3.94 (s, 3H), 3.92 (s, 3H), 3.78-3.73 (m, 2H), 2.36 (s, 3H), 1.35-1.25 (m, 3H), 
1.12 (d, J = 7.3, 18H), 1.00-0.94 (m, 2H), 0.01 (s, 9H). 13C NMR (101 MHz, CDCl3) 
δ = 165.27, 164.92, 164.64, 162.48, 157.78, 152.57, 146.79, 116.02, 111.23, 99.78, 
94.37, 92.74, 66.79, 53.70, 53.31, 18.17, 18.02, 12.83, 12.03, -1.27, -1.30. HRMS 
ESI calc. for C28H49O5N2Si2+ [M-H]+: 549.3175, found: 549.3181. 
 
 
4,4’-Dihydroxy-2,2’-bipyridine (6.7): To a solution of TIPS protected 2,2’-bi-
pyridine 6.4 (45 mg, 80 µmol, 1 eq.) in dry THF ( 2 mL) was 
added TBAF (400 µL, 400 µmol, 5 eq., as a 1 M solution in 
THF) at RT and the resulting mixture was further stirred at 
50 °C until TLC indicated full conversion. The white suspension 
was acidified using aqueous 1 M HCl and extracted with EtOAc. 
The aqueous phase was extracted with EtOAc, washed with water and the combined 
organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude oil was 
washed with CHCl3 (3 x) to afford after removal of all volatiles 4,4’-dihydroxy-2,2’-
bipyridine 6.7 (15 mg, 60 µmol, 75%) as colorless solid. 
 
M.p. = >350 °C (decomposition). Rf = 0.05 (EtOAc). FTIR: ν = 3105, 2857, 1610, 
1560, 1477, 1370, 1211, 1165, 1062, 855 711 cm-1. 1H NMR (400 MHz, d4-MeOD) 
δ = 7.28 (d, J = 1.9 Hz, 2H), 6.54 (d, J =1.7 Hz, 2H), 4.10 (s, 6H). 1H NMR 
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(400 MHz, d6-DMSO) δ = 10.69 (s, 2H), 7.45 (d, J = 2.0 Hz, 2H), 6.14 (d, J = 1.9 Hz, 
2H), 3.89 (s, 6H). HRMS ESI calc. for C12H13N2O4+ [M-H]+: 249.0870, found: 
249.0873. 
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9 APPENDICES SECTION 
9.1 Crystal structures 
 
Table 9.1. Crystal data for 2.27 (CCDC 816947). 
Formula                             C28H42O4 
Formula weight                     442.64 
Z, calculated density              4, 1.174 Mg · m-3 
F(000)                              968 
Description and size of crystal    colorless, 0.08 · 0.17 · 0.23 mm3 
Absorption coefficient              0.076 mm-1 
Min/max transmission               0.99 / 0.99 
Temperature                        123 K 
Radiation (wavelength)              Mo Kα (λ = 0.71073 Å) 
Crystal system, space group        orthorhombic, P 21 21 21 
a                                   8.8903(2) Å 
b                                   11.1253(3) Å 
c                                   25.3120(8) Å 
α                                   90° 
β                                   90° 
γ                                   90° 
V                                   2503.54(12) Å3 
Min/max Θ                          2.000° / 37.817° 
Number of collected reflections    87315 
Number of independent reflections  7430 (merging r = 0.045) 
Number of observed reflections     5937 (I>3.0σ(I)) 
Number of refined parameters       289 
r                                   0.0451 (I>3.0σ(I)) 
rW                                  0.1064 (all data) 
Goodness of fit                    1.0530 
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Table 9.2. Crystal data for 2.36 (CCDC 816949). 
Formula                             C28H40O6, C4H8O2 
Formula weight                     560.73 
Z, calculated density              4, 1.273 Mg · m-3 
F(000)                              1216 
Description and size of crystal    colorless prism, 0.09 · 0.14 · 0.25 mm3 
Absorption coefficient             0.090 mm-1 
Min/max transmission               0.99 / 0.99 
Temperature                        123 K 
Radiation(wavelength)              Mo Kα (λ = 0.71073 Å) 
Crystal system, space group        orthorhombic, P 21 21 21 
a                                   11.8379(5) Å 
b                                   13.3459(6) Å 
c                                   18.5218(9) Å 
α                                   90° 
β                                   90° 
γ                                   90° 
V                                   2926.2(2) Å3 
Min/max Θ                          1.881° / 32.358° 
Number of collected reflections    65338 
Number of independent reflections  5762 (merging r = 0.045) 
Number of observed reflections     4785 (I>3.0σ(I)) 
Number of refined parameters       416 
r                                   0.0287 (I>3.0σ(I)) 
rW                                  0.0479 (all data) 
Goodness of fit                    1.1101 
 
The solvent molecule in compound 2.36 (EtOAc) has been refined using restraints 
in order to keep the geometrical parameters within reasonable ranges. 
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Table 9.3. Crystal data for allylic alcohol 2.43 (CCDC 924130). 
Formula                             C28H40O6 
Formula weight                     472.62 
Z, calculated density              4, 1.256 Mg · m-3 
F(000)                              1024 
Description and size of crystal    colorless, 0.030 · 0.090 · 0.270 mm3 
Absorption coefficient              0.087 mm-1 
Min/max transmission               0.99 / 1.00 
Temperature                        123 K 
Radiation (wavelength)              Mo Kα (λ = 0.71073 Å) 
Crystal system, space group        orthorhombic, P 21 21 21 
a                                   11.3881(10)  Å 
b                                   13.7611(13) Å 
c                                   15.9461(16) Å 
α                                   90° 
β                                   90° 
γ                                   90° 
V                                   2499.0(4) Å3 
Min/max Θ                          1.955° / 36.318° 
Number of collected reflections    42220 
Number of independent reflections  6467 (merging r = 0.050) 
Number of observed reflections     4541 (I>2.0σ(I)) 
Number of refined parameters       307 
r                                   0.0394  
rW                                  0.0673 (all data) 
Goodness of fit                    1.1096 
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Table 9.4. Crystal data for acetonide 3.16 (CCDC881462). 
Formula                              C11H13NO4 
Formula weight                      223.23 
Z, calculated density               4, 1.374 Mg · m-3 
F(000)                               472 
Description and size of crystal   colorless, 0.030·0.110·0.230 mm3 
Absorption coefficient              0.105 mm-1 
Min/max transmission                0.99 / 1.00 
Temperature                         123K 
Radiation(wavelength)               Mo Kα (λ = 0.71073 Å) 
Crystal system, space group         monoclinic, P 21/n 
a                                    9.3296(17) Å 
b                                    12.264(2) Å 
c                                    10.4903(19) Å 
α                                    90° 
β                                    116.015(6)° 
γ                                    90° 
V                                    1078.7(3) Å3 
Min/max Θ                           2.442° / 26.371° 
Number of collected reflections     9848 
Number of independent reflections   2203 (merging r = 0.107) 
Number of observed reflections      1516 (I>2.0σ(I)) 
Number of refined parameters        145 
r                                    0.0432 
rW                                   0.0903 
Goodness of fit                     0.9781 
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Table 9.5. Crystal data for N-oxide 5.63. 
Formula     C7H8N2O4 
Formula weight    184.15 g · Mol-1 
Z, calculated density   12, 1.605 Mg · m-3 
F(000)     1152 
Description and size of crystal  colorless, 0.050 · 0.080 · 0.330 mm3 
Absorption coefficient   0.134 mm-1 
Min/max transmission   0.99 / 0.99 
Temperature    123K 
Radiation (wavelength)   Mo Kα (λ = 0.71073 Å) 
Crystal system, space group  monoclinic, P 21/c 
a      11.6811(6) Å 
b      10.1479(5) Å 
c      19.3476(9) Å 
α      90° 
β      94.720(3)° 
γ      90° 
V      2285.66(19) Å3 
Min/max Θ    1.749° / 31.552° 
Number of collected reflections  35833 
Number of independent reflections  7601 (merging r = 0.072) 
Number of observed reflections  4068 (I>2.0σ(I)) 
Number of refined parameters  352 
r      0.0613 
rW      0.1602 
Goodness of fit    1.0818 
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Table 9.6. Crystal data of 4-hydroxypyridine 5.64. 
Formula     C7H9NO2 
Formula weight    139.15 g · Mol-1 
Z, calculated density   4, 1.298 Mg · m-3 
F(000)     296 
Description and size of crystal  colorless, 0.020 · 0.080 · 0.190 mm3 
Absorption coefficient   0.096 mm-1 
Min/max transmission   0.99 / 1.00 
Temperature    123 K 
Radiation (wavelength)   Mo Kα (λ = 0.71073 Å) 
Crystal system, space group  monoclinic, P 21/n 
a      4.6487(6) Å 
b      14.2532(18) Å 
c      10.8700(15) Å 
α      90° 
β      98.746(8)° 
γ      90° 
V      711.86(16) Å3 
Min/max Θ    2.374° / 30.104° 
Number of collected reflections  7111 
Number of independent reflections 2094 (merging r = 0.058) 
Number of observed reflections  1035 (I>2.0σ(I)) 
Number of refined parameters  95 
r      0.0530 
rW      0.1046 
Goodness of fit    1.1020 
 
Bond length C-OMe    1.353 Å 
Bond length C-OH    1.345 Å 
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Table 9.7. Crystal data of acylated auxiliary 5.73. 
Formula     C24H27NO3 
Formula weight    377.48 
Z, calculated density    4, 1.221 Mg · m-3 
F(000)      808 
Description and size of crystal  colorless, 0.070 · 0.110 · 0.230 mm3 
Absorption coefficient             0.080 mm-1 
Min/max transmission               0.99 / 0.99 
Temperature                         123 K 
Radiation (wavelength)              Mo Kα (λ = 0.71073 Å) 
Crystal system, space group        orthorhombic, P 21 21 21 
a                                    9.3102(9) Å 
b                                    12.0749(12) Å 
c                                    18.2636(18) Å 
α                                    90° 
β                                    90° 
γ                                    90° 
V                                    2053.2(3) Å3 
Min/max Θ                           2.022° / 27.506° 
Number of collected reflections    34925 
Number of independent refections   2671 (merging r = 0.122) 
Number of observed reflections     2113 (I>2.0σ(I)) 
Number of refined parameters       253 
r                                    0.0590 
rW                                  0.0754 
Goodness of fit                     1.0135 
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Table 9.8. Crystal data for alcohol 5.79 (CCDC916688). 
Formula     C16H26BrNO5 
Formula weight     392.29 g · mol-1 
Z, calculated density    2, 1.436 Mg · m-3 
F(000)     408 
Description and size of crystal  colorless, 0.030 · 0.110 · 0.350 mm3 
Absorption coefficient   2.288 mm-1 
Min/max transmission    0.78 / 0.93 
Temperature    123K 
Radiation (wavelength)    Mo Kα (λ = 0.71073 Å) 
Crystal system, space group  monoclinic, P 21 
a      11.2472(3) Å 
b      6.4690(2) Å 
c       13.0993(3) Å 
α      90° 
β      107.800(2)° 
γ       90° 
V      907.46(4) Å3 
Min/max Θ    1.902° / 31.503° 
Number of collected reflections  13039 
Number of independent reflections  5832 (merging r = 0.031) 
Number of observed reflections  4357 (I>2.0σ(I)) 
Number of refined parameters  209 
r       0.0283 
rW      0.0316 
Goodness of fit    0.9690 
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9.2 1H and 13C NMR Spectra 
1H and 13C NMR Spectra for the all characterized compounds can be found on the 
enclosed CD to this PhD thesis. 
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9.3 Representative Micrographs  
Neurite outgrowth activity of DMSO (A), ATRA 4.1 (1 µM; B), retinoids 4.3 (1 µM; 
C and 0.1 µM; D), 4.6 (1 µM; E) and 4.6 (1 µM; F) in human SH-SY5Y cells with 
MEM as cell medium.  
 A 
 
 B 
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O 
ATRA (1.0 µM, no UV) 
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Neurite outgrowth activity of DMSO control without UV irradiation (no UV, A), 
DMSO control, with 180 s UV irradiation at 366 nm (180 s UV, B), retinoid 4.3 
(0.1 µM, no UV, C), caged retinoid 4.5 (1 µM, no UV, D), 4.5 (1 µM, 60 s UV, E), 
4.5 (0.1 µM, 180 s UV, F), 4.5 (1 µM, 180 s UV, G) in human SH-SY5Y cells. 
 A 
 
 B 
 
DMSO (no UV) 
DMSO (180 s, UV) 
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